0001019687-15-003028.txt : 20150810 0001019687-15-003028.hdr.sgml : 20150810 20150810163626 ACCESSION NUMBER: 0001019687-15-003028 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150810 DATE AS OF CHANGE: 20150810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RadNet, Inc. CENTRAL INDEX KEY: 0000790526 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 133326724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33307 FILM NUMBER: 151041217 BUSINESS ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 3104787808 MAIL ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: PRIMEDEX HEALTH SYSTEMS INC DATE OF NAME CHANGE: 19930518 FORMER COMPANY: FORMER CONFORMED NAME: CCC FRANCHISING CORP DATE OF NAME CHANGE: 19920703 10-Q 1 radnet_10q-063015.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 10-Q

 

(Mark One)

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2015

 

OR

 

o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number 001-33307

 

RadNet, Inc.

(Exact name of registrant as specified in charter)

 

Delaware 13-3326724

(State or other jurisdiction of

Incorporation or organization)

(I.R.S. Employer

Identification No.)

   
   
1510 Cotner Avenue  
Los Angeles, California 90025
(Address of principal executive offices) (Zip Code)

 

(310) 478-7808

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

       
Large accelerated filer o Accelerated filer x Non-accelerated filer o Smaller reporting company o
    (do not check if a smaller reporting company)  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o No x

 

The number of shares of the registrant’s common stock outstanding on August 7, 2015 was 44,466,338 shares.

 

 
 

 

RADNET, INC.

 

Table of Contents

 

 

  Page
   
PART I – FINANCIAL INFORMATION  
   
ITEM 1.  Condensed Consolidated Financial Statements (unaudited) 3
   
Condensed Consolidated Balance Sheets at June 30, 2015 and December 31, 2014 3
   
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2015 and 2014 4
   
Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2015 and 2014 5
   
Condensed Consolidated Statement of Stockholders’ Equity for the Six Months Ended June 30, 2015 6
   
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2015 and 2014 7
   
Notes to Condensed Consolidated Financial Statements 9
   
ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
   
ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk 37
   
ITEM 4.  Controls and Procedures 37
   
PART II – OTHER INFORMATION  
   
ITEM 1.  Legal Proceedings 38
   
ITEM 1A.  Risk Factors 38
   
ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds 38
   
ITEM 3.  Defaults Upon Senior Securities 38
   
ITEM 4.  Mine Safety Disclosures 38
   
ITEM 5.  Other Information 38
   
ITEM 6.  Exhibits 38
   
SIGNATURES 39
   
INDEX TO EXHIBITS 40

 

2
 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1.  Condensed Consolidated Financial Statements (unaudited)

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)

 

   June 30,   December 31, 
   2015   2014 
   (unaudited)     
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $5,319   $307 
Accounts receivable, net   155,964    148,235 
Current portion of deferred tax assets   17,246    17,246 
Due from affiliates   5,153    1,561 
Prepaid expenses and other current assets   28,528    24,671 
Assets held for sale   31,179     
Total current assets   243,389    192,020 
PROPERTY AND EQUIPMENT, NET   225,867    223,127 
OTHER ASSETS          
Goodwill   196,672    200,304 
Other intangible assets   46,000    47,624 
Deferred financing costs, net of current portion   4,893    6,122 
Investment in joint ventures   30,502    32,123 
Deferred tax assets, net of current portion   37,188    35,334 
Deposits and other   3,992    4,026 
Total assets  $788,503   $740,680 
LIABILITIES AND EQUITY          
CURRENT LIABILITIES          
Accounts payable, accrued expenses and other  $94,078   $97,816 
Due to affiliates   729    6,289 
Deferred revenue   1,400    1,964 
Current portion of notes payable   23,666    19,468 
Current portion of deferred rent   2,206    2,100 
Current portion of obligations under capital leases   6,256    5,637 
Total current liabilities   128,335    133,274 
LONG-TERM LIABILITIES          
Deferred rent, net of current portion   25,461    20,965 
Line of credit       15,300 
Notes payable, net of current portion   612,399    551,059 
Obligations under capital lease, net of current portion   4,329    6,143 
Other non-current liabilities   5,795    6,241 
Total liabilities   776,319    732,982 
EQUITY          
RadNet, Inc. stockholders' equity:          
Common stock - $.0001 par value, 200,000,000 shares authorized; 44,409,449, and 42,825,676 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively   4    4 
Paid-in-capital   183,803    177,750 
Accumulated other comprehensive loss   (153)   (112)
Accumulated deficit   (173,439)   (172,280)
Total RadNet, Inc.'s stockholders' equity   10,215    5,362 
Noncontrolling interests   1,969    2,336 
Total equity   12,184    7,698 
Total liabilities and equity  $788,503   $740,680 

 

The accompanying notes are an integral part of these financial statements.

 

3
 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS EXCEPT SHARE DATA)

(unaudited)

 

  Three Months Ended   Six Months Ended 
  June 30,   June 30, 
   2015   2014   2015   2014 
NET REVENUE                    
Service fee revenue, net of contractual allowances and discounts  $188,403   $168,675   $353,433   $327,438 
Provision for bad debts   (8,387)   (7,520)   (15,862)   (14,413)
Net service fee revenue   180,016    161,155    337,571    313,025 
Revenue under capitation arrangements   24,273    17,927    47,985    34,933 
Total net revenue   204,289    179,082    385,556    347,958 
OPERATING EXPENSES                    
Cost of operations, excluding depreciation and amortization   175,796    147,808    344,717    292,838 
Depreciation and amortization   14,941    15,199    29,235    30,770 
Loss on sale and disposal of equipment   74    46    36    292 
Severance costs   94    383    130    864 
Total operating expenses   190,905    163,436    374,118    324,764 
                     
INCOME FROM OPERATIONS   13,384    15,646    11,438    23,194 
                     
OTHER INCOME AND EXPENSES                    
Interest expense   10,423    10,336    20,419    22,108 
Meaningful use incentive           (3,270)   (1,762)
Equity in earnings of joint ventures   (3,207)   (1,646)   (4,309)   (2,713)
Loss on early extinguishment of Senior Notes       471        15,927 
Other expenses (income)   413    (4)   410    (2)
Total other expenses   7,629    9,157    13,250    33,558 
                     
INCOME (LOSS) BEFORE INCOME TAXES   5,755    6,489    (1,812)   (10,364)
(Provision for) benefit from income taxes   (2,192)   (1,233)   899    3,245 
                     
NET INCOME (LOSS)   3,563    5,256    (913)   (7,119)
Net income attributable to noncontrolling interests   168    112    246    161 
                     
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS  $3,395   $5,144   $(1,159)  $(7,280)
                     
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS  $0.08   $0.13   $(0.03)  $(0.18)
                     
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS  $0.08   $0.12   $(0.03)  $(0.18)
                     
WEIGHTED AVERAGE SHARES OUTSTANDING                    
Basic   43,370,024    40,817,333    43,059,686    40,413,863 
Diluted   44,685,599    43,262,995    43,059,686    40,413,863 

 

The accompanying notes are an integral part of these financial statements.

 

4
 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(IN THOUSANDS)

(unaudited)

 

  Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2015   2014   2015   2014 
NET INCOME (LOSS)  $3,563   $5,256   $(913)  $(7,119)
Foreign currency translation adjustments   (4)   (1)   (41)   (19)
                     
COMPREHENSIVE INCOME (LOSS)   3,559    5,255    (954)   (7,138)
Less comprehensive income attributable to non-controlling interests   168    112    246    161 
                     
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS  $3,391   $5,143   $(1,200)  $(7,299)

 

The accompanying notes are an integral part of these financial statements.

 

5
 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

(IN THOUSANDS EXCEPT SHARE DATA)

(unaudited)

 

   Common Stock   Paid-in   Accumulated   Accumulated
Other Comprehensive
   Total Radnet, Inc.'s    Non- controlling   Total 
   Shares   Amount   Capital   Deficit   Loss   Equity   Interests   Equity 
BALANCE - JANUARY 1, 2015   42,825,676   $     4   $177,750   $(172,280)  $      (112)  $5,362   $2,336   $7,698 
Issuance of common stock upon exercise of options   719,350        594            594        594 
Stock-based compensation           5,459            5,459        5,459 
Issuance of restricted stock and other awards   864,423                             
Distributions paid to noncontrolling interests                           (613)   (613)
Change in cumulative foreign currency translation adjustment                   (41)   (41)       (41)
Net (loss) income               (1,159)       (1,159)   246    (913)
BALANCE - JUNE 30, 2015   44,409,449   $4   $183,803   $(173,439)  $(153)  $10,215   $1,969   $12,184 

The accompanying notes are an integral part of these financial statements.

 

6
 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(unaudited)

 

   Six Months Ended June 30, 
   2015   2014 
CASH FLOWS FROM OPERATING ACTIVITIES           
Net loss  $(913)  $(7,119)
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation and amortization   29,235    30,770 
Provision for bad debts   15,862    14,413 
Equity in earnings of joint ventures   (4,309)   (2,713)
Distributions from joint ventures   6,195    5,041 
Amortization and write off of deferred financing costs and loan discount   2,631    3,156 
Loss on sale and disposal of equipment   36   292 
Loss on early extinguishment of Senior Notes       15,927 
Stock-based compensation   5,571    1,636 
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:          
Accounts receivable   (19,368)   (27,361)
Other current assets   (3,058)   (2,877)
Other assets   (3,687)   55 
Deferred taxes   (1,854)   (4,117)
Deferred rent   4,602    420 
Deferred revenue   (564)   132 
Accounts payable , accrued expenses and other   (2,423)   (7,977)
Net cash provided by operating activities   27,956    19,678 
           
CASH FLOWS FROM INVESTING ACTIVITIES           
Purchase of imaging facilities   (34,407)   (1,811)
Purchase of property and equipment   (31,649)   (26,798)
Proceeds from sale of equipment   205    4 
Equity contributions in existing and purchase of interest in joint ventures   (265)   (900)
Net cash used in investing activities   (66,116)   (29,505)
           
CASH FLOWS FROM FINANCING ACTIVITIES           
Principal payments on notes and leases payable   (3,969)   (9,368)
Proceeds from borrowings   74,401    205,737 
Payments on Term Loan Debt/Senior Notes   (11,369)   (211,344)
Deferred financing costs   (531)   (2,387)
Net proceeds on revolving credit facility   (15,300)   18,980 
Distributions paid to noncontrolling interests   (613)   (139)
Proceeds from issuance of common stock upon exercise of options/warrants   594    786 
Net cash provided by financing activities   43,213    2,265 
           
EFFECT OF EXCHANGE RATE CHANGES ON CASH    (41)   (19)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS    5,012    (7,581)
CASH AND CASH EQUIVALENTS, beginning of period    307    8,412 
CASH AND CASH EQUIVALENTS, end of period   $5,319   $831 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION           
Cash paid during the period for interest  $18,283   $23,464 

 

The accompanying notes are an integral part of these financial statements.

 

7
 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(unaudited)

 

Supplemental Schedule of Non-Cash Investing and Financing Activities

 

We acquired equipment and certain leasehold improvements for approximately $10.8 million and $13.8 million during the six months ended June 30, 2015 and 2014, respectively, which were not paid for as of June 30, 2015 and 2014, respectively. The offsetting amounts due were recorded in our consolidated balance sheet under accounts payable, accrued expenses and other. 

 

Detail of non-cash investing activities related to acquisitions can be found in Note 2.

 

8
 

 

RADNET, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

 

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. At June 30, 2015 we operated directly or indirectly through joint ventures, 276 imaging centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York.  Our operations comprise a single segment for financial reporting purposes.

 

The condensed consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). The condensed consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

 

Accounting Standards Codification (“ASC”) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

 

Howard G. Berger, M.D. is our President and Chief Executive Officer, and Chairman of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which is 99% or 100% owned by Dr. Berger.

 

We contract with seven medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Four of these groups are owned by John V Crues, III, M.D., RadNet’s Medical Director, a member of our Board of Directors and a 1% owner of BRMG.  Dr. Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities. 

 

RadNet provides non-medical, technical and administrative services to BRMG and the seven medical groups mentioned above (“NY Groups”) for which it receives a management fee, pursuant to the related management agreements. Through these management agreements we have exclusive authority over all non-medical decision-making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. These management agreements are designed such that all net cash flows of both BRMG and the NY Groups are transferred to us.

 

We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue, expenses, assets and liabilities of each such entity.  These VIE’s on a combined basis recognized $28.2 million and $21.4 million of revenue, net of management service fees to RadNet for the three months ended June 30, 2015 and 2014, respectively, and $28.2 million and $21.4 million of operating expenses for the three months ended June 30, 2015 and 2014, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations $114.9 million and $92.6 million of total billed net service fee revenue relating to these VIE’s for the three months ended June 30, 2015 and 2014, respectively, of which $86.7 million and $71.2 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the three months ended June 30, 2015 and 2014, respectively.

 

9
 

 

These VIE’s on a combined basis recognized $53.7 million and $42.0 million of revenue, net of management service fees to RadNet for the six months ended June 30, 2015 and 2014, respectively, and $53.7 million and $42.0 million of operating expenses for the six months ended June 30, 2015 and 2014, respectively. RadNet recognized in its condensed consolidated statement of operations $213.9 million and $181.6 million of total billed net service fee revenue relating to these VIE’s for the six months ended June 30, 2015 and 2014, respectively, of which $160.2 million and $139.6 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the six months ended June 30, 2015 and 2014, respectively.

 

The cash flows of these VIE’s are included in the accompanying consolidated statements of cash flows.  All intercompany balances and transactions have been eliminated in consolidation.  In our consolidated balance sheets at June 30, 2015 and December 31, 2014, we have included approximately $89.7 million and $79.7 million, respectively, of accounts receivable and approximately $9.1 million and $9.0 million, respectively, of accounts payable and accrued liabilities, related to these VIE’s combined.

 

The creditors of each of these VIE’s do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of any of these VIE’s. However, because of the relationship RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

 

At all of our centers, aside from certain centers in California and centers in New York City where we contract with BRMG and the NY Groups for the provision of professional medical services, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee intended to compensate us for the fair market value of our services which in some instances may be based on the practice group’s professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.  We have no financial controlling interest in the independent (non-BRMG or non-NY Groups) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2014, filed on March 16, 2015, as amended.

 

Significant Accounting Policies

 

During the period covered in this report, there have been no material changes to the significant accounting policies we use, and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended. The information below is intended only to supplement the disclosure in our annual report.

 

Revenues

 

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to centers affiliated with both BRMG and the NY Entity, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Entity as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Entity. As it relates to non-BRMG and NY Entity centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG and NY Entity centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

 

10
 

 

Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payors.

 

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

 

Our revenue, net of contractual allowances, discounts and provision for bad debts for the three and six months ended June 30, 2015 and 2014 is summarized in the following table (in thousands):

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
                 
Commercial insurance  $117,107   $104,901   $216,872   $204,977 
Medicare   42,088    39,412    79,172    77,317 
Medicaid   5,974    6,230    11,469    12,049 
Workers' compensation/personal injury   8,130    7,853    15,559    15,034 
Other   15,104    10,279    30,361    18,061 
Service fee revenue, net of contractual allowances and discounts   188,403    168,675    353,433    327,438 
Provision for bad debts   (8,387)   (7,520)   (15,862)   (14,413)
Net service fee revenue   180,016    161,155    337,571    313,025 
Revenue under capitation arrangements   24,273    17,927    47,985    34,933 
Total net revenue  $204,289   $179,082   $385,556   $347,958 

 

Provision for Bad Debts

 

We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

 

Deferred Tax Assets

 

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.

 

Deferred Financing Costs

 

Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method.

 

11
 

 

Meaningful Use Incentive

 

Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software will be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. Once an attestation is accepted by Medicare, payments will be made in four to eight weeks to the same taxpayer identification number and through the same channels as their claims payments are made. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $3.3 million and $1.8 million during the six months ended June 30, 2015, and 2014, respectively, relating to this incentive.

 

Liquidity and Capital Resources

 

We had cash and cash equivalents of $5.3 million and accounts receivable of $156.0 million at June 30, 2015, compared to cash and cash equivalents of $307,000 and accounts receivable of $148.2 million at December 31, 2014. We had a working capital balance of $115.1 million and $58.7 million at June 30, 2015 and December 31, 2014, respectively. We had net income attributable to RadNet, Inc. common stockholders for the three months ended June 30, 2015 and 2014 of $3.4 million and $5.1 million respectively, and net loss attributable to RadNet, Inc common stockholders for the six months ended June 30, 2015 and 2014 of $1.2 million and $7.3 million, respectively. We had stockholders’ equity of $10.2 million and $5.4 million at June 30, 2015 and December 31, 2014, respectively.

 

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment.  Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

 

Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

 

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

 

We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.

 

Included in our condensed consolidated balance sheet at June 30, 2015 is $632.3 million of senior secured term loan debt (net of unamortized discounts of $11.1 million), broken down by loan agreement as follows (in thousands):

 

   As of June 30, 2015 
   Face Value   Discount   Total Carrying Value 
First Lien Term Loans  $389,367   $(8,061)  $381,306 
2015 Incremental First   74,013    (570)   73,443 
Second Lien Term Loans   180,000    (2,451)   177,549 
Total  $643,380   $(11,082)  $632,298 

 

Our revolving credit facility had a $0 aggregate principal amount outstanding as of June 30, 2015.

 

As of June 30, 2015, we were in compliance with all financial covenants under our Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan, and the Second Lien Credit Agreement, each as defined below.

 

12
 

 

2015 Incremental First Lien Term Loan:

 

On April 30, 2015, we entered into a joinder agreement to our existing Credit Agreement (the "2015 Incremental First Lien Term Loan Joinder") to provide for the borrowing of $75.0 million of incremental first lien term loans (“2015 Incremental First Lien Term Loans”). The 2015 Incremental First Lien Term Loans are treated as part of the same class as the existing tranche B term loans currently outstanding under the Credit Agreement. We used the proceeds from the 2015 Incremental First Lien Term Loans to repay all of the borrowings outstanding under the first lien revolving loan facility and to pay approximately $1.1 million of fees and expenses associated with the transaction.

 

Interest. The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.

 

Maturity Date. The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.

 

2014 Amendment to the Credit Agreement and Second Lien Credit Agreement:

 

On March 25, 2014, Radnet Management simultaneously entered into two agreements which resulted in the creation of a direct financial obligation as follows:

 

2014 Amendment of the Credit Agreement. Radnet Management amended that certain Credit and Guaranty Agreement dated October 10, 2012 (the “Original Credit Agreement”), by that certain first amendment dated April 3, 2013 (the “2013 Amendment”), and subsequently by entering into a second amendment dated on March 25, 2014 (the “2014 Amendment”) ( the Original Credit Agreement, as amended by the 2013 Amendment and the 2014 Amendment is collectively referred to herein as the "Credit Agreement") to provide for, among other things, the borrowing by Radnet Management of $30.0 million of additional first lien term loans (the “2014 First Lien Term Loans”).

 

The 2014 Amendment provides for the following:

 

Interest. The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015.

 

Guarantees and Collateral. The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, are guaranteed by RadNet, Inc., all of our current and future domestic subsidiaries and certain of our affiliates (other than certain excluded foreign subsidiaries). The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, and the guarantees are secured by a perfected first priority security interest (subject to certain permitted exceptions) in substantially all of our tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

 

Restrictive Covenants. In addition to certain covenants, the Credit Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

 

13
 

 

Financial Covenants. The Credit Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.

 

Events of Default. In addition to certain customary events of default, events of default under the Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, within five days after the due date, failure of any loan party to comply with any covenant or agreement in the loan documents (subject to applicable grace periods and/or notice requirement), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Second Lien Credit and Guaranty Agreement. Radnet Management entered into a Second Lien Credit and Guaranty Agreement dated March 25, 2014 (the “Second Lien Credit Agreement”) to provide for, among other things, the borrowing by Radnet Management of $180.0 million of second lien term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans and the 2014 First Lien Term Loans were used to redeem the outstanding senior notes, as more fully described below under the heading “Senior Notes”, to pay the expenses related to the transaction and for general corporate purposes.

  

The Second Lien Credit Agreement provides for the following:

 

Interest. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.

 

Payments. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.

 

Termination. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.

 

Restrictive Covenants. In addition to certain covenants, the Second Lien Credit Agreement places limits on our ability declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transaction, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

 

Events of Default. In addition to certain events of default, events of default under the Second Lien Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Second Lien Term Loans within five days after the due date, failure of any loan party to comply with any covenant or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Second Lien Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Revolving Credit Facility

 

The $101.25 million revolving credit line established in the Credit Agreement was unaltered by the agreements above and remains in place. The termination date for the $101.25 million revolving credit facility is the earliest to occur of (i) October 10, 2017, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Credit Agreement, which addresses voluntary commitment reductions and (iii) the date of the termination of the revolving credit facility due to specific events of default pursuant to section 8.01 of the Credit Agreement. The revolving credit line bears interest based on types of borrowings as follows: (i) unpaid principal at the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 4.25% per annum or the Base Rate (as defined in the Credit Agreement) plus 3.25% per annum, (ii) letter of credit and fronting fees at 4.5% per annum, and (iii) commitment fee of 0.5% per annum on the unused revolver balance. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.

 

14
 

 

Senior Notes

 

On April 6, 2010, we issued and sold $200 million of 10 3/8% senior unsecured notes due 2018 at a price of 98.680% (the “senior notes”). All payments of the senior notes, including principal and interest, were guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc., and all of Radnet Management’s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture dated April 6, 2010 (the “Indenture”), by and among Radnet Management, Inc., as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee. We paid interest on the senior notes on April 1 and October 1 of each year, commencing October 1, 2010, and they were scheduled to expire on April 1, 2018.

 

We completed the retirement of our $200 million in senior notes on April 24, 2014 and following such retirement we completed the satisfaction and discharge of the Indenture. The transactions leading to the retirement of the senior notes are described below:

 

Tender Offer. On March 7, 2014, we commenced a tender offer to purchase for cash any and all outstanding senior notes. In connection with the tender offer, we also commenced a consent solicitation to amend the Indenture to eliminate or modify certain restrictive covenants. On March 25, 2014, we made a payment in cash for all senior notes tendered prior to 5:00 P.M., New York City time, on March 20, 2014 (the “Consent Payment Deadline”). As of the Consent Payment Deadline, we received tenders and consents in respect of $193,464,000 aggregate principal amount of the senior notes, representing 96.73% of the outstanding senior notes, all of which were accepted for purchase. The total consideration for each $1,000 principal amount of senior notes validly tendered and not withdrawn at or prior to the Consent Payment Deadline and accepted for purchase was $1,056.88, which amount included a consent payment (the “Consent Payment”) of $30.00 per $1,000 principal amount of senior notes. In addition, all senior notes accepted for payment received accrued and unpaid interest in respect of such notes from the last interest payment date prior to the applicable settlement date to, but not including, the applicable settlement date. The tender offer expired on April 3, 2014 and between the Consent Payment Deadline and the expiration of the tender offer, no additional senior notes were tendered. With a net carrying amount including discount and unamortized issue costs of $189.2 million, a loss on early extinguishment of debt of $15.5 million was recorded in the first quarter of 2014.

 

Exercise of Optional Redemption on March 25, 2014. On March 25, 2014, we called for redemption of all of our remaining outstanding senior notes not purchased prior to the expiration of the tender offer described above, with a redemption date of April 24, 2014 (the “Redemption Date”). Upon redemption on April 24, 2014, the holders of the senior notes being redeemed received a redemption price equal to 105.188% of the outstanding principal amount of the senior notes being redeemed (or $1,051.88 per $1,000 in principal amount of the senior notes) in accordance with the terms of the Indenture, or approximately $6.9 million in total, including approximately $43,000 of accrued and unpaid interest up to, but excluding the Redemption Date.  As of that date, we completed the satisfaction and discharge of the Indenture in accordance with its terms and no senior notes remained outstanding.  With a net carrying amount including discount and unamortized issue costs of $6.4 million, a loss on early extinguishment of debt of $471,000 was recorded in the second quarter of 2014.

 

NOTE 2 – ASSETS HELD FOR SALE

 

On August 7, 2015 we announced a proposed expansion of our existing New Jersey Imaging Networks (“NJIN”) joint venture, which includes NJIN’s acquisition of all of RadNet’s 10 wholly owned New Jersey imaging centers and one center owned by Barnabas Health.

Under the terms of the purchase agreement, which is subject to customary conditions to closing, including the approval of certain New Jersey state licensure bodies, third party consents and consummation of acquisition financing and is expected to close in the third quarter, NJIN will pay RadNet a purchase price of $35.5 million.

The company committed to the board approved plan for such sale prior to June 30, 2015. As such, the following assets are presented as assets held for sale as of June 30, 2015 (in thousands):

 

Property and equipment, net  $11,428 
Goodwill   18,833 
Intangible assets   755 
Other assets   163 
Total assets held for sale  $31,179 

 

15
 

 

NOTE 3 – FACILITY ACQUISITIONS

 

On April 15, 2015 we completed our acquisition of New York Radiology Partners (“NYRP”), consisting of eleven multi-modality imaging centers located in Manhattan, New York for cash consideration of $29.8 million and a note to seller of $1.5 million. The facilities provide a full range of radiology services including MRI, PET/CT, Mammography, Ultrasound, X-ray and other related services. We have made a preliminary fair value determination of the acquired assets and assumed liabilities. In total, RadNet acquired assets of $34.5 million, assumed equipment debt of $2.3 million, and assumed current liabilities of $891,000. Asset amounts acquired were $4.6 million in equipment, $12.0 million in leasehold improvements, $12.9 million in goodwill, $600,000 of other intangible assets, and $4.4 million of accounts receivable and other current assets. Current liabilities assumed related to accounts payable, payroll and other related short term obligations. Our preliminary fair value determination will be made final with the help of an outside valuation expert which we expect to have completed by the end of our third quarter of 2015.

 

On May 1, 2015 we completed our acquisition of California Radiology consisting of six multi-modality imaging centers located in Los Angeles, California for cash consideration of $4.2 million. The facilities provide MRI, PET/CT, Ultrasound and X-ray services. We have made a fair value determination of the acquired assets and approximately $217,000 of equipment, $1.7 million of leasehold improvements, $34,000 in other assets, $100,000 of other intangible assets relating to a covenant not to compete contract and $2.1 million of goodwill were recorded with respect to this transaction.

 

On June 1, 2015 we completed our acquisition of Healthcare Radiology and Diagnostic systems, PLLC, consisting of a single multi-modality imaging center located in the Bronx, NY area for cash consideration of $425,000. The facility provides MRI, CT, Ultrasound and X-ray services. We have made a fair value determination of net assets and approximately $134,500 of fixed assets and $290,500 of leasehold improvements were recorded.

 

NOTE 4 – NEW ACCOUNTING STANDARDS

 

In April 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2015-03 (“ASU 2015-03”), Interest – Imputation of Interest, (Subtopic 835-30). ASU 2015-03 changes the accounting method for debt issuance costs from a deferred charge (i.e. an asset) to a contra liability in part because such costs provide no future economic benefit. Debt issue costs related to a recognized debt liability are to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with the presentation of debt discounts. The update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

In February 2015, the FASB issued ASU No. 2015-02 (“ASU 2015-02”), Consolidation – Amendments to the Consolidation Analysis, (Topic 810). ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The update was effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which has recently been extended to December 31, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

16
 

 

NOTE 5 – EARNINGS PER SHARE

 

Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
Net income (loss) attributable to RadNet, Inc.'s common stockholders  $3,395   $5,144   $(1,159)  $(7,280)
                     
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS                    
Weighted average number of common shares outstanding during the period   43,370,024    40,817,333    43,059,686    40,413,863 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders  $0.08   $0.13   $(0.03)  $(0.18)
                     
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS                    
Weighted average number of common shares outstanding during the period   43,370,024    40,817,333    43,059,686    40,413,863 
Add nonvested restricted stock subject only to service vesting   897,892    1,019,930         
Add additional shares issuable upon exercise of stock options and warrants   417,683    1,425,732         
Weighted average number of common shares used in calculating diluted net income per share   44,685,599    43,262,995    43,059,686    40,413,863 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders  $0.08   $0.12   $(0.03)  $(0.18)

 

For the six months ended June 30, 2015 and 2014 we excluded all outstanding options and restricted stock awards in the calculation of diluted earnings per share because their effect would be antidilutive.

 

NOTE 6 – INVESTMENT IN JOINT VENTURES

 

We have ten unconsolidated joint ventures where our ownership interests range from 35% to 50%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method.

 

The following table is a roll forward of our investment in joint ventures during the six months ended June 30, 2015 (in thousands):

 

Balance as of December 31, 2014  $32,123 
Equity in earnings in these joint ventures   4,309 
Distribution of earnings   (6,195)
Equity contributions in existing joint ventures   265 
Balance as of June 30, 2015  $30,502 

 

We earned management service fees from the centers underlying these joint ventures of approximately $1.4 million and $2.2 million for the three months ended June 30, 2015 and 2014, respectively, and $3.8 million and $4.6 million for the six months ended June 30, 2015 and 2014, respectively. At the end of the period we eliminate from total fees recorded the uncollected portion of these fees that are associated with our ownership interests and offset this with an increase to our equity earnings.

 

17
 

 

The following table is a summary of key financial data for these joint ventures as of June 30, 2015 (in thousands) and for the six months ended June 30, 2015 and 2014 (in thousands):

 

Balance Sheet Data:  June 30, 2015 
Current assets  $18,987 
Noncurrent assets   48,583 
Current liabilities   (8,501)
Noncurrent liabilities   (5,144)
Total net assets  $53,925 
      
Book value of RadNet joint venture interests  $25,532 
Cost in excess of book value of acquired joint venture interests   4,970 
Total value of Radnet joint venture interests  $30,502 
      
Total book value of other joint venture partner interests  $28,393 

 

Income statement data for the six months ended June 30,  2015   2014 
Net revenue  $56,639   $48,835 
Net income  $9,476   $5,738 

 

NOTE 7 – STOCK-BASED COMPENSATION

 

Equity Incentive Plans

 

Options

 

We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we amended and restated as of April 20, 2015 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 11, 2015. As of June 30, 2015, we have reserved for issuance under the Restated Plan 12,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over two to five years and expire five to ten years from the date of grant.

 

As of June 30, 2015, we had outstanding options to acquire 1,130,009 shares of our Common Stock, of which options to acquire 1,086,676 shares were exercisable. During the six months ended June 30, 2015, we did not grant any stock options under our Restated Plan.

 

The following summarizes all of our stock option transactions during the six months ended June 30, 2015:

 

       Weighted Average   Weighted Average Remaining     
       Exercise price   Contractual   Aggregate 
Outstanding Options      Per Common   Life   Intrinsic  
Under the Restated Plan  Shares   Share   (in years)   Value 
                 
Balance, December 31, 2014   2,092,509   $3.58           
Granted                  
Exercised   (937,500)   2.66           
Canceled, forfeited or expired   (25,000)   2.22           
Balance, June 30, 2015   1,130,009    4.36    1.20   $3,216,338 
Exercisable at June 30, 2015   1,086,676    4.46    1.11    3,014,838 

 

Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on June 30, 2015 and the exercise price, multiplied by the number of in-the-money options ) that would have been received by the holder had all holders exercised their options on June 30, 2015. Total intrinsic value of options exercised during the six months ended June 30, 2015 and 2014 was approximately $5.4 million and $5.9 million, respectively. As of June 30, 2015, total unrecognized stock-based compensation expense related to non-vested options was $25,000, which is expected to be recognized over a weighted average period of approximately 1.4 years.

 

18
 

 

Restricted Stock Awards

 

The Restated Plan permits the issuance of restricted stock awards (“RSA’s”). As of June 30, 2015, we have issued a total of 3,441,208 RSA’s, of which 2,600,013 RSA’s have previously vested and 841,195 RSA’s remained unvested at June 30, 2015.

 

The following summarizes all unvested RSA activities during the six months ended June 30, 2015:

 

      

Weighted-

Average

     
       Remaining   Weighted- 
       Contractual   Average 
   Shares   Term (Years)   Fair Value 
RSA's outstanding at December 31, 2014   942,023        $     1.96 
Changes during the period               
Granted   724,423        $8.66 
Vested   (825,252)       $4.45 
RSA's outstanding at June 30, 2015   841,195    0.92   $5.28 

 

We determine the fair value of all RSA’s based on the closing price of our common stock on the date of award.

 

In sum, of the 12,000,000 shares of common stock reserved for issuance under the Restated Plan, at June 30, 2015, we had 3,441,208 RSA’s (of which 841,195 shares were subject to further vesting), outstanding options to acquire 1,130,009 shares, and 3,915,042 shares of common stock available for future awards. We had previously granted options and other awards to acquire 3,513,741 shares which have been issued.

 

NOTE 8 – FAIR VALUE MEASUREMENTS

 

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

 

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

 

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

 

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

 

19
 

 

The table below summarizes the estimated fair value of our long-term debt as follows (in thousands):

 

   As of June 30, 2015 
   Level 1   Level 2   Level 3   Total Fair Value   Total Face Value 
First Lien Term Loans  $    –   $388,880   $    –   $388,880   $389,367 
2015 Incremental First       73,920        73,920    74,013 
Second Lien Term Loans       176,400   $    176,400    180,000 

 

   As of December 31, 2014 
   Level 1   Level 2   Level 3   Total   Total Face Value 
First Lien Term Loans  $    –   $394,753   $    –   $394,753   $399,750 
Second Lien Term Loans       178,200        178,200    180,000 

 

The carrying value of our revolving credit facility at December 31, 2014 of $15.3 million, respectively, approximated its fair value. There was no revolving credit facility balance at June 30, 2015.

 

We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.

 

NOTE 9 – SUBSEQUENT EVENTS

 

On August 3, 2015 we sold a 25% interest in two of our wholly owned multi-modality imaging centers located in Owings Mills and Baltimore, Maryland for approximately $5.0 million to Lifebridge Health, Inc. (“Lifebridge”). This transaction resulted in the formation of a partnership with Lifebridge under the name of Baltimore county Radiology, LLC.

 

20
 

 

ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this quarterly report.

 

Forward-Looking Statements

 

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.

 

In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Statements in this quarterly report concerning our ability to successfully acquire and integrate new operations, to grow our business, our expectations for further trends in revenue or expenses, our future cost saving efforts, our increased business from new equipment or operations and our ability to finance our operations and repay our outstanding indebtedness, including our increased amortization payments, are forward-looking statements.  

 

The factors included in “Risk Factors,” in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended or supplemented by the information, in Part II – Item 1A below, among others, could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. These forward-looking statements speak only as of the date when they are made. Except as required under the federal securities laws or by the rules and regulations of the Securities and Exchange Commission, we do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of those statements. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by the forward-looking statements contained in this quarterly report.

 

Overview

 

We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. At June 30, 2015 we operated directly or indirectly through joint ventures, 276 imaging centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York.  Our operations comprise a single segment for financial reporting purposes.

 

We seek to develop leading positions in regional markets in order to leverage operational efficiencies. Our scale and density within selected geographies provides close, long-term relationships with key payors, radiology groups and referring physicians. Each of our facility managers is responsible for managing relationships with local physicians and payors, meeting our standards of patient service and maintaining profitability. We provide corporate training programs, standardized policies and procedures and sharing of best practices among the physicians in our regional networks.

 

We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities. For the six months ended June 30, 2015 and 2014, we performed 2,603,777 and 2,382,108 diagnostic imaging procedures, respectively, and generated total net revenue of $385.6 million and $348.0 million, respectively.

 

The condensed consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). The condensed consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management.  All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

 

Accounting Standards Codification (“ASC”) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

 

21
 

 

Howard G. Berger, M.D. is our President and Chief Executive Officer, and Chairman of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which is 99% or 100% owned by Dr. Berger.  

 

We contract with seven medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Four of these groups are owned by John V Crues, III, M.D., RadNet’s Medical Director, a member of our Board of Directors and a 1% owner of BRMG.  Dr. Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities. 

 

RadNet provides non-medical, technical and administrative services to BRMG and the seven medical groups mentioned above (“NY Groups”) for which it receives a management fee, pursuant to the related management agreements. Through these management agreements we have exclusive authority over all non-medical decision-making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. These management agreements are designed such that all net cash flows of both BRMG and the NY Groups are transferred to us.

 

We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue, expenses, assets and liabilities of each such entity.  These VIE’s on a combined basis recognized $28.2 million and $21.4 million of revenue, net of management service fees to RadNet for the three months ended June 30, 2015 and 2014, respectively, and $28.2 million and $21.4 million of operating expenses for the three months ended June 30, 2015 and 2014, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations $114.9 million and $92.6 million of total billed net service fee revenue relating to these VIE’s for the three months ended June 30, 2015 and 2014, respectively, of which $86.7 million and $71.2 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the three months ended June 30, 2015 and 2014, respectively.

 

These VIE’s on a combined basis recognized $53.7 million and $42.0 million of revenue, net of management service fees to RadNet for the six months ended June 30, 2015 and 2014, respectively, and $53.7 million and $42.0 million of operating expenses for the six months ended June 30, 2015 and 2014, respectively. RadNet recognized in its condensed consolidated statement of operations $213.9 million and $181.6 million of total billed net service fee revenue relating to these VIE’s for the six months ended June 30, 2015 and 2014, respectively, of which $160.2 million and $139.6 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the six months ended June 30, 2015 and 2014, respectively.

 

The cash flows of these VIE’s are included in the accompanying consolidated statements of cash flows.  All intercompany balances and transactions have been eliminated in consolidation.  In our consolidated balance sheets at June 30, 2015 and December 31, 2014, we have included approximately $89.7 million and $79.7 million, respectively, of accounts receivable and approximately $9.1 million and $9.0 million, respectively, of accounts payable and accrued liabilities, related to these VIE’s combined.

 

The creditors of each of these VIE’s do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of any of these VIE’s. However, because of the relationship, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

 

At all of our centers, aside from certain centers in California and certain centers in New York City where we contract with BRMG and the NY Groups for the provision of professional medical services, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee intended to compensate us for the fair market value of our services which in some instances may be based on the practice group’s professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.  We have no financial controlling interest in the independent (non-BRMG or non-NY Groups) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

 

22
 

 

We typically experience some seasonality to our business. During the first quarter of each year we generally experience the lowest volumes of procedures and the lowest level of revenue for any quarter during the year.  This is primarily the result of two factors.  First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations.  It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures.  Second, in recent years, we have observed greater participation in high deductible health plans by patients.  As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures.

 

Critical Accounting Policies

 

The Securities and Exchange Commission defines critical accounting estimates as those that are both most important to the portrayal of a company’s financial condition and results of operations and require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to our consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2014, as amended, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below.

 

Use of Estimates

 

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements that were prepared in accordance with U.S. generally accepted accounting principles, or GAAP.  Management makes estimates and assumptions when preparing financial statements.  These estimates and assumptions affect various matters, including:

 

  · our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements;

 

  · our disclosure of contingent assets and liabilities at the dates of the financial statements; and

 

  · our reported amounts of net revenue and expenses in our consolidated statements of operations during the reporting periods.

 

These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could differ materially from these estimates.

 

During the period covered in this report, there were no material changes to the critical accounting estimates we use, and have described in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended.

 

Revenues

 

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to centers affiliated with both BRMG and the NY Entity, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Entity as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Entity. As it relates to non-BRMG and NY Entity centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG and NY Entity centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

 

23
 

 

Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payors.

 

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

 

Our revenue, net of contractual allowances, discounts and provision for bad debts for the three and six months ended June 30, 2015 and 2014 is summarized in the following table (in thousands):

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
                 
Commercial insurance  $117,107   $104,901   $216,872   $204,977 
Medicare   42,088    39,412    79,172    77,317 
Medicaid   5,974    6,230    11,469    12,049 
Workers' compensation/personal injury   8,130    7,853    15,559    15,034 
Other   15,104    10,279    30,361    18,061 
Service fee revenue, net of contractual allowances and discounts   188,403    168,675    353,433    327,438 
Provision for bad debts   (8,387)   (7,520)   (15,862)   (14,413)
Net service fee revenue   180,016    161,155    337,571    313,025 
Revenue under capitation arrangements   24,273    17,927    47,985    34,933 
Total net revenue  $204,289   $179,082   $385,556   $347,958 

 

Provision for Bad Debts

 

We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

 

Accounts Receivable

 

Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

 

Depreciation and Amortization of Long-Lived Assets

 

We depreciate our long-lived assets over their estimated economic useful lives with the exception of leasehold improvements where we use the shorter of the assets useful lives or the lease term of the facility for which these assets are associated.

 

24
 

 

Deferred Tax Assets

 

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized. At June 30, 2015, we determined that approximately $54.4 million of our net deferred tax assets are more likely than not to be realized.

 

Valuation of Goodwill and Indefinite Lived Intangibles

 

Goodwill at June 30, 2015 totaled $196.7 million. Indefinite Lived Intangible Assets at June 30, 2015 totaled $6.8 million and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. Management evaluates goodwill and trade name intangibles, at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill, to the fair value of the reporting unit. The fair value of a reporting unit is estimated using a combination of the income or discounted cash flows approach and the market approach, which uses comparable market data. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered impaired and a second step is performed to measure the amount of impairment loss, if any. Impairment of trade name intangibles is tested at the subsidiary level by comparing the subsidiary’s trade name carrying amount to its respective fair value. We tested both goodwill and trade name intangibles for impairment on October 1, 2014, noting no impairment, and have not identified any indicators of impairment through June 30, 2015.

 

Long-Lived Assets

 

We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment whenever indicators of impairment exist. The accounting standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. No indicators of impairment were identified with respect to our long-lived assets as of June 30, 2015.

 

New Accounting Standards

 

In April 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2015-03 (“ASU 2015-03”), Interest – Imputation of Interest, (Subtopic 835-30). ASU 2015-03 changes the accounting method for debt issuance costs from a deferred charge (i.e. an asset) to a contra liability in part because such costs provide no future economic benefit. Debt issue costs related to a recognized debt liability are to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with the presentation of debt discounts. The update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

In February 2015, the FASB issued ASU No. 2015-02 (“ASU 2015-02”), Consolidation – Amendments to the Consolidation Analysis, (Topic 810). ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The update was effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which has recently been extended to December 31, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

25
 

 

Industry Updates

 

On April 16, 2015, the President signed into law the Medicare Access and CHIP Reauthorization Act (H.R. 2), which provides for sweeping changes to how Medicare pays physicians, as well as averts the 21% reduction to Medicare payments under the Medicare Physician Fee Schedule that was scheduled to take effect on April 1, 2016. H.R. 2, among other things, repealed the Sustainable Growth Rate (“SGR”) formula enacted in 1997 and freezes payment rates at their current levels until rates increase by 0.5% for services furnished during the last 6 months of calendar year 2015. For services paid under the physician fee schedule and furnished during calendar years 2016 through 2019, Medicare’s payment rates will increase by 0.5% per year. Fees will remain at the 2019 level through 2025, but high performing providers participating in alternative payment models will have the opportunity for additional payments. Such payments will be based upon quality, resource use, clinical practice improvement activities and meaningful use of electronic health record technology.

 

Results of Operations

 

The following table sets forth, for the periods indicated, the percentage that certain items in the statements of operations bears to revenue, net of contractual allowances and discounts and inclusive of revenue under capitation contracts.

 

RADNET, INC. AND SUBSIDIARIES

(unaudited)

 

  Three Months Ended   Six Months Ended 
  June 30,   June 30, 
   2015   2014   2015   2014 
NET REVENUE                    
Service fee revenue, net of contractual allowances and discounts   88.6%    90.4%    88.0%    90.4% 
Provision for bad debts   -3.9%    -4.0%    -4.0%    -4.0% 
Net service fee revenue   84.6%    86.4%    84.1%    86.4% 
Revenue under capitation arrangements   11.4%    9.6%    12.0%    9.6% 
Total net revenue   96.1%    96.0%    96.0%    96.0% 
                     
OPERATING EXPENSES                    
Cost of operations, excluding depreciation and amortization   82.7%    79.2%    85.9%    80.8% 
Depreciation and amortization   7.0%    8.1%    7.3%    8.5% 
(Gain) loss on sale and disposal of equipment   0.0%    0.0%    0.0%    0.1% 
Severance costs   0.0%    0.2%    0.0%    0.2% 
Total operating expenses   89.8%    87.6%    93.2%    89.6% 
                     
INCOME FROM OPERATIONS   6.3%    8.4%    2.8%    6.4% 
                     
OTHER INCOME AND EXPENSES                    
Interest expense   4.9%    5.5%    5.1%    6.1% 
Meaningful use incentive   0.0%    0.0%    -0.8%    -0.5% 
Equity in earnings of joint ventures   -1.5%    -0.9%    -1.1%    -0.7% 
Loss on early extinguishment of Senior Notes   0.0%    0.3%    0.0%    4.4% 
Other (income) expenses   0.2%    0.0%    0.1%    0.0% 
Total other expenses   3.6%    4.9%    3.3%    9.3% 
                     
INCOME BEFORE INCOME TAXES   2.7%    3.5%    -0.5%    -2.9% 
(Provision for) Benefit From income taxes   -1.0%    -0.7%    0.2%    0.9% 
                     
NET INCOME (LOSS)   1.7%    2.8%    -0.2%    -2.0% 
Net income attributable to noncontrolling interests   0.1%    0.1%    0.1%    0.0% 
                     
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS   1.6%    2.8%    -0.3%    -2.0% 

 

26
 

 

Three Months Ended June 30, 2015 Compared to the Three Months Ended June 30, 2014

 

Service Fee Revenue

 

Service fee revenue for the three months ended June 30, 2015 was $188.4 million compared to $168.7 million for the three months ended June 30, 2014, an increase of $19.7 million, or 11.7%.

 

Service fee revenue, including only those centers which were in operation throughout the second quarters of both 2015 and 2014 experienced a nominal increase of $66,000 or 0% as a result of a decline in reimbursement rates offset by an increase in procedure volumes. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, service fee revenue from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $19.9 million. For the three months ended June 30, 2014, service fee revenue from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $208,000.

 

Provision for Bad Debts

 

Provision for bad debts increased $867,000, or 11.5%, to approximately $8.4 million, or 4.5% of service fee revenue, for the three months ended June 30, 2015 compared to $7.5 million, or 4.5% of service fee revenue, for the three months ended June 30, 2014.

 

Revenue Under Capitation Arrangements

 

Revenue under capitation arrangements for the three months ended June 30, 2015 was $24.3 million compared to $17.9 million for the three months ended June 30, 2014, an increase of $6.3 million or 35.4%.

 

Revenue under capitation arrangements, including only those centers which were in operation throughout the second quarters of both 2015 and 2014 increased $5.6 million, or 31.2%. This 31.2% increase is due to both new and expanded contractual relationships with private insurers. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, revenue under capitation arrangements from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $748,000.

 

Operating Expenses

 

Cost of operations for the three months ended June 30, 2015 increased approximately $28.0 million, or 18.9%, from $147.8 million for the three months ended June 30, 2014 to $175.8 million for the three months ended June 30, 2015. The following table sets forth our cost of operations and total operating expenses for the three months ended June 30, 2015 and 2014 (in thousands):

 

   Three Months Ended June 30, 
   2015   2014 
Salaries and professional reading fees, excluding stock-based compensation  $94,513   $81,667 
Stock-based compensation   2,017    611 
Building and equipment rental   17,606    15,648 
Medical supplies   11,954    10,455 
Other operating expenses *   49,706    39,427 
Cost of operations   175,796    147,808 
           
Depreciation and amortization   14,941    15,199 
(Gain) loss on sale and disposal of equipment   74    46 
Severance costs   94    383 
Total operating expenses  $190,905   $163,436 

 

*     Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses.

 

27
 

 

Salaries and professional reading fees, excluding stock-based compensation and severance

 

Salaries and professional reading fees increased $12.8 million, or 15.7%, to $94.5 million for the three months ended June 30, 2015 compared to $81.7 million for the three months ended June 30, 2014.

 

Salaries and professional reading fees, including only those centers which were in operation throughout the second quarters of both 2015 and 2014, increased $4.9 million, or 6.0%. The 6.0% increase is due to higher procedure volumes as compared to the same period in the prior year. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, salaries and professional reading fees from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $8.0 million. For the three months ended June 30, 2014, salaries and professional reading fees from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $64,000.

 

Stock-based compensation

 

Stock-based compensation increased $1.4 million, or 230.1%, to approximately $2.0 million for the three months ended June 30, 2015 compared to $611,000 for the three months ended June 30, 2014. This increase was driven by the higher fair value of RSA’s awarded and vested in the second quarter of 2015 as compared to RSA’s awarded and vested in the prior year’s second quarter.

  

Building and equipment rental

 

Building and equipment rental expenses increased $2.0 million or 12.5%, to $17.6 million for the three months ended June 30, 2015 compared to $15.6 million for the three months ended June 30, 2014.

 

Building and equipment rental expenses, including only those centers which were in operation throughout the second quarters of both 2015 and 2014, increased $448,000, or 2.9%. This 2.9% increase is mainly related to additional radiology equipment operating leases in support of operations. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, building and equipment rental expenses from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $1.6 million. For the three months ended June 30, 2014, building and equipment rental expenses from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $64,000.

 

Medical supplies

 

Medical supplies expense increased $1.5 million, or 14.3%, to $12.0 million for the three months ended June 30, 2015 compared to $10.5 million for the three months ended June 30, 2014.

 

Medical supplies expenses, including only those centers which were in operation throughout the second quarters of both 2015 and 2014, increased $177,000, or 1.7%. This 1.7% rise is attributable to both increased purchases stemming from higher procedure volumes along with supplier price increases. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, medical supplies expenses from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $1.3 million. For the three months ended June 30, 2014, medical supplies expenses from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $6,000.

 

Other operating expenses

 

Other operating expenses increased $10.3 million, or 26.1%, to $49.7 million for the three months ended June 30, 2015 compared to $39.4 million for the three months ended June 30, 2014.

 

Other operating expenses, including only those centers which were in operation throughout the second quarters of both 2015 and 2014, increased $6.3 million, or 16.4%. This 16.4% increase relates to added staffing and contract labor expenses to support the increase in capitation revenue in the quarterly period ending June 30, 2015 over the same period ending June 30, 2014. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, other operating expense from centers that were acquired or divested subsequent April 1, 2014 and excluded from the above comparison was $5.2 million. For the three months ended June 30, 2014, other operating expenses from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $1.2 million.

 

28
 

 

Depreciation and amortization

 

Depreciation and amortization decreased $258,000, or 1.7%, to $14.9 million for the three months ended June 30, 2015 compared to $15.2 million for the three months ended June 30, 2014.

 

Depreciation and amortization, including only those centers which were in operation throughout the second quarters of both 2015 and 2014, decreased $1.4 million, or 9.1%. The decrease is primarily due to several of our assets completing their depreciation schedules subsequent to the end of our first quarter of 2015. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2014. For the three months ended June 30, 2015, depreciation expense from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $1.1 million. For the three months ended June 30, 2014, depreciation expense from centers that were acquired or divested subsequent to April 1, 2014 and excluded from the above comparison was $9,000.

 

Loss on sale and disposal of equipment

 

We recorded a loss on sale of equipment of approximately $74,000 for the three months ended June 30, 2015 and approximately $46,000 for the three months ended June 30, 2014.

 

Interest expense

 

Interest expense for the three months ended June 30, 2015 increased approximately $87,000, or 0.8%, to $10.4 million for the three months ended June 30, 2015 compared to $10.3 million for the three months ended June 30, 2014. Interest expense for each of the three months ended June 30, 2015 and 2014 included $1.4 million of combined non-cash amortization of deferred loan costs, discount on issuance of debt, and unfavorable contracts. Excluding these non-cash amounts for each period, interest expense increased approximately $95,000 for the three months ended June 30, 2015 compared to the three months ended June 30, 2014. This increase was primarily due to interest expense stemming from the 2015 Incremental First Lien Term Loans transaction. See “Liquidity and Capital Resources” section below.

 

Equity in earnings from unconsolidated joint ventures

 

For the three months ended June 30, 2015, we recognized equity in earnings from unconsolidated joint ventures of $3.2 million against $1.6 million earned over the same period ended June 30, 2014.

 

Loss on early extinguishment of Senior Notes

 

For the three months ended June 30, 2014, we recognized a $471,000 loss on early extinguishment of debt through our tender offer for our senior notes. See “Liquidity and Capital Resources” below and Note 1 to the condensed consolidated financial statements contained herein for more details on our debt refinancing.

(Benefit from) provision for income taxes

We had an income tax expense for the three months ended June 30, 2015 of $2.2 million or 38.1% of income before income taxes, compared to the three months ended June 30, 2014 of an income tax expense of $1.2 million or 19.0% of the income before income taxes. The difference primarily relates to the negative impact of the loss on debt extinguishment on the projected annual effective tax rate for 2014.

Six Months Ended June 30, 2015 Compared to the Six Months Ended June 30, 2014

 

Service Fee Revenue

 

Service fee revenue for the six months ended June 30, 2015 was $353.4 million compared to $327.4 million for the six months ended June 30, 2014, an increase of $26.0 million, or 8.0%.

 

Service fee revenue, including only those centers which were in operation throughout the first two quarters of both 2015 and 2014 decreased $1.3 million or 0.4% as a result of a decline in reimbursement rates offset in part by an increase in procedure volumes from that of the prior year. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, service fee revenue from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $28.5 million. For the six months ended June 30, 2014, service fee revenue from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $1.2 million.

 

29
 

 

Provision for Bad Debts

 

Provision for bad debts increased $1.4 million, or 10.1%, to approximately $15.9 million, or 4.5% of service fee revenue, for the six months ended June 30, 2015 compared to $14.4 million, or 4.4% of service fee revenue, for the six months ended June 30, 2014.

 

Revenue Under Capitation Arrangements

 

Revenue under capitation arrangements for the six months ended June 30, 2015 was $48.0 million compared to $34.9 million for the six months ended June 30, 2014, an increase of $13.1 million or 37.4%.

 

Revenue under capitation arrangements, including only those centers which were in operation throughout the first two quarters of both 2015 and 2014 increased $11.1 million, or 31.7%. This 31.7% increase was mainly due to both 4 new and 3 expanded contractual relationships with private insurers. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, revenue under capitation arrangements from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $2.1 million. For the six months ended June 30, 2014, capitation revenue from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $101,000.

 

Operating Expenses

 

Cost of operations for the six months ended June 30, 2015 increased approximately $51.9 million, or 17.7%, from $292.8 million for the six months ended June 30, 2014 to $344.7 million for the six months ended June 30, 2015. The following table sets forth our cost of operations and total operating expenses for the six months ended June 30, 2015 and 2014 (in thousands):

 

   Six Months Ended June 30, 
   2015   2014 
Salaries and professional reading fees, excluding stock-based compensation  $184,731   $162,314 
Stock-based compensation   5,571    1,636 
Building and equipment rental   34,723    31,263 
Medical supplies   23,140    19,242 
Other operating expenses *   96,552    78,383 
Cost of operations   344,717    292,838 
           
Depreciation and amortization   29,235    30,770 
(Gain) loss on sale and disposal of equipment   36    292 
Severance costs   130    864 
Total operating expenses  $374,118   $324,764 

 

*     Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses.

  

Salaries and professional reading fees, excluding stock-based compensation and severance

 

Salaries and professional reading fees increased $22.4 million, or 13.8%, to $184.7 million for the six months ended June 30, 2015 compared to $162.3 million for the six months ended June 30, 2014.

 

Salaries and professional reading fees, including only those centers which were in operation throughout the first two quarters of both 2015 and 2014, increased $12.6 million, or 7.8%. The 7.8% increase is congruent with the rise in total procedure volumes over the same period in the prior year. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $11.4 million. For the six months ended June 30, 2014, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was approximately $1.6 million.

 

30
 

 

Stock-based compensation

 

Stock-based compensation increased $3.9 million, or 240.5%, to approximately $5.6 million for the six months ended June 30, 2015 compared to $1.6 million for the six months ended June 30, 2014. This increase was driven by the higher fair value of RSA’s awarded and vested in the first quarter of 2015 as compared to RSA’s awarded and vested in the prior year’s first quarter.

  

Building and equipment rental

 

Building and equipment rental expenses increased $3.5 million or 11.1%, to $34.7 million for the six months ended June 30, 2015 compared to $31.3 million for the six months ended June 30, 2014.

 

Building and equipment rental expenses, including only those centers which were in operation throughout the first and second quarters of both 2015 and 2014, increased $1.5 million, or 4.9%. This 4.9% increase is mainly related to additional radiology equipment operating leases in support of operations. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $2.2 million. For the six months ended June 30, 2014, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was approximately $254,000.

 

Medical supplies

 

Medical supplies expense increased $3.9 million, or 20.3%, to $23.1 million for the six months ended June 30, 2015 compared to $19.2 million for the six months ended June 30, 2014.

 

Medical supplies expenses, including only those centers which were in operation throughout the first and second quarters of both 2015 and 2014, increased $2.4 million, or 12.3%. This 12.3% rise is primarily attributable to both increased purchases stemming from volumes along with supplier price increases. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, medical supplies expenses from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $1.5 million. For the six months ended June 30, 2014, medical supplies expense from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $17,000.

 

Other operating expenses

 

Other operating expenses increased $18.2 million, or 23.2%, to $96.6 million for the six months ended June 30, 2015 compared to $78.4 million for the six months ended June 30, 2014.

 

Other operating expenses, including only those centers which were in operation throughout the first and second quarters of both 2015 and 2014, increased $10.3 million, or 11.7%. This 11.7%increase is in line with added staffing and contract labor expenses to support the increase in capitation revenue. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, other operating expense from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $8.6 million. For the six months ended June 30, 2014, other operating expense from centers that were acquired or divested subsequent to January 1, 2014 was $695,000.

 

Depreciation and amortization

 

Depreciation and amortization decreased $1.5 million, or 5.0%, to $29.2 million for the six months ended June 30, 2015 compared to $30.8 million for the six months ended June 30, 2014.

 

Depreciation and amortization, including only those centers which were in operation throughout the first and second quarters of both 2015 and 2014, decreased $3.2 million, or 10.3%. The decrease is primarily due to several of our assets completing their depreciation schedules subsequent to the end of our first quarter of 2015. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2014. For the six months ended June 30, 2015, depreciation expense from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $1.8 million. For the six months ended June 30, 2014, depreciation and amortization from centers that were acquired or divested subsequent to January 1, 2014 and excluded from the above comparison was $121,000.

 

Loss on sale and disposal of equipment

 

We recorded a loss on sale of equipment of approximately $36,000 for the six months ended June 30, 2015 and approximately $292,000 for the six months ended June 30, 2014.

 

31
 

 

Interest expense

 

Interest expense for the six months ended June 30, 2015 decreased approximately $1.7 million, or 7.6%, to $20.4 million for the six months ended June 30, 2015 compared to $22.1 million for the six months ended June 30, 2014. Interest expense for the six months ended June 30, 2015 included $3.0 million of combined non-cash amortization of deferred loan costs, discount on issuance of debt, and unfavorable contracts. Interest expense for the six months ended June 30, 2014 included $3.2 million of non-cash amortization and write-off of deferred loan costs due to refinance, discount on issuance of debt and unfavorable contracts. Excluding these non-cash amounts for each period, interest expense decreased approximately $1.4 million for the six months ended June 30, 2015 compared to the six months ended June 30, 2014. This decrease was primarily due to a reduction in interest expense stemming from the redemption of the $200 million senior notes. See “Liquidity and Capital Resources” below for more details on our debt refinancing.

 

Meaningful use incentive

 

For the six months ended June 30, 2015 and June 30, 2014, we recognized other income from meaningful use incentive in the amount of $3.3 million and $1.8 million, respectively. These amounts were earned under a Medicare program to promote the use of electronic health record technology. See Note 1 to the condensed consolidated financial statements contained herein for more detail regarding this meaningful use incentive.

 

Equity in earnings from unconsolidated joint ventures

 

For the six months ended June 30, 2015 we recognized equity in earnings from unconsolidated joint ventures of $4.3 million versus $2.7 million for the six months ended June 30, 2014, an increase of $1.6 million or 58.8%.

 

Loss on early extinguishment of Senior Notes

 

For the six months ended June 30, 2014, we recognized a $15.9 million loss on early extinguishment of debt through our tender offer for our senior notes. Completion of the tender was conditioned on the closing of the amendment to the First Lien and Second Lien Credit and Guaranty Agreement. See “Liquidity and Capital Resources” below and Note 1 to the condensed consolidated financial statements contained herein for more details on our debt refinancing.

 

(Benefit from) provision for income taxes

We had a tax benefit for the six months ended June 30, 2015 of $899,000 or 49.6% of loss before income taxes, compared to a tax benefit for the six months ended June 30, 2014 of $3.2 million or 31.31% of loss before income taxes. The difference primarily relates to the negative impact for loss on debt extinguishment incurred during 2014 and a positive impact due to a larger ratio of discrete items compared to the six months loss before income taxes for 2015.

Adjusted EBITDA

 

We use both GAAP and non-GAAP metrics to measure our financial results. One non-GAAP measure we believe assists us is Adjusted EBITDA. We believe that, in addition to GAAP metrics, Adjusted EBITDA assists us in measuring our cash generated from operations and the ability to service our debt obligations. We believe this information is useful to investors and other interested parties because we are highly leveraged and our Adjusted EBITDA metric removes non-cash and certain other charges that occur in the affected period and provide a basis for measuring the Company's financial condition against other quarters.

 

. We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and exclude losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, bargain purchase gains and non-cash equity compensation.  Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period.

 

Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

 

32
 

 

Adjusted EBITDA is most comparable to the GAAP financial measure, net income (loss) attributable to RadNet, Inc. common stockholders. The following is a reconciliation of GAAP net income (loss) attributable to RadNet, Inc. common stockholders to Adjusted EBITDA for the six months ended June 30, 2015 and 2014, respectively: 

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2015   2014   2015   2014 
Net income (loss) attributable to RadNet, Inc. common stockholders  $3,395   $5,144   $(1,159)  $(7,280)
Plus provision for (benefit from) income taxes   2,192    1,233    (899)   (3,245)
Plus other expenses (income)   413    (4)   410    (2)
Plus loss on early extinguishment of Senior Notes       471        15,927 
Plus interest expense   10,423    10,336    20,419    22,108 
Plus severance costs   94    383    130    864 
Plus loss  on sale and disposal of equipment   74    46    36    292 
Plus depreciation and amortization   14,941    15,199    29,235    30,770 
Plus non-cash employee stock-based compensation   2,017    611    5,571    1,636 
Adjusted EBITDA  $33,549   $33,419   $53,743   $61,070 

  

Liquidity and Capital Resources

 

We had cash and cash equivalents of $5.3 million and accounts receivable of $156.0 million at June 30, 2015, compared to cash and cash equivalents of $307,000 and accounts receivable of $148.2 million at December 31, 2014. We had a working capital balance of $115.1 million and $58.7 million at June 30, 2015 and December 31, 2014, respectively. We had net income attributable to RadNet common stockholders for the three months ended June 30, 2015 and 2014 of $3.4 million and $5.1 million respectively, and net loss attributable to RadNet common stockholders for the six months ended June 30, 2015 and 2014 of $1.2 million and $7.3 million, respectively.  We had stockholders’ equity of $10.2 million and $5.4 million at June 30, 2015 and December 31, 2014, respectively.

 

On April 15, 2015 we completed our acquisition of New York Radiology Partners, consisting of eleven multi-modality imaging centers located in Manhattan, New York for cash consideration of $29.8 million and a note to seller of $1.5 million. The facilities provide a full range of radiology services including MRI, PET/CT, Mammography, Ultrasound, X-ray and other related services. On May 1, 2015 we completed our acquisition of California Radiology consisting of six multi-modality imaging centers located in Los Angeles, California for cash consideration of $4.2 million. The facilities provide MRI, PET/CT, Ultrasound and X-ray services.

 

Under the 2014 Amendment to the Credit Agreement and the 2015 Incremental First Lien Term Loans explained in further detail below, the scheduled annual amortization payments on total First Lien Term Loans increased from 1% per annum to 5.3% per annum. As a result, scheduled amortization increased by $20.8 million from pre-amendment terms. This $20.8 million additional cash obligation will be partially offset by annual interest savings of approximately $5.0 million under the terms of the Second Lien Term Loan as compared to that under the retired Senior Notes. We expect to fund this approximately $15.8 million net increase in amortization payments from cash provided by operating activities. Cash flows from operating activities were $28.0 million for the six months ended June 30, 2015 and $19.7 million for the six months ended June 30, 2014.

 

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

 

Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

 

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

 

33
 

 

We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.

 

Included in our condensed consolidated balance sheet at June 30, 2015 is $632.3 million of senior secured term loan debt (net of unamortized discounts of $11.1 million), broken down by loan agreement as follows (in thousands):

 

   As of June 30, 2015 
   Face Value   Discount   Total Carrying Value 
First Lien Term Loans  $389,367   $(8,061)  $381,306 
2015 Incremental First  $74,013   $(570)  $73,443 
Second Lien Term Loans  $180,000   $(2,451)  $177,549 
Total  $643,380   $(11,082)  $632,298 

 

Our revolving credit facility had no amounts outstanding as of June 30, 2015.

 

As of June 30, 2015, we were in compliance with all financial covenants under our Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan, and the Second Lien Credit Agreement, each as defined below.

 

2015 Incremental First Lien Term Loan:

 

On April 30, 2015, we entered into a joinder agreement to our existing Credit Agreement (the "2015 Incremental First Lien Term Loan Joinder") to provide for the borrowing of $75.0 million of incremental first lien term loans (“2015 Incremental First Lien Term Loans”). The 2015 Incremental First Lien Term Loans are treated as part of the same class as the existing tranche B term loans currently outstanding under the Credit Agreement. We used the proceeds from the 2015 Incremental First Lien Term Loans to repay all of the borrowings outstanding under the first lien revolving loan facility and to pay approximately $1.1 million of fees and expenses associated with the transaction.

 

Interest. The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.

 

Maturity Date. The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.

 

2014 Amendment to the Credit Agreement and Second Lien Credit Agreement:

 

On March 25, 2014, Radnet Management simultaneously entered into two agreements which resulted in the creation of a direct financial obligation as follows:

 

2014 Amendment of the Credit Agreement. Radnet Management amended that certain Credit and Guaranty Agreement dated October 10, 2012 (the "Original Credit Agreement"), by that certain first amendment dated April 3, 2013 (the “2013 Amendment”), and subsequently by entering into a second amendment dated on March 25, 2014 (the “2014 Amendment”) ( the Original Credit Agreement, as amended by the 2013 Amendment and the 2014 Amendment is collectively referred to herein as the "Credit Agreement") to provide for, among other things, the borrowing by Radnet Management of $30.0 million of additional first lien term loans (the “2014 First Lien Term Loans”).

 

The 2014 Amendment provides for the following:

 

Interest. The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

34
 

 

Payments. The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $986,842.11 to approximately $6.2 million, beginning in June 2015.

 

Guarantees and Collateral. The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, are guaranteed by RadNet, Inc., all of our current and future domestic subsidiaries and certain of our affiliates (other than certain excluded foreign subsidiaries). The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, and the guarantees are secured by a perfected first priority security interest (subject to certain permitted exceptions) in substantially all of our tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

 

Restrictive Covenants. In addition to certain covenants, the Credit Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

 

Financial Covenants. The Credit Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.

 

Events of Default. In addition to certain customary events of default, events of default under the Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, within five days after the due date, failure of any loan party to comply with any covenant or agreement in the loan documents (subject to applicable grace periods and/or notice requirement), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Second Lien Credit and Guaranty Agreement. Radnet Management entered into a Second Lien Credit and Guaranty Agreement dated March 25, 2014 (the “Second Lien Credit Agreement”) to provide for, among other things, the borrowing by Radnet Management of $180.0 million of second lien term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans and the 2014 First Lien Term Loans were used to redeem the outstanding senior notes, as more fully described below under the heading “Senior Notes”, to pay the expenses related to the transaction and for general corporate purposes.

  

The Second Lien Credit Agreement provides for the following:

 

Interest. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.

 

Payments. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.

 

Termination. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.

 

Restrictive Covenants. In addition to certain covenants, the Second Lien Credit Agreement places limits on our ability declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transaction, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

 

35
 

 

Events of Default. In addition to certain events of default, events of default under the Second Lien Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Second Lien Term Loans within five days after the due date, failure of any loan party to comply with any covenant or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Second Lien Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Revolving Credit Facility

 

The $101.25 million revolving credit line established in the Credit Agreement was unaltered by the agreements above and remains in place. The termination date for the $101.25 million revolving credit facility is the earliest to occur of (i) October 10, 2017, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Credit Agreement, which addresses voluntary commitment reductions and (iii) the date of the termination of the revolving credit facility due to specific events of default pursuant to section 8.01 of the Credit Agreement. The revolving credit line bears interest based on types of borrowings as follows: (i) unpaid principal at the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 4.25% per annum or the Base Rate (as defined in the Credit Agreement) plus 3.25% per annum, (ii) letter of credit and fronting fees at 4.5% per annum, and (iii) commitment fee of 0.5% per annum on the unused revolver balance. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.

 

Senior Notes

 

On April 6, 2010, we issued and sold $200 million of 10 3/8% senior unsecured notes due 2018 at a price of 98.680% (the “senior notes”). All payments of the senior notes, including principal and interest, were guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc., and all of Radnet Management’s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture dated April 6, 2010 (the “Indenture”), by and among Radnet Management, Inc., as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee. We paid interest on the senior notes on April 1 and October 1 of each year, commencing October 1, 2010, and they were scheduled to expire on April 1, 2018.

 

We completed the retirement of our $200 million in senior notes on April 24, 2014 and following such retirement we completed the satisfaction and discharge of the Indenture. The transactions leading to the retirement of the senior notes are described below:

 

Tender Offer. On March 7, 2014, we commenced a tender offer to purchase for cash any and all outstanding senior notes. In connection with the tender offer, we also commenced a consent solicitation to amend the Indenture to eliminate or modify certain restrictive covenants. On March 25, 2014, we made a payment in cash for all senior notes tendered prior to 5:00 P.M., New York City time, on March 20, 2014 (the “Consent Payment Deadline”). As of the Consent Payment Deadline, we received tenders and consents in respect of $193,464,000 aggregate principal amount of the senior notes, representing 96.73% of the outstanding senior notes, all of which were accepted for purchase. The total consideration for each $1,000 principal amount of senior notes validly tendered and not withdrawn at or prior to the Consent Payment Deadline and accepted for purchase was $1,056.88, which amount included a consent payment (the “Consent Payment”) of $30.00 per $1,000 principal amount of senior notes. In addition, all senior notes accepted for payment received accrued and unpaid interest in respect of such notes from the last interest payment date prior to the applicable settlement date to, but not including, the applicable settlement date. The tender offer expired on April 3, 2014 and between the Consent Payment Deadline and the expiration of the tender offer, no additional senior notes were tendered. With a net carrying amount including discount and unamortized issue costs of $189.2 million, a loss on early extinguishment of debt of $15.5 million was recorded in the first quarter of 2014.

 

Exercise of Optional Redemption on March 25, 2014. On March 25, 2014, we called for redemption of all of our remaining outstanding senior notes not purchased prior to the expiration of the tender offer described above, with a redemption date of April 24, 2014 (the “Redemption Date”). Upon redemption on April 24, 2014, the holders of the senior notes being redeemed received a redemption price equal to 105.188% of the outstanding principal amount of the senior notes being redeemed (or $1,051.88 per $1,000 in principal amount of the senior notes) in accordance with the terms of the Indenture, or approximately $6.9 million in total, including approximately $43,000 of accrued and unpaid interest up to, but excluding the Redemption Date.  As of that date, we completed the satisfaction and discharge of the Indenture in accordance with its terms and no senior notes remained outstanding. With a net carrying amount including discount and unamortized issue costs of $6.4 million, a loss on early extinguishment of debt of $471,000 was recorded in the second quarter of 2014.

 

36
 

 

ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk

 

Foreign Currency Exchange Risk.   We sell our services exclusively in the United States and receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency, exchange rates or weak economic conditions in foreign markets.

 

We maintain research and development facilities in Prince Edward Island, Canada and Budapest, Hungary for which expenses are paid in the local currency. Accordingly, we do have currency risk resulting from fluctuations between such local currency and the United States Dollar. At the present time, we do not have any foreign currency exchange contracts to mitigate this risk. A hypothetical 1% decline in the currency exchange rates between the U.S. dollar against the Canadian dollar and the Hungarian Forint would have resulted in an annual increase of approximately $34,000 in operating expenses.

 

Interest Rate Sensitivity. We pay interest on various types of debt instruments to our suppliers, investors and lending institutions. The agreements entail either fixed or variable interest rates. Instruments which have fixed rates are mainly leases on radiology equipment. Variable rate interest obligations relate primarily to amounts borrowed under our outstanding credit facilities, which allows elections of either Adjusted Eurodollar or prime rates of interest. Under the 2014 Amendment to the Refinance Agreement’s election facilities’, borrowed funds bear a 1.00% floor or 6 month Adjusted Eurodollar Rate plus an applicable margin of 3.25% for both 2014 First Lien Term Loan and 2015 First Lien Incremental Loan. Under the Second Lien Credit Agreement’s election facilities’, borrowed funds bear a 1.00% floor or 6 month Adjusted Eurodollar Rate plus an applicable margin of 7%. At June 30, 2015, we had $457.2 million outstanding subject to an Adjusted Eurodollar election on the 2014 First Lien Term Loans and $180.0 million on the Second Lien Term Loans. As the Adjusted Eurodollar floor exceeds the current spot rate of 6 month Adjusted Eurodollar, the spot rate would have to increase more than 56 basis points before an additional interest expense would be accrued. An increase of 156 basis points would be necessary to realize a hypothetical 1% increase in the borrowing rate and an annual increase of $6.4 million of interest expense under our first and second lien term loans.  At June 30, 2015, an additional $12.4 million in debt instruments tied to the prime rate. A hypothetical 1% increase in the prime rate for 2014-2015 would have resulted in an annual increase in interest expense of approximately $124,000. 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to process, summarize and disclose this information within the time periods specified in the rules of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information we are required to disclose in the reports that we file or submit to the SEC is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an evaluation of the design and operation of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report for their intended purposes.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting during the six months ended June 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

 

37
 

 

PART II – OTHER INFORMATION

 

ITEM 1.  Legal Proceedings

 

We are engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of our business. We do not believe that the outcome of any of our current litigation will have a material adverse impact on our business, financial condition and results of operations. However, we could be subsequently named as a defendant in other lawsuits that could adversely affect us.

 

ITEM 1A.  Risk Factors

 

For information about risks and uncertainties related to our business, please see the risk factors set forth in Part I, Item 1A, of our annual report on Form 10-K for the year ended December 31, 2014, as supplemented and amended by the risk factors in Part II, Item 1A of our quarterly report on Form 10-Q for the quarter ended March 31, 2015. Those risks are not the only risks relevant to our business; we may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial as of the date of this report on Form 10-Q.

 

ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

ITEM 3.  Defaults Upon Senior Securities

 

None.

 

ITEM 4.  Mine Safety Disclosures

 

Not applicable.

 

ITEM 5.  Other Information

 

None.

 

ITEM 6.  Exhibits

 

Reference is made to the Exhibit Index immediately following the signature page of this report on Form 10-Q.

 

38
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  RADNET, INC.
  (Registrant)
   
Date: August 10, 2015 By: /s/ Howard G. Berger, M.D.
    Howard G. Berger, M.D., President and Chief Executive Officer
(Principal Executive Officer)
   
   
Date: August 10, 2015 By: /s/ Mark D. Stolper
    Mark D. Stolper, Chief Financial Officer
(Principal Financial and Accounting Officer)

 

39
 

 

INDEX TO EXHIBITS

 

Exhibit
Number
  Description
     

 

10.1

 

Joinder Agreement, dated as of April 30, 2015, by and among Barclays Bank PLC, RadNet Management, Inc., RadNet, Inc., certain subsidiaries and affiliates of RadNet Management, Inc. and Barclays Bank PLC as administrative agent and collateral agent (incorporated by reference to Exhibit 10.1 filed with Form 8-K on May 1, 2015).

 

10.2   RadNet, Inc. 2006 Equity Incentive Plan (Amended and Restated as of April 20, 2015) (incorporated by reference to Appendix A to RadNet, Inc.’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 30, 2015).
     
31.1   Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2   Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of Howard G. Berger, M.D pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2*   Certification of Mark D. Stolper pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS**   XBRL Instance Document
     
101.SCH**   XBRL Schema Document
     
101.CAL**   XBRL Calculation Linkbase Document
     
101.LAB**   XBRL Label Linkbase Document
     
101.PRE**   XBRL Presentation Linkbase Document
     
101.DEF**   XBRL Definition Linkbase Document

 

* This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
   
** Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

40

 

EX-31.1 2 radnet_10q-ex3101.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Howard G. Berger, M.D., certify that:

 

1.     I have reviewed this quarterly report on Form 10-Q of RadNet, Inc.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.     The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d –15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 10, 2015

/s/ Howard G. Berger, M.D.

Howard G. Berger, M.D.

President, Chief Executive Officer and

Chairman of the Board of Directors

(Principal Executive Officer)

EX-31.2 3 radnet_10q-ex3102.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Mark D. Stolper, certify that:

 

1.     I have reviewed this quarterly report on Form 10-Q of RadNet, Inc.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.     The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d –15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 10, 2015

/s/ Mark D. Stolper

Mark D. Stolper

Executive Vice President and

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 radnet_10q-ex3201.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of RadNet, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2015, as filed with the Securities and Exchange Commission on August 10, 2015 (the “Report”), I, Howard G. Berger, M.D., Chairman of the Board of Directors and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.

 

/s/ Howard G. Berger, M.D.

Howard G. Berger, M.D.

Chairman, President and Chief Executive Officer

(Principal Executive Officer)

August 10, 2015

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 radnet_10q-ex3202.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of RadNet, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2015, as filed with the Securities and Exchange Commission on August 10, 2015 (the “Report”), I, Mark D. Stolper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.

 

/s/ Mark D. Stolper

Mark D. Stolper

Chief Financial Officer

(Principal Financial Officer)

August 10, 2015

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 6 rdnt-20150630.xml XBRL INSTANCE FILE 0000790526 2015-01-01 2015-06-30 0000790526 2015-06-30 0000790526 2014-12-31 0000790526 2014-01-01 2014-06-30 0000790526 us-gaap:RestrictedStockMember 2015-06-30 0000790526 2013-12-31 0000790526 2014-06-30 0000790526 2015-08-07 0000790526 us-gaap:CommonStockMember 2015-01-01 2015-06-30 0000790526 us-gaap:CommonStockMember 2014-12-31 0000790526 us-gaap:CommonStockMember 2015-06-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-06-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0000790526 us-gaap:RetainedEarningsMember 2015-01-01 2015-06-30 0000790526 us-gaap:RetainedEarningsMember 2014-12-31 0000790526 us-gaap:RetainedEarningsMember 2015-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-06-30 0000790526 rdnt:TotalRadnetMember 2015-01-01 2015-06-30 0000790526 rdnt:TotalRadnetMember 2014-12-31 0000790526 rdnt:TotalRadnetMember 2015-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2014-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2015-06-30 0000790526 rdnt:FirstLienTermLoanMember 2015-06-30 0000790526 rdnt:SecondLienTermLoanMember 2015-06-30 0000790526 us-gaap:ShortTermDebtMember 2015-06-30 0000790526 us-gaap:RestrictedStockMember 2014-12-31 0000790526 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0000790526 2015-04-01 2015-06-30 0000790526 2014-04-01 2014-06-30 0000790526 rdnt:Incremental2015FirstMember 2015-06-30 0000790526 rdnt:Incremental2015FirstMember 2015-01-01 2015-06-30 0000790526 rdnt:SecondLienTermLoanMember 2015-01-01 2015-06-30 0000790526 rdnt:FirstLienTermLoanMember 2015-01-01 2015-06-30 0000790526 us-gaap:RevolvingCreditFacilityMember 2015-01-01 2015-06-30 0000790526 us-gaap:RevolvingCreditFacilityMember 2015-06-30 0000790526 rdnt:NJINMember 2015-06-30 0000790526 rdnt:NYRPMember 2015-01-01 2015-06-30 0000790526 rdnt:NYRPMember 2015-06-30 0000790526 rdnt:CaliforniaRadiologyMember 2015-01-01 2015-06-30 0000790526 rdnt:CaliforniaRadiologyMember 2015-06-30 0000790526 rdnt:HealthcareRadiologyMember 2015-01-01 2015-06-30 0000790526 rdnt:HealthcareRadiologyMember 2015-06-30 0000790526 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000790526 us-gaap:EmployeeStockOptionMember 2015-06-30 0000790526 us-gaap:EmployeeStockOptionMember 2014-12-31 0000790526 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-06-30 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:FirstLienTermLoansMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:FirstLienTermLoansMember 2014-12-31 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:FirstLienTermLoansMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:FirstLienTermLoansMember 2014-12-31 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:FirstLienTermLoansMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:FirstLienTermLoansMember 2014-12-31 0000790526 rdnt:TotalFairValueMember rdnt:FirstLienTermLoansMember 2015-06-30 0000790526 rdnt:TotalFairValueMember rdnt:FirstLienTermLoansMember 2014-12-31 0000790526 rdnt:FirstLienTermLoanMember 2014-12-31 0000790526 rdnt:SecondLienTermLoanMember 2014-12-31 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:Incremental2015FirstMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:Incremental2015FirstMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:Incremental2015FirstMember 2015-06-30 0000790526 rdnt:TotalFairValueMember rdnt:Incremental2015FirstMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:SecondLienTermLoanMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:SecondLienTermLoanMember 2014-12-31 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:SecondLienTermLoanMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:SecondLienTermLoanMember 2014-12-31 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:SecondLienTermLoanMember 2015-06-30 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:SecondLienTermLoanMember 2014-12-31 0000790526 rdnt:TotalFairValueMember rdnt:SecondLienTermLoanMember 2015-06-30 0000790526 rdnt:TotalFairValueMember rdnt:SecondLienTermLoanMember 2014-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure RadNet, Inc. 0000790526 10-Q 2015-06-30 false --12-31 No No Yes Accelerated Filer Q2 2015 -913000 -7119000 -1159000 -1159000 246000 3563000 5256000 10215000 5362000 719350 937500 3800000 4600000 1400000 2200000 44466338 -173439000 -172280000 -153000 -112000 183803000 177750000 4000 4000 .0001 .0001 200000000 200000000 44409449 42825676 44409449 42825676 42825676 44409449 594000 594000 594000 5459000 5459000 5459000 864423 -613000 -613000 -41000 -41000 -41000 30361000 18061000 15104000 10279000 15559000 15034000 8130000 7853000 623300000 53925000 5144000 8501000 48583000 18987000 4970000 25532000 28393000 9476000 5738000 56639000 48835000 0 15300000 30502000 32123000 5153000 1561000 225867000 223127000 11428000 243389000 192020000 28528000 24671000 17246000 17246000 155964000 148235000 788503000 740680000 3992000 4026000 37188000 35334000 4893000 6122000 46000000 47624000 755000 196672000 200304000 18833000 12900000 2100000 128335000 133274000 6256000 5637000 2206000 2100000 23666000 19468000 1400000 1964000 729000 6289000 94078000 97816000 776319000 732982000 5795000 6241000 4329000 6143000 612399000 551059000 0 15300000 25461000 20965000 788503000 740680000 1969000 2336000 12184000 7698000 4000 4000 177750000 183803000 -172280000 -173439000 -112000 -153000 5362000 10215000 2336000 1969000 389367000 180000000 643380000 74013000 399750000 180000000 8061000 2451000 11082000 570000 381306000 177549000 632298000 73443000 53700000 42000000 28200000 21400000 53700000 42000000 28200000 21400000 160200000 139600000 86700000 71200000 213900000 181600000 114900000 92600000 89700000 79700000 9100000 9000000 115100000 58700000 841195 942023 724423 825252 P11M1D 5.28 1.96 8.66 4.45 5319000 307000 8412000 831000 31179000 0 31179000 353433000 327438000 188403000 168675000 15862000 14413000 8387000 7520000 337571000 313025000 180016000 161155000 47985000 34933000 24273000 17927000 385556000 347958000 204289000 179082000 344717000 292838000 175796000 147808000 29235000 30770000 14941000 15199000 -36000 -292000 -74000 -46000 130000 864000 94000 383000 374118000 324764000 190905000 163436000 11438000 23194000 13384000 15646000 20419000 22108000 10423000 10336000 -3270000 -1762000 0 0 0 -15927000 0 -471000 -410000 2000 -413000 4000 13250000 33558000 7629000 9157000 -1812000 -10364000 5755000 6489000 -899000 -3245000 2192000 1233000 246000 161000 168000 112000 -1159000 -7280000 3395000 5144000 -.03 -.18 .08 .13 -.03 -.18 .08 .12 43059686 40413863 43370024 40817333 43059686 40413863 44685599 43262995 -41000 -19000 -4000 -1000 -954000 -7138000 3559000 5255000 246000 161000 168000 112000 -1200000 -7299000 3391000 5143000 15862000 14413000 4309000 2713000 3207000 1646000 6195000 5041000 2631000 3156000 5571000 1636000 19368000 27361000 3058000 2877000 3687000 -55000 1854000 4117000 -4602000 -420000 -564000 132000 -2423000 -7977000 27956000 19678000 34407000 1811000 31649000 26798000 205000 4000 265000 900000 -66116000 -29505000 3969000 9368000 74401000 205737000 11369000 211344000 531000 2387000 -15300000 18980000 613000 139000 594000 786000 43213000 2265000 -41000 -19000 5012000 -7581000 18283000 23464000 10800000 13800000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><b></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. At June 30, 2015 we operated directly or indirectly through joint ventures, 276 imaging centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York.&#160;&#160;Our operations comprise a single segment for financial reporting purposes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The condensed consolidated financial statements include the accounts of Radnet Management, Inc. (or &#147;Radnet Management&#148;) and Beverly Radiology Medical Group III, a professional partnership (&#147;BRMG&#148;). The condensed consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (&#147;DIS&#148;), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as &#147;RadNet&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148; or the &#147;Company&#148; in this report.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Accounting Standards Codification (&#147;ASC&#148;) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (&#147;VIE&#148;). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#146;s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE&#146;s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Howard G. Berger, M.D. is our President and Chief Executive Officer, and Chairman of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California&#146;s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which is 99% or 100% owned by Dr. Berger.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We contract with seven medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Four of these groups are owned by John V Crues, III, M.D., RadNet&#146;s Medical Director, a member of our Board of Directors and a 1% owner of BRMG.&#160; Dr. Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">RadNet provides non-medical, technical and administrative services to BRMG and the seven medical groups mentioned above (&#147;NY Groups&#148;) for which it receives a management fee, pursuant to the related management agreements. Through these management agreements we have exclusive authority over all non-medical decision-making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. These management agreements are designed such that all net cash flows of both BRMG and the NY Groups are transferred to us.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue, expenses, assets and liabilities of each such entity.&#160; These VIE&#146;s on a combined basis recognized $28.2 million and $21.4 million of revenue, net of management service fees to RadNet for the three months ended June 30, 2015 and 2014, respectively, and $28.2 million and $21.4 million of operating expenses for the three months ended June 30, 2015 and 2014, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations $114.9 million and $92.6 million of total billed net service fee revenue relating to these VIE&#146;s for the three months ended June 30, 2015 and 2014, respectively, of which $86.7 million and $71.2 million was for management services provided to these VIE&#146;s relating primarily to the technical portion of total billed net service fee revenue for the three months ended June 30, 2015 and 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">These VIE&#146;s on a combined basis recognized $53.7 million and $42.0 million of revenue, net of management service fees to RadNet for the six months ended June 30, 2015 and 2014, respectively, and $53.7 million and $42.0 million of operating expenses for the six months ended June 30, 2015 and 2014, respectively. RadNet recognized in its condensed consolidated statement of operations $213.9 million and $181.6 million of total billed net service fee revenue relating to these VIE&#146;s for the six months ended June 30, 2015 and 2014, respectively, of which $160.2 million and $139.6 million was for management services provided to these VIE&#146;s relating primarily to the technical portion of total billed net service fee revenue for the six months ended June 30, 2015 and 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The cash flows of these VIE&#146;s are included in the accompanying consolidated statements of cash flows.&#160; All intercompany balances and transactions have been eliminated in consolidation.&#160; In our consolidated balance sheets at June 30, 2015 and December 31, 2014, we have included approximately $89.7 million and $79.7 million, respectively, of accounts receivable and approximately $9.1 million and $9.0 million, respectively, of accounts payable and accrued liabilities, related to these VIE&#146;s combined.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The creditors of each of these VIE&#146;s do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of any of these VIE&#146;s. However, because of the relationship RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">At all of our centers, aside from certain centers in California and centers in New York City where we contract with BRMG and the NY Groups for the provision of professional medical services, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee intended to compensate us for the fair market value of our services which in some instances may be based on the practice group&#146;s professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.&#160;&#160;We have no financial controlling interest in the independent (non-BRMG or non-NY Groups) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2014, filed on March 16, 2015, as amended.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Significant Accounting Policies</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">During the period covered in this report, there have been no material changes to the significant accounting policies we use, and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended. The information below is intended only to supplement the disclosure in our annual report.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Revenues</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Service fee revenue, net of contractual allowances and discounts, consists of net patient fees&#160;received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to centers affiliated with both BRMG and the NY Entity, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Entity as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Entity. As it relates to non-BRMG and NY Entity centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG and NY Entity centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payors.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Our revenue, net of contractual allowances, discounts and provision for bad debts for the three and six months ended June 30, 2015 and 2014 is summarized in the following table (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 50%; text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Commercial insurance</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">117,107</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">104,901</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">216,872</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">204,977</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Medicare</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">42,088</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">39,412</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">79,172</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">77,317</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Medicaid</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">5,974</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">6,230</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,469</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">12,049</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Workers' compensation/personal injury</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">8,130</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">7,853</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">15,559</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">15,034</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Other</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">15,104</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">10,279</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">30,361</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">18,061</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Service fee revenue, net of contractual allowances and discounts</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">188,403</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">168,675</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">353,433</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">327,438</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Provision for bad debts</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(8,387</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,520</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(15,862</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(14,413</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Net service fee revenue</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,016</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">161,155</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">337,571</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">313,025</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Revenue under capitation arrangements</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">24,273</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">17,927</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">47,985</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">34,933</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Total net revenue</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">204,289</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">179,082</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">385,556</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">347,958</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Provision for Bad Debts </i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient&#146;s ability to pay nor are revenues recognized based on an assessment of the patient&#146;s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Deferred Tax Assets</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Deferred Financing Costs </i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;<i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Meaningful Use Incentive</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software will be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. Once an attestation is accepted by Medicare, payments will be made in four to eight weeks to the same taxpayer identification number and through the same channels as their claims payments are made. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $3.3 million and $1.8 million during the six months ended June 30, 2015, and 2014, respectively, relating to this incentive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Liquidity and Capital Resources</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We had cash and cash equivalents of $5.3 million and accounts receivable of $156.0 million at June 30, 2015, compared to cash and cash equivalents of $307,000 and accounts receivable of $148.2 million at December 31, 2014. We had a working capital balance of $115.1 million and $58.7 million at June 30, 2015 and December 31, 2014, respectively. We had net income attributable to RadNet, Inc. common stockholders for the three months ended June 30, 2015 and 2014 of $3.4 million and $5.1 million respectively, and net loss attributable to RadNet, Inc common stockholders for the six months ended June 30, 2015 and 2014 of $1.2 million and $7.3 million, respectively. We had stockholders&#146; equity of $10.2 million and $5.4 million at June 30, 2015 and December 31, 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment.&#160;&#160;Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Included in our condensed consolidated balance sheet at June 30, 2015 is $632.3 million of senior secured term loan debt (net of unamortized discounts of $11.1 million), broken down by loan agreement as follows (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of June 30, 2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Discount</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Carrying Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 29%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 2%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">389,367</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">(8,061</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">381,306</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">2015 Incremental First</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">74,013</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(570</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,443</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(2,451</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">177,549</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Total</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">643,380</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(11,082</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">632,298</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Our revolving credit facility had a $0 aggregate principal amount outstanding as of June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">As of June 30, 2015, we were in compliance with all financial covenants under our Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan, and the Second Lien Credit Agreement, each as defined below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt"><u>2015 Incremental First Lien Term Loan</u>:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">On April 30, 2015, we entered into a joinder agreement to our existing Credit Agreement (the &#34;2015 Incremental First Lien Term Loan Joinder&#34;) to provide for the borrowing of $75.0 million of incremental first lien term loans (&#147;2015 Incremental First Lien Term Loans&#148;). The 2015 Incremental First Lien Term Loans are treated as part of the same class as the existing tranche B term loans currently outstanding under the Credit Agreement. We used the proceeds from the 2015 Incremental First Lien Term Loans to repay all of the borrowings outstanding under the first lien revolving loan facility and to pay approximately $1.1 million of fees and expenses associated with the transaction.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt"><i>Interest. </i>The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt"><i>Payments. </i>The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt"><i>Maturity Date. </i>The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt"><u>2014 Amendment to the Credit Agreement and Second Lien Credit Agreement</u>:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">On March 25, 2014, Radnet Management simultaneously entered into two agreements which resulted in the creation of a direct financial obligation as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt"><i>2014 Amendment of the Credit Agreement. </i>Radnet Management amended that certain Credit and Guaranty Agreement dated October 10, 2012 (the &#147;Original Credit Agreement&#148;), by that certain first amendment dated April 3, 2013 (the &#147;2013 Amendment&#148;), and subsequently by entering into a second amendment dated on March 25, 2014 (the &#147;2014 Amendment&#148;) ( the Original Credit Agreement, as amended by the 2013 Amendment and the 2014 Amendment is collectively referred to herein as the &#34;Credit Agreement&#34;) to provide for, among other things, the borrowing by Radnet Management of $30.0 million of additional first lien term loans (the &#147;2014 First Lien Term Loans&#148;).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">The 2014 Amendment provides for the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Interest. </i>The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Payments. </i>The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Guarantees and Collateral. </i>The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, are guaranteed by RadNet, Inc., all of our current and future domestic subsidiaries and certain of our affiliates (other than certain excluded foreign subsidiaries). The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, and the guarantees are secured by a perfected first priority security interest (subject to certain permitted exceptions) in substantially all of our tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Restrictive Covenants. </i>In addition to certain covenants, the Credit Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Financial Covenants. </i>The Credit Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Events of Default. </i>In addition to certain customary events of default, events of default under the Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, within five days after the due date, failure of any loan party to comply with any covenant or agreement in the loan documents (subject to applicable grace periods and/or notice requirement), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Second Lien Credit and Guaranty Agreement. </i>Radnet Management entered into a Second Lien Credit and Guaranty Agreement dated March 25, 2014 (the &#147;Second Lien Credit Agreement&#148;) to provide for, among other things, the borrowing by Radnet Management of $180.0 million of second lien term loans (the &#147;Second Lien Term Loans&#148;). The proceeds from the Second Lien Term Loans and the 2014 First Lien Term Loans were used to redeem the outstanding senior notes, as more fully described below under the heading &#147;Senior Notes&#148;, to pay the expenses related to the transaction and for general corporate purposes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The Second Lien Credit Agreement provides for the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Interest. </i>The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Payments. </i>There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Termination. </i>The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Restrictive Covenants. </i>In addition to certain covenants, the Second Lien Credit Agreement places limits on our ability declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transaction, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Events of Default. </i>In addition to certain events of default, events of default under the Second Lien Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Second Lien Term Loans within five days after the due date, failure of any loan party to comply with any covenant or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Second Lien Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><font style="font-size: 8pt"><u>Revolving Credit Facility.</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The $101.25 million revolving credit line established in the Credit Agreement was unaltered by the agreements above and remains in place. The termination date for the $101.25 million revolving credit facility is the earliest to occur of (i) October 10, 2017, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Credit Agreement, which addresses voluntary commitment reductions and (iii) the date of the termination of the revolving credit facility due to specific events of default pursuant to section 8.01 of the Credit Agreement. The revolving credit line bears interest based on types of borrowings as follows: (i) unpaid principal at the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 4.25% per annum or the Base Rate (as defined in the Credit Agreement) plus 3.25% per annum, (ii) letter of credit and fronting fees at 4.5% per annum, and (iii) commitment fee of 0.5% per annum on the unused revolver balance. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0"><font style="font-size: 8pt"><u>Senior Notes</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">On April 6, 2010, we issued and sold $200 million of 10 3/8% senior unsecured notes due 2018 at a price of 98.680% (the &#147;senior notes&#148;). All payments of the senior notes, including principal and interest, were guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc., and all of Radnet Management&#146;s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture dated April 6, 2010 (the &#147;Indenture&#148;), by and among Radnet Management, Inc., as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee. We paid interest on the senior notes on April 1<b><i>&#160;</i></b>and October 1 of each year, commencing October 1, 2010, and they were scheduled to expire on April 1, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">We completed the retirement of our $200 million in senior notes on April 24, 2014 and following such retirement we completed the satisfaction and discharge of the Indenture. The transactions leading to the retirement of the senior notes are described below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Tender Offer. </i>On March 7, 2014, we commenced a tender offer to purchase for cash any and all outstanding senior notes. In connection with the tender offer, we also commenced a consent solicitation to amend the Indenture to eliminate or modify certain restrictive covenants. On March 25, 2014, we made a payment in cash for all senior notes tendered prior to 5:00 P.M., New York City time, on March 20, 2014 (the &#147;Consent Payment Deadline&#148;). As of the Consent Payment Deadline, we received tenders and consents in respect of $193,464,000 aggregate principal amount of the senior notes, representing 96.73% of the outstanding senior notes, all of which were accepted for purchase. The total consideration for each $1,000 principal amount of senior notes validly tendered and not withdrawn at or prior to the Consent Payment Deadline and accepted for purchase was $1,056.88, which amount included a consent payment (the &#147;Consent Payment&#148;) of $30.00 per $1,000 principal amount of senior notes. In addition, all senior notes accepted for payment received accrued and unpaid interest in respect of such notes from the last interest payment date prior to the applicable settlement date to, but not including, the applicable settlement date. The tender offer expired on April 3, 2014 and between the Consent Payment Deadline and the expiration of the tender offer, no additional senior notes were tendered. With a net carrying amount including discount and unamortized issue costs of $189.2 million, a loss on early extinguishment of debt of $15.5 million was recorded in the first quarter of 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.3pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Exercise of Optional Redemption on March 25, 2014. </i>On March 25, 2014, we called for redemption of all of our remaining outstanding senior notes not purchased prior to the expiration of the tender offer described above, with a redemption date of April 24, 2014 (the &#147;Redemption Date&#148;). Upon redemption on April 24, 2014, the holders of the senior notes being redeemed received a redemption price equal to 105.188% of the outstanding principal amount of the senior notes being redeemed (or $1,051.88 per $1,000 in principal amount of the senior notes) in accordance with the terms of the Indenture, or approximately $6.9 million in total, including approximately $43,000 of accrued and unpaid interest up to, but excluding the Redemption Date.&#160; As of that date, we completed the satisfaction and discharge of the Indenture in accordance with its terms and no senior notes remained outstanding.&#160; With a net carrying amount including discount and unamortized issue costs of $6.4 million, a loss on early extinguishment of debt of $471,000 was recorded in the second quarter of 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. At June 30, 2015 we operated directly or indirectly through joint ventures, 276 imaging centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York.&#160;&#160;Our operations comprise a single segment for financial reporting purposes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The condensed consolidated financial statements include the accounts of Radnet Management, Inc. (or &#147;Radnet Management&#148;) and Beverly Radiology Medical Group III, a professional partnership (&#147;BRMG&#148;). The condensed consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (&#147;DIS&#148;), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as &#147;RadNet&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148; or the &#147;Company&#148; in this report.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Accounting Standards Codification (&#147;ASC&#148;) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (&#147;VIE&#148;). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#146;s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE&#146;s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Howard G. Berger, M.D. is our President and Chief Executive Officer, and Chairman of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California&#146;s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which is 99% or 100% owned by Dr. Berger.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We contract with seven medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Four of these groups are owned by John V Crues, III, M.D., RadNet&#146;s Medical Director, a member of our Board of Directors and a 1% owner of BRMG.&#160; Dr. Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">RadNet provides non-medical, technical and administrative services to BRMG and the seven medical groups mentioned above (&#147;NY Groups&#148;) for which it receives a management fee, pursuant to the related management agreements. Through these management agreements we have exclusive authority over all non-medical decision-making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. These management agreements are designed such that all net cash flows of both BRMG and the NY Groups are transferred to us.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue, expenses, assets and liabilities of each such entity.&#160; These VIE&#146;s on a combined basis recognized $28.2 million and $21.4 million of revenue, net of management service fees to RadNet for the three months ended June 30, 2015 and 2014, respectively, and $28.2 million and $21.4 million of operating expenses for the three months ended June 30, 2015 and 2014, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations $114.9 million and $92.6 million of total billed net service fee revenue relating to these VIE&#146;s for the three months ended June 30, 2015 and 2014, respectively, of which $86.7 million and $71.2 million was for management services provided to these VIE&#146;s relating primarily to the technical portion of total billed net service fee revenue for the three months ended June 30, 2015 and 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">These VIE&#146;s on a combined basis recognized $53.7 million and $42.0 million of revenue, net of management service fees to RadNet for the six months ended June 30, 2015 and 2014, respectively, and $53.7 million and $42.0 million of operating expenses for the six months ended June 30, 2015 and 2014, respectively. RadNet recognized in its condensed consolidated statement of operations $213.9 million and $181.6 million of total billed net service fee revenue relating to these VIE&#146;s for the six months ended June 30, 2015 and 2014, respectively, of which $160.2 million and $139.6 million was for management services provided to these VIE&#146;s relating primarily to the technical portion of total billed net service fee revenue for the six months ended June 30, 2015 and 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The cash flows of these VIE&#146;s are included in the accompanying consolidated statements of cash flows.&#160; All intercompany balances and transactions have been eliminated in consolidation.&#160; In our consolidated balance sheets at June 30, 2015 and December 31, 2014, we have included approximately $89.7 million and $79.7 million, respectively, of accounts receivable and approximately $9.1 million and $9.0 million, respectively, of accounts payable and accrued liabilities, related to these VIE&#146;s combined.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The creditors of each of these VIE&#146;s do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of any of these VIE&#146;s. However, because of the relationship RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">At all of our centers, aside from certain centers in California and centers in New York City where we contract with BRMG and the NY Groups for the provision of professional medical services, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee intended to compensate us for the fair market value of our services which in some instances may be based on the practice group&#146;s professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.&#160;&#160;We have no financial controlling interest in the independent (non-BRMG or non-NY Groups) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2014, filed on March 16, 2015, as amended.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Significant Accounting Policies</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">During the period covered in this report, there have been no material changes to the significant accounting policies we use, and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended. The information below is intended only to supplement the disclosure in our annual report.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Revenues</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Service fee revenue, net of contractual allowances and discounts, consists of net patient fees&#160;received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to centers affiliated with both BRMG and the NY Entity, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Entity as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Entity. As it relates to non-BRMG and NY Entity centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG and NY Entity centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payors.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Our revenue, net of contractual allowances, discounts and provision for bad debts for the three and six months ended June 30, 2015 and 2014 is summarized in the following table (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 50%; text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Commercial insurance</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">117,107</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">104,901</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">216,872</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">204,977</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Medicare</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">42,088</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">39,412</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">79,172</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">77,317</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Medicaid</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">5,974</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">6,230</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,469</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">12,049</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Workers' compensation/personal injury</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">8,130</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">7,853</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">15,559</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">15,034</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Other</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">15,104</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">10,279</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">30,361</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">18,061</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Service fee revenue, net of contractual allowances and discounts</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">188,403</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">168,675</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">353,433</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">327,438</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Provision for bad debts</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(8,387</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,520</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(15,862</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(14,413</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Net service fee revenue</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,016</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">161,155</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">337,571</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">313,025</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Revenue under capitation arrangements</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">24,273</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">17,927</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">47,985</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">34,933</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Total net revenue</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">204,289</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">179,082</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">385,556</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">347,958</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 50%; text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Commercial insurance</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">117,107</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">104,901</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">216,872</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">204,977</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Medicare</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">42,088</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">39,412</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">79,172</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">77,317</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Medicaid</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">5,974</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">6,230</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,469</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">12,049</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Workers' compensation/personal injury</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">8,130</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">7,853</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">15,559</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">15,034</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Other</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">15,104</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">10,279</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">30,361</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">18,061</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Service fee revenue, net of contractual allowances and discounts</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">188,403</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">168,675</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">353,433</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">327,438</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Provision for bad debts</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(8,387</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,520</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(15,862</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(14,413</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Net service fee revenue</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,016</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">161,155</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">337,571</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">313,025</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Revenue under capitation arrangements</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">24,273</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">17,927</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">47,985</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">34,933</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Total net revenue</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">204,289</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">179,082</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">385,556</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">347,958</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Provision for Bad Debts </i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient&#146;s ability to pay nor are revenues recognized based on an assessment of the patient&#146;s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Deferred Tax Assets</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Deferred Financing Costs </i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Meaningful Use Incentive</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software will be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. Once an attestation is accepted by Medicare, payments will be made in four to eight weeks to the same taxpayer identification number and through the same channels as their claims payments are made. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $3.3 million and $1.8 million during the six months ended June 30, 2015, and 2014, respectively, relating to this incentive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><i>Liquidity and Capital Resources</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We had cash and cash equivalents of $5.3 million and accounts receivable of $156.0 million at June 30, 2015, compared to cash and cash equivalents of $307,000 and accounts receivable of $148.2 million at December 31, 2014. We had a working capital balance of $115.1 million and $58.7 million at June 30, 2015 and December 31, 2014, respectively. We had net income attributable to RadNet, Inc. common stockholders for the three months ended June 30, 2015 and 2014 of $3.4 million and $5.1 million respectively, and net loss attributable to RadNet, Inc common stockholders for the six months ended June 30, 2015 and 2014 of $1.2 million and $7.3 million, respectively. We had stockholders&#146; equity of $10.2 million and $5.4 million at June 30, 2015 and December 31, 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment.&#160;&#160;Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Included in our condensed consolidated balance sheet at June 30, 2015 is $632.3 million of senior secured term loan debt (net of unamortized discounts of $11.1 million), broken down by loan agreement as follows (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of June 30, 2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Discount</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Carrying Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 29%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 2%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">389,367</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">(8,061</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">381,306</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">2015 Incremental First</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">74,013</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(570</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,443</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(2,451</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">177,549</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Total</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">643,380</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(11,082</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">632,298</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Our revolving credit facility had a $0 aggregate principal amount outstanding as of June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">As of June 30, 2015, we were in compliance with all financial covenants under our Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan, and the Second Lien Credit Agreement, each as defined below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt"><u>2015 Incremental First Lien Term Loan</u>:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">On April 30, 2015, we entered into a joinder agreement to our existing Credit Agreement (the &#34;2015 Incremental First Lien Term Loan Joinder&#34;) to provide for the borrowing of $75.0 million of incremental first lien term loans (&#147;2015 Incremental First Lien Term Loans&#148;). The 2015 Incremental First Lien Term Loans are treated as part of the same class as the existing tranche B term loans currently outstanding under the Credit Agreement. We used the proceeds from the 2015 Incremental First Lien Term Loans to repay all of the borrowings outstanding under the first lien revolving loan facility and to pay approximately $1.1 million of fees and expenses associated with the transaction.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt"><i>Interest. </i>The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt"><i>Payments. </i>The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt"><i>Maturity Date. </i>The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt"><u>2014 Amendment to the Credit Agreement and Second Lien Credit Agreement</u>:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">On March 25, 2014, Radnet Management simultaneously entered into two agreements which resulted in the creation of a direct financial obligation as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt"><i>2014 Amendment of the Credit Agreement. </i>Radnet Management amended that certain Credit and Guaranty Agreement dated October 10, 2012 (the &#147;Original Credit Agreement&#148;), by that certain first amendment dated April 3, 2013 (the &#147;2013 Amendment&#148;), and subsequently by entering into a second amendment dated on March 25, 2014 (the &#147;2014 Amendment&#148;) ( the Original Credit Agreement, as amended by the 2013 Amendment and the 2014 Amendment is collectively referred to herein as the &#34;Credit Agreement&#34;) to provide for, among other things, the borrowing by Radnet Management of $30.0 million of additional first lien term loans (the &#147;2014 First Lien Term Loans&#148;).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">The 2014 Amendment provides for the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0pt 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Interest. </i>The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Payments. </i>The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Guarantees and Collateral. </i>The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, are guaranteed by RadNet, Inc., all of our current and future domestic subsidiaries and certain of our affiliates (other than certain excluded foreign subsidiaries). The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, and the guarantees are secured by a perfected first priority security interest (subject to certain permitted exceptions) in substantially all of our tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Restrictive Covenants. </i>In addition to certain covenants, the Credit Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Financial Covenants. </i>The Credit Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Events of Default. </i>In addition to certain customary events of default, events of default under the Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, within five days after the due date, failure of any loan party to comply with any covenant or agreement in the loan documents (subject to applicable grace periods and/or notice requirement), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Second Lien Credit and Guaranty Agreement. </i>Radnet Management entered into a Second Lien Credit and Guaranty Agreement dated March 25, 2014 (the &#147;Second Lien Credit Agreement&#148;) to provide for, among other things, the borrowing by Radnet Management of $180.0 million of second lien term loans (the &#147;Second Lien Term Loans&#148;). The proceeds from the Second Lien Term Loans and the 2014 First Lien Term Loans were used to redeem the outstanding senior notes, as more fully described below under the heading &#147;Senior Notes&#148;, to pay the expenses related to the transaction and for general corporate purposes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The Second Lien Credit Agreement provides for the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Interest. </i>The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Payments. </i>There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Termination. </i>The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Restrictive Covenants. </i>In addition to certain covenants, the Second Lien Credit Agreement places limits on our ability declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transaction, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 31.5pt 0 0.25in; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Events of Default. </i>In addition to certain events of default, events of default under the Second Lien Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Second Lien Term Loans within five days after the due date, failure of any loan party to comply with any covenant or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Second Lien Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><font style="font-size: 8pt"><u>Revolving Credit Facility.</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The $101.25 million revolving credit line established in the Credit Agreement was unaltered by the agreements above and remains in place. The termination date for the $101.25 million revolving credit facility is the earliest to occur of (i) October 10, 2017, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Credit Agreement, which addresses voluntary commitment reductions and (iii) the date of the termination of the revolving credit facility due to specific events of default pursuant to section 8.01 of the Credit Agreement. The revolving credit line bears interest based on types of borrowings as follows: (i) unpaid principal at the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 4.25% per annum or the Base Rate (as defined in the Credit Agreement) plus 3.25% per annum , (ii) letter of credit and fronting fees at 4.5% per annum, and (iii) commitment fee of 0.5% per annum on the unused revolver balance. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0"><font style="font-size: 8pt"><u>Senior Notes</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">On April 6, 2010, we issued and sold $200 million of 10 3/8% senior unsecured notes due 2018 at a price of 98.680% (the &#147;senior notes&#148;). All payments of the senior notes, including principal and interest, were guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc., and all of Radnet Management&#146;s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture dated April 6, 2010 (the &#147;Indenture&#148;), by and among Radnet Management, Inc., as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee. We paid interest on the senior notes on April 1<b><i>&#160;</i></b>and October 1 of each year, commencing October 1, 2010, and they were scheduled to expire on April 1, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">We completed the retirement of our $200 million in senior notes on April 24, 2014 and following such retirement we completed the satisfaction and discharge of the Indenture. The transactions leading to the retirement of the senior notes are described below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Tender Offer. </i>On March 7, 2014, we commenced a tender offer to purchase for cash any and all outstanding senior notes. In connection with the tender offer, we also commenced a consent solicitation to amend the Indenture to eliminate or modify certain restrictive covenants. On March 25, 2014, we made a payment in cash for all senior notes tendered prior to 5:00 P.M., New York City time, on March 20, 2014 (the &#147;Consent Payment Deadline&#148;). As of the Consent Payment Deadline, we received tenders and consents in respect of $193,464,000 aggregate principal amount of the senior notes, representing 96.73% of the outstanding senior notes, all of which were accepted for purchase. The total consideration for each $1,000 principal amount of senior notes validly tendered and not withdrawn at or prior to the Consent Payment Deadline and accepted for purchase was $1,056.88, which amount included a consent payment (the &#147;Consent Payment&#148;) of $30.00 per $1,000 principal amount of senior notes. In addition, all senior notes accepted for payment received accrued and unpaid interest in respect of such notes from the last interest payment date prior to the applicable settlement date to, but not including, the applicable settlement date. The tender offer expired on April 3, 2014 and between the Consent Payment Deadline and the expiration of the tender offer, no additional senior notes were tendered. With a net carrying amount including discount and unamortized issue costs of $189.2 million, a loss on early extinguishment of debt of $15.5 million was recorded in the first quarter of 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.5pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 22.3pt 0 0; text-indent: 0.5in"><font style="font-size: 8pt"><i>Exercise of Optional Redemption on March 25, 2014. </i>On March 25, 2014, we called for redemption of all of our remaining outstanding senior notes not purchased prior to the expiration of the tender offer described above, with a redemption date of April 24, 2014 (the &#147;Redemption Date&#148;). Upon redemption on April 24, 2014, the holders of the senior notes being redeemed received a redemption price equal to 105.188% of the outstanding principal amount of the senior notes being redeemed (or $1,051.88 per $1,000 in principal amount of the senior notes) in accordance with the terms of the Indenture, or approximately $6.9 million in total, including approximately $43,000 of accrued and unpaid interest up to, but excluding the Redemption Date.&#160; As of that date, we completed the satisfaction and discharge of the Indenture in accordance with its terms and no senior notes remained outstanding.&#160; With a net carrying amount including discount and unamortized issue costs of $6.4 million, a loss on early extinguishment of debt of $471,000 was recorded in the second quarter of 2014.</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of June 30, 2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Discount</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Carrying Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 29%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 2%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">389,367</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">(8,061</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">381,306</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">2015 Incremental First</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">74,013</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(570</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,443</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(2,451</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">177,549</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Total</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">643,380</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(11,082</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">632,298</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">On August 7, 2015 we announced a proposed expansion of our existing New Jersey Imaging Networks (&#147;NJIN&#148;) joint venture, which includes NJIN&#146;s acquisition of all of RadNet&#146;s 10 wholly owned New Jersey imaging centers and one center owned by Barnabas Health.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">Under the terms of the purchase agreement, which is subject to customary conditions to closing, including the approval of certain New Jersey state licensure bodies, third party consents and consummation of acquisition financing and is expected to close in the third quarter, NJIN will pay RadNet a purchase price of $35.5 million.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The company committed to the board approved plan for such sale prior to June 30, 2015. As such, the following assets are presented as assets held for sale as of June 30, 2015 (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left"><font style="font-size: 8pt">Property and equipment, net</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">11,428</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Goodwill</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">18,833</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><font style="font-size: 8pt">Intangible assets</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">755</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Other assets</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">163</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total assets held for sale</b></font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">31,179</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left"><font style="font-size: 8pt">Property and equipment, net</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">11,428</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Goodwill</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">18,833</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><font style="font-size: 8pt">Intangible assets</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">755</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Other assets</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">163</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total assets held for sale</b></font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">31,179</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; text-indent: 0.5in"><font style="font-size: 8pt">On April 15, 2015 we completed our acquisition of New York Radiology Partners (&#147;NYRP&#148;), consisting of eleven multi-modality imaging centers located in Manhattan, New York for cash consideration of $29.8 million and a note to seller of $1.5 million. The facilities provide a full range of radiology services including MRI, PET/CT, Mammography, Ultrasound, X-ray and other related services. We have made a preliminary fair value determination of the acquired assets and assumed liabilities. In total, RadNet acquired assets of $34.5 million, assumed equipment debt of $2.3 million, and assumed current liabilities of $891,000. Asset amounts acquired were $4.6 million in equipment, $12.0 million in leasehold improvements, $12.9 million in goodwill, $600,000 of other intangible assets, and $4.4 million of accounts receivable and other current assets. Current liabilities assumed related to accounts payable, payroll and other related short term obligations. Our preliminary fair value determination will be made final with the help of an outside valuation expert which we expect to have completed by the end of our third quarter of 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; text-indent: 0.5in"><font style="font-size: 8pt">On May 1, 2015 we completed our acquisition of California Radiology consisting of six multi-modality imaging centers located in Los Angeles, California for cash consideration of $4.2 million. The facilities provide MRI, PET/CT, Ultrasound and X-ray services. We have made a fair value determination of the acquired assets and approximately $217,000 of equipment, $1.7 million of leasehold improvements, $34,000 in other assets, $100,000 of other intangible assets relating to a covenant not to compete contract and $2.1 million of goodwill were recorded with respect to this transaction.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; text-indent: 0.5in"><font style="font-size: 8pt">On June 1, 2015 we completed our acquisition of Healthcare Radiology and Diagnostic systems, PLLC, consisting of a single multi-modality imaging center located in the Bronx, NY area for cash consideration of $425,000. The facility provides MRI, CT, Ultrasound and X-ray services. We have made a fair value determination of net assets and approximately $134,500 of fixed assets and $290,500 of leasehold improvements were recorded.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: left"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: left"><font style="font-size: 8pt">In April 2015, the Financial Accounting Standards Board (the &#147;FASB&#148;) issued ASU No. 2015-03 (&#147;ASU 2015-03&#148;), <i>Interest &#150; Imputation of Interest</i>, (Subtopic 835-30). ASU 2015-03 changes the accounting method for debt issuance costs from a deferred charge (i.e. an asset) to a contra liability in part because such costs provide no future economic benefit. Debt issue costs related to a recognized debt liability are to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with the presentation of debt discounts. The update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><font style="font-size: 8pt">In February 2015, the FASB issued ASU No. 2015-02 (&#147;ASU 2015-02&#148;), <i>Consolidation &#150; Amendments to the Consolidation Analysis, </i>(Topic 810). ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period.&#160;We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><font style="font-size: 8pt">In May 2014, the FASB issued ASU No. 2014-09 (&#147;ASU 2014-09&#148;), <i>Revenue from Contracts with Customers</i>, (Topic 606). ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The update was effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which has recently been extended to December 31, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 50%; text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Net income (loss) attributable to RadNet, Inc.'s common stockholders</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,395</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,144</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">(1,159</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">(7,280</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Weighted average number of common shares outstanding during the period</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,370,024</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">40,817,333</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,059,686</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">40,413,863</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.08</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.13</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.03</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.18</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Weighted average number of common shares outstanding during the period</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">43,370,024</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">40,817,333</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">43,059,686</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">40,413,863</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Add nonvested restricted stock subject only to service vesting</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">897,892</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">1,019,930</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Add additional shares issuable upon exercise of stock options and warrants</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">417,683</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">1,425,732</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Weighted average number of common shares used in calculating diluted net income per share</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">44,685,599</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,262,995</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,059,686</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">40,413,863</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.08</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.12</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.03</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.18</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">For the six months ended June 30, 2015 and 2014 we excluded all outstanding options and restricted stock awards in the calculation of diluted earnings per share because their effect would be antidilutive.</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months Ended</b></font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30,</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 50%; text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Net income (loss) attributable to RadNet, Inc.'s common stockholders</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,395</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,144</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">(1,159</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 10%; text-align: right"><font style="font-size: 8pt">(7,280</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Weighted average number of common shares outstanding during the period</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,370,024</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">40,817,333</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,059,686</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">40,413,863</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.08</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.13</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.03</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.18</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Weighted average number of common shares outstanding during the period</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">43,370,024</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">40,817,333</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">43,059,686</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">40,413,863</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Add nonvested restricted stock subject only to service vesting</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">897,892</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">1,019,930</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Add additional shares issuable upon exercise of stock options and warrants</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">417,683</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">1,425,732</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Weighted average number of common shares used in calculating diluted net income per share</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">44,685,599</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,262,995</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">43,059,686</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">40,413,863</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 8pt">Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.08</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.12</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.03</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">(0.18</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We have ten unconsolidated joint ventures where our ownership interests range from 35% to 50%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The following table is a roll forward of our investment in joint ventures during the six months ended June 30, 2015 (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left"><font style="font: 8pt Times New Roman, Times, Serif">Balance as of December 31, 2014</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">32,123</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-indent: -10pt"><font style="font: 8pt Times New Roman, Times, Serif">Equity in earnings in these joint ventures</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">4,309</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 20pt; text-indent: -10pt"><font style="font: 8pt Times New Roman, Times, Serif">Distribution of earnings</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(6,195</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-indent: -10pt"><font style="font: 8pt Times New Roman, Times, Serif">Equity contributions in existing joint ventures</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">265</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif">Balance as of June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">30,502</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We earned management service fees from the centers underlying these joint ventures of approximately $1.4 million and $2.2 million for the three months ended June 30, 2015 and 2014, respectively, and $3.8 million and $4.6 million for the six months ended June 30, 2015 and 2014, respectively. At the end of the period we eliminate from total fees recorded the uncollected portion of these fees that are associated with our ownership interests and offset this with an increase to our equity earnings.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The following table is a summary of key financial data for these joint ventures as of June 30, 2015 (in thousands) and for the six months ended June 30, 2015 and 2014 (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"><font style="font-size: 8pt">Balance Sheet Data:</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30, 2015</b></font></td><td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 63%; text-align: left"><font style="font-size: 8pt">Current assets</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">18,987</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">Noncurrent assets</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">48,583</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><font style="font-size: 8pt">Current liabilities</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(8,501</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Noncurrent liabilities</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(5,144</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt"><font style="font-size: 8pt">Total net assets</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">53,925</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Book value of RadNet joint venture interests</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">25,532</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Cost in excess of book value of acquired joint venture interests</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">4,970</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 40pt; text-indent: -10pt"><font style="font-size: 8pt">Total value of Radnet joint venture interests</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">30,502</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 40pt; text-indent: -10pt"><font style="font-size: 8pt">Total book value of other joint venture partner interests</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">28,393</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><font style="font-size: 8pt">Income statement data for the six months ended June 30,</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt; width: 47%"><font style="font-size: 8pt">Net revenue</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">56,639</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">48,835</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt"><font style="font-size: 8pt">Net income</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">9,476</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">5,738</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left"><font style="font: 8pt Times New Roman, Times, Serif">Balance as of December 31, 2014</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">32,123</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-indent: -10pt"><font style="font: 8pt Times New Roman, Times, Serif">Equity in earnings in these joint ventures</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">4,309</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 20pt; text-indent: -10pt"><font style="font: 8pt Times New Roman, Times, Serif">Distribution of earnings</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(6,195</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-indent: -10pt"><font style="font: 8pt Times New Roman, Times, Serif">Equity contributions in existing joint ventures</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">265</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 8pt Times New Roman, Times, Serif">Balance as of June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">30,502</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"><font style="font-size: 8pt">Balance Sheet Data:</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>June 30, 2015</b></font></td><td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 63%; text-align: left"><font style="font-size: 8pt">Current assets</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">18,987</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">Noncurrent assets</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">48,583</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><font style="font-size: 8pt">Current liabilities</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(8,501</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Noncurrent liabilities</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(5,144</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt"><font style="font-size: 8pt">Total net assets</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">53,925</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Book value of RadNet joint venture interests</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">25,532</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Cost in excess of book value of acquired joint venture interests</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">4,970</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 40pt; text-indent: -10pt"><font style="font-size: 8pt">Total value of Radnet joint venture interests</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">30,502</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 40pt; text-indent: -10pt"><font style="font-size: 8pt">Total book value of other joint venture partner interests</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">28,393</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b>Equity Incentive Plans</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b><i>Options</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we amended and restated as of April 20, 2015 (the &#147;Restated Plan&#148;). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 11, 2015. As of June 30, 2015, we have reserved for issuance under the Restated Plan 12,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over two to five years and expire five to ten years from the date of grant.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">As of June 30, 2015, we had outstanding options to acquire 1,130,009 shares of our Common Stock, of which options to acquire 1,086,676 shares were exercisable.&#160;During the six months ended June 30, 2015, we did not grant any stock options under our Restated Plan.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The following summarizes all of our stock option transactions during the six months ended June 30, 2015:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted Average Remaining</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Exercise price</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Contractual</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Outstanding Options</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Per Common</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Life</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Intrinsic </b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Under the Restated Plan</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Shares</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Share</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>(in years)</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 31%"><font style="font-size: 8pt">Balance, December 31, 2014</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">2,092,509</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">3.58</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font-size: 8pt">Exercised</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(937,500</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.66</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Canceled, forfeited or expired</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(25,000</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.22</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Balance, June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,130,009</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">4.36</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">1.20</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">3,216,338</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Exercisable at June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,086,676</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">4.46</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">1.11</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">3,014,838</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on June 30, 2015 and the exercise price, multiplied by the number of in-the-money options ) that would have been received by the holder had all holders exercised their options on June 30, 2015. Total intrinsic value of options exercised during the six months ended June 30, 2015 and 2014 was approximately $5.4 million and $5.9 million, respectively. As of June 30, 2015, total unrecognized stock-based compensation expense related to non-vested options was $25,000, which is expected to be recognized over a weighted average period of approximately 1.4 years.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b><i>Restricted Stock Awards </i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The Restated Plan permits the issuance of restricted stock awards (&#147;RSA&#146;s&#148;). As of June 30, 2015, we have issued a total of 3,441,208 RSA&#146;s, of which 2,600,013 RSA&#146;s have previously vested and 841,195 RSA&#146;s remained unvested at June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The following summarizes all unvested RSA activities during the six months ended June 30, 2015:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-size: 8pt"><b>Weighted-</b></font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-size: 8pt"><b>Average</b></font></p></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Remaining</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted-</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Contractual</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Average</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Shares</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Term (Years)</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Fair Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%"><font style="font-size: 8pt">RSA's outstanding at December 31, 2014</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">942,023</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;1.96</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">Changes during the period</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">724,423</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">8.66</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Vested</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(825,252</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">4.45</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">RSA's outstanding at June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">841,195</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.92</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">5.28</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">We determine the fair value of all RSA&#146;s based on the closing price of our common stock on the date of award.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">In sum, of the 12,000,000 shares of common stock reserved for issuance under the Restated Plan, at June 30, 2015, we had 3,441,208 RSA&#146;s (of which 841,195 shares were subject to further vesting), outstanding options to acquire 1,130,009 shares, and 3,915,042 shares of common stock available for future awards. We had previously granted options and other awards to acquire 3,513,741 shares which have been issued.</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted Average Remaining</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Exercise price</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Contractual</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Outstanding Options</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Per Common</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Life</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Intrinsic </b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Under the Restated Plan</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Shares</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Share</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>(in years)</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 31%"><font style="font-size: 8pt">Balance, December 31, 2014</font></td><td style="width: 2%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">2,092,509</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">3.58</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font-size: 8pt">Exercised</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(937,500</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.66</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><font style="font-size: 8pt">Canceled, forfeited or expired</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(25,000</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.22</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Balance, June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,130,009</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">4.36</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">1.20</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">3,216,338</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">Exercisable at June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">1,086,676</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">4.46</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">1.11</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">3,014,838</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-size: 8pt"><b>Weighted-</b></font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-size: 8pt"><b>Average</b></font></p></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Remaining</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted-</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Contractual</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Average</b></font></td><td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Shares</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Term (Years)</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 8pt"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Fair Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%"><font style="font-size: 8pt">RSA's outstanding at December 31, 2014</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">942,023</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;1.96</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">Changes during the period</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">724,423</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">8.66</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; text-indent: -10pt"><font style="font-size: 8pt">Vested</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">(825,252</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">)</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">4.45</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">RSA's outstanding at June 30, 2015</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">841,195</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">0.92</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">5.28</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">FAIR VALUE MEASUREMENTS &#150; Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Level&#160;1&#151;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Level&#160;2&#151;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">Level&#160;3&#151;Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The table below summarizes the estimated fair value of our long-term debt as follows (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="18" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of June 30, 2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 1</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 2</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 3</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Fair Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 20%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">388,880</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">388,880</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">389,367</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">2015 Incremental First</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,920</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,920</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">74,013</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">176,400</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">176,400</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="18" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of December 31, 2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 1</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 2</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 3</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 20%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">394,753</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">394,753</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">399,750</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">178,200</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">178,200</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The carrying value of our revolving credit facility at December 31, 2014 of $15.3 million, respectively, approximated its fair value. There was no revolving credit facility balance at June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">The table below summarizes the estimated fair value of our long-term debt as follows (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="18" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of June 30, 2015</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 1</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 2</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 3</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Fair Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 20%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">388,880</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">388,880</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">389,367</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">2015 Incremental First</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,920</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">73,920</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">74,013</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">176,400</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">176,400</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="18" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>As of December 31, 2014</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 1</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 2</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Level 3</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total Face Value</b></font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 20%; text-align: left"><font style="font-size: 8pt">First Lien Term Loans</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">394,753</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#150;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">394,753</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 11%; text-align: right"><font style="font-size: 8pt">399,750</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><font style="font-size: 8pt">Second Lien Term Loans</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">178,200</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#150;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">178,200</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">180,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><font style="font-size: 8pt">On August 3, 2015 we sold a 25% interest in two of our wholly owned multi-modality imaging centers located in Owings Mills and Baltimore, Maryland for approximately $5.0 million to Lifebridge Health, Inc. (&#147;Lifebridge&#148;). This transaction resulted in the formation of a partnership with Lifebridge under the name of Baltimore county Radiology, LLC.</font></p> 1100000 The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%. The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015. The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below. 30000000 180000000 75000000 101250000 The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below. The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015. 163000 29800000 4200000 425000 1500000 34500000 2300000 891000 4600000 217000 12000000 1700000 290000 600000 100000 4400000 34000 134000 0 0 897892 1019930 0 0 417683 1425732 265000 1130009 2092509 0 25000 1086676 4.36 3.58 2.66 2.22 4.46 P1Y2M12D P1Y1M10D 3216338 3014838 12000000 5400000 5900000 25000 P1Y4M24D 3441208 2600013 3513741 0 0 388880000 394753000 0 0 388880000 394753000 0 73920000 0 73920000 0 0 176400000 178200000 0 0 176400000 178200000 216872000 204977000 117107000 104901000 79172000 77317000 42088000 39412000 11469000 12049000 5974000 6230000 EX-101.SCH 7 rdnt-20150630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 2. ASSETS HELD FOR SALE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 3. FACILITY ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 4. NEW ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 5. EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 6. INVESTMENT IN JOINT VENTURES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 7. STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 8. FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 9. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 2. ASSETS HELD FOR SALE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 5. EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 7. STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 8. FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details - Revenue) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 1. NATURE OF BUSINESS (Details - Notes payable) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 2. ASSETS HELD FOR SALE (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 3. FACILITY ACQUISITIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 5. EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Details-Joint ventures) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Details-Key financial data) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 7. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 7. STOCK-BASED COMPENSATION (Details - RSU's) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 7. STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 8. FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 8. FAIR VALUE MEASUREMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rdnt-20150630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 rdnt-20150630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 rdnt-20150630_lab.xml XBRL LABEL FILE Outstanding Options and Warrants [Member] AwardType [Axis] Non-Plan Outstanding Warrants [Member] Level 1 FairValueByFairValueHierarchyLeve [Axis] Level 2 Level 3 Total Fair Value TotalCarryingValueMember RestrictedStockMember FairValueInputsLeve1Member Warrant [Member] Common Stock Equity Components [Axis] Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Income / Loss Total Radnet Inc Equity Noncontrolling Interest First Lien Term Loan Short-term Debt, Type [Axis] Second Lien Term Loans Short-term Debt [Member] 2015 Incremental First Revolving Credit Facility Credit Facility [Axis] Senior Notes Long-term Debt, Type [Axis] NJIN Business Combination, Separately Recognized Transactions [Axis] NYRP Business Acquisition [Axis] California Radiology Healthcare Radiology Stock Options First Lien Term Loans Financial Instrument [Axis] Document and Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer Is Entity a Voluntary Filer Is Entity's Reporting Status Current Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Accounts receivable, net Current portion of deferred tax assets Due from affiliates Prepaid expenses and other current assets Assets held for sale Total current assets PROPERTY AND EQUIPMENT, NET OTHER ASSETS Goodwill Other intangible assets Deferred financing costs, net of current portion Investment in joint ventures Deferred tax assets, net of current portion Deposits and other Total assets LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY CURRENT LIABILITIES Accounts payable, accrued expenses and other Due to affiliates Deferred revenue Current portion of notes payable Current portion of deferred rent Current portion of obligations under capital leases Total current liabilities LONG-TERM LIABILITIES Deferred rent, net of current portion Line of credit Notes payable, net of current portion Obligations under capital lease, net of current portion Other non-current liabilities Total liabilities STOCKHOLDERS' (DEFICIT) EQUITY Common stock - $.0001 par value, 200,000,000 shares authorized; 44,409,449, and 42,825,676 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively Paid-in-capital Accumulated other comprehensive loss Accumulated deficit Total RadNet, Inc.'s stockholders' deficit Noncontrolling interests Total equity Total liabilities and equity Common stock - par value (in Dollars per share) Common stock - shares authorized Common stock - shares issued Common stock - shares outstanding Income Statement [Abstract] NET REVENUE Service fee revenue, net of contractual allowances and discounts Provision for bad debts Net service fee revenue Revenue under capitation arrangements Total net revenue OPERATING EXPENSES Cost of operations, excluding depreciation and amortization Depreciation and amortization Loss on sale and disposal of equipment Severance costs Total operating expenses INCOME FROM OPERATIONS OTHER INCOME AND EXPENSES Interest expense Meaningful use incentive Equity in earnings of joint ventures Loss on early extinguishment of Senior Notes Other expenses (income) Total other expenses INCOME (LOSS) BEFORE INCOME TAXES (Provision for) Benefit from income taxes NET INCOME (LOSS) Net income attributable to noncontrolling interests NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS WEIGHTED AVERAGE SHARES OUTSTANDING: Basic WEIGHTED AVERAGE SHARES OUTSTANDING: Diluted Statement of Comprehensive Income [Abstract] NET INCOME (LOSS) Foreign currency translation adjustments COMPREHENSIVE INCOME (LOSS) Less comprehensive income attributable to non-controlling interests COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, value Issuance of common stock upon exercise of options, shares issued Issuance of common stock upon exercise of options, value Stock-based compensation Issuance of restricted stock and other awards, shares Issuance of restricted stock and other awards, value Purchase of non-controlling interests Distributions paid to noncontrolling interest Change in cumulative foreign currency translation adjustment Net (loss) income Ending balance, shares Ending balance, value Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Provision for bad debts Distributions from joint ventures Amortization and write off of deferred financing costs and loan discount Stock-based compensation Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Accounts receivable Other current assets Other assets Deferred taxes Deferred rent Deferred revenue Accounts payable, accrued expenses and other Net cash provided by operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of imaging facilities Purchase of property and equipment Proceeds from sale of equipment Equity contributions in existing and purchase of interest in joint ventures Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Principal payments on notes and leases payable Proceeds from borrowings Payments on Term Loan Debt/Senior Notes Deferred financing costs Net proceeds on revolving credit facility Distributions paid to noncontrolling interests Proceeds from issuance of common stock upon exercise of options/warrants Net cash provided by financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the period for interest SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Purchase of equipment and leasehold improvements not yet paid for Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Combinations [Abstract] ASSETS HELD FOR SALE FACILITY ACQUISITIONS New Accounting Pronouncements and Changes in Accounting Principles [Abstract] NEW ACCOUNTING STANDARDS Earnings Per Share [Abstract] EARNINGS PER SHARE Equity Method Investments and Joint Ventures [Abstract] INVESTMENT IN JOINT VENTURES Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK-BASED COMPENSATION Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Subsequent Events [Abstract] SUBSEQUENT EVENTS Nature of Business and Basis of Presentation Significant Accounting Policies Revenues Provision for Bad Debts Deferred Tax Assets Deferred Financing Costs Meaningful Use Incentive Liquidity and Capital Resources Service fee revenue Loans Assets held for sale EARNINGS PER SHARE Investment in joint ventures Key financial data in joint ventures Stock option activity Restricted Stock Awards activity FAIR VALUE MEASUREMENTS Commercial Insurance Medicare Medicaid Workers Compensation/Personal Injury Other Service fee revenue, net of contractual allowances and discounts Net service fee revenue Total net revenue Term loans face value Term loans discount Term loan carrying value BRMG and B&C Entities revenues BRMG and B&C Entities operating expenses Total billed net service fee revenue Management services provided to BRMG and B&C Entities BRMG and B&C Entities accounts receivable BRMG and B&C Entities accounts payable Working capital Senior notes Line of credit balance outstanding Line of credit maximum borrowing amount Payments of loan fees Debt interest rate Payment frequency Debt maturity date Property and equipment, net Intangible assets Other assets Total assets held for sale Cash consideration paid Note issued Assets acquired Assumed equipment debt Assumed current liabilities Equipment acquired Leasehold improvements acquired Other intangible assets Accounts receivable and other current assets Other assets Fixed assets Net income (loss) attributable to RadNet, Inc.'s common stockholders BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS Weighted average number of common shares outstanding during the period Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS Weighted average number of common shares outstanding during the period Add nonvested restricted stock subject only to service vesting Add additional shares issuable upon exercise of stock options and warrants Weighted average number of common shares used in calculating diluted net income per share Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders Beginning balance Equity earnings in these joint ventures Distribution of earnings Equity contributions in existing joint ventures Ending balance Key financial data for joint ventures Current assets - joint ventures Noncurrent assets - joint ventures Current liabilities - joint ventures Noncurrent liabilities - joint ventures Total net assets -joint ventures Book value of Radnet joint venture interests Cost in excess of book value of acquired joint venture interests Total value of Radnet joint venture interests Total book value of other joint venture partner interests Net revenue Net income Management service fees from centers underlying joint ventures Award Type [Axis] STOCK BASED COMPENSATION Begining Balance Granted Exercised Canceled or expired Ending Balance Exercisable at the end Weighted Average Exercise price Per Common Share Begining Balance Granted Exercised Canceled or expired Ending Balance Exercisable at the end Weighted Average Remaining Contractual Life Ending Balance Exercisable at the end Aggregate Intrinsic Value Aggregate value outstanding Aggregate value exercisable RSA's outstanding, beginning balance RSA's granted RSA's vested RSA's outstanding, ending balance Weighted-Average Remaining Contractual Term Weighted-average fair value, beginning balance Weighted-average fair value, granted Weighted-average fair value, vested Weighted-average fair value, ending balance Shares authorized under plan Aggregate intrinsic value Unrecognized stock-based compensation expense Unrecognized expense weighted average period Total shares issued RSA's previously vested Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards Common stock issued upon exercise of options and other awards Fair Value, Hierarchy [Axis] FAIR VALUE MEASUREMENTS Long-Term Debt fair value Line of credit Aggregate Intrinsic Value Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Deferred tax assets policy text block Document and Entity Information Remaining vesting period of restricted stock awards Key financial data for joint ventures Key financial data in joint ventures Meaningful Use Incentive policy text block Net revenue from joint ventures WestCoastRadiologyMember Purchase of equipment and leasehold improvements not yet paid for Total book value of other joint venture partner interests TotalCarryingValueMember TotalFairValueMember Weighted Average Exercise price Per Common Share Weighted Average Remaining Contractual Life abstract Workers Compensation/Personal Injury Working capital Liquidity and Capital Resources Medicare insurance revenue Medicaid insurance revenue Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Health Care Organization, Patient Service Revenue Provision for Bad Debts Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Operating Expenses Operating Income (Loss) Gains (Losses) on Extinguishment of Debt Other Nonoperating Income (Expense) Other Expenses Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Share-based Compensation Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Current Assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Deferred Income Taxes Increase (Decrease) in Deferred Charges Increase (Decrease) in Deferred Revenue Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Productive Assets Payments to Acquire Property, Plant, and Equipment Payments to Acquire Investments Net Cash Provided by (Used in) Investing Activities, Continuing Operations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Repayments of Debt Payments of Debt Issuance Costs Payments to Noncontrolling Interests Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash and Cash Equivalents, Period Increase (Decrease) Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost-method Investments, Description [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Debt Instrument, Unamortized Discount (Premium), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Equity Method Investment, Summarized Financial Information, Current Liabilities Equity Method Investment, Summarized Financial Information, Liabilities Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Fair Value Inputs [Abstract] Lines of Credit, Fair Value Disclosure EX-101.PRE 11 rdnt-20150630_pre.xml XBRL PRESENTATION FILE ZIP 12 0001019687-15-003028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001019687-15-003028-xbrl.zip M4$L#!!0````(`)6$"D?#W5*ZV,,``(+L"``1`!P`))9TKQ):WNQ/;83GK[J8L6(1G3%*$F*!%`0B)E<:8J MG8@DSG<./APC MXZ-_?OSO_SK"__OP/X/!T14$GGMV=('&@Y$_0?\XNG9FX.SH,_!!X$0H^,?1 M=\=;D%_0%?1`<'2.9G,/1``_2"2='6DGEG,T&#`4^QWX+@J^W8W6Q3Y%T?SL M]/3'CQ\G/GIV?J#@S_!DC-B*NT>+8`S6906.ZX/H#UGZZW^5"T62=H"ZKT0C$^FZ/D4/\#OR]I`D@>JO'H]`)-2R,8I?KIZ$89( M4V2S2K_DC=4'BW`P=9SY^H.)$S[&+R\?$#!Z%@Q^$B`/A(7?Q$\*/O*1[R]F MQ;C<*#B-7N?@%+\TP&^!`([7WVW^*/L!QD!^+D87/RE`%[C^6Q4G#0@WO]GI MJOD/<750\H8O+6WT#U>/B9"?SH.(?$8QT>GJZ*2 MEC)&?@1>HB/H_G1\%:#9"ILD1RCYNS%XD[_^#/@1C%[7OZY_ARYY,H'81<4H M0<9X*Y*=CWX]_H@;K63:DJX8'T[IC]_$G1;*6TJ;8\,C-X\"MZ`@(L[FXYLZ MJY+>GN4^PVXQ]1'1^TV\F_ED]7L&P.K'I4G+[3P,;R9[:]O$/T4%1EH]$6HD M;2`KI*'LK9&6"FS'2,L6JZ5:K+:7K,JT6*U.B]5VUV+_N`-AA%U^!-S["(W_ M_`IFCR!HS>)O1@33&4AQ:_W(Q6!>YAXN1"_&82H2X[VK/A#R=P'W!? M,7R!X?''U<^%NGXX+2PV#>FT&-->.!UUWYV.NDVGL_;,^^AH,IYY^TS";+4& MDKF_1EHJL-7NJR#@_&/I?O[``]T9\M^1FR4#6$"^O_QK@7&3@3SR\3_#K-O- MZ;UKE[L?,?0RNNKITC9==A7Q4I%87^_=J?>M1F8,7<70=6&$C>AXMPYT1_ZY M,X>1XQT4'RIMT')WO'D[:ZKO$BC-#LCP>$!X)W\9:E M@Z`&V69UEE.Z[X:JNJ&>*BU2I:4NI:_S;M1YVR.;:^23+P+D>7BD-\+?!B`\ M#"ZL7JLR0=]QL(Q?>A)UBD0MCU)Z-G25#;O8G$D%&%%&B\F'5^SW`[[B'5?%E.A](S:_\?\9$[[K6"Q\? M1)WG%TP+CB'(BBE)EJ08^U[]>W+V8A=GF:JW6_3G;OK18A%EM/=U8%7KI)VU ME)WW\_0/?QE4HWO.(;:=TSYWVN=/N;/_U+Z/K]U'AGQ8A]$$8GJ/9(_0=&]UO_F..3Z][O;]\6%X?BO!0SC M$W;INE[KV?<3+"ZBI\7!N(!SQX,3%/C0N7--@F<#JZ7(8^Q3I/6M]O;=?[RVEW^XYT#8']BNC^(HN5PX, MXJM-1OY\$85?P#/PY,12I^+VQ-U+CZOVQ&4EKMH3MT,>MR=N3]S.>MQT#J9UC?2$31/V+5\39:`#I^DN M_6M/TYZF'?:F%$W[8S`=2#O20KWW9^<.IN9KK,J\WZ.Y>SJ]W9U3PRUG2V*8 M)^S)V[&9PIZ\[%,N/7D[-NER\.1E&,_VI.W$B/;@JQK<=')IU M94VF)VY/7"[B=F5.0>F)V^%!60>)VQ6/VQ.W)^Y>>ERU)VZ'9Q(Z2-RN>-R> MN#UQ.^MQ&2;`#IVPG9C^ZB!-.[;OJ*=I3].=>-.%#Q..?KN_R)%K!IQP$8"/ M,$2:(IMG^)U58:M'61&DM)+R[Y^<`(2E(I;VBE^J+0/CNRV1X\)GS.J\;.^3(Z%,Y>?[N-*2TN+&^*G+GGCRG.FS&(FCA>"1$*F@'3)YXL@(#_# M<.QXOP,GX-5EL/*"5:7E"?`;\+Q???3#O\6EQFC. ML;FG*&!O4L/Q&'C$.P+W*"XA+3I39%$#2*HZ(>X5_HU=R7\I6?+G2BH71YC% M)XS\O4CL].[Q M%C$Q75Y;B4_1#%'H95XDJ3&#R5BB>\?,&1 M)`RQN^>D[3F:S9"?OG;O38=EJ)]28W1]=?S1E&U5I]7@`KE[-=`5`>(='Y?Z".3BK;M$6":938`M%U<;#W5'%GFU[>+@] MGJQMVSY\?E!1>/"DHL>W5IOP[F81D9D*%].QQ#U:`\G<3'9-TPQ#5:U,J%HA MC#85'3/@0'0Q6W@D$+T`$S*74]M[#V13U=1L1[Y9G!B`3/X=`U042VH(,/7& M3?2$`W4TFP?@B/4N'B8XD!WY)\[ M.T&9R!@NHB<4D)MOV&Q8@BSI)\NJE1;5$%7>9KM!E025C>R$^V_)UC2[`E`B MI0$89O-HBH7'>:;1',SF\$:8>2J"&UY8(@U5`8L'2Y-Q7QZE&&@"AJ3Y>MT, MK7@8%WNW)D/.#7,`=K9OXD:Q*S76M5$2,K!,;.V/LO4F%H7K-W3_C8&0T5_X M@$H,'Q/[T<%?DT`71[GQ57-#WUV5>C-)RQ+#6HV:0-T"T.[80@CU#\MB-=M/ M"T:JG+V[`V$4P#$.L0%&`<`&X_H<$%6\^'C(K;3`RI>P/@YF9X6LV!F4`MFHM"UK+6`-:"=F:9J MBN0*!0!._61I>OR:NJH4-Z_X7U[2V-;-]!.8X&_HZ9S:_-#DC`VVA+5;)GGK M;3;/8S$QZ2"-6'-EN!U;)5=OG6-'?A-,'1_^'7\8"Q>Z&"2I1E:_S8+%0.5> M)Y(MJ26H_$M(NBQI;5F5;W5)EA33K@DUWJ#[&PK^Q'U(.M":XW^3F&SD_WO! MOB%I@T7U91S()K0Y1'Y^ZI*J[10B-R^M.(#8K1'YZ&A:RQ4G/H3K@!CX$`77 M*`)A[?4(0U%5:L(V52PM,=F3\15$3PB//YY!XM:'TVD`IKB;/D=A_=5,7;65 M[%X4!FEL`.\7LYD3SSBGMM_CKF@6&_D+=!ZAAT=6#=B,=`?Y\&0@TB(ZIG7554IHB8J0T M-;O"@^@V0'A@%KW>>@Z.CGR7N-\YL3]V(/7[:$6WC&S,5B6G*28F*RF**BN[ MPT1-75[_,KIFF;.494VQ:H-,(L2F#%P`VLL:%TW3:RDRE5."Y&'IJ],Q^1E1BBI M)9?&T9F"C9^E>[[T>O+9(C%554R-4_YRH^07LEWLYM&#TWAYH[$M#/K,?K6< MYJC8#M4;JMD`U:K+NL//DOF]QF-C12H>8^1$-,+"YKGH)L.,)5X/OW5>2:3? MV"*J861-4E!Z30",$P>:8?$">#-5?D,.EPNACYQ3!=>0RZBT41S4ELE=@`>T MGD]M6N>FDIT>*BR]-@2V\%2Q:F!8#727Y!CZ+OXE6`!78*]B:Y*9Y2.'5,&` MF4QIFY9LB`(L8H>&:1HJE0&I8J/%!HELLP6J8EL*J\1XOBWU7,``6C?M;"!2 M+J,9&L;&5;1UE@E-205+3?5?]8$Y6 M5)MJ0`7EU\7`%KKILJ37P`!]L%J,%;7PO"J/5U:#!>4RD?D034#+4'2-7@&L M$-,4$N.HVC;TVI!2G@;W/0)SA!7,/F^2)0);W1EK7FSTL:(F$S#9IDN77$"2G+?*R%_.3]V2Y)O('T;)3B'B;LK.4S680Y"M@G/"C0'M3DTV=V3'$!'J.W>XNNG#$8SLBD M-P//XPOG"VZ7JMZ'9-DJM2>Z#()`J*4W86TZL$_OKMDFUA5G[I]P=1*[B4>+-4EU>.J;=/CG!U`;9FK MWWQG1MS)W\`EAW_(![>XGN%BQK;%OY:EM?TJ>U=9%FR MZ"V0;2O3T`7I9E5+::#0N1,$Y+CRMOM0[$#I_3?E,`1#KNF?3%/7[)UCKM^G MJHIBTWNY=V;CVGVKJFE5?6LUZ.].`$GLN(H5+^.;$8;C"#[C_WX"T0\`_.^C M2W+\:GE97KS+1M"!XGB/6QI[;3Q;58S_2+)"]\S=5(P[&X]BT3=[=%,Q_AM+ M;ZM*TUL"6>;:K71P':@5AO-:S>UM?/&)4JM9(KV)B!)-\1F^90- MJ7'E%:+;G<[\^>-4F[X):]]TYD](9S3VJ.U7,V>&.WDWS"Y.XR@R=Z@BJ_3) MGTJAC1'62!DJTTUJNPCY,X7*VLYMR,=76VEDPF)RGR,_1!YTR=)?=E#5\`"U M9;,YE$T`MJ<&VT:ICJ@A8A^^31\P:@!BR_JP'71@BY:Y]%EG.\4O-;Y<3M97 M%B\HEE,BVR9MR]PL<+T.1RXG^)2[FR$('#^YU/+3Z]LKM\YKG."4W%UPC?SD MOH;5ZMUJ5B9]@\_U@LSR5$T14=6$W>@1E=,E]_?5&#"."V2 M)2G&9EO:>,29N<9BGVR9%T6VKCP\.4LHX6=>%-O^XZTL?Y4O=F';&CKNK@*P#WN.ZYZ"%K>S"QP] MK)-)-NG5OI5?Z*F?*-8N:H%=T7TQ?NU^L:(VY!.;OCSQ8&HCV[7P58F`/J"B M5JP38R>UPFF!MGK?+E6-=J*)",M%6R!_:CA\&OHN^0\1]>QX1,APO:3<[`YM MG3[ISB1.&$:V%&H2G81EEQ!5%HAXD*>T:D:6&2Y5;@XQF1WZ&7CN%0KN\2?7 M*"(9?DER]'".0L?['*#%O'XF/UDVBW*_;I0H$"@3*5M%6#/;ES#C%D_DWN(_ M,87N0?`,QT#H96.ZJE%YRC@@"$;/O9A`LFQ1=PZTAYY_H<&R-*E#MN>\I4Y;UENHV6?D3O=U$,VV+1:&<=(&@^9N89C-%O-L$ MS;]S4E/,MD'S$]ZT%99^>"-H,GX*E\_HA%*1@T(W)2RJ-SGS2%PL\86C8";&"IUU?<&"#=S_#0B%THG1X@$ MS;J8FBQG>^"=[$#`_+Q4&L* M3^@(5%85O8!QI<.;30#X!YZJ3JW,-`/`S1@<'=AB#@_,"0OH&D*'O9DM)=H!_!=$3PD_(X8AX'[@8AR9; MU,[B'6K0,>/5Z/XEU:"O0#Y4ZW$W;#U_%_.AVH[;*1F:1<\]=D.TB-R[84)P3)XI*3^(P8;H& MT1L1N1.VUYZ-HR8&N5%L10W^G=P)-?B;`!56@9&M;H#8RI@S4B;0U3!M95(I);EIY%]!;1(`U MDXD(3BTE-@"V)5XU![8=;@DQ6%U^*=RXJ$/I2>*CFTDB(94$I:8O*SN`KTJZ M;5BI_`A<.(0K4V=B9!E>]9SVFU?VSU]YM,-D"B*:(,` M&P_)G%]_\U%5*(`@15(D!4JUN[,CDR`J*U^5F96/WIXI(25HX1V'EXIED.QA M(_N5C`-N9#OIZ)\/SLXN+YNTD>TDI-<][UZ:S0@?N)%EPQ=#EK!)U MVBOB-@S(="LW4[N![=%"V0^$Z0!;?'"8N_E;?'`(O/E;?'!X_'!;?/!QODP&^?A MU8A&@>ZK>]:J)1\*WN;'YD+?JTW`.UQ:&G#%JOR6K;)Z]ID)UKWHU*4Z'`K> MS75/M]+S].#XW;34KU\MP=D"WOK'W@:W@2\B/_V4O`U2UBF8,+431C[O5.Z6 M-X-A]SO8F+7/VI5(U\-V8#83^#1^'T1>-*(V]^F.5$?WO-*'=M6*#X5N\W3J M3J7;SB;0U?>0W@G6SJK=Y>K7VAZB+3R\2M7=>A#1A&4/B_+XOS]$ZC3[(D8B MN$5K83?_2NP)WBQ.J5W&9=P,NA_$H4%C?';[W3NXX@'P7L-ROMF5\7.?1["NPZP=B=P;FX2]-8E^]I@JB/OLS?'\PZ[78U&22[\90,9 MM\9Q=[&EP3;`[&]+6T3Q+N\]]K;9TF\BPZ$1%)GPA?]F_GN*6J?0[3R`&'Y9 M5^>R&R?BXO)LH1S@`4#M?XN;"]/E^<5"COT.MRAGV*3?XJL1>(P)MMOVPCTIN+ZD*8Y-D':85>C"[!8.DLU97G!AX&V1>^8LXO>Q9:P MF2C?&;(ZG=X*OMP6C,T1`W!4:O3N@^-SZ5N%NMU="-KFV*K. M'=H$-H/??@TB`;^Y!G]^5^T$.F>]ZNFZ;,$'0;:%>W`YV!8P;1^HC@YT4S*) M0U\DN[K%["TQ2>J6?#B`6T2&EKDJ:P%8J^2X.N'W"'[Q`3Z(R#.+_/IK*+1I M4YVA0K-BY7C6W4C[Y7+C>N<0/SIZ-B;_Q>#\\="SQ/+35[D'L+G[O6Y%0A\& MU/ZWN/FA4O79=KO#=^.Q&&6?QN]^C"8XD?F+EXE/4?T(V[W4#VT"P*Z!?W"M MST.`KW^*AUE7X\F[T:7MM68IUT.P:^BW"+J?#=:9L[P>^"I/\K,7;%?OOVC' M=`?UG9MQB4V7W\+T["]<92TNG_A1]LOG/`%F3>%8O9XY:38/Q=]>C.%'OSB=]BQS MO@53D3J_B3OG2SSU(I<_<)VO(%#CU\[42VZ"Z!>G_=K!94X#,"?PM^W661"] M^%\WV6M\,;[/?/=I&OQ'_.(,9IE^9*C^^+GX"Q_5_YC17_]/IR?_WR/"^X=P M9GS..G[@W43@N04C@@I8X`9+B%.>TI@Z@3*98.6;2,!S#I`IQD-9..KIDX]? M/KQR@533&?6GR.)I?)-XL\G<.;G^!M_0Y)&F<1[YK`.XDGA_$87P#K_J_IXDWAY>-PSQ. MXG04S^:.%_E.C-DD`#GUP\;-CX2?PT9:SE7F_#./A--KNP[RDW,G"`3N$`L/ M^T$"AV$X=T"T`-OJ7]DDB?.;B?-G'`"N;X$(^#YXQ\6YQ@L:I>@2`2/3JX+( MN?;"8!PG4>"YSD"?\`(!>_\RB8%< M'U+\`6T)O_QWG'QO_2]O.GO]_W3.VZ^+OS[EB1.;%AM(:`!'EN>``-Z$`@A\ M0Q<%`(LS9AO+"P%!,TQ?!-!G>0)$`P0UFI&-K3<9S&\3,A9\;)+G$S3PKS0. M@>3(%@7^4]!^K$:EX`G@,Z":JAF(Q\X7SPN%I]17@]>OB'O>X/R=<$[`?-'R\Q'E#N#X!_#VS/GPX8,+'`/2,A8DM?#- MS$NR"%AR$LR5^1WM M)?A1^[3O?)"R*>?0INHQ)7D$B7KHL]RM>J@02*?^$<+MVT(UU:]F8N[MAZ\& MX@#?8>C@A'V.B8`/0:_@V^`75#,Q^,@#`C;Z!=3 M8![V!O+-^32@?H$F82CH?AJTF9>6F0>\L0(J5D;%]Z`AB^^,W^5I_>=QGA1? MH!I%GBZ^1C?=B^;&(Z`GLTF02G5D5=`.P)2).\2+V)W#2WP6NNO8#\8@])3H M;?#EU==K4V=\%52O[X"SGF9*R!JF@-;CG`(M".HZ`#9D+4!BUT`*L[3?C[],LXSQ_-]FAN'&B,? MQ@F8(U5%DL^04Y15XSM#!@&U58"H!*8;OE*KJD@EPNPBZWO.#2H\YO/0`ZL3 M.10LW@2@`2*@**=..@,3>1SP.8X/`(I`5(/1Q!%4+#'"\]6H6C,`5(,Y7"<@ MEQVD6:`<>LZ_0*@I*UQY-@3$.\:=08]_?7A74K!_"%.KDMJ`1_#4 M!ZPP]?ZDD*ES&Q/]%2RDJ_3OT!#0/T1=`3LD4,!P``Z<.T/J[@J[2>:TNB_@ M-5,PTN!G@LRKXH=.S8]0.WFXEC:=/.>O',PAM/AOX:=`WSDX`LQ*B,\,L\9?Q'2P+XL#VI3SUM208(#`"`4-3.&'`FKN)2'PCM$D# M4*3RQP:[G+].'0%PQE,XD&;%)!@"[J3+`,3#,+AA)0!0>,,T3H9@M^*T#EC= ME5J;H$BP!Q`^E5!=@9`[`MD=@W_F.B4H0>N$8'#'&9*35,-0F%#C>S1-/D0* M/D0G'!N:*5QD+B4WTEA`)])@@5F`UE-TURP M-3^)[_!'H"[A.R<2-R"KI.1(?0+V@7>^"W:N"G2RUJ2D3$ZTD@QLZ['V*4DW+\A"6\3=12>`J0)"C7U74N+W\R58H\%@V^C!PTZ%OT_]6AFM)9(5FCY!-,I=>@ M@P8>ZR!]\$@X04I5OK+TB"7_&EZQD^-]#IU:VKKW;A+!?Y$PY)+1Q706QG-@ M\0EH"-"GX.?*Z!?+*SV,4A?GJ0P`(.UF@@AH_(SU";Q1?\3V0$JR)@,E:^V: M=++<+:]H[*S8/IV?A;$4#S,OB.1ANVH%U*],DTHD`?Q\7`PT;J0!3G-0`_JG M9A1#G;^F5X$,P@Y'XO-)A#)IOQ5JF1H.5)L&03#.@$8YWRJ3*3,`:0ZMD MAI2`]1$G*J;3P7!YJK(W@S)''C."F4.1J$A0&3Y,+"XB@R`>.-$)(T\(NAB(#K@95EN:)?**"5A1`;3?"UPB%L5\$Q6#<@"VJ"&C' MYU&::<;$7T9X3\GL^0/LQ4P&8/`#,&93H?;)GAA%6C0?NJ"MLX"\?^)&;QZS ME.F1@['RO>\8,+#A+@@K*DQ;>""TK>5H!3*23$M#([9\<=GK!AB\H;D^A MW<1]E7HDCB6`4JRMT4(A%9\T(J0JN5?OR9.AHN1!5CYZ$8@<6&/,&TD9&`4Z#:1!ZI(E(+YAPR]/I/:E9%?.0D.-O-?_\,YY$SK^< MZR2GT`N&B?#,I:"0$>(`9<;GL=R:.D1)8ZTOBD(81Q#1\*V1P(F\Y0VEPB>*(Y.)67`11"C M241$(I[QP&(-8_BU$2CX[=^L:8U@ MW"L^Q;2''V3*=TO+EM98"!=#_YABHUTS=6M29Y&EZ$BS-2$9MNXA=:=Q04!8<$*XYN8OQX*.\4S?L. M*80:AP5.E*EW9P8PR-N.HAP6'>;^C!<41$/MY=.3[(@DQ5M"Z9ICCMD(TZYDNGPI/(-62D$6NI4$!QJ#%K M5F((,-1Y\`"]"7$OL\FDA-,.PYL4=L^I=I/N#\:\]@9>#\]9% MB2$(](N.P3AW'J^XR!>&)[<,5+T7EJ,@G*L#I3B>9]R13N.(X%C$DV/BZ*$\ MT&@E5I=BT&B`Z[03JY=[--19KV`_EII^M]4VI69[[90&/UB];*F?[H=MA6Z" MQ257RN#UIMK)>;A.ZG9ZA4XJA+LSZ*RGF)RME%*Q\SJ4:S!6JR7@^.K1U>E= M&F#O1"D9%VYK*:;[<+0>"HY=)3493,J#T:9XV;FO,`$:>#+[15\Q8^8/94?( MN1XU0D:66K&$::-A3@B%%^1+0-^%=#%6>`%%*_Z4[=2A`&]3A."&1"IGK5@7 M'C/?_R%2L9D"+KF$DTX$6975]#I*D`'GDZ(JO0Z;H,Q\=T(Y4!()W@PDYP=( M0X8Y*B\'EU7]=V%\4B.[.F\J*9JOD>M=?N]EJ[-H]ET6FG75FV?<"$5>*5(K ME+)G5_9:%ZFNSB(K;;N2-JJJBQ,M;"K47(M^/W:B.&.^PP,N3U*A8H[RAD:^ M43EJ";MB42QO>+PDP1H)%D7CSAM.8'65D9,UH&[3(Y"QB1>.B8^B^3+0C'N2 MH1AY>:HOEDLW(_)PGGITLYX(:BG@FS=7.BV!P[TR589N>"CL@B`LV@T@]^+' MB.(JIETA3Q8;&]A)4I89.>>\4,X8QJLQ(AU>ZHQ$@E<^.INX?%]*GG_QC0JL M.]>4>T7L>B=JPNW1SBB&/ZHVL>0=; M9&[+N*:\A*2C+Q&>R<;%=5;YGADOU1:7T,76]) MWDNKU'>0&?PF58<#G:FS1/#M'F+(R$97R=]%DCG>K9)"J7E*DH[SD6H`Y8,) MR$\L,,Z!7>3E`0=-5]-*;8A2:UC)&/FKED-EF2H;U="0A`N5T$>*ENXSR8[79B[Y3\IVS:42E1<9-3@4 MNNV-XND21HKWEEA6<4"=P8[O4=E-'H(C&2)CZUG>CE-M*0*H81U[@FJ)ULBM'9*"Z95/@#0`;8! M+\TSTBG+\:AY\0].':3LH!7H5JZ3R\ZGW[&1:XR1AY36CD M#^.Z(XJ-O,"E]WX34=*+)W@/0EH:&`O_UDKZ59V2>$WV*.;%WLC0KQ_+ZZ=L M(0I<6VU`A$)-6FC(H,:XK_NMM01V9+B:OAZ;C9$'HBP'_JY;26%X<7!"P0'( M/APS"'EFQ/S,<6F6Y-+Y`VY^'X/R[[1/_U_M'G[)0Y3DTW:'J@[$3XPQ)VU1UJ=*%_^]];55 M)$BQGAF-Q`PW[169[+,$%@MFH3PM*&-)9/4L_AI3+-F'ES'A\+,Z.\42G&`E"JD%.^9AYF M:25V1F9>.8Z@#AU2),$44V>#V%\=X3&X8^KY0FK7VA4)]&A>>;WT?5CWJWT& ME$WJ4Q7!K>&F\&LE#M!T0>M`66CJO9OP=CHAUXH<'4]G#\+O_LPCKD_0S'W_ MR_B09^^Y'@6/9R4J_Z=$"=R>1+\9XI"QM7$0\MG^ MT4O`!NB<,VTX#6Y*/VNX+H5'@AJE&ARDX'5C*+\:M_!&^""^,]2-%$72W$AJR2[C1/N*$`W8RYC-I1B"-Y M>L%F,/`2LBW)AG6*N:XY!7T706RX)C@<4VXL]K)7^"/*=[??.C.@:@XN'T+R MKXO72ZXT`NB>3T5YD(4]K)+2%PW$ZA0M=Y4A1;8&_E`F/)-752!"^I`^Q[]4 M"K_,A^;4:)DG#9(T345X*P,E[#YCN`0LDGR�=2'"@7I!.V+S2(>'%&7C)6 M+[I.B(%.`^RQ44E`.RJLNY9SE7(&G:Q\C)7CS'9JD8!-MD@I\TH%W+B\SV6E M6'=Q)XUHVC1;*P@1O6MI(4(Y*B4]8W57JJ]NA_,ET*!JNQ-H^,IZ-5Z9S3>, M4G*TFRY"4O-:`W47!U/4"2`]:YE>K&(NI0I#4+)1)?/0K&]8@*X&Z]I'IFX( M>ALZA(K(-4$H(S@E$"B/GO,7RULPLS,+>]U,3QQ+D]-(*9%'5AUU9,A&!B]D MF<%].RB".=XTQHHX(H%>V"W'N48AB/N2[%(XD],XBD3(,CN,X^_?A9C1JZ.2 M3U702XD(YY9QL3@Z**5%%3:HR085*?%!1W=?*;8IRK#N+>3`T$QS)A$8+Q]5 M'QAC80IW"FXQ8BR!3)SX,BO.\\&RR`+L9N'*B)N"%>";QK)>N*CR.YH#]6B/ M`ZG_$B$IA;U3JE:AU"RL](MP:R**'`G6X:2\J3@-W.XIJ1J0`;IR]7-Y,6*\ M2U78!(E_2D%_EC*,/FLY#J>D;Q="H261H,-A^Q-D=[`GE( M6))02)CF2I+"IE#J7N"Y4M"NM7EK4R/6^-CXO MORJ(RL"4$Y4)B*+@S2#Q#(M.568LG\;(*MIF0"-`B%,X.TZ5&J>'*$A-#4.8 MV;A/B=1+>-+X3N`@+2V(1KLA+`M1)HAI5&]D"XQZ-&FLRF'PY M-:+.X<6)9-[CEVI'3<%RM?'B(9^>B@CC^4*1G),-*-5*9H-1Z8)WZP4AY8G4 MW*!L_"1]LD]42%JDHZK@=/V9X1:.F+*3#'TY M]%"##;-J,C<=C.NE#SK*WLZGJ%T-%BOZ9M!X;^>$/@>F@)^FKWYI-)(WY`7> MX`@2/U;+C>D:NM3/':\60J+JK]>@^CXV>07ND9] M[:R[Y1<%/`A*HM8A6QD.N%,/Y!D0`HYD%D^+I[%)(_W"5[^0P)^&8BQ7KN#P M%#_;!0XS7_U9_/7PUU5V!7@%]$=_>W&N<4^[D?A@CVOI;FCE=3`?RCZ0WTAT M/K+(O$.1(=B6=(;<#P:>%$*_@@9Z='3^G"4'EJ_7CGJ.WPA/[E[HJB#M9ZEM M^.>U(Q6D`ND--><"P!RZV]L=?^&!ID&$@VU=_CH,[BR9CH5,AU<13XO-NHU@ M,ZH+:AIK6=)(TO0M:9I*&BLUC25-\Z1FT[,2T`7HP;S?R$>7.4Y^<9*;X4FW M-W#E?UZM.D^E1WV&#K5)##Q?"T-[-Z?M=4W`?SVT*[__I_TQ9W6E172LN_;+ MS?94Q3QU$EUWK4[GPNVT+S;$XO9[VU2_6,(M(UR[[UZV.Y9PQT:X;N?<'5QT M+>&.CG`H<1=-4Y6[..__F`29.)S3K.[]5V-RW]QW*'G:FM_Z7;<]&&R^R#XV M\^R)T;MT^YTUE;8EQIZ)<7'I=M8]02TQ]DV,"[?76?-4;/Y1N(GKNX]3,?`M MNZU'^X> M9!,X-F7N3GM-YJYEAT-AP%)_']1ON]V+-<\92_VG1OU>V^V=KWEI;ZG_U*C? M&;CM!E/_2<0*ZCJJZ"H^!&?-KBK60K^'E0=NOVV=UX90XWS@GE^<66HT@AJ] MLY[;[UG9:`@UNA=`C4;DT1PZF+#\K-UC>.&S*H#70)4*X:WY^6CFY\G`[0W6 MS-38J?GYRA+]\8A^X9YUU[SPL41_*D3OG+F#\S4SY"S5GPS5^VZ_LZ;=>3BJ M/XFPPF_ULP"M[7U/E*#MMCOG3;"]+35>=\X[;N?,1@F:08U>#RRSBS6CP98: M^Z9&I^>VNXV0C6<1)9"=%35(*SLL6IORT6S*;M_M7CR&26DO+!M`_]E] MC(B1I7X#J-\'Z@_6/!(M]9\:]7M]]W+=2ZSGEZR@=MK%!LB[-HZ^Q9E1UH`3 M7=8*-RRC1G=739HW%PA:FKK&AV+O71XVA&#CY@_=P99Y>Y))'DL=6OH_G/Z= MBTNW/=@RHF[I?_3T[PVP/F3-2*:E_].C/QK#9VMFD3P*_:L&T<_4,[_X:!<= M__%_=\-*CSW/\'-I3,,;#\=2XI@&`L[.+]T1F'_H"52(9CFBK$BY=;P;#\=E MZVE"?)Q*-XBE-8U"0A^AZ'%/GY2,@)+DF"([Z=6R_,:=)/ MFH\FQOO4Z-.`P2@&8+%Y#6+Y'UJ6?D]SD-0C/$^P`)J''7/!(.!\(@?0T1F<\FB;,(Z_GZ*7(H?'\$PV'D^7B%#;\$02C^%1/0BS/6DJ=^([GT^1R@&`Q<`FG MS^CVFP!'B#-';FC^H)=E8@J\1=.>B52E=_)T)[TFP:#GCBU9`*?ZT=P4X$XB M*U_"RBF/-0O6/X]#>G"..K)?FHHTI0%3\9C'`Q4CSZ1@]<]?P\N'08B3`VE` MU1R'DSL\AXT'LY7F/RJ>J+[?6>O=-/56#O3")=1P'TEL*0OP[F`Z@X_,B5I9 M(B( M@;B"3V`#0T%CSY'5EW()3R=7^\$$_"#*88OA7$(L9[%KT`B$`KR%';-L`*M+ M,0UH[%F,H]/M-*]M3\6W8BP2'"W]S?OA7`$?9X\P\%=:2#@:-AC/CP35#P'S M0T3'6P8XQ_EX4\AQ.4BX\&"\,E`Z9"M#`/GW(S^%;1C3< MD8=?B_$89>>6UY"3_GZ7T\]@&7Z!"W(MR1\01*P;X1>T:%I:-2#]E^9A)J=& M@AJ.$R^9.WX`JR6"*FK4H*H`QXX&>@PWPH@:4\V7%')!!J_\B)J^50\#CPN? M@M+*$Z%4KMZ&`3O-:$-K`;89X)1D5!0`KHM:BPYRGC2'*T5S^N501&(<9*1\ MY8!7K>7UY#F!QDV$YY$\8#3N63&R98%SS?^8@#*%UWFSF?!`!TYC4/1A\%V$ M"(`7T:])T9OPXRSV(`SQ2P:A>"68!V2MR/M2;9_(<70T*K1L)"TB!A\(`#V% M.;1H"KV'PDS"&;XSS#0>SP*+V.:6S.W\67X."ZB`;V MX51=<4,C;H%OU/Q*_.IN(L@(HNF^*R#!H[,>K65:-%H;',7Y\)XE&FAS':?6 M;=HQF(Q3E""%9FT9:A&F<Z3(,DAJV4*"H*B<:\Q/* MVP-_#DT48(%PKGRA4.BQR'D6X%GF"/2*DC@*1FH2K)S3'X7..+2)!@B"+. M,[(AU(Q@'AB3NCRE6P(?H.XEH!2.:1D-.)EC0S:.!;@J%(Q2TUT+P[".SBW` MBT-!:C;,,$@DV'/7#SG:TRX88IICC"P#M2PM1%AJ3HXRAU#$%.PO,I]\M(45 MXO)4:_PRDH"R%),"LM[H1R3K`E=0U"62"S(-,=0"_#C#%"DX<01&K#<&'M48EV1(JP1B)PP`_PLD$T]MH7;KO=7KUB?]#JFBN^A>]))_2'$(>E'GK-51+Y*V`ZB-LT'K8NF&"+*%!%`RK`&OE-9"Y:SRW$T51"D&;QZ/LD#NEH+8]E7V<<.^&PU2_K06.7 M%76&7R.089RF)1`Y>%$"4T+IU$*X[KAX0KM)/83OHF"U"B()#(E,<]WBLH*X M"%0'O;A=??.9B8IM*-EH63X>E<-F!5H/+&9:'-%UCU+`M>M,P`X#P_2'P`S( M%`7'!\LRF;-1F2"=@32E>T4.BY*^4B\$GAWG>/G"A@Q8$F378LX#W\_PY6+Q MM>N0(41OQS#%PNO-MRMV#R)X&_P;#)PD.\UG\N*I\%%BC.+>.7[@W42P&7"` ME%D_]D8R/.SJZSUO!,NG@;HC5<#B@OII*:NU[T3H:=V6P1+ZKS=BY)&UG2>L M>,=A?"IQLP^#V\*W4Y:T%=X>/.P1D#3(1P4B9X MWP2`S7+X*Q42"N->78-;-5"4459Z>5G&)O$=D"*A6YTTIU@'BRCMD2_5`SRO M(]8C\B8K+MQ^UQGB99Q(4R.+0]Y_@\OG17-ED9X5+1#5-OSI<=]#D!E8+G75)Y2C/PZ4^Y!W3W/L15,#PL M]$P0UR^7B8H7]<:!CF+MJC]"E(*XEDJ@('ZJ=Y2A=P\%Y0=5;1[`#, M3QC[EQD5ZJJ`@O_$#EZ8QL7]G$HL`=\_2KT1LR[&!V7FAY-.@-78!)2I5,B] M(IJP20^MCW"MC<:97_1F#0>+\['!RRT#@LA]:2<@\2UM8!:`_JIVF%>S>6O4IT@G,(A#@`9E!9$7#<@0$9 M!G1AA\+"44#,?,/@6<"W[?1CMJH#5,]`;.QRF@CF>C@_1Q,0?73+0)3POWPA MIO@+?`3Y,9JKO,(XS\`@CWS%3$1Q>%+R`/$,,TF`Z5C!+0<.(W$39WSA"`\# MTT:(G>^8?V#(.^=B"&9$3"*AA_%0N0M2&_W;4:H1*`6.7RMC$(T83#KRZ9C` MJD$BE`KCI!.T-19<>S",7I[WND8(BY(M2ZH#SW^Z86;-<()Q$'@JCXJ+ZZ+? MKHI/=3I%+.45L$02?P=V\>.["-F#WN;=)$)>A6%\)"1GZX22C>!P`_9,7_W2 M:#)LR"UL/(U$&,K*@K^]:+^@?Z\"E*ML#_`)5@!"=MB:"F=?(]'GM MK"[<70H?@;8.C>"W0_SC*M40@GB5A)AV,:R/^Q\>C^'F1;UU_/6D>*C;"!9Z M[XV*3BW_0J^@<9QC"85_O)6GJ25/(\E3KNN_5B5+S92H0[>ADM9(]_*G[2LE MWP=)FCF_!F`P?D/;\U>P%M?L'B67[_RT]T)9M=$'['/-@EBUI]Y/#ZE\'5RZ MO?,UFP!I+!ZNVEFC\U"$>\CF#DFXDPVFS>Q@:VMV_K7D6BIG';?77K/#P,'D M[%':[*R[!0I$?,#0-08#O-`A_;\:@_OFNL9WNKSHN^UUFT3;MJ-[)L;)V<6> MAS'?HY:?/04N>FZ_WPAQ:&3?UW6W^!7OQ/WM3&_;OF\OLP;;F.:Y-05L]\:C M)O])U^V?/<:H23L`Y!%E_N+"/>LW=[CP09R)!W4_XPC=5OBS7=8>WF7MO-]S M>X,M#RW;9>_HZ7_2Z3Q:E\TM#RY+]AV(?:_K=B]M<\6&-E=\4')JCFEDMW%X MJU+&ROF$#"5PN+P0\[\Q03R(J-(P#"@MC"L-PM`H=,<>"?!WEAK)I-=,[2N5L>4B_::Q MS\7HLO?2DC@N@E`.*+@Z_]:,-RRN0=7ML)`OQE2M/11A?'?C.;T.G4;XFW:K"Z@_$J%E(CRP`N`*=":G%A1U MP2"XE.!`Z9Y9#%H64]I1,HL$2BSFP":*/X*4BNZKLN25ILZ)JE*]6'87 MM*A#=&7KX/4K;A^WUJ:XNUB6"$J.]5*JE5.],[@S1>BEJBU%@5!,A`4:4$%0WDJ?!5MPXN@-"-'^[;!:."EJ;F(]C2M*@V-$O% MZN$Q**`/=$['U4>YK(&B-Y<;1W0J5>!8GBAD18CL>9B:;:ED3:(P\\/WK[\? M+HE'I3;P$>KZ\$%V]VH5]BU]_FU2=/[BMI%(6^X2$*W%=*;H*#GA%Q7L7WFE MDAPNW67I<4J24_`DO(XJ8!?94[89XZ/3A9?L+^S-1;DZHD3H:\`A9\KO]*AU[7+;^NY8`5 M!J(3!ERX5Y:[I1AQ5^\0FRMY#O92G`+$XS#&LHJQTVFU?V(%N/27U:Q_+MV$ MU[5;_?Y/5B"7`[O#)K9*2C_+.K=]` M7K&XXW)`?4)<,)YA?Q$W+&)V.(S/M2]\/AV.^.AE6&[%E<1O06!;3IDMIO(! M!TMZM-6U)A.D$X^K?I5B]A+00M30*QZ-PUIY8QAT#9B:!.#+NE1U=%!U*#Q()X/N^5!W*G"9_'!.5Q1D(K@*MP.IN\K'MY[EH3S+CUXRFK!@GZD&/E\\ M'VOY/GJ1QUU$G!1LBQ"Z9K@"HP*?D@`V#ORSH#^*((!L`6^L MSB:WI_?%ZU&(Q>F1#/2J"]%G&A/FVYE?82-8ORW^RMGI&4H98;.*@C,IJ[OJ MLK$404>)7\W2_=JEG1,BA\(!`5(;CU4D*,*QQEYTR+6BO6D\`0_EP#Y>(-"J MN7SL8$.1(%*Q$!T#JM/T2P-$+AJP&!FB$QO;9]Y(1Z>(&@'`BPS%3>[*H:12 M\Y.R/V5$DVKP6E]18D20CD%DC^G$D0&YJFHI^B=+(Y;5/S"!/0`.WM9;QXO* M[@8!>&^\:(E,E6-$4G.4W[$\-NH6390(B)T$?9QM`SY+'9!E09\_`NK;G:J& M,$98MC;LM;C])9LE2'8<`W(.&?]1DG=<=O=NPSTU0E:$>^J"/&OQ3#'LRW6H MQV(EP-/GFX4BG*3;+,FA:2\O+\ZHD2PP;.U3U3N`LZ)UJ%L$^!,Q]7C*BVHX MPL-:9E[@(^^I$$;+^5J[:0[-JE7UIM`T>-DY-]I3\Y"Y1)Q6O5!L4D;-;T`" M!37\!DE),-I`/^F8T@^PE;4!85PJ/FY8*5,6V$C!7D\?\-X\BN3T,KWQ]2(@ M+-KWAO=46[T-5(8QAF<#:%#XRTB6<4+5]K-"]'.3Z(\527SFQ[7TH(1L&T4M MP%'!9]@EK1HR+!SMU>RS=AI'A8<<>3$L_2(X]&\4>+ZTYW779E>=A$8+37)' M9*,T/YX*ZM)JML;B[M?2DU.#.8LV62?*GY#WU.I)\4-V1@)1$L%-5'JGO"C> M.6YJKJ-;<+YR8EX$,>*H`0POOU/VD*EZ%97&K)AQWP MP@#6(=_0!1M(^#?<[4^V#5,PZB90-5&"HC?N)LQP&/?L&5HG7P#724"^/\<5 M5.Z7J4_*7:$UU^D\,;?>,IF%'C80)9Y)50==H[&K+T8A3:P):/@>=X'DKG7, M0/@OU=9.]V6DYN8N6@"5+G?Z26Q21MQ++6Z%[*DHHANJT1AT#\#T$FL)>FRR&8TCT$L#L._J#.:44'63Q7 M$S(S=$#5-4"LY0&LVW>3$OD)ALN1E4MGI M[I]W]8T)BWM]UJYQA*-B&W[$/T;JW4ZD\+V.CQ?R5W,[O"!AV"T6)V_7)F\: M[5P!W!_D,&98%^-@Y^H$.8VNS9@S6$QY]#$-&ZUKY&S5\)X8X-VMBK&7 MAPLI/,M4,/CZ`%TR=X1^@\]O-1+O)&7M!2-,^.?]+>45F+EF1UBV[ M[[*3XLD.V5%Q57R'LU+]7+C5U^*OM$5#/"=;0F(O5.R@*X16HM(34P[BO2&D M!UNT:LK3&&40CVO9-HCJX\61YPOC/.-HHXF85"`*<6A[2&"O2'_*XDM$M/I@*!AMZT?-5ET%.>A+PU:AHL:R2X:ZI6+9L.>0/M2-496[OM";_W1 M*,GY8I.9D"Q0@0+.<8M@.H55V/NMIBG(_$CQ0R2C0$YY9E95NT`:^(>Q6W<9 M6CM^']G(-3#OR>HO(%=?:%9RKFNR&%9>:^K+/G6IN7#AMS(OPKC^V]E]&L?[ M.H/*I9J\L%Q(REX.[8HD[,6$YB4_5-;U/=<)5++"Z=*Q,O;Q)^:!)-L5@Q)$ MOO+D3&X:N0D2F8Z28*B*1PPU,A&>[G]M;I/>]1N^J]B<:YR'1:*S:AXO$V`, M\YO5";QGQ9R+0ZJ&9V56?RLS7>U]>3,N(JW.?M@U9+UJH?#:-E>'BPJY;&3( M>[^+5GN;U/%5ZEZ^^;ST9E*H#,$6*>&K<<3*>I,[0H3CF[S+Y5N=F@46Q*SV MC8/#7CD^)T=RR6VCO$\'HSZ*G=6WCB7O;A4#_1Z%-(%%![HH)!=0496GYKW( M=Q1VOPH-*P\6,`+V4@P>+$?TV/2ZY8`86O(%/&IZ4=4K2Q;:)E-]C4IF(V/] M-@[!-?42CJP:7(^*/Y77R]U6IX='&,YD60CCF`\.6NT.ET@?,[,?F9;=X:W) MRM-SY0W*PO5)<6E2#/XYZ/4)N[K%#8KS"+\)V)KHP\V.W) MI#]NT*0>,Y(.(@ND$Z69X^3P&;/"+;I[A0-?2V-P1]3L+/ M*<`\,A(-5XXQ&6XYWYZ:WEX%5&A$;;?!M/N+@_G]$$J-]C`-1,Q[$;'AIPU?+"N9T.8/O@S;%&X.R[U>, MF.75"AL58"\YK^.%"(?\:#G"4#TCJ'!(!>-@M&C4L/M9LRMR*9?6`'ZK6Y6X M:0C$28NS8Z@&I^NAP$9O&K/PDRH]8+MY1.$CHVMB8QYZ)SGYP,0"G_5).[RA)DOHU1_$N0,V!Y1'=B3`B, M*W#2/9,',<]QVOMW9$9HU4TE1VEIDRWG:C2*$S19P[E,]U=)F\4RA!32"X6) MQNH,=T`O(E6IP^6ALBP,6\G6[RB/< MV&XH784>SDHP0#X&4VYW$'_B`Y+KD\^)I=O4_0U'<6.T'HN/8_`)7G;;I0O\ M#CC^/P]^4O?@>:1RR^E&G$X";.:!\N*AQ+'/<3EHG0_:/U7O^?DE!$E4O@1_ M!Y1JJZ M*5`[<%0OEA@4F>4+N0]J#^>OTY4IYW>3F-:^BTBW*&6IRAWN6 M6,"+()_6=WUM?6W!*1M^=WSR.V#&+R@YO5`V$-9X)'M"" M6MN16C?#$E4>P<\8$3378+B>=4^/(4C:T*/"`VP0.@>[P\50`V!CI*P[_9B2 M(YEK,F=*%7=@Y++.<#YZ`1?]9G"`>-US575_"&7MS,!JDKT0>4R]JOW'F&I) MT6'HN9:-NGW94(&3;F0:!W`WM2?1[P1%6EJ/I1J8.!T;23LXR'P"N]5&MQ9+ MZ*04XA4`E!Y`PM\3\'Z\C7-`7)-GBN+&=>0NIO4I_%8).8=C>J+XURH MECC,):A)\,2%];D%,OZ0XJ[JE@0]V)&7^% M:5P"`GZ)X4N:*S(*9#(O!D3INJ3$I*3.\+XH(CL[X53HN8YV)Y6;JU%Q<_6I MVJ"$@)EZOD"K0=Y1X@46[AJWCSLN,3CO1/A\GG0^Q+'N1H^1L MQG#P@(XK['(VR[BJ4?.@5$CD5N$>`E_U0<.GZ&A\V2'(Z^`M4>[6"P,?+!]% M09V=B45_R*E^XMU%:$#B^HJZJ]#-,E$'-OEO"-C9>6LPT#$2!DS>H/C2^%.< MK]AO-6N82;.J>TR;?.D\^KE_N2Y51M>%QUM5.196&1>TS5F:IBTRCB7/TK%:TS]!W; M17YQTO:,9&;]=KP'#2% M1VH`=XF'\`-?SE&7Y)#I3A@,04,9A"9E-^9E9W!I%KA[3ABG9&%@O'$.H*,, MYT$Z,3.IZ5*:?GW6*D*8R-W`#CAF0P==N*A7UOSC3Q"#UKRLA[BWP[/_7:E$ M8^Q\FDGV^B)\,9TQ,U;/O5H#H70HCD`S2`V0&"\:FZ7-14,,0]F;'BVS-LJH MTHQ^6;6N%AC#E*00O`S.>29$*GA1-AY1>R M:@'?F8[4.M-W*!`1G&Q"KC6K2SYFS'=S=$+\A16(@(9.^ZS5&0QJS\UU#N'J MPB4G_1[!B#RVXHC)9UKYD0M]6(=/:=/(R?3_C+CA+S@:. M4AU^,'^)\<-619E*+"MXTA3T-4#<@\(_;_4W4/>4?Z1TR,O^!?-+G::7M31K MJOK_^CE/3V\\;_;+&YE1]):$F@AU%?EO,-3U:?S92%_X!L"]">/1][__S_^! M\Z7^2[]A\5EXP]?@)L+K'S#Q,9"?DS'ZF?P(D>IW47H"_..+&/_MQ7NP1C": M?MKNP/]E,?]]?MIKO_C[8]\`-S:X_X?0-5I^X-U$,<83V:&8>C=LYB>W`6;S M%=P*WP`[!R,T"^.(A$4]??+QRX=7%-2:Y5QB-(UO$F\VF3LGU]_@FUF-PSQ.8A"OV=S(Q%,E4%3VY5.-N'.UD/,OS]\9^B?"EUUA M,="*J7?Z7_(&B`/"SBTK$Z!3]^))7/!/>(&`O7^9Q$"N#VE(K@K\1[FHK;JK&IR` MQ3N@T`]2AII+>4Z*EV,H^C=\;P>[*NKQP0F,N2G7X0J_CL38>VB>`VI:+,3S MM:N(\P;L+ MV2_CBY:?CRAW`,<_@+=GSHOI2L4-,KY9H?5$-WNE)J=U#$!7W:Q M;8-BKG*!,14Z`R]5!G3-=KFE/KI@')28YS=A<`PKH^+[.\/B=HW?Y6G]Y^!@ M%%^H;`8S+C*=>='<>(3,DR"5ZLBJH%T,VM/VE/,5;58OD2GXU]1]8L2>F\&7 M5U^O39WQ5:7;=-JG^']GIYT^+!?,\I!2SJF5M:P?#CG;ESA/M91`/R3-@2W! ME,.:*>[!!6S(VD!FPF.&%K(D^',',K:@?'/<^8SVG&*'(H.@P`#1`!13E5R4F%^0PHDO%` M044-(\'A;\R=#2F+1@-87"A3!VL.?U*X_%\@U!3A4H6E!,0[QIU!CW]]>%=2 ML'\(4ZN2VH!'*)]-A6+Q:IB2@/_D]FRWL>RW:>3+ZM^A(:!_*-OBRIJ?@'JV M#(&X2#[XFU;W!6=X"5TN5/S0J?D1]]B'M;3IY*'G$=(5`27E>>$\#20K(3XS MQ#9S*4-VJW"EM\"DI,K2C$^<%=T5* M)DB7H>07YZ3#B7.S^(ZO;.0,`C[UM208(#`"L48-CCC6>=)E`(HN@W17,TSC9$B.)JWN2JW-V9F8_LL- M#B@P(G>4<6C8=4I0RKQP<)Q53[^A,*%6X2.BR8=(P<>1J$0SA?3Q66[TM0/8 M\^(67X*NOKP>"9)1/D6W?%1*\/B%\Q,%+BVC_09V%0CN8FB$"$RO5_L"TA,$ M9LL-_F'D9;*XH(8$"\R6FJDRD_C.N/"/Q`W(:C&4#J_&O.2[D/T;-#KE)1#6 M+,54/@1O8E&1FH__&X-$^-,*MT0F3F1TD/_F#;`"M\?O#L#\[QAL2]_Y1PL, M;RSUXJ/F8^MM"]4#P`DMYVVBEL)3@"1!N:ZNAB M.@OC.;#X!#0$Z-.(6C(6\DH/H]3%N2S\IA0G;!!'MW3Z9_K^4'_$]D!J-K-9 M:]>DD^5N>45C9\7VZ?PLC*5XB+?=\K!=M0)=O1%-*I$$\/-5?UD-,%W9Z9^: M40QU_II>A:M"NS1QO=H1K%C+U&BPTB08"$?.-(((4U+ M94"4Y@QN*.4;T,%91BNETBN[$>^,DR8,QFXKBP@4],8JT:#YT05MG`=ZNE,(#T?0F$-]B".P-CYWO=,V9@ MP5D25%">-%WXZ[0!@(ET$E9$8#,0C75$R'?#=2?]3*XLD.//X4AD`Q&K@E")&/C">N``F?MTZGWG M>_%2`[LXNHFI?:!J;V#<=T@AU#@L<*),O3LS@$'>-C<2'N;^C%(7 M+!!KJ5!`<:@Q:U9B'.@(H.,P)`N5:U\PZ0#$`?,:7G8'1>(:+?BRVRER&]31 MI^&,6!(-_E4H".>Z(ZH^GND2W,`1P;&()\?$T4-YH-%* M[!B[JBZ07B7PK]109[V"_5AJ^MUR`^+MM5,:_&#ULJ5^NA^V%;H)%I=<*8/7 MFVHGY^$ZJ=OI%3JI$.[.H+.>8G*V4DK%SNM0KL%8K9:`XZM'5Z=W:8"]$Z5D M7+BMI9CNP]%Z*#AVE=1D,"D/1IOB9>>^P@0>):/*BA)Y.8.9/Y0=0>EDM4)& MEEJQ1"E9-I17D?(EJO%"6G@!9H$@V:E#+)'015D$2+$N-<"RJO\NC$]J9%?G3;&W MJQL_5=Y[V>HLFGV7A69=]6:SGY3*=2YY=F6O=9'JZBRRTK8K::,&''&BA4V% MFFO1[\=4U$!\AP=@8Q-O'"LFM`M`G^F*Y=#,B#^>I1S?KLIV<7QK#H-(2 M.-PK4V7HAH?"+@C"HMW`TPDIKF+:%?)DL;&!G21EF9%SS@OEC&&\&B/2X:6. M[L4JLXG+]Z7D^1??E`M7[XA=[T1-^+PF[F#.)4).*QF8VNDK^+I+,\6Z5%$K-4Y)T MLE/5(J!\,'D!=7WD+L[R\H"#IJMII39$J36L9(S[F3MA=I0M"&8&;M4MT2)H MBF0GV7R&#`$G:;]-[2UP?-],#.!8P4[RVQK.*`.H.=&\1Q=I.'X$B&R-AZEK?CH"@QM)8;8SF\ M0&7J8)5RKJ]?])ME`!Z8&!MUXY4Y&V12?Q=MR":B@NFJ)ULBM'9*"Z95/@#0 M@8I]L5H)][L$1OXP MKCNBN#3O<,F]WT24].()WH.0EJ:JL^A4*^E7=4KBM:Q@4WW/L$F0O'[*%J+` MM=4&1*@X%8:&#&J,^[K?6DM@1X:KZ>NQV1AY(,H9AU?6K:0PO#AJF\X'D9U,O"*3'99`!O* MTT+5@-;BY36F6+(Y+04NGL&Y$^LLNJE144,MB*F1(^-49OHHPL`O(MP7JACL MT$6W>\;CYK?0:43>I3%<&MX:;P:R4.T'1!ZT!9:.J] MF_!V.B'7BAP=3V]P9[4S3H.;TL_6*+U]0.%LM0C7 MEMNN#]SFLQV-'`"C^$:AMVC:T.ASZ4B.S[=YHGH'L)J219:WTA\UR\GDF65H M0C#1=*-\;H*?JM"[F35 M*L30%*2YS?.5)T8&W-.87A!'\NS$=LGY;";[Y[!9GV*FK>Q_L`#BD=MTA;K< M3C%^8=?I"U]X(7;I)_.&Z<1'UW$23X^HS+I][!GTQ+39U\6;/%?:6YD>SP%N M&LJKAP5I^DY'MQ1)766SDEF'/Y2YY>3`%HC0O<`HU*BJ)63J.6>ARY1T4!O3 M5(2W,B;%D0J,3('QEV/3';,_OPDBWE%20,*C1G,TA\\`>VP4;="."D.:.N51 MLJ(L,HU5C()=@B+7G*EK=@ M)L(6KI&9"3J6UKV1O2//YSKJR.B8C!/)BH[[=F"T,C(&5NN%W7)(<12"N"]) MY`4#),7FF2'+[#".OW\78D:OCDKN:T$O)2*@+EA95V*!^)E0/QJLWV`,;H#HIID1Q#4;"-^K\#YJ\@$V`IC@B:RH;>=!#$^&%\H8"[.XHE9VU M$UF%#08NL38'U@)Y2'+A($6ZW\DMIRO.58:M9EF'EB24$B8Y:*>PJ90Z5Q,O M-`]06KVTJ)%6?VU\7GY5$)6!*>>$$Q!%;:%!XAG6]ZHD9#6B&L/=TF80-#WK M%,Z.4Z7&Z2&Z#Z#>+,QLW!)&ZB4\:?PX'V;C/-19$03#R5`U"9393/`T'!-9 MS)JS4'-TYYP$V#_AE7G8E?AM%"LD<*H\1>@I\4*R*C MCWRR_BD:Q%=.F#0TVG>.QX MLQ0657^]!M'QL\DO=&/]VEEWRR\*>!"41*U#MC(<<&H((L]&+)[&0!/]PE>_ MD,"?XKA$7KF"PU/\;!W%N<:].122/:ZENZ&5 MU\%\*(>Q?"/1^<@B\PY%AF#3@UH.@8$GA="OH($>'9T_9\F!Y>NUHYY3TTP[ MNQ>Z*DC[66H;_GGM2`6I0'I#?=``,!KDX>^.O_!`TR#B'+\U^>LPN+-D.A8R M'5Y%/"TVZS:"S:@$JVFL94DC2=.WI&DJ::S4-)8TS9.:3<]*0!>@!U.L(Q]= MYCCYQ4ENAB?=WL"5_WFUZCR5'O49.M0F,?!\+0SMW9RVUS4!__70KOS^G_;' MG-65%M&Q[MHO-]M3%?/4M'7=M3J="[?3OM@0B]OO;5/]8@FWC'#MOGO9[EC" M'1OANIUS=W#1M80[.L*AQ%TT357NXKS_8Q)DXG!.L[KW7XW)?7/?H>1I:W[K M=]WV8+#Y(OO8S+,G1N_2[7?65-J6&'LFQL6EVUGW!+7$V#9\U3L?E' MX2:N[SY.Q<"W[+9RH3.PP?I-X#9+B]?G(")M2XM&T*+3->GZ2>L=UP/MP>] MW9?O6GU[?[A[D$W@V)2Y.^TUF;N6'0Z%`4O]?5"_[78OUCQG+/6?&O5[;;=W MON:EO:7^4Z-^9^"V&TS])Q$KJ.NHHJOX$)PUNZI8"_T>5AZX_;9U7AM"C?.! M>WYQ9JG1"&KTSGINOV=EHR'4Z%X`-1J11W/H8,+RLW:/X87/J@!>`U4JA+?F MYZ.9GR<#MS=8,U-CI^;G*TOTQR/ZA7O67?/"QQ+]J1"]<^8.SM?,D+-4?S)4 M[[O]SIIVY^&H_B3""K_5CUVTMO<]48*VV^Z<-\'VMM1XW3GON)TS&R5H!C5Z M/;#,+M:,!EMJ[)L:G9[;[C9"-IY%E$!V5M0@K>RP:&W*1[,INWVW>_$8)J6] ML&P`]3L7[F7W,2)&EOH-H'X?J#]8\TBTU']JU._UW7[*"VFD7&R#O MVCCZ%F=&60-.=%DKW+",&MU=-6G>7"!H:>H:'XJ]=WG8$(*-FS]T!UOF[4DF M>2QU:.G_#IGLL(&'L5EC>G/;MNF- M)4WSVJ9;TEBI:3IIFB'#1PGX>RP@6,EG!TV M8(<-;"Y/V^=ZV6$#S2&&'3;0(&+880--(H8=-F"'#=AA`\^1%G;80'-H88<- M-(D8=MB`'3;03-:TPP::0PL[;*`YM+##!II%##MLP`X;>)I5G';8P+.FOATV M\(RI;X<-/&?JVV$#=MC`4['0[;"!)E'##AMH$#7LL(%&4<,.&SAH&T$[;*"I MYJ<=-O`,_7ML('G3'T[;.`Y4]\.&[##!AXL$$^FV;0= M-O"\Z6^'#3QO^MMA`\^<_D<\;*#HZ;]AB_YJA___%EZ83:Z]1'Q*;KPH^`^% M:MYX_EO,[.#Q`)4A`1MU^=_A'`2>9K"[,0MKTPH>"?`/G09#Z2^`(X>01$+S M"/. MZ@5#>B2"6YHFD4V\#-@S#WUG*$;Q5#AYA),B!`@#?1_#TWX^PB>%,_*29`Y" M[=QZ82XPBSC-1Q/C?2G^`)X,&`R19L'4RX0O[7>0^__0LO3[E@.0JT?@5T%J M`#WT4O@9<`ZNZ]W@HK!UVQC.'>$!)-E\1F#-O+E@$&+PA!Q`1V=P.@74 M39PPCK^?HAODS(`&L>]2RG.,]6#PQE#<>H#L,2B#.$E;SI63@JH*QN!+P<>S M.*&XK(1D5F)OE=V%;X$-(2H(@E%\"N!0#)>SJQ&?A-W4B>]@DX"R/'7&H!<` M[BR@!^\"`%7W]P0X0.?$^F(DT1`OB>8,#GY?)2L/KGK^'EPR`, MLCF^'$"&GP.Y$GVW3%3&V2O_`41IGJB^WUGKW2WG&Q"9P^VXQ*T']$?,,[&E M+,"[@^D,/E)[1?IFB8A\$%MB=R]U1A.,RZ>`0%H:0(SBZ=QU[B;!:$*?YDGD M3+Q;X13OD\P,9PY(`NR$`!GF<%Y'G)"_G$]@`T,!VL(G5E_*);"_5.C]X*D3 M1#EL,9Q+B)DY/`T:@5"`M[!CE@U@=2FF^`UP_0A0WUJB$XN#=HN34AVVB0]: M\*T8BP2TSS?OQQ506_WD8*?I2IW\Z&>KPHX#Z'$8/X<_5J4A]V<.[#&>/X.S M]D-$AV0&.!<_L`T'JY,@I;8<.1YU>8J'E511&4E0&"A--!6@QWWZD)_#MXSP M9UX482F.&(]1`F]YC00/DI;S.UT,DB[F%[B@'23Y`X*(-2S\@A9-2ZL&I$73 M/,SX#$!E'B=>,G?\`%8#01\5JFP<1*!+L+MT(NBX`QA1[_(KI?Y2**@\P@?N M>`D,I)X`?@_4E5"*6V_#@#U(IU:O;)\('^R2":AD>)TWFPD/ M-.DTAN,B#+Z+$`$`TN*OZ;@PX1>HD,,0OV00BE>"D4$VC[S6U59.P.<;'`%^ MQ=1:1`P^$`!Z"J-JT:!Z#Z&BL@@0/X'JT MEFFQ])19=414?38\03RN$$ MEQ+M&V"!<*[@8Y;$43!R)N172<,!<#":1'$8WY";"S^& MUVMG&",V8!9\@L,XCD8?IVG8%HZ)U\^?'U5+`=&0X;/\&XG M@*^A`.O*@R_1ZJE(P`COK3':@F]L$1!7*5N^\BOX#2S@I+P8?*[Q121(,$H2 MYQD9(*#Y*'+$0W%2EPB>2.`#5,D$E,(Q+:,!)UMNR):U`#^'XF%(0%*XVJJL MHW,+\.)0()ZM.HQ3"0X>Z(<<[>P7##'-,4R7@;:6YB4L-2=?G:,X8@K&&]E> M/AK2"G%YJ@^",I*`LA06`[+>Z$!0"?UV%>@B)R#!GA!7R?*IT,*SVG*%;_! M@$4DPA3#+111=$:A%TS3,B1D1@(4%$N4D4%))'*62C@J<)]K\?^'A^Q/D9(; M<`Y@R[$O0N">#,]<=*^(M$Z3*#`G7'H$X";`KI%`R# M8)27)XQIY\.P%`"4E[U6SYD"DJ\[+0&^@,_3\@C0$H%/QP*JS(U!`Y0 M=7"4(HY0=/`E%,2-4X^,>HW\M`Z-DDOP:_)4' M/OC?5Y%_3>FUX1>1`M."YK6&2=V!KC%&Y),X]MH7;KO=7KUB?]#JFBN^A>])N?2-$0 M>E'GK-51+Y)&".B?LT'K8NF&"+*%!J`RK`K/E- M9"Z:X2W$T51"D&:@&"9Q2&>TL@`R&L3-RL^I47Q:[]&V>JU^6:$:NZSH1?P: M@0SC-"V!R"&4$I@22J<6PD(YWP]?QZ0>PG=1L%H%D02&1*:Y;G'Q0EP$JH-> MW*Z^^'>=XD<06$9@D9"!C@@C?-?%%:?&UZY!% M16_',,C"Z\VW*W8/(G@;_!LLI20[S6?R$JUP=F*,)=\Y?N#=1+`9\*24?S#V M1C)([>JK2F\$RZ>!NN]5P.*"^FDIJ[7O1.AIW9;!$OJO-V+DD=F>)ZQXQV%\ M)R^!"SP0,'151SX3WO2-`0_DV2FD>F"*LV6/[I/$B<0=VRB$HFO'<%D`WL7CA&*[3>:V8]$)M^H*PMBBCQ) M\#8;@0J1B2GIH"PA0[#ZQ:U*XE!<5&4B/K>UOXK/@2,\WA7ZG(&ADI'P)V#5P>8".&D3/#6"P"; MY?!7*B041HZ`!K=JH"BCK/3RLHQ-XCL@14)W2VE.01,64=HC)P@$>%Y'K$?D M?5I94IS<"G/^514![!$%?!\+/,(R%6 MO!,%-\CEXV&&CG:A89B[:(_2IR"M))*IBD"HG^8I70/">T'5646S`S`_X=V" MS`Y15Q%TN4#LX(5I7-P2JB29S$B1I$"CS&)QT@FP&IN`,BT,N5=$$S;I@3,U M6_,E=&I>*QJGK#Q[?0R@92S.]*H_8S!(G%O8)GZDDEPPTXN,C!)@R,KRJANY MC86/-"-EK8#J<3`"JR)O8%C30:AT1!9,`2B&`U&&#\OXK+IM-@`&95/`BH^6 M(,6[ECC)]+4Y9X7!B1EG&+!`C22U"]KP0<80@4RAU,JPXPS5+,:6.56.KJN+ M@Q^@D3LTL0@[!1,D"<(YZ_;5YT*A[TVJZ$\)"OJ=,NN*HX)M!"3P?8>#0Q8: MQ_?06E+N0<+:.@#M0<9&.21KYB)*`Y/2AX@GF$F"3"U++CE"&0D;N*,+S3A86#:"+'S';,@ M#'GGC!#!C(BI+/0P'BIW0;HTC-@,.AT).WT@I<"!<&4,HA&#J4\^'1-88DF$ M4F&<=(*VQH)K#X;1R_->UPAA4>)H277@^4\WV*P93C`.`D_E47$Q7C0G5O&I M3J>(I;P"EDCB[\`N?GP7(7O0V[R;1,@[-8R/A.1LG5#*$QQNP)[IJU\:388- MN86-IY$(0UF&\;<7[1?T[W3FC=2_*7OO;R_X=NQ%I8($.W*@ M\P!'2*^+@**TE`"[IT)U52'J?BN<#[A497N`7Z`*$*+3UD0PLRN9/J^=U57. M2^$CT-:A$?QVB']1I)'G*31"N5?E5,R7JT#V[I#72O?QI^[+2]T&2 M9LZO`1B,W]#V_!6LQ35;;ECMJ??30\J$!Y=N[WS- MCDD:BXY2> M1.MN@0(1'S!TC<$`+W1(_Z_&X+ZYKO%M02_Z;GO=CMJV1^N>B7%R=K'GR=7W MJ.5G3X&+GMOO-T(<&MDD=]TM?L4[<7\[T]OV.MS+8,8VIGEN30';ZO*HR7_2 M=?MGCS&7TTY+>429O[APS_K-G<1\$&?B0:WB.$*W%?YL2[J'MZ0[[_?L+@&E'X94.5`X_D M^$<]O8@87%"@Z$4PTT_VGX_G]#IT&N%OVJTNH/Y(A):)\,`*@"O0F9Q:4-0% M@^!2@@.E>V8Q:%E,:4?)+!(HL9@#&T+^"%*JWJ_*DG."TL;8Z/574;Z04@+C MG[R4_N4K:MM9-+8E*=:9Z51<>G%FE#G#!X&QSIC6"7$=G56:.B>J2O5BV5W0 MH@[1E:V#UZ^XB=U:F^(>9UDB*#G62ZE63C7AX!87H9>J_A8%0C'!>33A]*DW M)NRR)"R0N&\7C`I:FKJ88'O6HMK0+!6K MA\>@@#[0.1U7'^6R!HK>7.Y`T:E4@6-YHI`5(;+S8FJVO9(UB<+,#]^__GZX M)!Z5VL!'J.O#!]D]K%78M_3YMTG168R;5R)MN4M`M!;3F:*CY(1?5+!_Y95* M4!'>*VX,Y6-;4WCV79[$/N9`)\X7-#9/ M##M!=LVLONX5E^^$>>KTX&3Y"7M-4X=/JI(X&?(*6/"Y_BL=>EVW_+J6`U88 MB$X8<.%>6>Z68L1=O4/LTN0YV-%Q"A"/PQC+*L9.I]7^B17@TE]6L_ZY=!-> MUV[U^S]9@5P.[`Y;Z2HI_2SKW.JD-)53$'QL))0`9V`'(BZR\%3-^P;RBL4= MEP/J$^*"\0S[B[CS$;/#87RN?>'SZ7#$1R_#%SUJQ2SEX`6HLY@\6B4DPXY"5XYGT99C/T].H77.&!'[20(6#72 M\O`:ULH;PZ!KP-14`U_6I:JC@ZI#X4$Z&73/A[I3@2!Z\R> M"F-OXS?VL4-CY"O?HR`3P56X'4C=53Z^]2P/Y5E^])+1A`7[3#7P^>+Y6,OW MT8L\[B+BI&!;A.`T")Y/4/([L[NX\#A3J02XKKLPD+#^7'=G+H(K84 M#T%.Z`%N8*+K_HZ._.%C-EG=H=.`G,!"JP5:&AF+GFNQPT7.438\MST1"766 MD*]`+?`/,&B\",ZP0CEP@6K-N=,UPQ48%?B4!+!QX)\%_5$$`60C>F-U-KD] MO2]>CT(L3H]DH%==B#[3F##?SOP*&\'Z;?%7SD[/4,H(FU44G$E9W567C:4( M.DK\:I;NUR[MG!`Y%`X(D-IXK")!$8XU]J)#KA7M34,2>,`(]O$"@58M[F,' M&XH$D8J%Z!A0G:9?&B!RT8#%R!"=V-B'\T8Z.D74"`!>9"AN.#,A554O1B%D:L:S^@0GL`7#P_N`Z7E1V-PC` M>^-%2V2J'".2FJ/\CN6Q4;=HHD1`["3HXVP;\%GJ@"P+^OP14`/P5#6$,<*R MM6&OQ>TOV2Q!LN,8D'/(^(^2O..RNW<;[JD1LB+<4Q?D68MGBL%EKD,]%BL! MGC[?+!3A)-UF20Z`>WEY<4:-9(%A:Y^JW@&<%:U#W2+`GXBIQ[-F5,,1'ADS M\P(?>4^%,%K.U]I->:!^8EXK3JA6*3,FI^`Q(HJ',X M2$J"T0;Z2<>4?H"MK`T(XU+Q<<-*F;+`1@KV>OJ`]^91)">QZ8VO%P%AT;XW MO*?:ZFV@,HQA0!M`@\)?1K*,$ZJVGQ6BGYM$?ZQ(XC,_KJ4')63;*&H!C@H^ MPRYIU9!AX6BO9I^UTS@J/.3(BV'I%\&A?Z/`\Z4]K[LVN^HD-%IHDCLB&Z7Y M\510EU:S-19WOY:>G!HR6K3).E'^A+RG5D^*'[(S$HB2"&ZBTCOE1?'.<5-S M/:WQH_TNC1^VD51S)8QAHB8:\]`S=FO`18T3HQ/7O+B_.S'Z6*I-SW#05Y:I MJ0,_L%$C[NX5"B@B(/.HN5TX-RD!'_)T`H00WJ__23.[#,WB4DL^[(`7!K`. M^88NV$#"O^%N?[)MF()1-X&JB1(4O7$W88;#N&?/T#KY`KA.`O+].:Z@)N?66R2STL($H\4RJ.N@:C5U],0II]$U`(P"Y"R1WK6,&PG^I MMG:Z+R,U-W?1`JATN=-/8I,RXEYJ<2MD3T41W>"X%10(+Q2G(9Y\-'"XW+IN MZGT7?.IJ)5O,&TK5:XTX!.)_"#*!O31=#L&4[B&`W7&""'5.*SK(XKF:D)FA M`ZJN`>)4)#=-HYPK@ M_B"',<.Z&`<[5R?(:71MQIS!8LICG&GD:5TC9ZN&]\0`[VZ5L_56C+T\7$CA M6::"P=<'Z)*Y(_0;?'Z#N_C1/6XDVDW.V`M"FCG*^5_**S)SR8JT;ME]EYT4 M3W;(CHJKXCNX7OU6227LT\,YC(ZF[ M9CS*V?\UC3S*(QK1MF\2U<$-++X@YDG@/^-TV3BK-#]_A?/PM#.LK\?O:&1` M-E>JHXB;52`(<`)[2/.P2'_(XTI&M_A@*AALZ$7?DWR6C>92F\C!YC1`779` M)\M[Q.?*2.*,>=1DT5&P+M2]486;GO"[WU1Z,D MYXM-9D*R0`4*.,T":>`?QF[=96CM M^'UD(]?`O">KOX!:VI+_O4I>;"A=_*O`CC^F]G]VD<[^L, M*I=J\L)R(2E[.;0KDK`7$YJ7_%!9U_=<)U#)"J=+Q\K8QY^8!Y)L5PQ*$/G* MDY/!:78G2&0Z2H*A*AXQU,A$>+K_M;E->M=O^*YB_] M+EKM;5+'5ZE[^>;STIM)H3($6Z2$K\81*^M-[@@1CF_R+I=O=6H66!"SVC<. M#GOE^)P+`^S'F$XDV4AC&,^.&BU.UPB?W)BM/ MSY4W*`O7)\6E23'XYZ#7)^SJ%C\)W)KHR\F"W)\]9 M)K<-H6\8.%\IK_5!='WD/&(0G<,MG-*T&$1?OWI=3T23+9>]DI@HF9'X]+TCQG MJDEH0J_L9:?=`=NAU.6CZ!,BFWZ%H"X=T`\@]T$Z69Y[3]&>/"+#J;B--92^ M-X3#@#0'YP_SO$FT>CE`9?CT?/5JNHH54)T%,'5#DY+WF&:K2I\Q2G7A5IQ' M3G!>U?T,5D!-[45L\<&W^8AO!OXCDAB-:YRFFO$49\/%&[Y:5FVG:R%\'U0Q M7C>4'<=B/BVO5ABX`'O)\QTOA$?D1\L1AKH=0843+A@'HT6+B'W7FEV1/[JT M@/!;W:K$34,@3EH).9.=N^QD`(OY6[>@=Y4GR/@;H_R70&?( M\HANU)@2&)7@E'VF#Z*>H[SW;\F,[ZI[3H[QTBY;SM5H%"=H\(9S62R@4CZ+ M90@KI!@*`X_U&>Z`7N3*S*5$AG(6J"T'&6M36Q];3N7((N#.$2O5T+1-;EOT M)[M=Y4]N;#B4+E(/9R88(!^)][LCB#_Q"?$TFWJ'8>#O#'6CZ7+,7@4 M+[OMTO5_I^WT?A[\I&[1\TAEIM-].AT%V`H$Y<5#B6./Y7+0.A^T?ZIF"?!+ M")*H?(7^"I0!AO.-PB(JB2G=W1):>V[B'0KAPAE3GXIF9W4 MK+EQV9B3"<7N'7B$S`:TA%&X+DE;1?P']7"U(IYVAADC!,?"YC0"4EX_<:N8 MH19YN&>)=4Q!(-X'[.H[`]'M418 M(9K@"2VH,1ZI=3.H4>41_(P105,1ANN9]_08@J0M/2I;P/:B(]CU75?>'4-;.#*PFV4F1A]RK MS@$8D2TI.@QZFYB;ZG:!(2^NQ5`,3IV,CY0?'H$]@ MM]KJUF(I_1DSQAQR`I)*'RIO8('O*=1?ON0Y0*;*Y!#4)GKBP/C=0QA]2U%;=L:`+._)23@S69\^2E+9*Z2G!4C36 M-):@];TPC4M`P"\Q^$E324:!3`7&<"I=MI28E-09WC9%9&/V<<=")^+WZA$]Q<0X,^MCW`* M(>'_'2??G6LJ'@+:L[]1=%5IUW=5N9:[EXD1SEL0.G0XRX:)-D>6/4Z[2<1( MP-9]":HL4>1?I.KB2=7_8_N2SF7/[9_WJ:YV55OT.E.H5,A\>=ZZZ/VDLRF6 MY3YRC)W-&(X>T'&%/=)F&==$:AZ4"HG<*MQ#X*LN:O@4'8TO.P1Y';PERMUZ M8>"#Y:,HJ',[L600.=5/O+L(#4A<7U%W%;I9)NK`)O\-`3L[;PT&.DC"@,G[ M%U\:?XKS%?NM9@TSY5;UGFF3[[PF'DA.U163:S!X80Y7]B3ATGREXN^X>^GB M:ENHS%IT//$K=:)MZ-%C\GGUE35?%)O7RHO&M>)-OA6D M3AV>@Z;P2(WO+O$0?N#+*>R2'#)9"H,A:"B#T*3LQKSL#"[-\GC/">.4+`P, M.,X!=)3A/$@G9AXV76G3K\]:10P3N1O8`8=TZ*`+EP3+C@'X$\2@-2_K(>[M M\.Q_5RKP&#N?9I*]O@A?3&?,C-5SK]9`*!V*(]`,4@,DQHO&9F%TT4[#4/:F M1\NLC3*J-*-?5JVK!<8P)2D&+X-SG@F1BAZ7[62.=I8UJ8$/;%]:.EM_GU%H MWD18^86L6L!WIB.USO0="D0$IZJ0:\WJDH\9\]T/!ED006=#D&TUCNI)-^CJ&@Q?T/%Y],%M\&E6_)J M+XY+PZV16AV.<3-\4OE)OT-`5]#1#WH/#/6_T-U#UE+RD=\K)_P?Q2 MI^EE)C"CI MZH72P'(B%38A]&8IZ&'UUVM'CD MZ<_-1E_6\=>3XJ%N(UCHO:J+1A#_Y86Y:!SG6$+A'V_E$6O)TTCR\-Q.U MLI2:*5&[&$.1JCWU*DMM-':T-[AT>^<7&V+Q[?(>S7C>!8R.^[@S:&`C?F@*'0X$E_Q[(?])U^V=K&O\[I?Z:;H`E^CYD M_N+"/>M?-E;F#^),5/=%:1;K[H,C=%OA;Z-U=LO#G$GBQ_DP%'MW=C>$8",& M/N_WW-Y@RT.+8'B\8\O2_^'T/^ETW/:@^RCTW_+@LF3?@=CWNF[W M7#]32@9^]%\_KY/N44T-^Q_"=>Y85QBGWAMTL:>4BJ MW]K(6T#9[AO6=_8Q!5J5\^4W\"Y98'#&_88BL#8XM7^6Q-A+UL=D/W!F9:X? MY@^*'T%*F>.X@W\"(<7<^3#U;OBC["Y.OJ?.29'!]]L_/_QF)D!369US*Y/0 MN.2`,JUEBC6@QO@%5L89?9:,7$:N)3.?Z[3+A7(&@($$D&\]52<<(?_-SQ,H MP[GSQDLB;^BESG\++\PF!YE,L!="_UZ:=5[*`M0Y[UZU*4"0.N88(#T%`$,< MLM45?@[B2;G;Y1EAE!MXRYV'5&4'[)]@D)1(,\S]#`/`/`HX6+O8NP4S-8/$ ME^U]5.&#KH+(IU.=;VIR@QQ.@1EW6,J94@/ED6RR8CHD/N>66QG*D$]60R:H2P7TZ^?.)"'T]>X[>[Z4+ MN5C."5$ISE,@8_IJ_\5G!\PZWV_^XOG^\A=WE-/0KUX,;F*@?(932*!&H#Z! M(/FR]ZXWARKLM7$2R(.N(S]1=\1U>,Q>2.SS0N)\3?5X MI)<1N[UN7QU*W"[;6,F`@DGY(N3G$!J&]8$<&_L\3.RSUW$[%UM>V3URZ'.G MT9_V;CA)ENX]+,Y:C=86SWP:_QI'-[]B?>P5"=9_@SR]CY.O7C-K^ZQO;'UC MZQM;W]CZQM8W?F(<9GUCZQM;W[BY3&U]8^L;/U_?N'!!-W0>J[[G&SD,ZSJ> M#N6`@>*-A\\,JGCJ>T@#6<@"886PH];=G;,BUZ=HHD2#W\H9-KHEYA?/#T"C MW-LGG7I:5 M;!R@(K6A#K"I633QL@S1I*'0+4W+S20Q,Z-[V1KHCE4\&0D[-_'8B##D3D:N\WN8)5Z*YX'K_-_3Q)L;\^7D8&_9;XU?2NVI)]YMT=0T MD:U2DSD.P4JP#29.Q1(UDS:(=(GP=2(&SZ'+L:M8&/!$OT!VD)2]O&3F%/4X MJ_R:LEWZ!;I<_2X=87!T>\%NJV<\9ZRK6ID;Z],/!I?4H`IS27!0GIP;50:$ M6BJ^[+?.S?[*1GCC9:?;*O5>IGF!V./-"::4U2*']N C;NM MNI85,\R"JA/"FP)8^F93>^P@1N.NN%F<'E#%]-5=W.D-+>>Z!A4*3<:0=_52 M`D2.O7(Q+RF)PW"1?9QT$B<9I70Y\1!4!;$$]LK-D_6X1TV\)8[#-*I0]XLC M&,`>F,GQ8=C[#*4#7\,_QBPK6%[U@9595[@/XN)"M\BQ/#1ZD;,'2SE8L@W9 M`>9C[$.W'K+]Y/Z.AH^@GCIKG@O7L#0HXRCPC).AK/33X$=%XR_D7AK:_M>8 M.?X*%"X-S3166*'U^T5/5.X.6Z/+2^JYT,@D2ZR4M?KE-GYE%;R5VBUW1NQV M+I22*>FOUH6I3K3ZDB=C287U^JH!9&PXKOB2B@)S%I07JPK9!-XK1B-B7T\Y M/A'VQ=,#O1$U)N2>D]U6QX1/:4U6S+JM("D+U368<@MQ$E;1@]Z*]..)-.56 MKBO3G.0\POS-0J:1F]\&WDT4T_B1=)YF8@J;^/SKK]=5,\]S,!,8!RO=9^B9 MDD]CKI(X^@%VWK\Q>W2UP'?/V'`PA'VN1#UE65^4L74!E/@,**<< M?P(`VWK2'-'T0V0^0[UFP\4/9W946RN^OOKXQ"S#D,*"KK[\[O\4MA\G7,QT[_$I^ M;/IW&EERZ+'L[2L?.6N_=CY,9WFFY4<]03BGW[C.R==\F,4S4"J#WAFP#(Y( M*%:38VWES+9BAU.136*.3Y'W@5O`'KX$$3?/I5[U'DZ5$PF>R[('\$G0$BVT M8DDZ7ZG#$`\];9//J<,R6*1@$(^\/!6<#<_O5?9$%*NI3-CM(9["#H8B$N-` M3H-^J^!2W7Q-ZYZ$_":BCK^T@6)ICV=C#,WT>:D?Y>P\,/8%:2+<'M@<(W3! MY%A&W:*?,5'I/RQME?**6G_3[!G5(]J<8ZP:"^NNQ7*N5#ZCOMU89C$>"YK5 M0209PV.RM]^<9BV>Z,%:P12G36"S8VR,+86=P"JML;::3^X^KJL\((H@Q.5L0K!L:U M@Z\!:UY`EG64)57."-'LF'(L,@0R[] M$H.U=6&7GI\:BAM@<7HS1YJR11V!0T)IM'E%&;B.J2LJ&@*4/BAC4A!\^#Q, M292ZV.L'(AZ(9P)@M'BO*@4"XR&*P;%*H>&`?R@"(\40B27ZH'_:OJS1!_AQ MO3[X@C%QL!'HW+Z6SC?O\%1L:QA+`-Q2%0%91D@W" MK(T-',-+JX%01RC1Y*"/,0@#9LTTP/I>].]3'`6A0]RZ[%/0V&0RGMB>T+,8 M$C$.!<&-^B7(9`20'A<_6!/I8=H+*Y"&H&%B&OYI3#/H0*_@_!*_R$NDN6$1 M!5G!,*,I'KJBM9`D\ZR/>(PWB_1 M518\4`!!2I.2D68J8,*!*SEW6&*K9";A%(8Z.\G9F8TD[%3%+]LQX'"BX>8/^PEWL`55>XPKMP:JN.,IP,#QTMU-B:685:FGF6(G(Y/)3*:>SY3,YCO1-X1X[!%)RW"THDRHE+,;*, M/R.^P<)F>!Z$#FC#)>+&!ZA2@'%Y$G`QMH428ZN_5E<=['(EP@.=,W>-*?#E MRF34;0+37Q`46EGO!T<:>4^KG_3B#798G\^"_?C'[/"C< MG'9VE/Y_D`Q)/57@?,54@1WF*DT2(9R/\--)ZKS#PVO=W"2+T%J$?@U^/#XZ M=S'JIFD2]RCYHFLQS^%F?.#%DP:QUW;79:[#X,Z2Z5C(9/7#KAFO&3.`&CEW MS9)&DJ9O2=-4TEBI:2QIFB"N<$9^.^TC!Y M698$PYSC"%DLDYQ=')'3^M]I*>HC!T*O1ZZ#ST8[8)5TE6*;%:BXO%VUVWE_^^R?7(5=I/ M)/"]9)_[4H1;<]Y#%K)C[BQ!+$$L09XU09K3_V$W)^>;JZ\?KIW?WGUS/OQV M_>GC.^?DUT]?OQ:.\^=W7YRO_WWUY9US]>W;EP]O?O]V]>;7=\ZW3\Z7J[?P M,Q=_U_K?7QWX\<=/OSE?OWVZ_C___>G7M^^^?+6,?42,;0EB"6()8@ER1`1I M3H.Q79_*?\A$QR)^O9#PJ$+6,N^Q2&5T_#Q12;F<+[P>K6PKLSVT,L.IC1=M MM]U=,ZAJQPT_.0YHNX/.A=M;M^6GY8`GQP$]MWUVZ9X/SBT'/%,.:+O]3L\= MV+Z6F_:UW'FXPTN#D08IJN8+&!4;^\H8L-TP=]\-L]UJ-WE$KB7^?HG?V5*M M6N(?/?%/0/0?A_IV*/IC$KWS./K>9E(H!.^;@VTHU!+$$L02Q!+DJ1*D.1&' MW9R<;S_\^ONW=V]M+H5E;4L02Q!+$$N0(R+(DW!>_ZCO#Z6AV67:Q+/GWTU3 M&ZQ"V3=!-LPTL`39OX1L=/%O";)_"=GH'K[Y1VZ3'.`KWW>B.+H5:4;CJ](L M"49F$B-W8$SSX9_8I3Z.PCE/8J.^KP[^#H"Q++QRH<'EA3NX[#:!?RTU7G?< M=N?2O>RM6#%V#<;.Y^SFTL#<:A) M^HSF,XID%*0TPY2/9!YVP'VV[[PD\2([__PQTT7!BSL?-#=7U))_K^3ON#C0 M[J*WII%G&>"I,<"FAZ;E`,L!MF"@$768>(B%%M4`RZ ML#+V:%96'XRL,_?LC`:KT\TA MCCMQ[@2.00US?,0+PU*&K7G-6*0'R3M([\Y+?!H1C1FX.GZ&@X-YIK,*HXF% M:;'.4(R\/!7XRR"18Y6=.QQ/#U_!3OW]+@1:N>>/LFYAG:@IB73 MTR&3U0^[9KS&C`FT$QP;2YKF37"TI+%2TW32-$]J[-Q3._=TO3W9N:?/CVQV M[NE1DLW./3TN)T$:4A#2A'I;._>TH655=N[I<^<`._?TN7.`+:Y][ASP/(IK M[=Q36W:UF7#9*EM+?#OWU!+?5ME:HC^Y*EN;2?$`#K:A4$L02Q!+$$N0ITJ0 MYD0<[-Q3R]I6UUB"6()8@CQ7@CP)Y]7./3T@_]JYITTCB)U[VC""V+FG#2.( MG7NZQ]/7SCT]``O;N:=-HH:=>]HL>LB%&C)FTQ*D801YN@4#=N[I4TH7M7-/ MGS/Y[=S39\X`FQZ:E@,L!]B"@4;48=JYIT#+APP^73GR=-=35A\R7_4/X4R\ M6[#I1.3D8/Q%9-1[RB[\,P[@Y[?PWAQ#;'<3`<9@G"=.?!>!D3<)9F`R9@(3 MCE(G\:(;X8P!K4[O["S(//"U"48)L(+X=-TGF9BFCIQ`@OY`=C6-W-GEG@C,,.%O#]%Z,9Q,A4^ M_A?G$^?)+.8+5X`98X+X9`RFK8H0>C=1G,)+G&#JW>!'/*LF;3F?DW@LTI3N M=+P6H9O;RTJ16O7L?5T.AY7O<:.1+2[E.W"P`4,'";"5XV;=3>-FZ[(QVZ&HI]5\>`W/DL-W-3'VS;^-SV#LN[WV MFC>$S>?23;3M@1@6/"0.ZX*%BYI7LZUERY4>][G;6??>\GB['1U6:9(_)%FQ MI#;%CX!J4S;2G/;:;H_7=MWSYM[9-R\S:G6(>*PZ(BHOA5T<[!N8,/PV`:1+!?B:\X\T+&7R)&*)T^_0"#T&$H*#(ZBQ-E MFC(>Z7&*?U)20IK&HT#'JBEVO"PV34'?\3@5"&$@`\U>A`D/B?!22FK`W\J0 MI[*$CR;H>1SRM#+\F>936&2.U/XNYLX8F"4"\H:.[V6>XLY%82J.Q&7A3B+^ M,NXF*.HYW$9-CR)J.MA?U'03TV]=0BE3[NM$@#)Z"[Q=PUB/[LP`EH$V0([N MB[H-,Y'`>E[I9#S8[,7?#O&/Y1;O4&]D8U^\MHSAN/T1=9&P49B^LK/K/$GP MO@F.5[%N+:H-NB]9JS-P+P<7FRWX-(+NVV[AMS@:;<"!^^:WQD:SU4."+YLJN##PAD$89(&]B+DOX@T\UN[LE\<>/^*]4_O`4&-K\YD-6^\Q M;'URYG;ZCS$*@V5=]G=L??0R8EQ_-VY]<*]W=J'IN:/E*:?E="8VWG9YCP86UG:SM; MC;MY+Y&ENF*E0P^8$; MY*29EU$V8"DYJ3YUSLQ;:*"CT[!,CVT2._:>QF%)(TG3;QQICL1>67:!HK5B M_V+MW)G?1!'W2P18*/F:O4QMELZRRY!S][RW9J7AP;)T:I:T=%O(?1GTUKS$ M>MK950>ZQS55#_<*/$[G?M_W#)=N_\).GGM4$N`8AS7[8EEWL.(.%BVZUN^M M5>W*A7=#B[\3Z2@):.3-=DVY;`,6VX#E6*T5VX#%-F`YZ-'_X#/4-F"Q#5@: MR):V`8MMP+(<;T\^9<%MFC?%NT?9:#&%NW;HOW]>K"V M:-\6[>\]2F*+]FW1_I&'.FS1_B,F>]BB_:8%.FS1_@Z5U[,W$&SAD2W:/X9, M+ENT;XOVK5ELB_8;74)JB_8;;CL?W26AM9VM[6PUKBW:?Q+:]XB+]O_KY\TS M+:K%$$6]Q*?Q=3R=B2CU,*GCBPAQ?@F:Y*D:?"[\S]Z0[TV!BQ^$>`?WR:<;XH`A5H M\"QR=S=_:N(!W\:1<,(85"*<8U."2JA2!\7:,V!MYVX2C"8X;"D18YSA'F.^ M(C:FZ+;;YTZM.+C%C[PI-ZW`^3=X7*)FD@F/5[,D".$M,H<'(3C!]TH\]B]> M?U$_P)>JCP>O7[4<'/I3^M:Y@Y?2`*Q;^&0XI\%+:09Z;A*'/@[0\C+ZS(NB MW`O+7TV%H&SD."JR,#L=AJOE7"T.`W)Q:X1%V)-(;N64^R!-2S5R$LG\M%EP+2<:[#CO"!2*S@WB1?AM_0#@F!Q!T!^,9V%\1RG M9GG2"R4*PS=_`6:#\1SI6S`1`ZK68&!T_G?F_0`4WN0A[2!M.5_-IPF&&P'F MEA>&LTR0=S@ MXH>L4&K?T!Z2T[(\1EV6HTS8Z$M18'N_$T-W@(Y#T,%:^8%'$R(%3JC9@Z_KJT MMF/8))CP:.-&L0T>/:M;PKRQ15NFVQ(+]K[(SB$6WR;G^PFCX^G08N/\^C\$ M&I&@'Z]`9+P;T71L65)I4H$),@5S'@_+AN/MZ1#M^-$1;A[IM\>F9:7&+7X0 M6KQCEU(XLR08V;/QT>EQ#=\EX.WE7MAT?#P=8FQLJ%S=W"3BQLN.06`>Z2S< M&*>?C+B:>6'28.S:T[(YBQ^$%I^%"N0V'1U/GQ:_!N-C4+]/A`H;J_,/V"@I M2H.1TW0\[?V,/%POB=_U/2?"M7#7N2DE[LV*;BH;'P[C7_F*[A@1VSR(#DKJ M91`318\2?Q)$&D)*JWAUE$AN'D3-)ON_J(3KX7A=&X=[24ZO,T%V M"E`SNW/MM?S@F4Y(LCC=5Q>YX]RI16HS5/R..N;UUI^()!LXNJ7A!D]UJ,&V M\Z6J:VY6X>.V+[ONV;K]XNT8K=5K;]CO\$&DZ[7.UIR48ZG60,G;&J.6B):( M1U&6_@^N=EF-F7USUK'4I)\UHR;=$L02I*$$:4C7!DN0AA'D4&[LFD"K#$9[ M[JU>Z.2R=P&.YYH-L?;2$=92X76W=6XGWC:#%,W2JI8@#2/(\?5EO\;8;2A\ M%ULWC$6`:3]Q(IL(W',\/DJX7[[KR3>B/.F>88>,K2FPIP;MCTOUQJNC;JN[ M92/$`W0/M;3;-Q(M!2T%F^$(+]OB1AT7]=5NJ4W(=K@]^E:/.[$,=M3S43<, M>@`M'D]7'885&J^M^JW>FFZ]I5\3Z==I=;V^[TW<%160I%<_W=M4VBVYSC0/LV`6!MSA&Y^(>ASO^XA`I.(D0ANB[=P'W#L5TPP8&]9 MU1I<@4``!8E^LP&W;!-.@T06\($]:N5/BE?=UY>6H%!O)FQ@44'1XOQ',`7R MA7/GY5FK[TR#,,36M_@S$',71*;;FQOLSN56$]"5?XZA>\$%*OQW) M'PWQ%7I):NKM.7>JHZ$G.QK.@.UCA@*'QY7VWH&M4QWJT31;/IQZ6!NXL#I\ M`3L@@+`A$;@5^Q4WD2_J].Y0?RQ,,F`(`+&GP92W^JI`B`"24$> MR?[\\3%'T0+ M+=4LJZ=9/"-YE?]43F*[["!NN2W5!/MT/;/$V>Q_#KZ=-;JNSQK%*13)V3?]LNL$^,KN^]('&>1L?77;4#7+\[WY>O M5_\[+0T\]K('M@9\VKVM>@_I;779[[KM;F]#=-KN9,VA8&.[DQTI$3?L[K@K MVJWY5Z=UN69*[]/H0E=W:F^RA>N)%]V4K]QE-M1*).Z;3QN?NMJLMAB6()8@ MEB!-LNN5HX([`?.^K7T]E4ETVMD@Y=LV$5UGH8MNW^VO:ZM;^7]6\M]<@NR[ M''?0D.9V!RVYW8W:_1=EIZZ'/-NC:Q\]N@;=,[=[]A@=GVR3KB?=)N@X*;CO MLZ+?ZF_97,!V=EHC2F^;..SH;-E1$P=9'O0`2CSU$O)GP@CMUN66-H;E@H=Q MP9HGVCZ)?];JV@8$3[`!P1_"\46&%:YPZF83+G>PF@M?M=^:GJ4U#:N7?K!2$5D.+6QWF6P_NX:KOE_,&[,FJD M;SB@K('`=6("5E9Z&U#UW+-.S[WH=_0^H!Q^]N93;`CR#=CH30C[_/O__!]X M//V7>MW7T43X>0@O*WYDOI::"WSB35YQ@?'\&Z))OQ'0&"&7?A'CO[UXG\13 M9(33=@?^+XOY[_/37OO%W^DHV&^)[N"@);IUWJ)-@WY>Z'@ZM"!@-IDXK\J! MG.-)6K>DD@U[;%6=U77;+/YDJCXL*UE:[)46[TH]\9J.DJ=/#UOF>`R&BNYY MV70T/=Y9N#%./QDQ$^G)-QV[]K1LSN('H<5GD3C7%(YK.CJ>/BU^#<;'H'Z? M"!4V5N"YD?QH-*>I,D)T"]$B9T_U780EB";+KA2Q!GCQ!#N7&K@FTRF"TY][JA4XN>Q?@>+;WRT+WM%-Y]E3H M-J1+DR5%P[2J)4C#"/(H[7Q?.P^(0E]C[#84OHNUP6,14.%O@G/2@\2V-]NR M^<1.VIOQ[/JM*6"[FSW.4=U]C(9TS;JV.E+:V"^^]CVW&[GW.WU MCJFOWU[[H6_%%C*"3CVO;/?:!AH([<&Y>WYA#Y@C/F#ZK;ZEWQ'3K]/J="S] MCI=^/;?=Z;N#H[(4B@[`15_-AS?"W+2U)E80)\$H$SZ]^_QM#BK7.\"9@ MPRK8AG/2\:#CZ=/"]HAM$#&.9ZK`DU&PSZ_'T3*(;?>YIT;1;R*9.B?_MMW( MGAA=W^,\NJ?1>6Q7;6G6[Q)3.V3W82UJGG:/A=Y#>BQ<]KMNN]O;$)VV2T9S M*-C8+AE'2L0-NPSMBG9K_M5I7:Z96O(TNJ$\-.?@>N)%-R)U_#S!HP2[9,]$ M$L2V@'Q_"]EZ64L02Y##$N2QRI-P)V#>M[6OI^9"GW8V&#YNFUFML]!%M^_V MU[75K?P_*_EO+D'V718R:$B3E8.6?NQ&[?Y+I/=JW<-$IIYKKXA!]\SMGCU& MYP';+.))EZL?)P7W?5;T6_TMB]QLAX$UHO2VF'!'9\N.B@D'_8[;N7P()9YZ M*=,S881VZW)+&\-RP<.X8,T3;9_$/VMUGWHAW(9E:]6J.+ROI^OZMT$Z"N,T M3T2Z78W;S$3'.I5HJ@"FJ'Q1GER[=19$&M5&\8W&U-X6NX>N[Z\^?''^=?7K M[^^(CV*4`#/TF$DXB_,S9>#?=T$V"2+',W\] M"43B):/)O$5`?)N(VF^=Q(N^IW0)]%<.#)W-";I$*/CF3CQV@F@&9HV3I[RX M+S*13(/(?&7+N1J-0&1!6,*YZWBU.R501EZ2!/`B+W.Q/>,,7Y5E>EOFUP;$ MB(!1"*\-QD&QY6S9MN"[&.`#V.F1.`SC.S3)1EXF;N)$P3)$L8$GZ2EX!(0& MY/E6A+QE^!ALN``H!)(."X^\B*CD+:'3+XM2W2`F7:5\&@3FKXA_XWI7R4^' MDH@(/$8\T$5SHN\,Y\"?2.(\\OP_I#@:!_1XX=`TL&"#5Z%TO8N-5H_!TGF;N;DEGJI!@D-T'21DZ5<9:1WP#O!,@030*5WY;R_DB0AIO'6B`'2],8T=!G$W@A&#%#;]'A))U@&`PYA`* M1."T]M2<+0XY)%!+&2\*,X6Z&D2T?D]52=K*M3K@N@V#I$K MC*.28,$W2@,'.??/W+_!H_)H6.$XF`+M.^XF,11@QQ`\:3Z%=\-C;-^!-`=3 MHJ=AO``9XSP!TP=\'&05X)AAA@J`3:;4.2$K*\Y3H&/ZRAHXVWHF^VWU<7G4 MK3X>)2ZO\^`[@T:,Y;Y*-80@E(MQXZ'>SR/C<8NX_)/GH69,=F?+0,'8:1S; M6"HM4JEKJ70$5.I9*C622M_BS"NHU.`B,TNN.G*-1$/)]4@U@=WV`TI3W@=) MFCF_!B)RJ(KVU]B+TO7P^92KD78U;WF=O]:>X6HKSII#X]Y@X`X&:[:_MX1K M#N&L<#Y]&EOA/%K"7;J]\XN&$:[1A;D8ZG,^1"/.)?!"ARRZU1C<-]<=2^+Y MVLK]N=8<':XDK^=>KCM,R!+#2L?S(HB5CB81H^^V.XTH'CYTO&G;W7P5HSCR M-PLR/7LVLTJX803I7)R[_77GD3]7:NR[\-!*A94*2XWEU!C@4.1&4&-Y.=+N M\NGP?W=SB??4<^^6W^/NBX=M6IY.RZMONCK4>WID7&[A2=2QV)/BHV9D/MC4 MO..CDDW-.P8JV=2\9E*)<[TL;9I+&YN'9_/PCB2;P*;Z/'T:]R[[[L69G;MP M=(2SPOGT:6R%\V@)=PF$:UH"9:/S\.PEM[W..WZ"="[`W6G&!9*EAA6/IA'$ MBD>CJ&%ONW=VV_V8+8BP>>,R/N+UDW MRQ+O6E]VSEH]9QJ$81`#Q(E(9]Q#BOI+SF9)_$/V,PJP;Y_1B1(@281SYZ5. M%!,,RQJ$7C<1"J^ZC:4^U;S"951\"[!_8'2Y*`U]P<[+,Y!-O"B8]ML4; MPV?IA/J/T1_8ZQ3(B6$,Q\G+=T@Q[GWK,9DXZB9-,3L>CKP%'\'AV)P2W#(U!RP61;*E7 M=$1+LR27?5L!+EK4$3^0?07V5@7=]1_Z#0M(XLR\.?5$\* MS#DU6%/-NT;>+,!RH5!XN(LA:$9Z>_WNG<6=:[+<"53:V'R5I[J7VP#J_J_C M.)GFH7SC(BV-)5--%-E`CMH)+A.NHKOQRO;#2WL5"`C]R=U?\4 M?1$("P`*#_P61XGZYQLO#=)R-^1F-#ANCA*PG>F>"*V>?';%\^G3V`KGT1+.=J:SG>ELRL^S(XCMO=4@8ECI:!A!K'0TB1BV M,YU-VK=*^-D1Q/;@6F-!VYFN&72P4O$\J6%S];>#^ZGGWBV_Q]T7#]NT/-N9 M[GCYJ!F9#S8U[_BH9%/SCH%*-C6OF52RG>F:3AN;AV?S\(XDF\"F^CQ]&MOF M5T=*."N<3Y_&5CB/EG"V,YV]Y+:7W,^.(+;U5I.H8<6C802QXM$H:MC;[@?< M=M=T=-I9DZ9J&ZBO^3`5?^4BRM[=8N^MPW=S>GBOM"5H;%([MT^1H M$5\P]6ZH01\%G%,'",>]_2+GTQU\D3H?@S#DAFIO//CI-$Z$2S!\]))YB)^/ MX\1L/@9+O3QKM54+0>Q<]FLP%L,D\&^$\]\"WC)QL:REY9Q(3NY?O"X>49\- M7K_"GH)!ZF0)F-O>B-J]P?Y@!PQA-N$>:M@833>#\YR9EV01;&82S)R[()N8 MRX.[(+NZ1=Z4NEWI70&_YA&@Y(OG!^!0W,Q=Y]=?K^]OFK94`*J2\E8,LP]I MFF/GP^LXS=(U)>3_&P'9X^G_9U0"X9<45OY(V05+`( MO`K^]IUK[EYY=9,(`L(%D0I&$P=8\\1[18]>^7_"9N'9=WD2^Y@1E#B(+W@@ M!7*,@TBS[,+K7CFS,$^=7@ME>`9K>U&43QV0JI,AO_T-=AC<\'7=\NM:SA6U M"`P#;B:(OQP3)D/$9!TFW-4[FP`H'DAY%$P!VG$8`\`@3YU6^R?J!;K\E]6N MG]0SM-WJ]W]J59AT.0_NEV79XT<>PU\CAZW/L/71`F+0;;C%?-T24E\`RK=@ MG#7>?%YZ\SUD7<$0JW'#[]V`2^AYZHTY\P*_[N75_=2_;=`8AB.EMAV_4>/> M-92BQUT?R^\HE-TR);@;M7#N>.-1B(4B70/DN+]2RF[A%2' MH.]JLZ.>NDO,C2!=241PWH`ZW3,D8;=S+PF7++(UR58=U27R@<""4P:>)HBT MD/VZ2=VG@OW!;JO3P^,)L"'(_<(=@F+RP$LL/3AHM3NLM)`Z0U!;U!CYH6SP M*VC`3^.*PO1^X/'P)DZ2&)WH:P^K"H!P)C=@I[X*_<2..S#.;;:3S(Y1$!9E6N>;J"/7UX.+C"H[8+F`1LF M0D,$5"/9&Q5;8RL$/`86EY]86>4<&E3OH.,.#,H11?E&(LD\0/84SB4OB\OG"1\<+OD*!2QW`9M#U=-, MFD?H3:@9%'1@+C]8CH::*[W0U31=YT43O6L(@)]9PPP&@(G M*42'^LO+BS,4'[1EZI]8"$)WBSDVY&+PG)$I,`(NK(;0P/N&,I+@9=K*:CE? MZS>L5]2;04/E9>>\-=`Q;]H&<-@I;>H*XXBT?\02#5:![U+X@.9W.`FR,OVD M8[K&`%?9569,`_!9`/PIIY$,29D*OP5*",D=27M';W@]!<5^[[U*3UF=:_K2 M@*(P]RG4N@$DZ(V5D2LU9V6R"A+YW"3R8?3J)U0_?)^VAJWPVS\__+;6$7K> M*YV?QBI5`"1PZ;?X:O17'B3B39["QN#9]!])G&XJ];_]^\OG=2#L7@XJULM] M@.P9\&LO#(`AH\#3=S;K[*/?;=8V^$ILY"5BPVVR:ZU1A4"!>Q].A/$R_P-E_$P7_$?X'O"8-Q@'^4%Y?\\;\\C4V?`<> MF[^^1*ZYDUZ_NI7=@[M/A%QS0,WXXA//\-H9AKJ]/2)H"?B'Q=@.D36X[!P0 M5_M$TSOX;D;VS.ZPTS_?(RMI@)N"E2U/KF[GXKAQ1!+\6QS)6/_.57:G6PVP M[!WZ)J)K2_8B[GKVR-O2'.M>/B'!H$VLNBU/CLX>D;=T.U4<&F$Y6'<:1U\GL(_T*LN28)A3RONW M^#JFD"4E55("*7S*SZV;[%T@@G]GXN+#;^]?_-W`PP-!.L`.^\8.^T]RAT"W M_L8T'%Q>#"Z[Q[3-OK'-M0G9:7>5F8%?0+=1^:1P!'F/2=7[1@92WCA`X&K"^-VIU=;^!1,-0_[71/>YU=8*C; MONR>'16&_@$/9NF'Z+-(@MC?Z/YM!_AJ[PY3-1O9-:[>_9@%G`JKUSD@KBKW ME7O8S.[Q)9)1D.*!(/#[O,RDZ;5VR'BUMQ7@]"YS2&P`IV]UMF@^>A,-]*I:Z-T1WK0 M1.^/-/@E"L*_OY. M4;W19O=X`#_Z\=+?S[F\,3J'U66E]YJ#2Y=@B/AW3,@TMHFQW[3TWB\(IJ&3 M)5054+ZH3%D,627>*,N]$!,BN[MCZ;]_[OR[^['3?5M![>/O<:^H-\C_J*CO M?.RT]X7Z[?>X1Z/J`ZP41&DPHIXX.U0;IKYH@_74[9SW>OLQH,I[6(]/%Q<: MWJ^9R@MU]H@ML%X'"]C:RR9VQEOL3GT:5Z5CWQ[B0H+3SG>PIS.\L-:HV?P* M2=R=D50-C)Y5K_@/L;>FX+/F0N3!^+QL`#XU["*YA<.G'H3?8HIUP^&#JZ7T M6O-[;(/T6YS]6V3%5;N!C)5Y)@]$8B4L=I#M'`R'3,7W<2(_PN`HN-X[!?!%[3C#))UW7/ MCUZ_#T>(<=1N#?"N#8]_$3W*A]*!D-+%),1.;W?V1]U>%O"%$#(JW^;8:Y'Y MBQ^NY]I-+C?68(6S3N^BWS%VO25$"Y6J<72#ACSV4]#])]=1H/KA#]$,[%T: MZ]1A(BZM4$W74;%F67H=<%OOH!IT/;X=K$.#[BYVT!O`_U1:!!R<%KO9R67_ MXJRWQYVL0Y->H[EJ'5HT>P>5U$ZR$/0/CDH>]K>#)LA!1;MNVYFE2?IUZ^XR MOG2K:=N= M#*I]%QY=/36,J[:PFAJV@PW4:\/E88\[V$X.N+CH&KSP3\F-%\F&/)_AB`KR MZ1=L8;5V&/V^(O/SP46W!.`Z:^\*WM5Y^W7PMON7%Q>/!N_J_/O:=OP7G?;C MP;LZA;ZVHK1_V>YL#6_B1]E:/_@H_`!KYW;"Q!>7'7VP`>^#L%?&,>[Z#* M;@#@&_/XV>5%OP%P;\SBY]RH:3NX_^OG'\,D#'[!_P___/\!4$L#!!0````( M`)6$"D=GSW=QU1(``.+T```5`!P`&UL550) M``-9"\E560O)575X"P`!!"4.```$.0$``-U=W7/B.!)_OZK['WRYNKK=!Q)( M9F9G^?__4\#ZQ'2!DB^/-)Z[1Y8D'L$1_AA\\GMVZC[7;Z_1.+A0#[("`8 M?C[!Y.1?__SSGRS^[^>_-!I6#\'`O[2ZQ&OT\93\PQJ".;RTOD`,*0@)_8=U M!X)(?$-Z*(#4ZI#Y(H`AY']85GQIO3O]"*Q&0X'M'<0^H;?C_BO;61@N+L_. MGIZ>3C%Y!$^$?F.G'E%CYY*(>O"5%P4^AN'OK>;WOYUWSYNM]\T/%\W3YRE7 MH@M"7D!\Q__4_,C_:S4GY\W+BXO+=TW%RD(01NRULN;SQV;SHMELGB_)?PX0 M_G8I_KL'#%H<&?F*=[21CAV!&`N1SY_.O0"`LZ\X@#%F1@(6$M4HW`I0;9P9#Y(%@9U$S MN50DMP\Q@_YZU:)U0H$IZ_322<3P,1H#->@%YVM_)4IRJD'_(>RL* MG>E5Q!"&C/%8=P48XM6-*&2\8J5(68Y+%7*W&>/!XYIWP3U"71`4.GXN0172 M]("'`NY9;8\[&$-*045&4PFR\*GM>23B/1=^<./X-Q`PKG8P:_1YRM_:@B4%[YP\75$8_S M'BIVM]VX'4Z/";@/JM)BDUBVD=6JVJ&I(0\I'GBS!C625D/`Z. MQ!!0,?!\K!:*%-=:HG!26>DPO$575_Y>UL)E>-31=RB:LX"LUMYCU73^J"35 MEG([B![?X$L/88`]!((N",'>JN0Q/(0VRHY>FE&-_?S*<"0*X^4+[MG.(FYZ M/,!]%8*HC`,JX'T`'<5=1;U2ZSL4279U):1*890%=JZ92S1+95@(I/: M`X$7!3$P`_YY@P(^AQ#[T%_Q$>+OM23#OQ8\<9=NVA:W?%;ZXSZ'?;$_[AJCUH#SNVY5[;]L1= MK7*MA`^(MR%P();9"-U$/9$W7DN;`G8?+ZA%K/$`P.),>,,9#$*V^B;VCT:S ME:RK_37Y^O=EHM6)J%B06540@'L8Q-7^GI3;*G:F3V`Q(M53V`>AM.E%[D3$J&H( MPV(_E%*IH7:N%345O8T#BP\7%P#Y]K/HIB%W.B><0;I4-Q\L.94:6!=:P5+1 MVSBPNG`*N5+^!#PO)?U""2L.\05D:G"]TPJ7DN;FX17!'M=V#`.18XP`#1%4 M@$M*I8;6>[UH*>AM'%BIB:DA"87HSK2+V((P$'"?BQ9%F90"`S4(/^CMS,I9 MPU`TB\`R)1V4@F!ZPQE1LH`T?!GQ(50\"N0IZT(,DGCZ(TLA9%1FY'NYN4.Q MPL:A](40_PD%03XB;R7,2.!RK+^MB'&6[N,0X`?$\_^E'MPK[&RM(L@M5-PZTMS4, MUL?MZ10%B&>>3.P(0CX"E*>?7'/BQ=_RB)VYQRNK+>[%UHP\+[>15F`RXQRA M"WENBD)6E/YMEU.#ZB==[3)+*0-MGS5&?PL@92(#BW]`(^F5T*L5$]T@Q7[&<>>@2IC'.,[L1G)#7 M7DEERBRKN.Y1I#)D4G7-`R>)=UL[_/+C^FM!W0-+=4"R530.BO5=BX6M)+.P M[I&D,B0258V#Y$1/>@<8=6DZ.V<4!UP`*%(!A`P*!S'Z"' MY;'/0K2*Z'0/_90A4S.`<;BMZ:>4LAJ5ON5`<4SI6:JAEQGF95,9E*PIA[>C M&.-AZ$R7XLJ:RGHI@]*TW+:2ULH\TQ/\,(%TGG6T)`."S-(&I6=Y4$BT-`Z2 MG.Y.)7HID!J4J)7K[H\@CL7[L]845(%,1F-0AI:#5;'&QH&4?SE'&IRLLCHC M`YG/"8Z%*MIHG"JI.[>4W(E""D0WU)':OA\?N0/!"""_CY.X)9G*S2/0G58J M8U.@LGD0>5XTC^(=?G&DRKAI:""606#H3"?@63H+7XZ1[O14'=+=3&05E!OG+#<*$QMH7(9\N M:5Z?6R&&>88Q#L&UH4,;^V52\V)*W:U45;?\*=9RL&FC&N=V+7<[M6C]L\BW5#OG9IZ[H3_N+&'7#6G M9SDC>]R>]'D!C0>4KR$(PEF'V]FA#P"C_RYO/>/_RHX7$)QIT>F7`C+=#5\5(R7M#>Q]N5/1UP-V+4GO MNUU0]\*'*C`Y&AK7?+IP0:$XX28,B/WV7,R1_!>LWUR6>70LGTCW2H8J0@J: M&X?6JVYO*V<*?>5Z86,ZG[0&VRTH)_F^!TB7B6+XGO85VN<5Y![9+(U;@*>(=O>;<$'*Y6Z0\U" MZ$ZI-%@\+^7/&!P8.9HQP&29D<"XUCRB9(I"^3!\O8SNMI"65QI=#X.\F7TM MURWQORN(X52VOS>70'<[5H0[5U7S&MP0ABI37UO%=#>[3*G3-VIN8V5:P]A0 M8[^MTCNPTMV85$#W`&PUW?T][8U_>^UWVY76VU1_R MS[;&'7H9RA8?YY$2Z9[0R3F!T^.].GK`RVL7O)<)!9@!+UD.NL%Y"GG%,N/^V43;?=:ZLW<+[J/.4BW@#CNL5[C+FUKEYN MN17Z^'5:M,V3G1>?/_O$J1:9S`J@/#XH!>\C7X;-%KB+A(6PSQS:16R93LF[ MH+)\=&^7J,47=C.F<='`G0$*K[:?[,['/J^\[ET4M6`L-XYQ6/+P1,4%?UVX M_-G'Z:=II8%=@5KW]7EUQ75EPYD7UM/2QQ.O;R8I.!6D2J_[K9P#02\SWC&` MK_Q*@P*I[N=W#@3YL;SZD!^G9&^^[!+RY?S4W.+3L;M%&>,:YRNZSKBUFL<% M^S&>B,OIM)+7`W;L[[>H%=$^LMFW,I8[ILY^;6OB+AW^!KDB\D,BNLX+'5I'-O-VI-<_Y`>@S@S0 MA]T"]RNI(M1'-@&G;#/SX#;A$'#KR.;ACOC8<(X]EBL#U2_W*_/5N8P,7N(% ML0EI>]\C1,5E>7XDY(5%_9H"J:&;`TH"OKV@K&HR\QI`ENA) M!;/%7/IN3QD>AFXHJ!Y_N1$-=`1*/`C]>(E<7&?C3'?QA#),#-UKL*C M<:.:E#LK[3"14QFZF:#B=G\4^TER3/$ZY*XXYU'FJ_7%G$4"I3-=/9`H$E?> M7)-WG5SH1;1@7:8<%T,SH9)ND'IQI[PAS6LAZT&\SU@DKEPI&OW):`Q->O:# MNMA(YG5L:R(/$(:L^*5="8FA^4MUJ&::R#A0UT..O(FF2QJ:E507@\V>?1EM MR+D*(@6+(U(B0_Y]_@>-Y,.QG;\L5PV+V>NHP/D'G+`I&&C57:^B.R3K2M8JA M,BXY$':,QQYL)N9='D$@FMD(4B2V_V^N4N7[6SDN.H^*3*?0"YVI_>S-`'Z` M8Q!"!V>+GZ]N.2ZZQ[&[0+Q]*&0'LYEY&UX%QJAHB7`/\]0W9*K//&4G$O

-Z3]XN(B7E]R+AY-K><;IR"_V@U MK"YB7D`8Y\$_M$ZM87MR.[;%K6[<_M%W7:@_%0T#OT>H6*7(EO_3MOSGIU;;=<5[F]?VH&OUG+'EM@=V;7+V@"?V M:[_$L^O+#4/9%PZTFMNB7IQ:O7:G/^A/_F.U.[_=]MW^\@'-NF0=PJ=DXWF< M&P'L`^KG2-O:EO8==PS[*Q>TX]P.)_WA%W$UPK#;'G?K$WCU*#IOWG&ZERWJ M^;:H[T\MNST>%N([ M,VY&]M"M-R;T`*)W((C@#8_N7(S-1:P->=]OR_M1-+;^V+IK#VYMZ\9NN]RX M\;T>]1DXNF?P>\2%M!_S)?VP+>DG;MG;*]?^[5;X@WU7JXQJ?<>(!,A#>1[] MTYY]B/7#BG]]CR*KZ3D1AW%RM-RWI[1^6'*O3\=4ERE31[7CK%_L[2`OD?H\ MU8=FAOKZ92O7XV<+D"F1*JSE70$]2N0V2/(Q$_UOOG]0OW2 MJP6E+@P!"EAC^PCIAEZI_KET=$JJX:1)13\>QT/N^7-$>[U5KE]9[LTHFN^J MY1:U[AFP71Y,5WJ!.=-*%<[Q4A^',7#-#Q?-&#;QS>]?"?T&*5N/F@O^F6`0 M]/$?$7W)`$P0*M#IGI_;`RI%#0V=B,]6/#[%N6,KW*35/;-85QO,LE#]+5`E M'MQ`'WEK\P9;C;$<"]TSGWNVRUWL91**R-\;1<%"]^Z+@Z'X9B]S9ZI7J>V0 MA'!U%T9V?IN:S\G.;]>RV)BGM5@R-22''P(J5A$>#2VT\*+6)I)9W" M59$5\[A&ZS'AKE'+;_`EV3P$@BX(0;:BY9=_5OQ_A2_6=%6!Y?,:]"DK;UT7 MJ>4A524/T!+X58B5MWA_D5I.DJZ&K2IRWBJR MR+(FBW^TGI*ZM%E@S*(<1`$`%0`<`')D;G0M,C`Q-3`V,S!?9&5F+GAM;%54"0`#60O) M55D+R55U>`L``00E#@``!#D!``#M7=UWXCBR?[_GW/_!FSWW[.P#"22==#H[ M??`/NI752J5 M2B7IUW^_3#SM"1+?Q>CK0>.P?J!!9&/'1>.O!S=63;>:IGF@^0%`#O`P@E\/ M$#[X]__^]W]I]+]?_U:K:6T7>LZ%UL)VS40C_"^M"R;P0OL&$20@P.1?VBWP MINP;W'8]2+0FGCQZ,(#TAZCC"^W3X3G0:K4/%T='S M\_,APD_@&9.?_J&-\S5GX2FQX:(M`AP$@[M&_:__.6X=UQNG];.3^N'+B()H M@8`68-_1G^KG])]&?7AKY_4Z_7CJ/JOGHM^ M7K!_[H$/-2H9Y%^\^.[7@QC$YY-#3,9'Q_5ZX^C_KCN6_0`GH.8B)B$;'LQK ML5;2ZC6^?/ER%/XZ+[I2\N6>>/,^3H[FY"Q:IK\ZP:)"O/#I4?1CO*@K:#I& MM.]>^"&2#K9!$.IB)D4:MP3[JS8O5F-?U1K'M9/&X8OO',SE%#*;8`\.X$AC M_Z@UT@.J19,C]M,1E>1T`E&@(\=`@1N\,K&224@J)3]LZX'`T=<#XJ"@ M]J8YOO/W/'6#UTM!P@#/XO`S(J5 M4M<'A#+G`0:N#;RU24UMI22Z'8A\Z,2[9@,9,IGZO5'OD9DY*LL\?"[:U%80 M,'M,X`,MXSY!DUK_"=P8BJ#-ZC'U1E:`[9\/V'/H!&/\-:6#;C-$HA:W(R/@ M/[0]_+RYDJVT5`;]73JQ$=@;74Y]%T'?I[;N$O@N[:Y/H$\[SF4IB[52!MVZ M[U/C<45GZS8F%O`R%9];H0QJVL!V/:I9NDT5S'=S&151G5(D"Y]UV\93.G.A ML16Z@<3)I$I5 M:7(FFS(KED%=:+EJS!5RF%6FQB'78,RH5HZ^NR3TA:\A\"GLT$)E*[R@4BG\ MFM[[\*\I;=9XRD,0K_SV[&J?VGG;S5:W]5K;'HXAN/?*0I%LJY*Y(A^Y&=6J ML(7Y"!/7JM0NYB,P9_4*;60^.G-5KLQ>YJ,Q1]7MC?,6#(#K^;4!I`9SFCEU M;]1H%:CF775Q`.G*\Y6QL2@(41M;ET07$+;P?"I7%"NM5F*%9YT5-L-+]:KR MWXMRN$@;5X]AD./&K@?C)`\ZX`2VMX"QH$_W11*O(GJ M*"L[\SWV9B&SNG(7$/ MM`EB3^]AS7$G+.3,PA2SCN*<6;1"K,PK!"]70A'.A%29O7V:I.PA&8>L':2CFO MGJ29?NVBT*WMT#\3=,.7`"('.G/*68,;[B_AE;3YK7B'^F[,U0?0QI72Q>T,_-WO=EM&UC!;[9/4Z9DL?TC\N]8[>;1J:=648 M0VOKM*?OOB:`G*P#1/LET?(_*P16>&Y3/G36D/[OVNA29+VVUNL;`WUH MT@+2<(FV:1,`3]AAU:K-V:9+7^??7VW()]R%)KTXT)I/7`/O;#ONUGAM+)'"I`^ MC,?#!&3/RBV3_*95.ID3/YNB82&".(,I(0<:)E15OQXTZF^T>)CJ]]>#@$Q3(,N04C20F!'!B!D4_<7- MHVOIU4J58:I'GR6SI"@X\A)A3A&?5$$MT=J:K1-X`N(4+U4PJZN6+*D(&8[S M`.`)Y[B^\]*Y:Z1@*$M`EE2$U2H87J6+*!L` M5UYR!39@X4,$G?E>4I:DTLO?I5EQQ40DH)P[-TD>3+8]G4P]MHCJT>4W25DH M9@ZLO$W?;-W1#3@3X(5\)<:;""*^7N/BG,8K^+VW M[5C!BG6YZ-VY'+GD#RND4LR=9"2'$99#E-&=1^3D)]!0-S[:<#6Y4.< MKG"B>$,9[:LO\O)@\DJQ`2R>W#^K*/?0))8G=G%SNRKU'*AX0C^7*O1K%V$2^KF1 M[]J"-H'4BK4IAP;0@9.L^2!G`\H+M@@.GBB_*"O*ENM'ZQ:&@;=NN8H6/NO) MND@/.ZT,A8&*TA$DJ@LO]MJA!JN-"73'J#DE!"+[=4@`]6?LF4,3_N5%[LW" M,;J$(\S./;[PM:>B#I57IBIQ*[H=U2=XY`8=H7_P5D9Y"2Z1RF5Z+`;XZ]$2 M"MK'3TF)B2NWE"2R]#ZOE8ZH6U=:N]/[45F^9<$+3!*0SEE.LNNS)"_:!OVC M<:AU]>'-P&"T7]Y89M>P+$WOLB19RPP1]0>&1=&%2:158>+?>)(@_\LR^<>' MFFY9+(GWRNBTM'9OH%EZI[+\3^$]*'%*&_5E2D\.M;;>-#OF\`]-;_Y^8UIF MI5FY&9>C)(AM+!/[B6J%\8/2V>S==(=F]QM3\FY+'[0JHY=[=4J"TN-E2D\/ M-4,?="F)EM8WJ/2O]$%EXL^^225![,DRL6>'FMF]-:QAF--K=K7O/9-^N*5_ MT1%8&6NS+EE)$/UIF>C/AU'J<8T:A-#T7?>I$:S4&HAO7TF0>[I,[CD;9^9` MN]4[-X9V;>@696UHG2MC+^]JE@2A9\N$?J%\O;FTC-]OF#(8MU62N.:=+`D` MGS><.K1?YNU7=L)BK4M;$B`WG1^U7Z+6*X.8==%+`DW>Z;)RJC-N@8D3?;PR M.S'D"`AK_D59)U,*L#O#.)+WP;B,-V"=/PZN=6;5US6.:," M#!>2SIT/%)JKLXY,I!26=7@HIU@R".=:>+E"852:R*>>-1N^;6!#?<+V*_B2 MX=60=9`E]\)#2+B:[FV2Y!L$)BS-_S_080MT1GN?FEUW.NG"W`(3-K)C,LS& MPC6%"HFU"0AY==&XV,!+UMHQP:40S[6/,I(6-KS\.!%/6]ES6CMJN.AH'V/; MQ]CV,;9]C&VWXCC[&)NZLMG'V-0,_9PIO>3-03R/Z6>W6+:^6Z5W!F[2:#C!HL\6:'_E%96;>>)CTZU=7Z2TJRI.;VT M')])P&.1,!3WEC:7A\I^TD8R4_GBQ0%\PMZ3B\9)PK,OD1-4NVM(VN01#ICE MN^0R`7!G(,E[/;>`N,R$SP\<1K?NZW;@/M'_7\+@&4)T:QJ+._UG^7""B6KM M)N\:J@='-X2FYN17&)3QPE)C!7&Y=5M\APJ00)8C="Y!_E<0>,%#$Q#8(V.` MW/^$,?.E!-M5(0NKJ2_)'.3SQ"7W.J;"*AB=$NX1=NXTQ_'J2)#&!X8_(0]R$)7]9"-FQ#D=SSMZ&^F(MBX49JRPW4 M_L#D)UL^1E?`<<*SR4(*\YI'+(^9W9]G$ MPLEJ9;>$EP\-5[AR/?\PB<_WIVPR:V)?Y-2O%%5?3!R2N;*0ZXLG$RKG_N6` M8F4[E5F2X5?<$3EE`>!*3:[CG&8*VB2\N,1^[8WZX'7VTNWL4X8LUVI.?0EO M`(LK=[GWF"9U]IJE%[/='\J/%O1MXC[&[P+*&K.Y_/_6[SN>=G*)IX MZP#:>(S8`9[8W:(9C\NNW:#::4T;\DFUK/$UX&0EY&S0I)PLJDU%NK&"*)Z/ MI9*.J)S9I8@>;36+OOO=[`K3BM\*2+J/8O/QB'EHU#3I?8+IG!>\]CT0KK[8 M$V2/3'&%QX]%M:3=M%#@:FTQ\6I*ZAO&SK/KI6WYS(K,2R@O@02AW'E,*K=- M%``T=JEK%ZT3J6X8+[-W^;(ED:>V\E+*#8([?-X*GCWR1Y&Q`>7$5P<$3Y:F,P%C:7?SYKD58 MN>29=S?__OZ#?;SL(\;+8D,J7SQLI<)NQ+LX.%5SJ=/(91\)S#QSGZ.JW/@4 M3P39`DOE@+)QIBIDMPMQHY+DN]WXSQ^#OCC^LR@@.?Z3/1XPC^JR31V'ETW@ MN2-,D`L&P'&QA\?\PY.L`K>\+$=Z+5:+47!-5C;!+VB'8$<`X=^AF/"6?5O/NL^`(T%P`U';.T%RW23AN\E5)> M&BO$JAGW3-D`>=OV,!T*U!V%IU^B\,9,LQR=7:BR..9"?YM.Z)<9P;?R^U)> M"RJ"K&8$MDRPT7.U\;-483AT.\K%Z?Q#:9N(!VI&HJM%+TOS/KC2"?5-[DF* M,H$O]J2WHV:+[CZ4=B51\Y1*[I&0,O&&!KN+D1V-JFVZ9ZE=?RAEXW.`IWAR M3[442#=178P)0GG4> M>*_`EXM*TE:@^Y1X;G8KCO1*[Q]*$85,$.VGOT<5W'[\(-;OQU6[[*B!Y*LF MRD3.337>CMYQN_]0ZB?F`E<+8W'X[>7>&8`@%XW]/B36`R#B,ZE?EM/M3@\U M0Q]TS>XW2^L;`\VZT@?Q$ZEO@$HEVD1/T`^B@_O?,=6,6_J14K1XH/S/^)>I M6$[JRUC.#C6S>VM80_:D//VH?>^9],,M_>MF8+QE$-;"'K6G6>OR0/Z$KVVJ MJLAV@=<"`4C'V5@;YV_P51O-.]`C"@49OM4O= M,EI:LW?=-[I6\MVO6N^M(PU'/6GT3^UYUM<^'7:?#OMNTV%UJN7.\JL_*27R;W=?E53.\I6E;BH_&6),'CW\"F'HPD7>6=9S(=PJ MDM*+*[40.#_T'9V=>,R9N>HQGWJ`/:^-"?MQ`Z.R5G_*'TRL$#9/KQ2?JO(# M[D[%!J?TKJ1I4^5*4IE2QACW/NW162'"/V8%^$;+W3E[/I0-+,6;NO#Z-1ZG.&ZY#MMR(R7 M1Y>$=1:CI#I#EM+9AU&ZBEC'TTJY>=^;HPU''HOU5>WNK72UU\A-&,?3QW53 M>'E/L$!W_!!`1W^"!(SAW%+WB6M#.CHHH@E&(?GZO1\08*=M]X&*3FP!;XI`0\64K:TD1`5M7J*HJ-WMX_;!BZDJE(G4M MCXCWK[(E\XJGMI*?T]J4"W.@LC6W$!U[Y2W.+E%RPVXK\,K"2IH*%Z)DK\3K M,(RKQKL=CXXMQN1XNCD)>/]*6R*?N+JZ;L@QWV)Z`!E'V>-Y&(7%N[S:.[5L%H+@BD6!F-M*5FT4U=:GP0,F+''_!E%:8T%NELC@)U1OP#2Y MMY*$FX-#[+VPXPP3(Y]`%4Q0'OU*L3N*,(\[`.1>_E`JBV)V6LT!L#Z!^P&P M*?.X`Z#D*+<^'A,XIO.728EPD>_:M\";\B9B3ND=$W<6DEW-Q0-_RCF#]VF=,WBTV,"Z^P.JG(_:'[7;%?=>>57: M'[7;K:-V`^A37]&F:^C0)/"WM$9B<>8+D;1:H+=G!.\FHC" MGH:LW,;)J`*]J[O-LVTFO#,-7$7-;A$;/@"4F@]5@186I.#]:N(ZC.#Z5>]4 M&V_IQ,#N^92GC4D*/K`VIC""ZW.]4VWDYS?S-IJJ.$Y:!9D?6*_7Y19/^>7> MABM^1*,D?TM)-2]( MX@?6]74XQ5-XQ0]WE.32*:GP!4G\P`J_#J=$^V^J;5IG7)5[NM;&=>R:7`7V M?U>49[]UO=^ZWF]=[[>N]UO7V]I+W&]=[[>N]UO7H<;M;XE]Y[?$EI*;D*:D M[TNR?-S<@:NXU\'=&P^WO7NCY>,X5>0B<+I2_CVE:A"K:2!*.B7]=CW%$`?` MV];!F#R]OU]U*\H$-3,+%K,J)$^N#=.YL=C6"('[(<+X[TWL!UT<_`&#MY?/ MXA>$YO!GJNQ>>1W<'A?43"BH#'\T(MN8S+YBY00GN+9+Q\=52SX[>/HI]\J( M%AQ!0K@SQ`\W>#"1XSZYSA1XD?L1W9O,5[6UFU1>:S9#QE,`%:],R'^T,=HZ M2CJH&7Y9R;TIKS:5@58SC:C0*)G=O,0F<[I6IM88,N/9GK*'+MG8`4AT957I M72FO2]4@YBF2Y+M_A;?TIT[96<]PK-FB\FJQ$;`T6H^RW[_99] M"5):#*'+U\7'*Q<22O?#:P<^04^\EY^WOMJ;_,6XH%KX--4,KN+(VHLMV(R< M_?J"DN*(N0BCE-NAER%NE??4MZ<2*N^B+V@VT>,T\$/=.S#`0'P/$$08KFU945MK)1B(0@E$TEZ3M(H!LEVT9ST\>9"P\>!447VF( M<:JV+SXD`/DC2'P=.='^%[L$>I2"PF>I3G[Z3UFN:+F]2%J89`@65XA8T87* M[BF/TLL<:0I6S;*',V&W7>(''1`QWX,*1**B%_AKB')O:I:3%F0N0N8DY*%94%J9IRXP@A%Q2M^UY"T MJ56UH,2`N6+Z+/L>)$P"1G`+W@?9Y^TXQ=5VE(485*9[N)22<)QZY M4W8'H_%<^7+<"I1:7)I@\O`;YZ5?37>7$?JVO&H#&^H3/$6"T<.KL4-2$D/@ M"2IV8D.-O,B,ZXT^KY$@&;_=*$0[0\K^87GJ])O_!U!+`P04````"`"5A`I' MPE.D4%9)``"T#@0`%0`<`')D;G0M,C`Q-3`V,S!?;&%B+GAM;%54"0`#60O) M55D+R55U>`L``00E#@``!#D!``#MO7USXT:2)_S_1=QWJ//>G=L1DOMUY\:> MF=V@1*J;MD1J2*H]$XX-!T@4)=@@P`%`M>1/?_4"@`#J!040+"3E?>*>V;:8 MF.C1QS%7AC\[:NWW[[Y"N%@%;I>?OF7__GW?#=F[?__N9/[]]\^[0F1@R=A!#0OY&?WOR9_,_;-XMW;[Y___[[ M#V\,/Y8XR2[./_;FZ<]OWKQ_\^;-.\[^5]\+?ON>_L_2B3$B/1/$WS_%WM^^ M*ICXY?VW873_^MV;-V]?_^/F>KYZP!OGW`MH#ZWP5QD7E2+C>_O==]^]9K]F MI`+ETS+RLV^\?YVIDTLFOWH:^H(FL?=]S-2[#E=.P@!6^QFDI*#_=9Z1G=,_ MG;]]=_[^[;=/L?M5UOBL!:/0QS.\1LS,[Y/G+0%M[%',?97^[2'":[DR?A2] MIORO`WQ/.MRE'_J.?NCMG^B'_BW]\[6SQ/Y7B%(2*"KM^JXD*V5Z;5O96QQY MH3L*VFE=Y>Y)?3)VHN0``XK\UDU8A(GCMU*^R&E=[0ENU^)[/OLM3684W*ZE M"YQ'43L156[D?K\F_2BKBIX3,E=C-E*0B-!Z8?8%-#*GL7'JX*LGU MJ3PI0-93DRW=`J(R7_\Y$21$R3Q#=XL<2Z' M&<$%F;&]KNI)!0RB3%DG6M58G%*\7H5DOMHFYSYO6\Z^CL)-$VW2%@K->7[Q ME_G7>,L2A11FE<@B'+-52Z..+=K6L*E313<^8:3+0AR>QYF5,U<]=3!U#[QAIHF45,X3MG/*AHIB;A6#MR2'(IG8Y)OT6FIK3J5>Y=RMJ$E[!X:9?LH-D<``P[FD9U%:IU*AL>E, MI.H5G4B)H'>,Z+2J(B.E`78(>!EN-F%0/]%(Z&SB0JEF$1L"$1A\J#2K8H33 M(48(`Q\T]@=O<)",_K7SDF<:`Q4&Y#]CS7%>#8]-W!BI7\20E@$,GDRTK&*+ MDZ(]+:BCN8'K>O0NUO%O'<\=!Y?.UB.+=*U/JN&Q>@UJHG[I6E3'``9G)EH* MUZ8Y#Z),Y^,`I6PPD#;#B>,%V!TY44"V?_);UCIBNQLLG<+E'9:,$@R:M.H) M,%JM=IN=3T.%"?7'@X6.-I4)A0ZG/T/%#6^>8=(5KYD_4M-8<2IVZN4=1$?:."Q/M!%PP M\HI3.7C)>@2OHEVY2"E[\RCJ=8J$K'?4U.M6XTLZN]-0^!&RLH[8<:?CTQ_9 M+*CV)#IJ:[ZD7N7T>&F7Y5=%`J5.!"C`6&1YGAQ]!_)$OIRPB[7G+E MK#R?[-AJ#@&U/';/`@W4+Q\):AAZQU<3+<4@C)0'<2:4<<$`6MD2S6I81FCU M:E6I:.EN5:`"`QZE:L+M:ADGH.Z_YCCPPF@2)EA_(2&AL[K*4:E96N-4B(-I+1$611W9E_YS=:EQ9X5=[KDQ0:>_*\I]Z!XE<'\&5$0)8KFRP M^M?.BUF,D(&K$JC[<$4*E66NID+:.TK,]%.ZB@+Y<=W`I>-[ZS`*/&?FN%[H MA_?R0YDZ8FM.HE;AW&I50;&G[PX4W4P[H\W6#Y\Q9D'U/.&3]H1%0V]SZJE5NSCY M*(E[!Y.IAL()#*7+\G/9BG;19%Q2T_87[Z+*L*0B[!T,)MJ9A+P`.9.[(GNH M8.4Y_CB(DVA'+[MT26Y4U%8S/^A5+F5]D)/V#B(S_408I=1H3W[TP7'&E M`G<4)%[R3%,J1QNVZQXLB0YD=RT;'V9\UKQ.$S-R#V3"U#N0FFI:A53&RK)' MU]^/C:Q1YU3Q_H/RCD/A2\$OG3+UR+&;[WJ.9!0O-W5ZQ6 MD]F`5)V2%$$JFMX!4Z.8\.".0V)/R]*I]P>+2X+5B+I+%S_]B)^5Q@ET=H&A M4+.,C`H1(&C(-5-@(R5&C!H1\C[0D?DQ>FLE,:O\LRTLR)3*(%#\#43/2Q12 M3A:4IL]>SO/BT\(0&ELJ=+;[7:IF%0`E(E!(D&FFA`0G)DL(EU7KZ`,=`Z*( M2Y6Y\IU[B5V5WVVA0:I6AH+2CR!Z7Z:1\'`PHT&4J(^^OMQ%$=71BU>._T_L M1&IGH":UA8`Z93,PJ.A`X*)&.>&`G9,C3H\H0Z_.@2]6?L*^_V,0?@GFV(G# M`+OC.-X)AV4&]':7DS5JEY>5"F(0(#+1L(JD<9QM3!U$.<]_HZPHXT6]ZS<%<[P-HP2 M+[CGI4=K%;IRD962@L(/%H%E1CZ.D8Y1UH_#J62^@,3P_(EF43O MPTA]_%&AL@L=J8IEQ)1(``%%II?BV".MIYC2]NA=]FG9Y@\.:9)"U0[U@-`R M6?8T!@94_(V&`Q"8#-14':D54NB=(.E`[2=D[7^EDAX*VPUYK;[`;V).Z5&^"2,8U#715GQS$#^P.*L5_0?>L\,`Y&"U M"G=$FQE>8:+9TL<3G*3C2S4&M2R6,[_6*E])]JJD!P,V`R4E*5T9"XIRGC,4 M8""):X9XC8GV[L)YXN[[8Q3&L1YC-3PV06:D?A%E6@8P,#/14G6]RX['R?*< M+-K=5`Q*G"?D,$%`4+?#5Z0?9YAE.KYUB,:X#G1:%JN8,U"^!#D-/1S$U2LI M'%;L,*(M@YSUVO,]!TQ2D]L(;QW/'3UM<1!CLC9@F;3Y0%*8KV>QB2X3Y8OH MTM >!DE5TI2P(,3%[[;:G=.!MSV=Z7&)HG[U%I6,/ALIJ^PPF/:4!5 M1^<@)KOV'L\]:L\[K*(EH2GXKTT/.[1Y_"&ZJ]LHW.(H>;XE^K)'2F3KNZ5G MO60[H_3A.A:[4V2]\N4I4DT/Q@49*"E,D;/I[6BV^"<:3(9H]/>[\>W-:+(X M0Y/1`@;*"K-\S2&LE-(FIC2J%J$D(0.#(+5N5>!,%Y]&,U!'KQ_#T/WB^2K3 M]C_;Q$15J2(0LM_`]'Y%H6J79S_#Z.YQD!#EO*6/.5Z)CQL]K?P=C:2I@8(9 MJTV8-#&F""$3/C#P:J"LX&W8ILW+!8!:"&4G;?Q^&U^&,;&-]#E?LZE70P9\ M?9R#UIHA.PM5,H%!GZFFPA%5=@"ZYN$+P3U:45YV`$]/2%?E0U,8F!P'CSA. MZ-HO'@>#_'!MOEO&GNLYD8=C,@C#%?LK62K^$)+!]9F0[TB[*\?O03+M^M,. MS"\[V@,$@AD#75@A!-;G,HE_1K]2#O28LL`8"_*;D/W8;W2!4F3K_Y9*-*+^ MHFK/`P:7AHHJ7?/^;@JV5Q[B+8U\B[7W"%4BNRB3*5C&5)$"$((D:HEXX43[ M>P`8L-#"H0\8J+N_AVXW/$;5GI]"VBY<>\Z25OGPV!3+7H,\A+Z+HYB7:*TY MYC)GMUI7H:%1I5H+AKQ@G$U#A86:#./!Q?AZO!B/YNS8=;Z87O[X:7H]',WF M7Z-7P]'5^'*\^(8=QR[^"0ZT9B&Q.H:>@&D0'*NFA@B^9F&R!=C!P%06U7;K M/-.(-C*4R%^B'79%$U6>OXF$/@(7&Y@FBV,T8`>#R^8Z*Z,;[Z-K@,QFMY:@SM;J5<#.1$`S2=-K)`LR2$%QX6;9SG>%''"@? M!`A4?1PX5%24G2^D)'``(M5+>7H0<3(8R&"%W5(?JG/_"#A-27-PO`E]/WX&H7:_=LUS2-2OT.B:[C]E,#"B_8M-Q@,&;D9H&H`OWO&@7 MN#1,FDM&/A4-9.UDO#OL>Q-HMM?K>4M7>[IJO'TK1ZKZ>S9PL-E?+)D?8LEX M>@*36GT%KD0&,*[+1$OA_'0Z^7B^&,UNX!UIB3._\36SG*7?59C9];*,'@S` M#)34;`R#!/:%\K47X.F:VZ4<8442NRY+5*[LH?:_@\&+1"G!_Q`2A@A&!`0( M87!/BU`5-[0J"Z6DMHNPJY2M%F&OTL$!BEHYH=!M\:``MD-1;"5J9S$#/@!; M/?U\5LL$!GNFF@IAU/H-'FQHLAAPZ7I1T4HZ!NOO@K2*"\^#I-1@X%>KHCQ\ M/PB#\U/8'M9O57K;^M5L],">'&B/#,!AH7%,%I0HK&9Q5R<0:=4XMNH48JD* M&:2UZ>`$,JLK*(62I053A08,;!2*"4?@/"%WS`HZGZ/__>V;-V_>DG5ZA!XI MUQDB7SM[P_]_%/-\W0@C[W?L_@5]^'#VXV3-Q:F``&BUVFUV+$,46Q62,;B-\`,.8H+R<;`*-_B:OOW`R72] M<)Y4#=%4BN7@OS8F5@(`FXB``]!6>DL"`3,I6;JFHASD$Q$PT#S#B>,%V!TY M44`<>US0?(C7WDIY*FO":!.SYH8485K/!0:9QJKJP.AR2AC8$]?&QHOHOGW,<8F7.T/$Z7W[=@(;$>3I1C+9D!\T.)+\!!TY>!7&0 M'ZK6-Y#(T1,85:HK0%@EAP@^A8XUH!-.QH&BC)44-T981MTKNLHJ:Y'%2>&B MJJ2?&:+X[0E0-*D+\IJQ](HK13%>$WJX"*LOQ"N'67B<$KR').^C!^5Y[<2: MX`,EM=V$>UJ5RZGTI*1@<*773TQ_1ZG1OM`EM)*6Z2/HNNS9(IG=ZP>YDN7+ MAC(-&,`H%!..]T8+-!M]'DWN1C"0\0D[?O)P27S@-+IW`N]W%AEZ2_Z7X'B. MHT=OA?4)"AI)L(FG%J85H=:`'0P*F^LLQ$YQ(K3&.,N)L(\(IF=Q!-L[FDS- M]\,O-(:5(]J@17X M.DBE;Q68Z:^EUU$L/883182.;?&`.'1:8RY.]547F1"HK%Z1RU4LW76726`Y M0+ER\MM`NE`&Y<:F6QP1[`;W:XMEU2L6+L\$`AK#V,UTC]KSB-EIIP]JIJ=23 M[]7"C#K/+`\,,/NGS*@P!$4%&[Z)Y?3FQ&ZFDUO4+I+ MFTZ`[,[88TO3?;Z+SO%$"NV#FI[GSVP2*VA9_?* M\!@)I>5:R2I5*Z61JV1@@*/630POXI391`4#+9,P\,HFS#![(;L(;W&T#J,- M78I=8>6*IXD`NR4-FAI6KG1@R@T&B8U5K@+T!COT/?5ZYZ-=C)%'J`.:L`0& M4/>3^A7I9_ZFYP8G#Z%;*(6K'*1&O/:C+`W-$6,N:QBAG1LT4;H*2TY-*Q+C M],$_/3B`6)V8GH[$U$@<3X/1$UV*[KSX@1HW76OF80,^VT=81F94C[&T3-`@ M::JPZCB+@-%_)G-YD9$"E1_T\F"V7?9L5)YFOKJ?S^3?H8G0UG8VRHZG%X!]PSJ32!D@=UP4.\%J9 M44U);7\X*546H2^00EMFZ-6L(NM5*02>8(M3(]I*B"\V4$(1#0-A1%NBG>:: MI4A@$T>B8D7H['^%M#BFBR\IF@V&!*B,TKU+2*$-],)*B:TAP&C+(-JEIGHPHF]E:)=%+0V8:55 MMP@O*2$8[Z73KHJTB\%\?(E$O-V.9FC^:4`6^R\#>4//WR7*C#Y*ZC[15U%9 MA[^4%"P"R_H)05".B(KM&[%:93F3!0G:=BFJ[YFGP0N)(Z M%+4EO1I*L9MZNI6)Y1S3C42`074[O87G`GFZKG"-2NPH3>AEEL8+PA'@.S!] M(U'J1$X`=<5JKL*(>-+@DE6N7#TO(B>("2[X\SGV7SY_3.?^NN/W+C7%BX[U M,>N7X4=K,.%6O?,O@1DS1S6O.OI2@6E]W]4S2O9"D)-+`7)>*6F5FI&EY;"< M<+5.]4J^514YK'/.>D6%U^O3F]O9Z--H,A]_'D%T_1J3#K@*.E@J$+2VO28Z M4"08]]R-'4(X*([C2DT[]8W2.>`K)4WS=%@=J/.O`!E<7=4+ZO@3)S/E=%A! M2#--G>@Q=;[%7=#FJ-M-IT2]'&*4%)2>43`*,'."5"WU":%+^CI*=+.=Z;'\!;[W`GH=BY:.3Y]HGJ75+'HZK01?#-'N*:EI;W=KFP%( M6'$P(+Z%&L^K`@UW$369-QJ#,?MQNF7A\*,G'*V\6!GHT4:0]4*AK0P5QD$C M*8"FPI:J"P\7B`R6Y(E5)"C4\MEMZ>/*E)LG2TPS)0(L):5H#E;NKP/[UB1^,)4%(&V M9!.A>>,+8TQU&TW(\Y#8"F0M?.UT(UF%)CM>*&O^*3#C\;CV"2$;#[0@&TWQ MN-IM=I3[$=.L(R81KM!C^M];[=-''"W#&.MNJB2ZR?(BO/()Q3=I,%M?5Y'M M+H/[N"`G$#U=^ M^*6N@H&>I:>'>$KE%:_N!'HPT[B!DOKW=(0),2[#5W164^!0[5B6,A>[%\]W M,7;'05X$9$!6)(]>XM46T6@CR'(RG9:&5C+N-)0"!L2M51>6F8/Y)W1U/?UI M7BK],OF(!I>+\>?Q8JS/EPAA.?G!;D@WF<-,%Y,?-(M)NI:$X39*]XHS3+O& M\W$IZ=,B[,:Q'.=3O=UC=]Q8RHOLCKX#QGT=T;CJ4"M\BIYO1=G'6$5K.@;9 MJ1?Y]XK.Z]OT>VCYC%[MZ/6W%WQ3**CFY)_]'L;8S3.27H71,-PMD_7.'ZQ6 MX4Z=[5G/8CD/:*WR%9^OI`>#;0,EA6N-8EI9LHUQD8N74"XRY,F7AQX=)X$; M3Z/20;*B49H*L9K$K)6!I=QFC22`06HKM?77""P3,L0Z-,5"T-/UE19+%XMEU'ZH1/0*LO,#\.`9);HLARJISLLE1!;?X>D5%@X?Q8HH9WZ:[6T M%1(9N4'"$/+F3^_?,'S0O_S"KW_BXHJ7%10?!.ZUYRP]GRU"V5/A](<5\>8$ M_64"\MMN0Q?.6>1$X69*M5?KX?LV4-Q;L]*!8?WCO;OYOBR6WZ/&]"*UL(UC M'^,3P_XS9VP?2&:2[.=4F2H=_9WJ0V5NLXBDI*`2D+TAV4RS@)$L<&0<9/L0 MLN7&WJ/FY;P9J^7:(\;&5`J1U/(!K$IBJK.P1$H)Z4%'2@D5C#R>@D4R)'ST M&S>'C+5?,*J-T8-1Y(,/1J7.\GI\/%@E2;TJ:#16IJEF+2(P`T"DPB`#3%8X M3P25Z29J$+CD+]$.%\\E&F_?],)@;*=-##;; M8.LDP8=S`RN4F_`MYSU##F?=UR;/GUC"P+]Y/)FLHN_!06IRH3`C"G4-T"ZZ M4"815I;23FR1!<$)03>R4!O00X1?G'<07*L5!&`H&!AJ`'^-E-ZO+`Y6O2ZX M=CSY/)HW"*ZU&$;F/&=Y9?BE!S'>W5$[L?8HS(#/:D"9J1FEJ+(Z)FA;/E.% M=:_GO8US3[WLVEFE:QFX0"130O)\2TQ):!XC\M8ZU&Y37K9\QADC$.1&X0IC-Z;/\^>.CZ?KQM!M(L%RG&Y3TRIANZ;L M8-8`S766!/4R"3PF,B8R*(*A@;8Z.O=QH,93?HFE5Y2&@%`1@&!H8:0%\C!TH57END6KW:1[AJFF0B;@&YC M7!'*3?BA+6Q:Z"ZNK#T"^ZWCHTP4"@,4A$EZK^+3"YS\\@4&GHO[B2SWYG1- M#3?8@%09^MK[R157;?7*U&"<::V*^HW<,HRB\`MQND!6`<7QI(&32-:7PU-! MITH#V7'IT%)P2=2WH6OZ\HPRO)[CP`LC-*&."@9X;DL69:-!]RA2R]''YE^C MNFSO+R&'!K1Z594Q-967CT!`5G"XUUZ`B6&71%G/9.:KT/)O-?,271?@Q]!\9M!A;=G/T#`1D^7E9EC:7O>Y\T"91KF/JYS!3 M9X#\.%/&`=6K:;4]*$W7U_R9)=W`3%V3/X0L,O:P)4_0:97#'&>(=&@ M.M"1O]G_?J/CYJO?LG3T09#N_UA6ZC=.7M-*7Z^_.%'D!%#&M?DAW.&W$<9" M81[#'G@;82CQ)&XCFMEB%"*Y7^1#NY$8K==XE4S7HZ<5>W4_(XN":4";A9WN MQ0_TBO+1\36WR\U$6$T3U<*X4I*H!OQ@IHT62@O7TE=7H\L%FEZAT3\N/PTF M'T=H-EB,$/_W'$TGB%Y+P$"PW#)>9ZGZ1$#19,U$V$1P&^.*"&["#\LYM]!< M<,6C!1I/+F>CP7R$7@U'_%_?D+\Q^*+!9,C_,?K[W?CSX'HT6?25.%=N[8#, M3U'T3.8-5C#,O(,KC#!KC3=377HO*NO!,[3,JXS3^$.FS,OL5H!E`YHIWJ!3 M,7U]9=*=%K/![;9;GR69=_PL+_TX6(?1AA>.J:D98,IM-5]<,Y-*">3,6,&L MDYKI*^26N[N]O1[=$&P.KM%P/+^\GL[O9B.Z9LHC-LA$#(HE2@E-CNT%Z$.JR$J`H><"I'V/)@V$5 M;,N&`JWG0OZY#\T+7,G&>.C%*S^,=Q&N\7:'B[6][.ZB$:I3^B$RP4"^(T.T M'G5^^6DTO+MF_G0RG9PSGUIXBT>6",<(A%-D]LS>LY!-=?86@&8[I%L/>ADR MWM"S'C:5Q),P^2=FWN!J+SQMP`-E6:BY>?;,MH)ZAWH7VNL>1>5/2O;! M;U0D\@HR:70<>J97NG3J(!,%C/EA&MT[09K0^3(,XM#W7">MFGA+VI^NITKY MH1T_K\54%]7VMVB!GY(+HLAOBI9O(\CF`&IO M:'&T-)<"9FBT5ETX[APLTAWHQ=U\/!G-YVR==#&8C^?TK[>ST9RNKN!L1S/3 M+\/-D@Q*789S,Y8^@*M37@91&3TX,&J4K,(N8T%%'G#^]`9']SCBRK1D=A0'YYRI=T0=N7F>B2,,>B?D&KU\[D&PW#JNS MIB@'8QTL%LPHZ,X6,2+K"]JSH;)LMD,L%!PI$68?`+>:.:"QZJ:";D2?R.#2 M3B-=R'T)PZMVWSGZB)*JWW4Q*#Q56= MGQH-9A/BH.;H=D0V;I\&,R`[-WE-5^J6?Z`9GCZG"9[J'%=3*?W7ZZTUL;Y@ MKU($')2VTEN1*(R+004Y;/W*)*%,%#QW*6\"\^.))@(`P-KPF,*<&SJ8S8\K M>`@'#?*@4=@_3,?D'Y_)?]W-H&0QVMLR71>?TLVP3]_+LC?];+IA=66S)[(U MSOE0H39!W4T#%(%^F$0PX._$#,ESZ50HO9HNBD6I7,0$G_&E<%K-.,]8`LW5 M&[?11;&-ZOS_P5)!CA]]$[0:0'*1IS>"M'8(@8.+Z>6/YQ>#^6B(+JS10^&6J6:VT+/8Q+*)\D6@ZNC!H-!`2>&6A;`@QH,*3."\K\RR M.M]:P],WVK1^4C18_*K)[;YLTBM=?LHDIP4#J1H%A1DR)T><'ISGJAI4Y[4T]'V"2NNME,1@ M856[\KJ[F(_^?D=W\Z//RNO?I8\3*35 ML)D.C"\%TQP@#PRP.S!"N/5TDG33G@=`TJ-8]B7ZU^*W8`R+@P8`1*BW!_6) MP?<@H!:82]$M*3L,;*8%B&=X%1)M6>HRJM]S'2P-^.PF338THYQ%N88)#`Y- M-:U",.4#@K5/V/&3ATLGPL670Q>.2W/WQMPB,_2UDF03CP>86D1H"S%@,-M> M=TENQ$ MD?S'#79H=-1ZY]_%.,\4JP=&$T9KOJ61(;FG,>+J'46-5:V":L^+"#/*N8\$ MJFOO7SO/]9+G?>F?6=H4L0&T&K%;`U@+HW*8->"%`;;F"EX#)0+ M@3$)SEKI1SL32\<@S43TCN## M]!8.1G#TZ*TP6F-,2V50%FC@I:N+!:V(9HY4&4L_L%0K+\>@2`\0<$HE!3<9 M$D#"P%,Q[(;6[[LF"P27;UD^89^F+*+ELIL$81E)Z2OHJH&)JB`K`Q%6L?F( MHV48XVO#V"IS]87W[8P!/1`.=LI!:Z##`/%^"%;??=`KEQ5[TN_O$KI];^0O M&TKKQY6V,EGN91N)@@;RP\PXE0=!]%A`C+'?IP>J`W<#?JM)-9N:5:3.1<]'GZK^RESV/ZTN=(N_P?\7.>(VWH),XX*#U5TCK8-@*L[?1; M&9;O]1MQ][YT;:UR%8!$1E:_ANSS72*E>R!VO4205\,JUK]*$]0^-UPMM!?< MS\+AT(:0KR':2NU]4'1NBG"FP,JC\6IH6:TG(.4VZVR>85JX<4463\R(N\!+ MXL$7)W(['2J-OP)IW+1LHB:#J.$G3F9$M;-+#"3)I"`^TIB(&-A(RP/^^6Z: M)HWVG"6MO.OA^`8[=)/N3DF3K'91Q!.G3\(@ROZ3A1`:#;9C?*B7!Q^=-Y3T ME4AG7X&VQSB:A2?U+$4>Z7,;X8VWVZ1W`HV"A*JL_4=NR8VI#]4J\X&9-!HH M*Q15"3<;6GZ6;$G&`<$W+5-[I.VPB98WV/56A$*V"6O&;VTSW,:L?"_%,+?H`X*Y=]:LQ\:CA3%HS*?CX2SGX*H]]P%!=7YUOR MWV'@^./@UUTDC3$U8+*&*&,#H&`5%G*,`)?+"AKD$5LZ0DM_T*1:=T M]2F*C!8,@&H4%'"$HPWR::@B6A-:]$A/$2%BZ2YP-F&4>+]C6KJ%S3?IGJHP MQK5M42.A/\09F:8&H9;=#BZ_X[@,\#U-XZ:-4FRLN@:QV<(#(EZS>O<-_%^5 MI3]$RI570[!,#]072I54H@NM4G)(+O&S$WGTFB8K.CX*$OJ2)[W\O,#)%XR# MS^/1('#Y3]G#>T4#'2#/)C@/-KN(W-;"P,#Z4`N$`GZSFX\\=\W_=3;;OUPB MQN61W5T$*F]#8[M'3_0T3'6BU%X<:.Q7C#X(^JFLTT5^V0!SX(=;'#DL30[F M$H`,`?DNOLW)*:!#T\8'4;^*7G^]AE^_B&!RB`W>XX6(4;TA37 M81Q?X'48X87SU-6(5@@'[9*U#7*0@Y9*!C,N.C5'N"1U`N>>%3#+ADZ,MO34 MTB4#*@F1TKE#'E7[XO78+>]7>&17HX:N%];_J#$UN'Z4U$D"/BH,U3=?PC@\ MU1]=Q*^P]TB_>)K(+X0R=M2B)8F0QX#$]$,&0D'@BJE:Z']W_W#L(U#J)X0N4`@64I*>[YVLOH*5M(NQZTF/SXN^6;YT- MGA%(M1/3/P4LZ_6*D:&EX]-($!3NDC@A7I>,0ABCKVC,E;.B<\;SC?/D;7:; MBS"*PB_C9!!DU?MT"&PIJ^^)UMC%Y1)^E#,`,$'+%=A?RGDS"Y=:)DNAYZ\3:,'?]C%.ZVLC8W9(7V M#JRIVO*X%`=L&MB\*'@X6)%I(<(7:?4]'!/#8M7(KF>S.=Q-C2A-^C4\8!R# MH:)"0@\G?J"O#&//9;%W88"V';R![P9U[-KAEM\:*LPND]A$DTRY(G**OX-! MB40IX5DA(4%>'.\P$!1D0+X,-TLO2(/\6"F\W[$[=FGEE36[S$[3,''XN^5T M3.0WLE=QM>N08WS(:@W:HS54J3)MYU\!,SJ.9IHBW[N3"GAYX^QR%T6X%#;" MEJ46VEWYY5,=B35->:RAJ?CLBQRK>ELE@YVRU<*$P)>[&6N;3,5W3W5$:IOQ6*-3^M$7.5)UE@H1>]B)\4/HN\C; MT.==F`=AO=PA/`YSN,V5?/I41WE=8QYYRRM\]T5.X37&"MM?\3$JB^P) MV0C/-L5_B.%M^?BY]-$7,:1M'CH7OOB2IV>EM6U#>DYSG"HC%2UT@>;;ISIJ M:YOS6(-7^>$7.17762O4L-MO6-X$)SS5R[4BV*E$`"@]LUPO63YLCY&A M5SXA_`8Y21)YRUW"%CY)B&:.2XC.$!'V[=7TYL1>G4]G<^_ MV9<^1X/%8C:^N%L,+JY':#%%L\&0D)]1^F^_GB/"=#.=H/EB>OGCI^GU<#33 MEGT[8J_^A+W[AX1X0[)*KF1`'BQ^>W4%U)F MI%*0P\6@@,GAM1ZX.V("BR_[D;NC]0(1604B,N=XH?;\U?;`-A[0\+I4KZ8P MENFO+&E@>98A7<([[<7,-T//WU&D-YMQ!*X^YQR%"3J05EC`SCMR/85G=N/K MN\5H^*+GGK0E!!?<8/91B8#GK-H:8'\&LN>XB&.-V-6DXU\RW7DS#`I^>!%> MA@'-*4RH_&>69!(,(ZS&SN$0W7714$8/.*8 M#J)H7QJ=S>LHWBU_Q:L$A8'_3-<`68)A2@\F2Y-1R^PKRF>)!J*(-`0/!3BD MR6L$@QL]1@W1>`!II9[6&#(Q13:,'-?UZ"&.0+3;DHD(/]%:TS'+ M'<5'5\@R"_`">%\<^I7>3M-Z6).\M_OHE>Q/.EV1O#]T1;(C"".;+[1R_-7. MYY4"7/ZUXKXLWY`!V2:G#=)@#P)O]5FGJ+#]$+OER-OEH\X2=/9FWFP<#-9K MS_>0 M;DP2SESPO1=0X&49+WM#0';]<$7^3N]ZDN<;G#R$;L%NQ5*@GA'054LS?67! MWLDSPJFSH+Z:;!G)!/XK[6VR!N;=W9=?EEHS]&CQ@L"-I]'0B[E'HFL,J;MN M),%6MYK7`6RIO^C<]U1TEL[Z&\;FYC8*5QB[&@"K#)YA`L]@NI;G$#^"?*O9 M+[INEDINK&Z$@W&$75ND<)6LP'?&2?TE?O+800$,EPELY6-W`\17/J-`ZU*[ M,4A`!S]V-5CT'%`QX4?\?.4%Y`.>XP^=Q+D*HY)VBON?AKS6JBPT-2>OOV#* MV+MO:J-M%5F$':TS?II^T6&IILR]C<5K2:G;G>\V&S*L?L=NW@SC@)BP8?%< MEP9/\#J0:_5JLZMFJ%_)-A#:^V#HVA(A,U8I/!Z=OY@ATOG8.)5!T>UH>`'# M0(O__4O1ES<$C%.;="4<^M`P2U72C>33.!1I:95J%BED'GE!X^@X`^BD1LX1 MALP+&ROU@Z0PU9SJ.!GL^6@QFT:-5^'L'^]24^HQ76(#OBR2Z2I/R4SO M+[/ES^F@L9DW!N%E&WA/Z(MN98G4,/P-/3K^C@6TS!R7@JL$JKST$&ATW04N MCGQ:');_/@XFN,V)BU9._X@T,+,>JQHAP%%UP?P?YX[C`[30GV[,D4^OEKRAX@*$Z4"]\F>JQG3-WMD7U:!L:HSBO$B6M-07GUL5)O@L1K! MEJ/_.VJ(QB%_6JF]([US4]2Y&F`,B1LGQ8=+U)0I?V14 M>+HR"WW_*HSHCXJ6.M;';'J5XS98$?;'^1(8OW94\ZJCCSW/1Q>#^6A(7^S? MCB;SP6(\G;RX0UX^"6-;:NM.=1OG1*0T[35%T..LEG7LP\I[:M.MH8I;[NP#&A0I^@ MCEE)S"%+A,(5YB^AN<([VHI:ZZ?Q#DT\<=67F#366B8EG$:W4D M+.,>#@Y>(RFNDRL9?+(EV6WDK3"93@H9GW1O0=M(L7;YW-[$_$ZZN8C>=VB' MZ:U,T)1*0IDHM*6R$!&&N#0TK\N[=#H31&%ZU+7D\2=G_==/:3)IV*1'6M'I M/OW"CS0-3'\A!YUQH[.G8PSP+C4`-HMSUA,:XYG% MO0[SADJ7-.K;&/Z'N`J`NIU\V=<&1J;_P2X3>C@K,OXZJ*FFVR8]TG4$F(G%]B5% M^P5E+U<7,[QQV#$5K>="C[)WCG_MK:LCKAEK7Y<4=<:H;B94?+VO@%HH6WL' MD?.C@@!$)0":4I;5L<@CI0:[Y"%D"7/8*_M"X!0M)QR7!MN,CMW"G)L.58/6 M7.!H\T[G*2!H9WU*@F"T8LKJ7[7>/07,]CB9)6Q7+5:8R@'ZFT.T.UE_VV;4*"='C![0/-3-\9(6@!:^=TK');7-=J33SQ['D^W3SH:C,TT8M.<' M-#Z%F4YLD&7]&5&Y0=XVFEJ[^6#_J[DN&ZY^@=;%UX".T6/:6C=(\5X`H$': MQFM-PH`W2I:T,4ZB';M;//I+^D:?/HFIM45C=C++-OCNBXI7;6YW=6#/YH.O MX^*<>X:634J(GL`(%]N&YB-^S,9BT4_`,L M8]NWBBKXZ5P?_$1%O'171?P]7QA4FI3M&89D87/E>-%1[HLZ5>UE.*;FG6'' M'YGK]:+.S[IO%Z4C+/\$X;3O M*)[I#WE*",\?-=;O9?BCEMW2QT'D?_NCMBW2R!^=YM'F'V$[\)*.1H_1+HU@ M_J(.4?D9\G1=C0GO_$!;^9V3F`WKFJF;RP[%1TY_=JJQ3"C^PLB0D]/Q$EAH M2ZA.?+RI,MVPDIQ6(L/-/GT2H[)%8Q[A0;WVNZ<_=IL;JXY+]?*G'8]PGG:, M-EL_?,9XS@OPR1LJ7U2P-HF9\<7?:97P29C\D]91787W`?5:Q=M-F>I5+V-#X,9SS:MK0[HNR#*R5%,Z<]9$#M:%633+$SDWR]]D'-G>!5& MZ9\HG>K-B&TE7L2PUS:PE?$OU>#E.P*=V5J/D`Y\]"5+;I+MHOG!``R',,1K M'$7*U=!/7O(P)AO]1\_=.3[?D/`*48IN.$">S6%ZL-G%$==:&)C!QQ_IW9O\4Z?T)E+76%V^AI1]!\S0.J)Q\DC7 M;80?O7`7^\\&-Q%`)YI+7KV$+JEGF%:$QW0"OMK1)6]9AA-:,D\UWE/4,A7P(GR$RGED:5Y3BR.F M%\_Y/S]Y9$\7K1Z>K_$C^?"3)^U],T[+]],&-4L:ZEWM9,K#LQ>=H9P-_4QY M_@N&7\NM&@?;71(K"N'54MOT2C4J2V%7)@6+,JF:`J@&XQGZ/+B^&Z&;T6!^ M-QO=C":+.0P\78?!/7VH,<3+I"X43T%K$TM:=8M(DA*"F9MTVE7A0VG/*3&B MU(6(%B``\@(<3]>79`WK[6T9>O'*#V.RNE2U0"V;55@9&E%"6`T/-*=EJ*\` M/\)&ES8KQF=Y(=-)4D4W7%GK!_(M%MS&EI.5CC!0LI/DBL?JA\L'NBN-Q\%T MBVG=E^!^$,>83'^!>^TY2\_W$@_'$YQ,U^D/JW_M:#V7,@'YC301C6@EC?M` MEN`+LM.,R?1)5\[*JKQC;*OC[S]SA@*< M4'^1_9PJ4Z6COU-]J,QMJA%*"BI]WP?$L].8A?/$V_(V]+W5LX!&!1TLX.B5 MK/9Q1HT2YRGKO"UC0`E^2M"2K"%^ZZ5/4CL)G$=!PD*(UV&TX2=E*G=AP@2L MM\PU%KHN965CC#.C`G8X_=!+G*HQ^"+T@^4P:8T>C?E5CS)015CH MB>H&O4K6)?UWZ@UVJ`-9[_R[F/B=%5'%>\1\'E=WIA$7K$YLHG*U\_:\B#"C MG!O&\F5"0[,(AG;XBORQ!$VAXS2TL+JK7M%J)Q$.,NDQ%D1;!\#@FO"*&<6\ M..FMIV*E4L<`K(_,M!6?T,7)9>C$R1\]E&U5IVOZ>'";+H^O M,?G30^B[X\TV"A]YK5H>!'GK>/1&7.BYMH)@]>B!5E1[.A-'UZ,X$\CWZ9E( MY!5DHB!,T#,9QULBEJYZ^H`$"]2[",/?V%)\NF:/2(L.Z-:)D@!'XR#!=)$M M.MG&$F"!H*WZ\HC')1&4E898IU?6)<],.IN)HT^`N+S>>OV2N*]GXL:8X0H7 MK2($V(=J+:5=)2'OK2?RK;"N%RI$`'M`KJ&T]2ND?;2\K@3N+8[2V#`:UZ+< ML3<7`:O76NM?6[XU$X6V5!8BPE`:\,/$`>COSJOP0N[9&J4/J,:+G!09O71I M&/V&H[@8V3KX7K),]G*I,K.TO:(ZPZZ&O#" MZISFBHMA&:D$MF%+9:!<2!\]^0D[?O)`UJEX&MT[@?<[,_\VPAMOMTF/BVZP MZZV<2)RUFC##ZLL6FHLGF/QGLLF*=Q$-Q<_.RF#WH^<>T(^>>ZK]F&LN[T?/ M[;T?LY@O?N]_N8LB8GFQKZ0$EL.Y=0&25W)+&=M"#=+*5X?D/ M92TL4@%J:(URPAO#`NG7B!.C09)$WG*7L$>'28ANG1ZA+AHS#E;^CEZ.W881 M"[4JJ+L()T0D/4`(?9]77&9'X&9]V$;R+Q\`]_M!!IE@Y0SEGT#I-P3XE#^# MLN_T[SK)3LYLM-?Q`!K[QJIJ/"\/2F3D/7628F%/_I,%U&,?38.C%VS!F692R"'L9)+0,@#K<3,]J=U(N](KR?8-(#Q58 MZ;TQZ;HMCLAD3P-.$I1')YRAT5/FT*>>SUS!1R?>T],_+#QZHY;_K:?^SA]7 MC'@2+&D?"T2`^E6M6[4O]5N3DM$Z"N,==5YNYBWCN8>[PR.W5Z5$!? M`X?&Z9"5<%C&7CJ2'A7+YRG5(\+'."U)_5?"E)`[5ZG8;4'4IP3AJP;T*N4IR_,TVO\ M"#\07;Q'S/5C[U.)CK(^T9`#ZA<3+25)@_8\Y4G_#$WX0UG"?P;KE$QC:5?' M91U_XC1@S`(4.LF3\IWA@JTH*IP*5M> MH`0T`&L4E/9!F@:_R-#?4B:BKR^&F/_?<3!8K<)=D,0SO,+>(QVSBG5-+1^@ M3FJDKF3%PYC0JXS]&_I<,Y.`]B+`=");)J?7O.HS1!,^T)VH4=>P$_E^(A6! M>@U(4)A72E3E_#KLRS MP^QWFWWN]A4&7I*Y_+YI+Z9,)]7V;]E[*#Z[CTCO`9AV7,IU$QU5U;=IQ MLU[#2-6KM5OGF:ZS!H%+_A+ML%L33-9.$N@N;F1`TZ5L*I1=E*9B4?]A;1.< M7#KQ`[NQ=[%[\7P7T]EEOUQ8)=XC#X,,`_*''?E;^J.B!MQA$@'AHR-#9.DS MJ%R4"4;+9_2*RB9P^::XQLKEGZ']%]#^$SU!)BT4$B_"-#TA,<3=466Q>AU= MRP2HX\UU%?(PI)ST*"[E17OF?E?-,JM8F`:+]*"YZK)8#]/^DW,#[\@:I0U[ ME$DYXT$R9WE<'!,%I7O'K-P<^YM1AQ;H(7>A3$V33BOPP9IJN6)=3K6&$@'U M&-)QJ<_%@I]H9WJ90GJZ+B>;W;TWG>+6+E&OT)OR`X-!*;3%G9R:$WI^Q MU/M)EGK_K/#?V8-;EGP)39>^=^^DI9.*[W'W7P2`!55(5Y4&:)]J`[;*_=9C M:-9M2=^L*!Z MMWIT?(IM7OFM>G0GC4MJP`\(#JW4%B**:,?SU0OY1T'.&>*2D.2TLJ=^WI>M MX8N]:^\1N_RDY!/V:=++N:/(=]U2!*#>;JNY4#<@EY,M=A$3E1XY(2KL?!U& MYS$1AWYFF;01%8N87&U%O&/&*JT>L+OS:1I4)Z))OBC0LZ@?;T7&P=#S=PDM M?*'*>7Z@*$!8.-0"(1PJE4<1D4EDZ?"8S#/$I#(OD?FQ MS1#'J\AC93FU2#!F!M3WS746@TCCY'S#1!3/NLY000KIX-Z[-D^_*2M]=$,F M(N+#W&DPH]MM6NJ5$)"U;)3])P6MI@+"\;X"""Q'-$Y=116E@E-4Y<*9`RF* MA^-%V`XWB).(98NZ"YP-C9K^';MTMJ27LFE&*+)4EJXJS-D!@:.-UF(!*;K) MSX6@MG:B>R92:-X.:\,(Q8_#PAC?5A=Q6BF`RHHP=Q2J@8JZI$M M@P?%$G;%S!:I,O2)1:;..5]`[Q7J]_JVRS8OA?6RT,YC8UO\X@N%L\902P@N M!UR?\=#=GD#+D\54%[;SW6;C1-3$O-I3H<9=JG]-]%DWD@&!L&.#JF!+4WC= M5#<(9VC_"91_HUAS<(^H_J/5VC32$8#T['BI]=-5^HZ>ME][$C`-^>G\,"$H^`\BW'=.Z8\*P\%T:#,Z_ M?+)`9(55Z&KT>)Y0^,B+`J'*MN-",/_JB7O"8OU#3?F@(T_0ND^_S&G;R&)K MD[FZX!-3""JVXYKV_LCJ>6:34^?X[N[SI^20CV!U&YS'ID#G^NQ7"B>+=O.9 MT+8G-_ST*:&\8XNM+49>)K8+D]4X2"(OB+T5NT$]\KJD_+$7A-]Z&ZVM/?+O M\SOQ/A&ZK&_09;U#*#?H6R5$C_(U:!@]KI'6W"H@D+89]9,PX'9EI2JR,(0C M'\4V^.Y+V.:U,?<($"9JG',]LBHS!4U>Q#&NV+[T0G;QX*3M'W_&<4(#'XYP MMMOPV]`KFUQ,L8?F8V5[0?;[0Z=!.1QLR5R6%;/7QBR720$Y MY3H--='#G`/]G/'T%1-\34.NINO+"+M>DMNS?SXCZY@Z'D`]9*RJ6.:+,-*7 M(ISUK#!RT)Y=TFG%/Q$AOY$_9W\B_T.'./G+_P=02P,$%`````@`E80*1S:: MCS5[+@``B1T#`!4`'`!R9&YT+3(P,34P-C,P7W!R92YX;6Q55`D``UD+R559 M"\E5=7@+``$$)0X```0Y`0``[5U;=]LXDG[?<_8_:+-GS\X^V/$E?4EV>O?( MEI2HVY8TDIQL/_6A24CFA"+4(.G8_>L7('6A*%Q)0@`5S4./8P,@JKY"H5"H M*OS]?U\60>L9H,B'X2]O+L\OWK1`Z$+/#^>_O'F8G+4GM_W^FU84.Z'G!#`$ MO[P)X9O__9]__9<6_M_?_^WLK-7S0>!]:'6@>]8/9_"_6P-G`3ZT/H(0(">& MZ+];GYT@(;^!/3\`J'4+%\L`Q`#_(?OPA]:[\Y^=UMF9Q+"?0>A!]##N;X9] MBN/EA[=OOWW[=A["9^<;1%^C!"7+!9BSD>"&(_[B\^/,_KCI7%Y<_ M7/QX?7'^,L-$=)P8-R"_PW^Z^!G_Y_)B>G7QX?KZP[L+R8_%3IQ$FX]=O/Q\ M<7%]<7%QE77_>^"'7S^0_SPZ$6AA9,+HPTOD__(F1^*WZW.(YF^O+BXNW_[? M_=W$?0(+Y\P/"4(N>+/N14:A];M\__[]V_2OZZ9[+5\>4;#^QO7;]70V(^._ M^ISVN9E$_H7YR^1]V;-_)2# M"`9@#&8M\O]84#9?S<#%HK%X2_[T%L.3+$`8MT.O&\9^_$JP0HMTJGCZZ5A/ M",Q^>8.\,#[;BD/D_;M,W_AUB9=+Y!-I?]-Z6VJ.MS",8.![6/B\&R<@G)T\ M`1!'H@D*.VJ=WHH-H$!--H.!LNB>[" M6,KP676H@U!`E"P"3[B-_PSZ6*4O0&52.&/JIVDXF\30_?H$`P_O&MT_$[SH MJE'$&_$P&#G14R^`WZH+V=Y(=$ZG6OB5/$;@SP0/VWV6F1"K_>'TZ@CK>=<7BUNYT0Y'Q]1Y#.JB M8G.O^LQ=3FCG80.KZ"UYX?.J'K M.T''B9W*I+`&/`0UTH*N/)#&?7[-.)C$Z?4%ENSA,EUZ6,%](1.1.0?4,/8! M:!Q'2552\D/HG[&T1"D.H\TBDU2A,GUUSU%A6U(8A#?K9L!;#T3F7^E.!O^:C'"1_>^R==9:]\K_B%=E*QNBE1]C->_US`/H[DPV(%=5 M$(DX1W[S!V^N[<.F]);%B>;EH8W< M%D0>0!BQ]9@.D8/^V;]7B[3*]`CISG_Q@(T`S!!>JK%RQ#0H(R7,73^'@ M$-QB0I`3]/%Z>?D-O/(PV&LJ"<*E?2@PJ#8!PYJ.*1Z6SOW=%I),O[*)Z30: M3?(:'S=\B"GP2(@%G^F%II+='KA/\#AS$%7QV:TD0?K`)!!'MYC;>+R`(?@OAMW""36$8 M`J\?10E`O`V8V442F1]M0D:*"^;@^0R#!',0O:81A!$/EKVFDG#\9!\<#*H- MFJ?9^AV#)42K((`XX:+!ZB$)RL_V@<+G@3EL4AFYQ_N0 MH%)L<''`Q0*&J;\J]9Y'PZUSD+M$N/VD3W7VX2/#$)/GCLP,R>SP'OX=0Y%Q MFLN"8]696TB^>4R(:2B-2*ZQ+!Y6'L<9I%/0^/M;JM=5DTM6'$F^XX^]:IVU M-J&I^.?;X:#3'4RZ'?+39'C7[[2G^!\W[;OVX+;;FGSJ=J>34F[9O)S-G.@Q MQ2R)SN:.LR3"]L-;$,31^C>I`S*NNLOUKKR, MRI.779&+"2FV,^725>+K[EIB4%*_4JN*QLJ$E`5EK[DQ3R^?PS08&*3:@0:) MFL?*FOP?B?Y_=@)R`=:.;QV$7K&1DMZ-L=&1[&[,12P%!"Q#DDT@KD+2HS%P M`9[P8P`&(%Y1RUE9W%[&_,HE().AWPZD.F`&\+2\J?.2$?@1P2@20B7H9LP9 M70(K*0Y8`E8">IC4,0B(W3=R4.P#":RXO8RYK,M`)4&_'4B-$%@ZOM=](<$Q M`&OO8?P$4$8K&RE^+V,N[!)(R=!O!U)[X:H#&!/)&LXZ?K2$D1-@?9`L1?:@ MQ`#&?-YE-C`UKM@$I=C,V&UFS.M=&A:VQL-SSS:SNXQJY@S3Z<4P=H*TI6%= M"9<`Q:^CP,G\--C(79)C)K:9>+J2U\N8`[V4KA33;\<"RREQ\3F9VMB-S\(V"!L6YASBTMP$S(F;1.S^YA9X=S'9[F,"+PZNR]ND)"; M$S$0\2W,((SQJ&;J8+N)N-1%=9Z+3Y)^2ADV:$ M';AM\U>B?MB>S?S`Q\>_B&2#^Y[O('P&Q&1#-_TMWC^I^?VT%5EI6%F\M?DX M5)9J#0RT0Q;HSIJM\*IZK/(]91'5Y@I17\$B-M@"VI+<$D4B]T>QG2P@VCP> M*H#02+2#_2*VJ[);FX-"GMU,-C?R`'SG.X\D%=E/M>]^_2OQ64M^!%F0M;D[ MY$%698L=JRTW:^DK95X?6<"TN3*486"B:/6]\_K*;E4A`I.*?X,2K$GV"!#? M8$H-(GT';2FR)3AF!]2=!$SAQ@Z6N3^C-9>%3YM#I2)\7"Y8`M1J,R]4FF$; M]YN&LN!H++%S:?!VUK28&-^P`[=99^N1``IP(#!\#?YZ5*!8B)^HG"Y\VQT9%^.3X M8@>&*M9B%:-0F\^C=G/_"$_I6T>;TMF.UDT6;VU.E_KP9G/%CJ6YOPNH^(WI MO63AT^9.D>._:#NTU7-\YX=@.,OFR%MB^5:RD!S"82(-"8U02R"`X7P*T()6 M/I,"!;6U=.BV59!P"+<#&H9=)*/5)+K*@G8(_X8T:-(LL0/!U!E.I9,-':^/ M+&:'<'M(8R9F@AU@Y:8H9>[)PW$(-X?"5K1'9M--]S)7:C5>^'$*7%9&*`8>"LO?V6LCAJ.U"IS,8)UC2^+N[:S>0WKMPIGF[[F11LR!;=:?]L9^;].!;@.X&/`+!^B M=,)>>@`O/EO*=3NP.S>W5)<";^PP`/9*6K:3^`D;+']MUSD7Q/U.IFMYU8,> MBQF6HI:6M59!;-W!="VO.M':98*E2/%KZ+)(*U-!5Z.]4Q]F*G6TSV$,V=T/\K>[<;_Q=3 M-@'HV7>!,#E!:1#3I@<3#UB>IH8B.D+PV8_P7V<0W3A>!SSRLF@K#VS:C*D? M>1X#U?T"[[.=+01SLI>9]PEBK)*H,`AL^NI;G8G" M^:ILJ4R1.W87T^5:);$4$FW'FB)%JH8SH?XK-#-= M*1%%6!=Z[06Y`?QKYPUH:D4?=B?3A5=5P9'@@!U0?73\D$0R#<.L6&_JU1K. M1'6`!-U,EU15A4N*"\T_ADRPLD";,GZ7'&.CV-!X+5951!FDVK'H]HA1,!IL MJ,ZJB`63W*,Q`K<1H1)(YAN;+^):%LM]DAN/)@GT53#GZMIHE<>/PKF@HC>VHP"J)"(=<._`8P-#?G>/JF94I'`&4OIF(=]X>X&UL M*F/846U5$CUUYM@!ZE:ADW=SLLB\>Q`_02]7$UAT,RKL;D>=5NF%J,"2YA\/ MR"DH(M0"?!#JOI`])/&CIRST@:]T);K:43)6X4`HQ8KFHYZR!2LMN&O9K1@E ML'\X_>RH'JMB!`F9<"1@2YPZ=YL9KRNK#.6QG31W=Z);&&(93;"8;D.S;@`V M+5:IB5/G!43%3)QVZ-6ZQ6N>A/&*M^4-A8/`8Y/1B`E:,>H&A&#&RR]E=C!> M(E<=;R;9S=\G1@AB>O@.K7P;XS5T5=#;)Z[IV\,`Q%OE42V%L<10QBOT*AW/ MR[+*#H6[,WU)%"THREL:H6-9H>O*`^NTJ!LG\ETV?HSFQJOSJN#()=F.U52< M8L MC\;=3[A=_W.WU1_@?W?MR)#/2,6'?0H#E)+EY08ZOB/D`;(\53!2.5J:]OLR MBICU(,):)LQ*\+NO4^2$$:8PBUQ,_Q5D('C_3#(GE+A$G*[OF4YYJT=*]*)A MA\11R!.+#;>3Z:2W>K"7X$O3S[H<$JOYIBH/;#K+3;L(-<^AQ2&FWMILM7_( M=%J<=F&RIH*;36<7?+QF%S#;.;G\J'AR(0>7R71X^]NGX5VG.Y[\9ZO[CX?^ M]'<[#B[EZJ)+=3=:$'(UPRG_K9)B.]':WUL$NC5`B8*-NQ3E,SAL``2O8=#' M/W).C[2VE@&S(U8L!'+3ST.2FCW@'AMN99IL:DU?@X%.)@4 MVW'08+S1(`)'T,T:IX0"4%*OBQ^N+%"SRFS^FY%P]3H^Z3$1(0TH[TY5FE-C. MH,&F14/WG(C6";^7Z0HR99:&#!_L0$PA'J%"Q(%V;/;.U,53CT0\@9HW;PF0 M#XGS#,7F[R6.[/4/_<:*4%[L>/3#/B'+2G-W$D0XD\:,,R8UEC(TD)3RE&6;(GT.>?/GY0#\Z\H:RQR4K"+&:3'2AOPRRB*60< MG%.1?732&Z,%">M;E_U:T[1RSZ\HY?D:-'S,&LM0)"D:66V'+'$UWACOA,AW MTZM&W*S]S4'>1\2-GBL[GNE*A_5L$4*&60UZJO_JPUPTG.GZB;5L%PU!O)C9 MVP$N`EAED:3>,?#`0K0-2`]@NLRB-*J*++$?QXX?90<;,FW6P>93=C(J![3: M%XS79ZQ%%,IPU0Y9J3>B-RL6<,``Z]P'C5>7E)8DS3RW0[`T95'H*R@I#5^- M6?C/`#W""%C@_*G@)_[CRH+BD>5=Q63ZM?CQNJ$%]2^:X2I6$1E+''ZUT*Q) MSFP*,R8IDD[TU`O@-\:K>S^52HQL3SZU>G?#+R9?W.L&P0W,8>QE' MVXE!*V8-?50G_^Q@!R:/\2P)VJX+$VYY37XOT_?Z!\19AGUV`&U5S71M=_T' MA/X[J[A.)[#C$RZ&7C1$.QYQMB"ICF,Z)N"`$E6.Q7:HE_P.-YSU_-#!?`KG MZ9-6'".3V\OT3?`!H9=AGQU`'^$^CMYP,^.%SJT72(?6&"^DP<^UL57 M=V/F!#=3E/;&;X8/*!Y\GIF\J&2D=]T^.>$<1'E:4]V'S\EWOO/H!RG5:667 MU1]<;!CA>>\VP']+%H1EHP2Y3YC^W,TYS[]%YG#8*1B_Z#Z$-!Z>K39919B1 M:6C0.D2H'ZZ]`)C=P'_FEVR1ZVWNQMT8MGLG;FDF-W\OW*^;1>F@KL/69)&H-G$"9*MOE>5W//AUHO207V M-C]LFGT&&3FOY`!";OM=%R4@S]PR1S_^>.;>.;56YE2`:+X@RDH!I>F%]!A>R:^UZ(HVY8YE[Y=-N,90`P`Z/*M;BZ_H*&6\P M)5Y")@U$;@J)KL;?`:T`#U0E]EBL>!JI>'W%KZ/`"6[AI2P:W\7L;? M2]6G!HXR4E6>7;6:VUR5`^'C_2(LPG>K.&(PQW+^.NPNN5)@I-V M[#ICL%QIUN'L#H;S*4`+$IA'7KE:%8,#;H($KD"U4631UQ8R6P&T8O%X=>XU M?Y?*FUBDB!AF&A`%QO+Z2"?762\/8L[8M^KYN.VWE$7KT'G6U5;O<04CCW;H M6DNB(*.%VTD6]4.G/Y=8HV+>'($`Y!31G1\"4N@$$^%+:NA"%UGP#^URK*:@ MJ7RQ0S]O3[OK0GYIJ/R3J-2AJ)\LD(=V"Y9?Q7P.'=="WEH465VPAQ#3VL>_ M"%.7>>C1\RF(WRO:%(&2JY&M^;.RXVBBR M,G1H!Z>Z#)7AGAWZA3['K#)Y,62*C;O:*+*X']H1J8Y[&>XU75/0:6YCCB+T MBIF7UK-7%96][K(R8K^[4HE?Q_%0U"%$1*%`[#O[?9C2)-6/RVA$;S=U6LI#IJ_6N MR.EBL/D^R7:`L::%5*#&/V[O7D./(HX=/W(#&"4(B)=C]9%E0==7(KX2Z'6Q M5M,KR>N88'Q*6<=BD>AA8IH2!UY_L<3J*2O0/8#Q[R`5WMYV\$))C/+#R<*L MS1]:&U"P#G8P03]LS?:!$V,2A[.;)"(N>A)Z?N-$?D1"^;;?V$QWIU[[SZVS MUI9-^!^7YZU!>_HP[I+"[#'` M8,'V(9H[X:J0VK9:?5:%-4_XILB:$VP+V8N58DW#&]PPUO+0`9&+_.5J[A31 MF&)QN\$3^`KU4^"AM&>=8:UQ99JL`G$!`=1B)^Z8KA?5$Q7)VW MVI-)=SII?>K>=5J]X;@U:=]U#2J`-0BW/IK;$3>@[R&.OLLKC.WF&KN/L%+[';X<-@VA]\)"\8#3KM<QU.,>/*897[9I%.79([.T^,ZB?5=/O;V4T[ M>^GS?M0=3$S[A[=3',[R1(U!0&*5TPR&5(NF9*\#I,7KM^JX)A]ZDYWZ37[J M$FN\\L"&%WX]LE)\&:X>;AM7#CW'1VD4RSUP"#6[101V5,,/1=7P,W%0]<>M MS^V[AV[KOMN>X&T\??C7H&;8$)1S"XK7/;^7P55-FYC$FA5T,[PB93`JK#,I2(+3WZSC[Q*0"[15;HT<@/1EN:<'4!_`DX0/]UBKN695`L]J!,W"?@)5D!\#06RPGR;U"LK'Z9$['J0$?L)RG) M5#N,L.WDB<&1+F$E^&F]CMH-(L$OX[O!7OH/3_'+)@'9H."/+.\@'SQ`2B7? M89O1VP=/+31#:J#F92*4Y%7-+\.9#4KF+..KO;0A:FBR#8OX2&*4MSM!<7K$ M\G;3Y+0@B8D31G5351S0=$"E6GQS1;XU>D$S(Z=Y*WLO44D0/VW%&O\>`ZE) ML-]^1/`V>UQ"!R@,87K5UQ)&KV.=KH](RQ$D6^B_F54O80^IA%WQSDU2U0RA\RO=D8$:^2D,LC6Z"4%8#;P!#M/YG>L""> M^\)/%@5)D8VV+/8V;8,#5E"_0/05H"A_5%GB?\/0"?KA/Q/$BH&6Z'>TT=#2 M/+/#4T"7MF'\!%#)W72W[S%'3:<6H:(/?)3QX74QIZSPV?84JP(C[D`4;9C1 MJUD$V8-+BJ&VQ^PL$4,1]VW>#K,DC,PK7VHKI`P@*1;:WJ\[O%@PN6@']"1Z MP!A$(^>5>,CI[N&]\F%T]W#. M"9R.V5IF@QH-C<`:4^7-+59[D\ML+7C3/$*4559H)UID>V*IYRJ8"T!QZ11( MR.L!&Q#`"Q#T\8\<"XC6U@XDZ'+$0B`W_8UGUS`*3Q#%4X`6:1H/_EK[Q>)"SH%.0N3FQ"HP,7CA\JX+'N8`DB/.D2`;,F97MW7J<#N>>C"*]'$))/ MWD$GO`>+1\!Z1I#9VO2%G$!B\NY?`<6:'/7I^^+96Y7DC^DDN*SF=3!]7:;` M;3'=FA@^`2XDP1R2DLUN;OH:2X'9(IHM.=KE"6*"0J->$1)M5U.2D/!(L`D0 M,J]^B(WGA"S4GN."]H)4=..?9.@]C&\$3'.:4E"'1[2-T#R$S@++DO\7("_= MI57W5K?.7!>)TB#&]Y9R`$JQIOD.]EVB;QV$7DE0HM)R+?8ROL&50YQ.O'6> M,&[DY`#3X)#24'3?V%Y%\-*ADYL/G4(G+0Z=;+8W3JO?^^2\,^TP.CGO[,'B MY+P[.>\,.96T!>@TP:ET6&^IMF@#Z[VEAW;>7=K@F&Z&]^X6GYG]>/-^/7>G MI;6U1*G+;+.TZ>?<']:`(-I@Z:WM`((M3EPP:MI7:WM7`@;/?CC?G:/(M2WH M)JNZM/EE>$*V_SZ$F`-VZ*_/#O+)FN^',<`1`N,%UW,(INP`R2TJ@O-2Y9QOBF,^?T+6`N0VT6 MDJW?&7B[%T19?0]5H1"/9SJ!KJ(0R#*LF:#G:KG4A_S.H,:]9KK@I[#.#AD8 MP-!?TY#9&:O*7U,X`@CKJH43NJ`'>)"KC&$Z8TP:877&:"Q*0,Z"V6,Y#)]= ML9%QGZB0S;19V[0P)B#T(4JS8SB7+?E&YKVCLK)-H9VX/-]=U6 MLFPW?VB@46>RY'+]F&U<5;2,J!L\"A-91$R;\DSZ;0(ADV8WMK>'&/BR+V6"!1>1UF( MS%O;DCRP`S#:BN\A\&<"0O=U.%N5T"517-E/`AA+#B<+KGE#NQ*_[(!\5S[O M2/!#,B]MB"[4IG=92$U:-2K$<2$T/"#;JLPW\T$=Z*(?Y)^T6TUS.E) MMU-$KP1;Z0>U4Z"NZ>!0>P-U*?(T`9AR/.'@=0Q<.`])`D_^N51^@%'I`1N$ M9VD:[0@'+C%]43Q3A2'MP+WB.J@N('K#D@>_]@?<>,U\`],)HY7E,^\>WJ?< M#G-_A.`2H/AU%#CIP80\V+4DBH>;-\KO91HX:=M>AOCF.S4_0NA]\P/:=]Z.`8Q'#HJ'LXX?+6'D!!\13)9L/*0':$Q`ER)+ M:JUJ?>@'S%:9`2[>M2,_L[^DDN=_+KJ]KLE+9K?]N_[T]U;[]A\/_4F?),E/ M+,N2/WG`3AZPDP?LR#U@.74FY^':Z]`@/)@TV.6ARD^/_(B`,'5=HJL=.`GD M3@*P`EF:/$>_CT=\SU&N@6D'A+3<['B(]BC4%(1YZP3^#*+0=\:.Y\,`SMD) MB:0#I[WILV@I1@OIU\3W+,^&O.]/'D5)\%])OQZ%R_2[T%*Y(6A,+ M(GQTBC@[LKBG:<4D[QF59((=D-'>$J"%]N=;-<;327THP0JV4XY`VVN1OH=I M\V=I9LGJ!>5,DKS=EY3QWY(%_J7`F#FAWX,[OQG\L_= M`(W#+'7A).S/]S;!E8KW]=;$R6@P][*6>!3@/Y.>A[6Z*5^7=O,=E0B+T#@^ M?;I#\>'=##O?;4[%AL,@<-*4>3XQ(YT/([":O;'@_Z@X^3UJ@[;DT^M<=VI)$6Z1('T+%[F+SR M`G%6BN^.>R59:&;Z_E'$_.+5%XU(.\R((B7D)2=7798*W4Q?2BKB(\4$._#Z M`OSY4XRU,=[>G3D8)"3P8#A+IQT-DSC"YRV2F)"2P,9/<1C3-XQR`,$J)!Z+ MM45EE>)"-G_/5P9P+N7'!VS'#Q(BWLJZ>J^CZ2NV.L!F<,-JI;V:\YY&4E;; M[(%,7W')PB2END7\:OX:SSW[A$]G"QAFM+;C&/F/24P.95-X"_$)+9SC5L%K M6B0-_S9KQQ:_;#9Q#%66W.7Z$?QI_QCPD>?N6[//MG_I=4=^CU1=$=^N-YJS_XW)U, M[[N#*?ZQ]>NPCW_XC/_U,.YN\XS/TB^VGE>C&_63_IFD[W3%3]#;\H0\6K[# M%8ECE.I`1DV%S?SZ87LV\P/?B4$T21XCW_,=E#GPH9O^MD@!STJH-*RDEM"F M(\I)PIZ]4`-K2VN6)4`^]":Q@V+S^\?6I]W#O&:PEVMSRG0W[DNN26P4>&6' M)4F?9,=_]CV\#45#A+>&S$@F-0-4%2=['./.YEH`+\<]=<7P/E,,(9B3AU#, M*X41@BX`'D?,63P8`\S7<#ACOZJR^D:-GS#NYZY%UFKGN1T*R$8K1N&8J\]? M;MZ0J>$0G)DRW;"HLRP[)GT%KST_=$+,AZ#CQ`[]I'19^J3T&WAMS=8?:'GX M"Z?3DC31C`H%OQ4PZT$D.WW27[Y[LT\T:K3:M#/0"9\DBP766W\!;T-2/TQ? MA2-XW,IE`]4PM+'HI%*`RIBM)3C;7$'1(2&*HE'_8=:0:!R+3*AD1- M1N>DP0B<&@3"[,UJ#3&@#&_4E)28OX'PZV@V<0)H!_-CQ%D?#+GSJ M(?K>"9TL>+L'0+129VS2&,V;??G#I\V2M3F)H?OU[)$$WM_"Q1*$43KH^NX4 M;J.RA\OLY9+0^T*65?Z4C.?%OHK/A)4DPV_6`;P M%8#46LH,(>:#+&OCD=W%=&T=GR[1BD^#EPG M639ICMJ0$M@H2:9RL!:3=#^;L(&RO-JJB#M3MRQ3/F6Z8F"C))D)E5DY9L0P M%0I=K4VB$?)=@#>47/DS08)DF8%,%Q`4>W_*4F;5X:.^U<-CQ4%V5_X$C%4; MK"@FVK92&;R^$X\/\X:`ZD/0).AU3L)H6/?AA+U^W)I?$K@RT]9\,2WOBO,P M&[INC\R7@J\AQHB8]CV7AS'A59R)V0!_F\2W%(0-$>`CL:85/%B:TA&:9E"? M/%8,-X@9.9>>@*R4ZRFJ88V4*P+6!&_6&)!`+[QLR7,.A'6)$]SY,YK04:!@ M]Y:5&'V75&4<5R)N6+2_[F5WK!Y@2.(GF%;Q2%/"Y)+0OVI'3,1'[X5XR MB`1/I@`MK@1ZR88)RDJAGOH;JL)%458V,/%H13^GSNT4_2H3E!5]/35,+!+] MZBAKRHW?5-+IX\_Z8>2[:=(^8^=EMI8.@[,):"Y%UBF<>@Y&0ICK/XN5E14] M[A41X-J.I$(!:_81=$]3[C/I47RBV672I>H65\\W9054CSNEA(!JY7W#BX0+ MTM#'4<+(-G]7)ML<-QM/'O[SE%1^2BH_)96?DLI/2>66\OZ45'Y**M="OQ5) MY6-`BG6YY`548OV($LH9S:U/U*POF9S+L(;[``8PS&S]=5%63&J2LN\0B1=* M7S9%D0[*=YQVV1B#0"&TS6`$QX$9GT#L9QOX-QT)`T>Z6WF<%9,IM1QW/()3!;@3V(5K\B[3@IM8>> MAW%CSKA,<@&R0S@[*R6K9_@]"2)C.]?KA, MXB@E\5)T9\GM9/JVJ93XLI!D<\6.$P)MHE=EX+M2A$_;!8XN^*Z:`M]U&?BN M%>'3=OVA"[[K>N%CU`A.?=DY$AA`D+;TIJ8]_978SR;+JC7CAT[H^N2N=1U0 M+S`H61WL,#GD+$@6#3EU;!"3*7+":`90U`Z][.Z(5+Z?468=DV!]3,`44UIJ_X`U]BN!M[T_9UE;QL?>4'Y!G.IZ0)V[0=F?#R'.?18=.N M6W`E*5PR%SM(HF,\_$%`<>FR`=8\-7\'P_E:2"7J7#":6^,G9<`$98BP::61 MJ6W-]9[C@O8")B&O9`&SAS5>5"EP1)1;'5`DJ+3Q4XG((CL*;1Q9C!%1^_AD M?(O5M1]39LE1@,*>AK>V$@%(LMRH>;=C+]O57\A_2-`R_LW_`U!+`P04```` M"`"5A`I'8YPA:&8+``!480``$0`<`')D;G0M,C`Q-3`V,S`N>'-D550)``-9 M"\E560O)575X"P`!!"4.```$.0$``.U<6W/B.A)^WJW:_^"E:NO,/G`+22;) M2NA&3[3/F"*.7(9_U6[18XG2UB'.)AK+3:;.]C% M4!&T=*8=5DZ05BX7$'N+JJI0]HB>&'\0%8L5$V>*TOU+;N MT(>K`ZMO+[X,J^2+'X^_/#L?FC?-=M#DN;"F M>(8T@)V*BU+,E4^-"N.3ZD&M5J_^>=TU?;I20'BV<`A]R"*OGYZ>5OW:B#1% MN;CG3B2Z4975]TC@I62H)0IZ0H6+J+5&;[M+ACCQ436H7",EF:3'`2F)2&V< MH!/8JDS88Q4J@+Y^6*[5RXUZ1.Z)\@2A^9)EC,2]+SJLD"Q'*1;.'"PR>?R: M#";**/5FV=ZQ75YUG^>X"D1EH,*<6$N^EYG6&4`'69RMG5^3H1VWZ0J(8"#! M,)Q5HV$$4XF#9YBZ'<9G;3Q&G@/TWSSDD#'!=DES$9]@5_9U,4<65LJ*A@NB ME,&H@DDD+)%E\SF!80,%?SN7_>M,^G,$6FOR`::.+,FRJ@HCSI,:-JFM4Y>X MSW+X\9DOOZ01^Z*DI)`M0OM^FS8>$TI\Q6K!O[I6UB+V^".BMA;(TF+"SJM) M,3'AGL!VG_[F/\\Y%B#&9^I"0<@8DN0P63K+;S?8E0P MA]@PT=J7R)'#W)QB[(K`]?G5:K_#[.K/O#AT?*O?:^L]4V_+)[/?-=K-$?RX M;':;O9:NF5>Z/C+?W+_R[P!QL'"*70)ZOX#%.JT:F,8VP&COUIKX]WX"96,* M`N,H+!TI^N/^7$9>H,!JY!1F4$-V6`PRL]@*O?T?H#?=@<&4#P!E;: M]S(:YG@*-.01&Q!LSW!!U+(XU?`=;0-?JW\]&.I70&?[$&JS'%_?.D)0K$0$'!? M(D'`YX.8C0%,!6G5$)W(F!PR;(<)$`8_ZA6MUQS=#'6)Q>6-:?1TT]2:/1F1 MF(:/$,R+)J#E+VY[B%%3"`CYKK!C0TIG(B=?FI;%/,C#Z01F:FHC;H>NSJE3.[N>=/8A3"?Z'?BYU;_IC8S> M!SG;]]K-87L?_:TC3L&;8H"Y.86$+O!TJE3MXX.DCX\JFMX<]L"YI@9)!Z2, MS>$^3AL&?<3"E;&&03\R0MU;>`07A1TZOUKM[T;2W\<5R`=N=7/DQYE&3_O8 M-^#A%G[!NKF/_=J/YLMR1]N6Z1D$C[$X):]2[?7#I-??5X)XO@QQB!]!7@\@ MEMS7(*2#"/?/1*XQD@[R(_-HC1QFV&WXE5CF-H8V'K<+5O<1UQ3*4OHE9R$ M)JI58Y/:&\C-:$)Y^^CYK$.Y[/%3B%*-2"KESSO.>QL6F?GFVJC(JU1#D$KS MBL.WW M.I6SY1-U:>:Y\@J4O)+7G_MQ`\3>=])AJ_.X[Y&@QC2UH:'<4XI:[*]:U%C0 MI'_MY2EL]`WF%$A#X15#TR=4@[;)&P1K>Q?FS2]OV*1U$21%ZN+X5E4X['%R5Y,[<<79W]"J95%C,G(I&B%1>N?9"3 MW@@;CD0@;J6DI"Z$@Q`VQ]PE6%0CY2,!+G$E>WSK4)/MP#"N_@B3'72_J-Q,T-+Z=7 M5[?3P]_)&^SG8#CCKD93%^%5GT,(/N30998O2L$B?Y4COK(L*MB=I& MF_37&;97QY>UA3X%/DQ1I*?$.7L!H^PJI[*KU(^_4YGM%'E)B_`+%WZX(R>K MKW>,/V`NXHD!S!Z"4>08]"^//Y=\E2]*10B)X\BSRHN2R^7QM_^ME#.@(LP> M^7.F[?'P=?.@[CZXFG]1LCBVB5O2@JDUJ)PQ".00?S9MZ:PRO3'\G;U//QX2Q=2$"QO71LS6-`?@URDQ]S/V!T@(H]&(SN_ M@W][1'^N2R!`P1SZS`@M@M-@_[7MY5247[V!08'JP1>+SER\<"\=9CW\`.4A M>90G=6//N1'RJP=0"9E=H.(H:BG5TPBMM![,UM]WEVUO9^ZG`%K0Y7KO'L'B]7EF*DVW9FF\T0 MH3\BL`$8P'R7%J^OO^W;H;WEG.#U1\>K:=@@7;I=@.L)\UF6()ER=6_WJ MFIO88A!4YZJNJ']UW2&L#,XRD".W2GPOKVNOI'AU_7L?C5YB)H^7O+Y^GX># MA'[QDE?7KR4_8,HX)0CF`\(<-GE>5U=%\.K:!W&7C"ASM%<1O+KVJ2E-O##E M[5`LHOJ4;!-D&J_VV; M.^?R9*[<86O[J2EW%:??.5/O,)E,70#N$8">8'V!N44$'G!BX0'F+3:#O,Y_ MFSMI]#:[(,NHKZB&G2\8XQ^9\\ITSM#F9<#Q!+J0(4J0@EI\P M1(;E5K^B(>?5X%P)'O\+4$L!`AX#%`````@`E80*1\/=4KK8PP``@NP(`!$` M&````````0```*2!`````')D;G0M,C`Q-3`V,S`N>&UL550%``-9"\E5=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`E80*1V?/=W'5$@``XO0``!4`&``` M`````0```*2!(\0``')D;G0M,C`Q-3`V,S!?8V%L+GAM;%54!0`#60O)575X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`)6$"D<++GAK(!@``/AX`0`5`!@` M``````$```"D@4?7``!R9&YT+3(P,34P-C,P7V1E9BYX;6Q55`4``UD+R55U M>`L``00E#@``!#D!``!02P$"'@,4````"`"5A`I'PE.D4%9)``"T#@0`%0`8 M```````!````I(&V[P``&UL550%``-9"\E5 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`E80*1S::CS5[+@``B1T#`!4` M&````````0```*2!6SD!`')D;G0M,C`Q-3`V,S!?<')E+GAM;%54!0`#60O) M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`)6$"D=CG"%H9@L``%1A```1 M`!@```````$```"D@25H`0!R9&YT+3(P,34P-C,P+GAS9%54!0`#60O)575X C"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``#6 EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`#"."D>)6B0\O`$``"88```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_/3!Y!5!+ M`P04````"``PC@I'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)` M#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL M#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`,(X*1\3+)$.4`0``/!<``!H```!X;"]? M&?/ODKC;671NJN@^S]^;: MANWP?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9 ML^-IG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ- M?U28KPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T) MVJ2#-I`@RA49C-&;%;T9HSC-&;U;T M9HS>K.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@M MBMZ"T5L4O06CMRAZ"T9OF>@=*NO=Z3GZNBW#O6N^#5>+)GB'>+NZ^Z>,4]7[ MR(G6<=C)F?%Y=Q3'J9\AYM=%^>$#4$L#!!0````(`#"."D?R,X[[Q0(``+`* M```0````9&]C4')O<',O87!P+GAM;+U637.;,!#]*QI.[2%@XR1./0XS"B@- M+0;'`F=Z5$".F6!@D.))^NN[@.WBA'@*A_KBU>J]_7I",$W%8#(OLIP7,N8" MO6Z25$S`>:VLI.7'Z+(+9-U MO%%'7[."1Y#T*/K!66'NWJ#/I.2::Y8^\:B)_;BYG\62%Z+L=*BK`_@=1K#W MU[$YB^+T:<[B0AC3K9QL>2BS8B?35O95*`E'LD%;L2$6WV+0= MV_^%L'D?V-3V;:BN%7P.Q9`'P)E>X/JV^[VLW;7PPFK'7ZB(X(4+0(KF!*JX MPXOV,BY59+M+0GW0R`<3_?!L,):P@M[;HX]52.^9/\]@$M5,9W.8+B[+;\5? ME:W:"[3$3D#0C&`*H&_0?C@AI+[H"R)+#\%GI1HV$/6X5476=$7GSW" M[?#O"NP97[M+H0^[2E$FZRA'55_WL>GG'3A?+"Y9G(CVF^=TGO:G^U-YZDR= MGKX=J8NDNWYZ:#H:]."TGX/3'+W[V;%X=\ZH_1R/._>\]KQ]^GQA]02P,$%`````@`,(X*1Q*@<;<_`0``:0,``!$```!D;V-0 MGKQUX%%!.-OJVH1"N&FR0G0%8T&L M0/,PBA4F)A?6:XXQ]$OFN%CS);!QEETR#<@E1\YVP-3UQ*0JI2B$!X[6=W@I M>KS;^)I@4C"H08/!P/)1SI+JQ:R-;4S)!GU51L[EQ)4MK6_WJ1_1T:NJO@!02P,$%`````@`,(X*1YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I M=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/`0LZ?O.14?GZ#AY\^XN M8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5 MRU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$ MP&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C M\7@XMLO2BW`A(5 MM>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*= MD`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S% MUGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZKR2.FJW" M$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)> M-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/ M)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]': M-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4) MRU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A M[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@ M,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'! M51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4S MMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYN< MKGHB=OJ7=\%@\OUPR4TB42 M%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB M5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K M6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+ MK#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+ M`P04````"``PC@I'H6QEAJ&T8A,-C*H/G0;T6V94>@%T^6,[N_?GKQ2QP(Z;*N M-%]T>G3WW'-GY>RH5AW%#UN,%6@9Y74,MTI57SROSK:8H7HI*LSU22$D0TIO M9>G5E<0HKTT0H][*]T./(<)A$O&&K9FJ028:KF*X&B'@XN]$CF/X=/'Q5R/4 M[0?@UL6GQ<)_NKP]Q"_LP24$CN-;'L,@O(;>RTF7_G%>?79`'1IJKZ\AB0K! MYZ48((GJ9[!#5/L'QCT35$B@=*^T!HMPQ+#SN$.4I)(8L$",T,[!*P/8]O9^ MC'`A;6Z7X3#/TI\RR3*-H=__7IXNG=CM8LHCE,[+TT`254@I+/E:;T!O;[I* M%\<%QTZD]3OA74K4!:OKO0"[Z+RID#F68^8`#E`245PH'2!)N36K$I61+I02 M3!LY0:7@B!K*(:(W-&V&*7TPE_FQF'&W!7`^YAG[$!@5@ZD;T9O3-;!-]?;9 M'/<^K7\6+VB+,8&.1E5%NZ^4E)QA)]9!:]'O3M$'1^B3"`VL8"LD>=;^YB)D M&L`2@AV6BF3[R&^)J@UN57^#O;8XIO#KSZ4=F_YWP0.;;WIHS)+Q"<\R[Y]U*"]^KM*N;?U3F]=-W;\3/ M!OR(@K0A5!$^2$#FE7QO9-/9[)V&N^;,VVFNVU.%4OU!-,NBR7)P MQ$?"E,XX6&E\2TR*#)W[Z&!1-#4V8XFF[:_ORD"[;A1/>$*RK>/=U4'>=WK\ M7%9?G\KR*_F^RPL]KB;>UIC]N-O5ZZW2>6I46>BMVFOO1--OH>E])=-,;Z4TN_P(VZ6J\-Z_T^.- MRN5*5AK`)-WOXW0G)][WW"-YJ@W/E)'9Q.O#M'R6C0O587][4+F=#'H#KVMA MYU0?*[(N,WF$)5NE/Y]N>"23F_20FP2"/;]WXOFT3^GPR+"/K91\UAAH+Y!T M;=0WF:1/$Z_GD?1@RCN5&UF%J9$?JO*P5\478'EDHRIMA$VW?G*G"K53/VW< M,-/;\OF^K-3/LC!I+M95F>?U*GNC7@1OT+^O0(Q&K1L/FO1I87=BX@U[`/RF MM'I2N3(_)EX]SJ7-I/M7*G7Y_XQ(41?GO,4D+3+""P,4$A7'S8/2V!C@X2BK M7UR-%0RJ*/./I<*@Z3P.>2QX2&`DYK,H#!*8W`:S()YR@D`4@>BE((9`#('8 MFT$B@9\''B-0'X'ZEX(&"#1`H,&EH"$"#1%H>"EHA$`C!!J]!/D=$@?)\GH0S;\,RR?SI=Q$L4?;$7B,%B$ M#4S#9(?*@P[AP2*&]8(\-@A4;SB(@'-$AB2_^81#%8P M@U(W8L$.^PZ)1QW(83[]^"_L1[W=#X^P\8$M#<9@@WV'PM>VNM&"K(+9DI,' M'@@(Q$;7"`;KZSO\O8%@EK>"?UK:O/CJ[_786M^A;:MM/M;6Q][ZEXKK7V,4 M-M=_N[KD"L[A7&J,P@[[#HF=YIQ!_^`S$*M,'2JW*D1]C,(Z4X?.+0K9T#"J M<30[Q'Y=HSI)C,)B4X?8K1M(^QB%Y:8.N=VHJU":5.6Z\>G!AE.'X>U1X1.: M8MFI0_97M3K&A5%8=NJ0_;6S\<3"*"P[=_E!C MV]FEMC-L.\.V,X?M[2B*4=AVYK"]]8\32HQJM"*7'>/DBF';&;:=.6QO1^%N MA&';FQ';^`$W^Q+.=.#3=ASR?PK5Y,2O3NE\]DL\M_/M?4$L#!!0` M```(`#"."D=(D=?K90(``+\(```8````>&PO=V]R:W-H965T&UL?5;;CILP$/T5Q`($M(!9VPG;OZ]M"*'V MT!=\X9PY,V:&<=8S_B%*2J7WU=2MV/FEE-TV"$11TH:(%];15KVY,-X0J9;\ M&HB.4W(VI*8.>>' MV@=:TT)J$T0-=WJD=:TM*>7/T>A34Q/G\X?U;R9_J+$OE;>A[ M9WHAMUJ^L_X['6-(M,&"U<(\O>(F)&L>%-]KR-._Q4XNH@(%HC`"")#CV;T&*;'(#TV M]'A&3ZP#Q@056H,#* MH2,[4P#(0JJL08FUR[=RY0!`%I)E`TIL7'YL20"0!);0_P>HI$+70FH7%8!9 M+:@L%"YR+=B?',(LJ8#5NT?8M;"Q55P,#A=4X!)&D6L!V2H`!B^HP)6.W$+& MD?4O&C'S6HSC.$VC:+V@!1<]VXDV8M(Y9BG3X*)';DUC)]-2)R(<.AD= MS/I%0_G5]%'A%>S6FK8]VYUZ]1Z;?O.$YUE'KO0GX=>J%=Z)2=6U3&^Y,":I M_OM*LN-59H;;2_3A M=\B7I/APR*PN3?NMVU=5O_A>'T_=XW+?]^>'+.NV^ZHNN\_-N3H-OSPW;5WV MPV/[DG7GMBIW4U!]S-`8G]7EX;1H.S6G15L^/RU_@86-QE$R*OP[5I9O= M+T;S3TWS;7SX8_>X-*.'ZEAM^[&(!Q+&FK^YU;HCSK'P/G]>^F_ M3^Z_-Y??JU@8W%KAMCMWT=[%][?JF M?@]9+NKR^_5Z.$W7R_67:&YA>@#>`O`>`/:G`70+(!:079U-[?JU[,OUJFTN MB_8Z&.=R''-XH*'GMN/+J:.FWX:6=^2 M;*C_;@)5$SC%TSP^U^-)C:L\XL@*L'H9I_TU8JBLCXDO$352Y1>'/,212T$ M$/B7*U5&]Y&K/G+I@WT#1:ZTEBAR(U(&.1I,N!D)JT')2#^"2D8:0A=]X&S2 M=`28F->0P"0(1%$"<:`S#E"V*>=M0J7WO`^"MU(WK,MD;,*13DV0V+0-CBF$Z4B$7Q$BMF*A3$"4%+:<@2KKEU@0^ MXIHL1$CYT1F((/U$[@=DWR%?(Q21QYC(^#"1,DJ<6HY35'!J!;LTU3P?^^A& M1RE*E#J.4I2,1/*>YUJ*#'+K4_FTCE*4*'4$(?7UZ"C%(%#A4B7H M^$.)/\?QAQ)KZ*P'WB1%9G*?V'B@#C^4"24?RP)EJBBFII)-.DI]?:1CE"1& M'<7!)A(+TDE*DJ2. MDY0D(UW(^6Q05$,.F-@046(K+TGJQ5Y>(C($KVSG%=W0AS&1")+.4K)B=J8V MG*3SCR3_/.DX\4HD6*(DG2="$$EYJ;.OE()I'\ M)*0@F1Y^DN<"J@I2(ZU3E"1%/:F M[YMZ.ME];IJ^&LHTGX?6[:MR=W\X5L_]>!N&^_9ZNGU]Z)OS^V']_3\&Z_\` M4$L#!!0````(`#"."D<#TB#7V@$``&(%```8````>&PO=V]R:W-H965T&ULC931CJ,@%(9?Q?@`@R+:F<::;+N9[%YL,IF+W6NJQVH&Q`%: M9]]^`:UK+9F,%P*'_S]\!X5\$/)--0`Z^."L4[NPT;K?(J3*!CA5#Z*'SLS4 M0G*JS5">D.HET,J9.$,XBC+$:=N%1>YB+[+(Q5FSMH,7&:@SYU3^W0,3PRZ, MPVO@M3TUV@90D:/95[4<.M6*+I!0[\)O\?:06843_&YA4(M^8-F/0KS9P<]J M%T86`1B4VF:@IKG``1BSB07E66O"K)0PX_1C;MG/M,,YDF\GF-^#)@&=# M3#XU)),A61G02.;J^DXU+7(IAD".WZ*G]I/'V\3L7&F#;J/BEV$0Y MNM@\DV0_2O!"@F\5!X_B<98@L_X,@;T0V/F3)43L]R=>?^+\9.E?(>X]DF15 MQ:>2&PKBI2#W?K*B&"6IDW3C1D73LX+YBO*&*?4RI?=,Z8HIO5N)$!(]$?*T M0O((\2-.LTWF)\J\1-D]4;8BRKY*Y!'ZB=#B./3T!+^H/+6="HY"FY/E_O]: M"`TF:?1@\C7FPIL'#&IMNQO3E^,=,`ZTZ*\WVGRM%O\`4$L#!!0````(`#". M"D?CZB^D9P4``&T;```8````>&PO=V]R:W-H965T&ULC9E! M<]LV$(7_BD9W1=@%0``>63.AJ$Y[Z$PFA_;,V+2MB22Z)!VG_[XD)2OR[F/2 MBR12WP)X`(BW(%:O=?.U?:JJ;O;]L#^VM_.GKGN^62[;NZ?J4+8?ZN?JV/_S M4#>'LNLOF\=E^]Q4Y?T8=-@OV9AL>2AWQ_EZ-=[[U*Q7]4NWWQVK3\VL?3D< MRN;?O-K7K[=SFK_=^+Q[?.J&&\OU:GF)N]\=JF.[JX^SIGJXG7^DFZT=D9'X M:U>]ME>_9T/CO]3UU^'BC_O;N1G:4.VKNVXHHNR_OE6;:K\?2NIK_N=W??/?6M-?/9??50ONR[S_7K[]59@Q\*O*OW M[?@YNWMIN_KP%C*?'KIGZ=-:?A?BZ'644WOA^;N^'F.!3C?WW? MM?W=;^L05LMO0SEG)#\A?(W$]TBA$;H0R[[^2R,8-2)G%<[O*]AH(B31AE\6 MLOUI(>^::6%?V3'>7L5'@^,=C'=CO+N.)]'7)R2,R/'4D3$Z8T5W`"R+6?"B M2S1FO756E+8%&`=G(];FH3:OM8GNST^(OZIF$6T4LVT#J.#9"&6`(A\S.>(( MRQM@"U!:W- M"6U!5<..@YR0FJ*06(QMH2D74A3ZMYJR+MF),8M05]2Z1"UYU+J,XRA6E8W& M>F%&SNU"8S9Z[\4,V`*L[P$_\:0EJ"WI52C#\8-#HB7?Z-Y1:[X!NGU(D_3Y)OS\S[]J23#)>"@-"( MHI0'.'9A4B$V?=*NGZ3KD_9@LE;:S`9A/M/S$6!TG:J)ESY`P\/F.9P`(JD9>9.:#(LE?"0#I@_53^ MRMCL69L]&>GVK/W7![E5V@`JP&P*&?+%D"]XT_L%AG[/6N_)R,-G[7W6I^I9TU3GN5^J0#4 M(LGG=HNH0#3Q;H>QV[/>YY-\[Y(SVL)'*0U`G%DA-+:A?U*4T@`6>>I_&.`-AG8&03)US",E]+(34 M(HD@F7I":&HJXA2$=0I"TF-R!&E9J"3ETZ@D)0M!4V]/<>YA=>ZAGHO<@LS" MVF`,RQT#(DVD8-7Z",LT/F51/G"PS#Y1B-E$FF5Q2F)U2D)RVGTZ#315<_OQUN74[8UO\!4$L#!!0````(`#"."D&PO=V]R:W-H965T&ULC5;1DIL@ M%/T5Q_==145-QCBS&COM0V=V]J'[3!*2.*MB@23;OR^@,0;(MB\JUW/.O>>" M8'8A](,=,>;.9]MT;.4>.>^7GL>V1]PB]DQZW(DW>T);Q,60'CS64XQVBM0V M7N#[L=>BNG/S3,5>:9Z1$V_J#K]2AYW:%M$_!6[(9>4"]QIXJP]'+@->GGD3 M;U>WN&,UZ1R*]ROW!2RK5"(4X%>-+VSV[,C:-X1\R,&/W=PKSMUOPQO4G^DV0G!2`@FPI3'3@A'0G@C M1%\2HI$0_6\&.!*@EL$;O*O.K1%'>4;)Q:'#;/=(+BJPA&)NMC*HID*]$[UC M(GK.`8@R[RR%1DPQ8((9)DGO(6L3`B:$)PJ8J@AL512!00_N$Y0F(EEH-?Q3 MI/I2Y*[,T-JL4/'#NV9!NT!D%8B40#07\+4BBP&3*$RG,"&,0ZT=)@@&,-8: M8H*>%D!3JBR@!(`';8%65]!T!;1:B@$#YVFT959:($!S9%/1,)5-YH&=V&HG MMMA)-#NQD22$4%N0I0D2DP0U2R;H:0&UUE064`+"U.XJL;I*+*ZTK[A(C#0@ MUC"E!0.T);PV,4&D+8C*ENO!GI%:#:460]H,%*GY+84+;<&4)@B"2/M,UB;H M"8C#5C-E027!0E]]WFQS;C$]J&.1.5MRZKC<7F;1Z>1]">3FKL4+L"R!);X6 M)_5PL-[D\ZQ'!_P3T4/=,6=#N#A2U,:_)X1C4;S_+";C*/XEID&#]UP^)N*9 M#L?K,."DO_XL3'\L^5]02P,$%`````@`,(X*1_AP>!8``P``00P``!@```!X M;"]W;W)K`L.$WWVZ]YA,2V2G,I8'Y_24B*[$[.HGJO#YQ+Y[/(RWKJ M'J0\/GE>O3GP(JT?Q9&7ZLU.5$4JU6.U]^ICQ=-M*RIR#_M^Z!5I5KJS2;OV M4LTFXB3SK.0OE5.?BB*M_CWS7)RG+G(O"Z_9_B";!6\V\0;=-BMX66>B="J^ MF[H_T%."<(.TQ.^,G^N;>Z<)_DV(]^;AYW;J^DT,/.<;V9A(U>6#SWF>-Y:4 MY[^]T:O/1GA[?[&^:C]7A?^6UGPN\C_95AY4M+[K;/DN/>7R59P3WG]#T!C< MB+QN_SJ;4RU%<9&X3I%^=M>L;*_G[DWD]S)8@'L!'@2(C`I(+R"#`+-1`>T% M]"H8#RGH!<$@H.&H(.P%X=4#'16P7L#N%42](+IFJ?T&KRM'6\Q%*M/9I!)G MI^HZ\)@VC8Z>(M4NFV:Q[8[VG2IGK58_9@C[$^^C,=0SSQV#-0;IS!QBL,XL M((;HS!)BJ,ZL(";0F37$A#J30`P;&$_E;4@>!I.'6P-4,Q`9R>N8H&7*EJ$X MPD'(0M@3`3T1P%-L>.H8=NO)*))-(,988-1[86,/B&$<&=P2XI!1])4-!20T MH+4-84+,!L;+@'B-*?+,+"]12.G- ML-'\1*"?"/!C)'\=67X>0F0$DWP#::'$8"@Q$(HQ\):Q[84:/;>Z@TG&&2W8 MYE``;2D^$*[Q8U[T4*`/#ZNG[L/6`(:I->X!6_%7A4!?;)<(^#9F=%\/:3.? M4C^F](M&1_#V@H#]A9C[2P^-C7T`01&)?&+6Q.;4X">4&.E>@F!`S-H!;GV, MK)T:P.+0G!L0A5%D3CKOYMQS3/?\5UKML[)VWH141ZCVH+,30G)ETG]4!3JH M\_SPD/.=;&Z9NJ^Z$V[W(,7Q_/O(PF,1?>9%T#BS,R92W_J M&:T^ZN9GNR_+;O:K.I[:Q_F^Z\X/RV6[W9=5T7ZKS^6I_^>E;JJBZR^;UV5[ M;LIB-Q:JCDM*$K^LBL-IOEZ-][XWZU7]UAT/I_)[,VO?JJIH_LO+8_WQ.#?S MSQL_#J_[;KBQ7*^6MW*[0U6>VD-]FC7ER^/\R3QLK!LDH^+O0_G13G[/!O// M=?USN/AS]SA/!@_EL=QV0Q5%__5>;LKC<:BI;_G?:Z5?;0X%I[\_:_]][&YO M_[EHRTU]_.>PZ_:]VV0^VY4OQ=NQ^U%__%%>^S`ZW-;'=OR<;=_:KJX^B\QG M5?'K\GTXC=\?EW_2Y%H,%Z!K`;H5N+6#"_"U`'\5L&-/+\[&?OU6=,5ZU=0? ML^8R&>=BF'/SP/W(;8>;XT"-__4]:_N[[VO#V6KY/E1TU>07#4TU-\6RK_W6 M!*$FI09O@"BRLP(X5V+L*C!B%BR:,FM.H662& M14^`*!@3Z8R#7ASH#.$*/*S`J\ZDJ>C+1>(F-BDC=J(S6L5)")&!#=!+T%[$ MY.=!M6)J&6\R.4=:Y!(;"<^!9P@!"3!C)0,2O60\BQC9`!4;YR-V(D0R>LTH(AG= MCI=>M*9?Y!$KD%Q/AO22"=(*J682Z41+C,LH1+Q@QAG6L\0REJZBN^7@@IHE MK3*>8[.$B6DLP)2+5(%!9QQ8=S(BKZ*[8#,9^U3V">@HL(^%`D:GT>PT5LVX MYN*"$Z<<`1FE(3;KF)]&`]1827.CX;CH1RA(0UKF8C.&"6HT0HU5L0GP:%)G MI1O$6F-BPX,Q:@!'72(-:49:G\@'#%)1Y%E'&*2D0:I&AS0A%\[+P0&J:;#? MF\$8)8U1M9))(W)!EF12@V0ABZUDPBPES5+C9(Y%FI04,B?1#F0F\R&-&,)` M)9`UNM@88P@2R!N=?(Q?1??1:6TBPQ/I3&IBJ39F*@&FRM#+";"2C9=K=8-T MY$,6&V?,5`),=4Y:`AEI(G,=(+(1*YBF!&@J%U=.@*;DE1>@RI(8+S!.">#4 MJ1@%G/3>&!43*"O-7!(A/&&@4@:"(C+?C"G(()UT$H,,,,B9ERL0R>X>_O>& M,`E9D]!X^9!@S;C0!ZE,G8"L7Z>!(RQDS$(&+/22A:PAMS"&]1@!'?5"&XD- MCNRA07XI=V$YZ\QQX=0N`*F(T]@88;8R8*N7;&7$3,>)S,"!SJ19&@E7QFQE MP%;YY,X9,-.K8P*DFIZ[W-O!7&7`58FIG#4R72:S#2`*:60[P)BL#,CJ)5E9 M,],RZ<'1,IH"^-X/1BL#M'J)5H8IJ'2#TMG83&&H,LA2Y08F9[23-S)+!:I% M<&DD2;"8T!806F(EMV`KKW(6($JMB211%N/9`CP'B6>KN=MS1Z(0J%*.C0U& MLR7]``RQ*C!)+2!ID"2U8`^>4JK.$[6,V/H(VFWD=!/LU4/DN,IB]EG`OB#9 M=Q5-3S]-DBH8(QFG*G=:3HZPJ[)Y'8_VV]FV?CMUPV'QY.[M]<$3#4?@XGYN M'C:7EP!?U:Q7Y^*U_*MH7@^G=O9<=UU=C&PO=V]R:W-H965T&UL;5/1;NL@#/T5Q`>,-&W7 MJ4HCK9NN[GVXTK2'[9DF3H(&.`/2;'\_(&F6=7D!;'R.CXW)>C1OM@%PY$-) M;0^T<:[=,V:+!A2W-]B"]C<5&L6=-TW-;&N`EQ&D)$N3Y)8I+C3-L^A[,GF& MG9-"PY,AME.*F\\C2.P/=$4OCF=1-RXX6)ZQ"5<*!=H*U,1`=:#WJ_UQ$R)B MP(N`WL[.)&@_(;X%XU]YH$F0`!(*%QBXW\[P`%(&(I_X?>3\3AF`\_.%_4^L MUJL_<0L/*%]%Z1HO-J&DA(IWTCUC_Q?&$K:!L$!IXTJ*SCI4%P@EBG\,N]!Q M[X>;NV2$+0/2$9!>`=B0*,I\Y([GF<&>F*&U+0\ON-JGOA%%<,:ZXYT7:KWW MG*]VVXR=`]$8E'A.L+7/Q3>+A-L%@DV MD6#S@V!W5>)2S-U5$C;KJ0)3Q]&QI,!.QT&=>:?IO$_CFWR'YUG+:_C/32VT M)2=T_F5C_RM$!UY*F4VJH#Q>T5]J#]38-&<>=-TU+; M&^!U!"E)69K>4,6%3LHB^EY-6>#@I-#P:H@=E.+FSQ$DCH$!I`Q$/O''S/F5,@#7YPO[4ZS6JS]Q"P\H?XO:=5YLFI`:&CY(]X;C,\PE M7`?""J6-*ZD&ZU!=(`E1_'/:A8[[.-WD^0S;!K`9P!;`71J%3XFBS$?N>%D8 M'(F96MOS\(+9GOE&5,$9ZXYW7JCUWG.9W?XHZ#D0S3''*8:M8Y8(ZMF7%&PK MQ9']!V?;\'Q381[A^3K[7;I-L-LDV$6"W3\$V;<2MV*^JZ2KGBHP;1P=2RH< M=!S4E7>9SGL6W^0KO"QZWL)/;EJA+3FA\R\;^]\@.O!2TJOKA'3^_RR&A,:% MXZT_FVFD)L-A?_D@RR\M_P)02P,$%`````@`,(X*1\3T"C^A`0``L0,``!D` M``!X;"]W;W)K&UL;5/!;N0@#/T5Q`>43)+9K4:9 M2)U6J]W#2E4/[9E)G`05<`IDTOW[!9))TS87P,;O^=F88D3S:CL`1]Z5U/9( M.^?Z`V.VZD!Q>X,]:'_3H%'<>=.TS/8&>!U!2K(T27XPQ86F91%]CZ8L<'!2 M:'@TQ`Y*YPRD-$#'@6 M,-K5F03M9\378/RICS0)$D!"Y0(#]]L%[D'*0.03O\V<'RD#<'V^LO^*U7KU M9V[A'N6+J%WGQ2:4U-#P0;HG''_#7,(^$%8H;5Q)-5B'Z@JA1/'W:1D\_]G,20T+AQ_^K.91FHR'/;7#[+\TO(_4$L#!!0` M```(`#"."D<^R5&PO=V]R:W-H965T.I/)H3UC:24Q`58%9*5_7T"R MHJ2Z`+OL>_MV6?(![:MK`3QYT\JX$VV][XZ,N;(%+=P==F#"38U6"Q],VS#7 M61!5`FG%>)8],"VDH46>?,^VR+'W2AIXML3U6@O[]PP*AQ/=T)OC13:MCPY6 MY&S&55*#<1(-L5"?Z./F>-[%B!3P2\+@%F<2M5\07Z/QHSK1+$H`!:6/#")L M5W@"I2)12/QGXGQ/&8'+\XW]6ZHVJ+\(!T^H?LO*MT%L1DD%M>B5?\'A.TPE MW$?"$I5+*RE[YU'?()1H\3;NTJ1]&&_VAPFV#N`3@,^`0Y:$CXF2S*_"BR*W M.!`[MK83\04W1QX:449GJCO=!:$N>*_%YO"0LVLDFF+.8PQ?QLP1++#/*?A: MBC/_#\[7X=M5A=L$WWY0N%\GV*T2[!+![@/!X5.):S%?/B5ABYYJL$T:'4=* M[$T:U(5WGLY'GM[D/;S(.]'`3V$;:1RYH`\OF_I?(WH(4K*[>TK:\']F0T'M MXW$?SG8AH*A`0``L0,``!D` M``!X;"]W;W)K&UL=5/;;MP@$/T5Q`<$+][TLO): MRB:JVH=*41[:9]8>VRC`.(#7Z=\7L-=Q4O<%F&'.F3/#4(QHGUT'X,FK5L8= M:>=]?V#,51UHX6ZP!Q-N&K1:^&#:EKG>@J@32"O&L^P3TT(:6A;)]VC+`@>O MI(%'2]R@M;!_3J!P/-(=O3J>9-OYZ&!EP19<+348)]$0"\V1WNT.IWV,2`&_ M)(QN=291^QGQ.1H_ZB/-H@104/G((,)V@7M0*A*%Q"\SYUO*"%R?K^S?4K5! M_5DXN$?U6]:^"V(S2FIHQ*#\$X[?82[A-A)6J%Q:234XC_H*H42+UVF7)NWC M=)-G,VP;P&<`7P!?$H!-B9+,!^%%65@Z"4!>\ MEW+W-2O8)1+-,:^3QD&H@$``+$#```9````>&PO=V]R:W-H965T0/*`YQTFWD6&JZ6NT>5JIZV)Z)/;91@?$"CMN_+V#' M=5M?@!GFO7DS#/F`YL6V`(Z\*JGM,6F=ZPZ4VK(%Q>T-=J#]38U&<>=-TU#; M&>!5!"E)69KNJ>)")T4>?8^FR+%W4FAX-,3V2G'S=@*)PS'9)%?'DVA:%QRT MR.F,JX0";05J8J`^)O>;PRD+$3'@GX#!+LXD:#\CO@3C3W5,TB`!))0N,'"_ M7>`!I`Q$/O'_B?,C90`NSU?V7[%:K_[,+3R@?!:5:[W8-"$5U+R7[@F'WS"5 ML`N$)4H;5U+VUJ&Z0A*B^.NX"QWW8;S9[2?8.H!-`#8#?J11^)@HROS)'2]R M@P,Q8VL['EYPQT'=>&=I_.>Q3?Y""_RCC?PEYM&:$O.Z/S+QO[7B`Z\E/1FEY#6_Y_9D%"[ M<+SU9S..U&@X[*X?9/ZEQ3M02P,$%`````@`,(X*1QMY"O*B`0``L0,``!D` M``!X;"]W;W)K&UL;5/!;MP@$/T5Q`<$+^LTRO!F&8D3[ZCH`3]ZT,NY( M.^_[`V.NZD`+=X,]F'#3H-7"!].VS/461)U`6C&>95^8%M+0LDB^9UL6.'@E M#3Q;X@:MA?U[`H7CD>[HU?$BV\Y'!RL+MN!JJ<$XB898:([T<7Z"4!>\ MEW+W<%^P2R2:8TY3#%_'+!$LL"\I^%:*$_\/SK?A^TV%^P3??U#XL$V0;Q+D MB2!?Y\^R3R5NQ7PNDJUZJL&V:70+V!GO0_J9!H[CSIFFI M[0WP.H*4I"Q-?U#%A4[*(OJ>3%G@X*30\&2('93BYOT$$L=CLDNNCF?1=BXX M:%G0!5<+!=H*U,1`4/X3M>N\V#0A-31\D.X9QU\P ME[`/A!5*&U=2#=:AND(2HOC;M`L=]W&ZR?(9M@U@,X`M@+LT"I\219D_N>-E M87`D9FIMS\,+[@[,-Z(*SEAWO/-"K?=>2I:R@EX"T1QSFF+8*F:W1%#/OJ1@ M6RE.[#\XVX9GFPJS",^^*,RV"?)-@CP2Y%\(\F\E;L7LOR6AJYXJ,&T<'4LJ M''0M["'VY:H2TYH_,O&_O?(#KP4M*;?4(Z_W\60T+C MPO'6G\TT4I/AL+]^D.67EA]02P,$%`````@`,(X*1T(F)."B`0``L0,``!D` M``!X;"]W;W)K&UL;5/;;N,@$/T5Q`<4AZ2WR+'4 MM%KM/JQ4]6'WF=AC&Q48%W#<_?L%[+ANZQ=@ACEGS@Q#/J!]=2V`)^]:&7>@ MK??=GC%7MJ"%N\(.3+BIT6KA@VD;YCH+HDH@K1C/LANFA32TR)/OV18Y]EY) M`\^6N%YK8?\=0>%PH!MZ<;S(IO71P8J]05"B1;OXRY-VH?Q MAM]/L'4`GP!\!MQE2?B8*,E\$EX4N<6!V+&UG8@ON-GST(@R.E/=Z2X(=<%[ M+GAVD[-S))IBCF,,7\1LY@@6V.<4?"W%D7^#\W7X=E7A-L&WGQ3>KA/L5@EV MB6#WB>#N2XEK,?=?DK!%3S78)HV.(R7V)@WJPCM/YP-/;_(17N2=:."WL(TT MCIS0AY=-_:\1/00IV=4U)6WX/[.AH/;Q>!O.=ARIT?#873[(_$N+_U!+`P04 M````"``PC@I'TJ_P!``![!@``&0```'AL+W=OG\O8$P_I(-6[K@%,\"%XJ\]A;4QW(D3G-0BFGV0'K=TII1+,V*6J MB.X4L,*3!"A>"*;^7(#+X1S&X3WPUE2U M<0&2I63F%8V`5C>R#124Y_`Y/EUB#_&(GPT,>C$/7/)7*=_=XGMQ#B.7`W#( MC9-@=KC!"W#NE*SS[TGTT],1E_.[^E=_7)O^E6EXD?Q74YC:9AN%00$EZ[EY MD\,WF,ZPO'8=PY1!,-)]")0%<$,AKY-+\P MP[)4R2%0X]UVS)4P/E%[$;D+^G/[/9NHMM%;1N,H)3,"6U1@ZP6V_QPQ7AT1PSS(:[!"!SO&WM!$2*Q+CT*>E#[^,%+C1&)=?51T+K\9-$_$M/YK0$``!8$```9 M````>&PO=V]R:W-H965T0'*`Y)FF[D M6&JZJMK#2E4/W3.QQS\J,"[@N/OV!>RXWI2+@6&^GP'&V8#ZW30`EGQ*H]%YAKT5 MK8(734PO)=?_CB!P."2KY!)X;>O&^@#-,SKCRE:",BTJHJ$Z)/>K_7'K,T+" M6PN#6+Y_*0I-X"""BL9^!N.,,#".&)G/#'Q/DMZ8'+^87],53K MW)^X@0<4?]O2-LYLFI`2*MX+^XK#$TPE!(<%"A.^I.B-17F!)$3RSW%L51B' M<>W/,\T#D2/1]MQ?X.K/7,'4?A@J#OL.:/&1<\Y M8[N,GCW1E',<<]@B9S5G4,<^2["8Q)']@+,X?!UUN`[P]5)]=QLGV$0)-H%@ M\U^)=UB42R[D^2;JX.`FZ#N_3D`)[%;IA$9U;X)Z% MB_].S[..U_"'Z[I5AIS0NN<3+KE"M."LI#?.2^.:=%X(J*R?[MQPU[$27X`9YKUY,PS%B/;-=0">O&MEW(EVWO='QES5@1;N M#GLPX:9!JX4/IFV9ZRV(.H&T8CS+OC$MI*%ED7POMBQP\$H:>+'$#5H+^^\, M"L<3W=&;XU6VG8\.5A9LP=52@W$2#;'0G.C#[GC>QX@4\%O"Z%9G$K5?$-^B M\;,^T2Q*``65CPPB;%=X!*4B44C\=^;\2!F!Z_.-_2E5&]1?A(-'5']D[;L@ M-J.DAD8,RK_B^`QS"8=(6*%R:275X#SJ&X02+=ZG79JTC]--GL^P;0"?`7P! MW&=)^)0HR?PAO"@+BR.Q4VM[$5]P=^2A$55TIKK371#J@O=:\IP7[!J)YICS M%,-7,;LE@@7V)07?2G'F7^!\&YYO*LP3/%]GO\^V"?:;!/M$L%\1Y(=/%7X- MX7G^*0=;M52#;=/D.%+A8-*)F@R/_>U_+)^T_`]02P,$%`````@`,(X* M1U1VBF6D`0``L0,``!D```!X;"]W;W)K&UL=5/; M;MP@$/T5Y`\(-O;VLO):RJ:JVH=*41[:9]8>VRC`N(#7Z=\7L-=Q$_<%F&'. MF3/#4$YHGFT/X,B+DMJ>DMZYX4BIK7M0W-[A`-K?M&@4=]XT';6#`=Y$D)*4 MI>D'JKC0255&WZ.I2AR=%!H>#;&C4MS\.8/$Z91DR!0>M2KKB&J%` M6X&:&&A/R7UV/!4OT3C>B\V34@#+1^E>\+I&RPE'`)AC=+& ME=2C=:AND(0H_C+O0L=]FF_R;('M`]@"8"O@4QJ%SXFBS"_<\:HT.!$SMW;@ MX06S(_.-J(,SUAWOO%#KO=>*Y45)KX%HB3G/,6P3DZT1U+.O*=A>BC-[!V?[ M\'Q781[A^3;[Y__D+W8)BDA0_$/`WI3X/H;EAS=)Z*:G"DP71\>2&D<=!W7C M7:?SGL4W>0VORH%W\(.;3FA++NC\R\;^MX@.O)3T[I"0WO^?U9#0NG#\Z,]F M'JG9<#C5#701KP$``!4$```9````>&PO M=V]R:W-H965T(#%`?':3MQ3#K=--V+ M39I>M->,_BHI!Q=P;-^^@(XU4VX$?KX3)XM1Z0_3`5CT*;@TAZ2SMM]C;*H. M!#4WJ@?I9AJE!;5NJ%ML>@VT#B3!,4G3'1:4R:0L0NU%EX4:+&<27C0R@Q!4 M?QV!J_&0;))+X96UG?4%7!9XX=5,@#1,2:2A.20/F_TQ]X@`>&,PFE4?^>PG MI3[\X&]]2%(?`3A4UBM0UYSA$3CW0L[X_ZSY8^F)Z_Y%_2FLUJ4_40./BK^S MVG8N;)J@&AHZ8EQ`25HJ;\$758*P2%TJ"!/V<6B9#.TXS^6ZFQ0ED M)I"%<)>&X)-1B/F'6EH66HU(3UO;4W^"FSUQ&U'Y8EAWF'-!C:N>2Y+M"GSV M0C/F.&'("K-9$-BI+Q8D9G$DO^@D3L^B";-`S];N]WE<8!L5V`:![4I@2ZY6 M^!M"LMNX1Q[UR","=UG9L`W8;K:5"E!AD>PZJZO(`'$L[]!UX6 M/6WA']4MDP:=E'6W)YQQHY0%%R6]<5DZ]T:7`8?&^NZMZ^OIVDX#J_K+(US^ M!.4W4$L#!!0````(`#"."D?F#Q%PKP$``!8$```9````>&PO=V]R:W-H965T M0'*#9QUC5R+#6=INUB4M6+[9K8QS8J M^'B`X^[M!]AQW8S=!#A\?\=`B@GUJ^D`+'E3LC?'I+-V.%!JJ@X4-WDGJKCHD[((M6==%CA:*7IXUL2,2G']YP02IV.2 M)=?"BV@[ZPNT+.C*JX6"W@CLB8;FF#QFA]/>(P+@IX#);.;$9S\COOK%]_J8 MI#X"2*BL5^!NN,`32.F%G/'O1?/=TA.W\ZOZU]"M2W_F!IY0_A*U[5S8-"$U M-'R4]@6G;["T$!)6*$WX)=5H+*HK)2&*O\VCZ,,XS3OW^4*+$]A"8"OA5EHG(B>/^W`_0EF!^8^1.6+H>^PYX(:5[V4+$\+>O%""^8T8]@& MDZT(ZM17"Q:S.+%_Z"Q.WT43[@)]MW5_>(@+Y%&!/`CD'UK,;EJ,8?Z3D/. M:-WU"8?<(%IP4=([EZ5SCW1=2&BLG]Z[N9[O[;RP.%Q?X?I74/X%4$L#!!0` M```(`#"."D=^`U62HP$``+$#```9````>&PO=V]R:W-H965T0/"%[LW48KKZ5LJJHY1(IR:,^L/;91@'$!K]._#V"O MXZ:^`#/,>_-F&(H1S9OM`!QY5U+;4](YUQ\IM54'BML[[$'[FP:-XLZ;IJ6V M-\#K"%*2LC0]4,6%3LHB^EY,6>#@I-#P8H@=E.+F[QDDCJ=DE]PR6".K9EQ1L M*\69_0=GV_!L4V$6X=D:GF;;!/DF01X)\G\(\B\E;L3DAR])Z*JG"DP;1\>2 M"@<=!W7E7:;S@<4W^0POBYZW\,Q-*[0E%W3^96/_&T0'7DIZMT](Y__/8DAH M7#A^\V4'4$L#!!0````(`#"."D=F.5PQ4P,``#8-```9 M````>&PO=V]R:W-H965TV,]+9D! M9L*CTQXZD\FA/3L@P!/;HK8)Z;>O9!L"JR7M!=OBOX_?KF3)DY.M7YN],6WT M7A95,QWMV_8PCN-FO3=EUCS8@ZGC:QQ[;(*_-41\VQ++/ZS]P4]C0=T=%YX#G?[5L_$,\F\<5NDY>F M:G);1;793D>/=+RBW$LZQ<_A>9N[R9 MA2D*[\E%_CTX_8CI#:_OS]Z_=K@N_9>L,0M;_,HW[=YE2T;1QFRS8]$^V],W M,S!([W!MBZ;[C=;'IK7EV604E=E[?\VK[GKJ_]%D,,,-V&#`+@:7.+@!'PSX MAX'XU$`,!N)_(\C!0(((<<_>56Z9M=EL4MM35/?M/F1^5M&Q=+U9^\&N%=U_ MKG:-&WV;,:$F\9MW-&CFO89=:92^E2Q#";TH8I?`)0N&93%G@3F[#;`(%2H% M.?S3R>I3)S=IE,+A)`HG$3C0HWFOD5=Q!",:E&`1JG@J*,AY&:I4 M2@,R1*4XO0.6H&!)""8)`$N",#)5`G"%HH1QX&D9BB@5"2CD"E'YCN%8"L52 M"!:8/G,5A-$49KP(14I+#K!"$9520BQ,1;C`L32*I1$L,"GF&@GCE@_@0E2$ M!:^=4,4)3T`A5X@O39([+\D4!4L#,`W;E2)1M""@%PM$ENA$24`6RKCD@@-O M*T3&E.`:9_/;-K8/D9`.=FW07$?ZHKF&;T9,IB2#ZPR34:D3^`)!=4)0?H?O MSCY+0SX.^2@V20A-(""B2ZA;3I`PU'&NI()S$].Y5<[D'4)T#W^D+"04D)`% MD9A@"LY/1$95RA3D"V5"I5I"O%#&1Y543O=C6'66[`^?6VM:X],F#Z\S>?<1< M'@JS;?VMPWH$2=P(` M`"D)```9````>&PO=V]R:W-H965TQ5YQJ^J*AOV*AQYK6LJ_NQ8Q;NMB]S[PEMY*919\/+,&^-.9R\=3^CS1X1`[&(GR7KY&3L&/$'SM_-Y/MIZ_I&`ZO849D45#]N;,^J MRF32S+^'I/\X3>!T?,_^U9:KY1^H9'M>_2I/JM!J?=U_YWB5BM?W$->IZ4?_+!O[[/HW!`]A<$`P!`1C``K_&X"'`#P+\'IE MMJXO5-$\$[QS1-^,EIJ>HPW6.W%K`J"(`500V/GQ0$<(),)@``PFB61D]AEA,8S$X27%,9K4`L#0E MD0_+"4$Y(2`GGLGI,=&$YU/BQPBFB4":"*"9E;.+%C0X0=B/89X8Y(D!GI7^ M$C`!>:(]9"&4A#[",$T"TB1/;'NRW/:(K#0W!5G2)W8]71:#PW"E&'/.0-;T M`:)T)<6*N]$3&S^`IF)1XNN_N*Z9S^BQ9>Z.^6<5*QLS)#HL>BO\G[B>+M_<-D_#K*_P)02P,$%`````@` M,(X*1\;X"Y;T`P``K!,``!D```!X;"]W;W)K&UL MC5C+CILP%/T5E'T+-AA#E(DT>:E=5*JZ:-=,XB2H@%,@D_;ORVLRP?=XDDT` M<^[CV-?G$L\NNOQ='96JG;]Y5E1/DV-=GZ:N6VV/*D^JS_JDBN;-7I=Y4C>/ MY<&M3J5*=IU1GKG<\T(W3])B,I]U8]_+^4R?ZRPMU/?2J)EZ;@\K4MFY=),WE52U5EK6>FLA_!J?O,5O#V_LW[YN.;I/^2U*I MIHSL,,40H]GJ!F.`8H&)6E&4\*6)6E-4T`3T,+$`$@L`,=\@UF/$ M'6(`!8A1%")&41\0$Y"8`,0"@Y@@81@+8L*,PF(>$F84Q9E/G*U!S(B%-FXA MY!8";L+@%I(X44@F>DE1DI&E75%4DS&!K0',CZW4)*0F`;70H"8IM9A06SV$ MVDBRA>0(-4HY@BE'(&5II!S1$F(DXT=`&P"R[HP8YAN3?&.S>&(2Q"R>-88CB0&&&I6XYW/4>[ MWBRZ`71;=(VZD*+C]#-Z#!LGA#6$(PTQ:P&!(ML_*BP,'.UY4@L`%%EZ*L?" MP)$PQ!876!CX(\+`Z8YG$5JDN[AQ2E@:.)(&LDH`%/F6.%@9.-KT9)4`*+)L M`Q\K@X\VO;EC$2@21ASWYF0A5^6A.P2JG*T^%W7[I_AF]'K0],S;DPEC?,&F M2P;&5VRZ[H^1WMW/9Z?DH+XEY2$M*N=%U[7.NU.+O=:U:G+W/C>5?%3)[OJ0 MJ7W=WLKFONP/D_J'6I_>SL:N!W3S_U!+`P04````"``PC@I'E0>2+#,"``!> M!P``&0```'AL+W=O8DOS)R98Y\<%P/C[Z(F M1'J?+>W$UJ^E[#=!(/8U:;%X8CWIU)@YP0=#:FD0A6$:M+CI M_+(P>Z^\+-A9TJ8CK]P3Y[;%_/]^'[8^J'V0"C92QT"J^%"*D*ICJ24 M/\:@?S4U\79^C?YBTE7V=UB0BM%?S4'6RFWH>P=RQ&8>T3E0&03 M)%`&)A>1TT5D^/$='\U<6`PRF,YBHB1+9[#*!8,@0FX[T&D'+NS`?.;&0I(; M&9"G*9H?S!*F_D`PC-UN8J>;V'$XVJ#FTO&40KY5VYI3)_E]+V5(E MRR!TJ^1.E?R!&LD7,BA)W"*Z\[F:1;B0`?%<9@3=I9.N)`-6FA)XH,I&$%HM M,ZL4W'3"'I_(#\Q/32>\'9.JJ9K6=V1,$A4R?%*F:_7830M*CE)/D9ISV_[M M0K+^^II-3VKY!U!+`P04````"``PC@I'5@;&">T"``!H#```&0```'AL+W=O M*JWV MT)[9Q$G0`DZQL]F^?8TAA&7&ZB6`F9G?C.V_F117V;^IDQ#:^VB;3FW\D];G MAR!0NY-H*_5%GD5GWAQDWU;://;'0)U[4>VM4]L$P%@2M%7=^65AQY[[LI`7 MW=2=>.X]=6G;JO_[)!IYW?C3'@:"L@AFOWW=BD[5LO-Z<=CXC_QA M"_%@8BU^U>*J%O?>D/RKE&_#PX_]QF=##J(1.SV$J,SE76Q%TPR1#/G/%/3. M'!R7][?HWVRY)OW72HFM;'[7>WTRV3+?VXM#=6GTB[Q^%U,--L.=;)3]]787 MI65[<_&]MOH8KW5GK]?Q38'68.[1!.#N'=(;*5CIG9NKY6NBJ+ M7EZ]?ER,9IM(&%S=TB,-%G M!%"()T#N\!FP)2PRFA"21836/UKXA_FJAM$DM2;=6$.>).DZ$VQF-GS((CJ; MB,PF0ME`#G2`F`P0$P'"53VC3;Q,-,\8HS$)B4D(3+3")`C#8Q)$ MB:L:[A`_)T!KY4Q&G_:`$86+1)X!CQS^+]')YC,H=X+HHX#CLR!B:U"(0.Z9 MHS7.L(/@LX/@Q"YMI.M,XY)?3U><*QTB-PYDI+G5-:1_L6 MBQUXZN#06N>4V-%NPFKGJ;,@6NX.SQ_06@="Z\SQ`01:Q8!5C+&/2EL_WU8G1NJA_!-H9W\[(X5T?Q ML^J/=:>\5ZE->VF;P(.46IA3R\FT_?-#(PYZN$W-?3\VPN.#EN=;7S__ MN2C_`5!+`P04````"``PC@I'YBT_E/P"```%#```&0```'AL+W=O MNZWC=#`+'J& M73!)>HTL782.1*`3&+-@6!8+YH2SZPERET@RD,-_159W1:[2Y&BQN(WGERZS M&SY#5""T`N%5M2-0[9Y)+-/T#,\`E+M01$.P;DL7^D9I!,JV0JB$I02W%:&V M(J<9H"83Q"1XCQ8N0PG()L<84*PEQH"Y5AASXW5(44,ILNPW!#)4(/O" MLF=N[<,XC:(,[.,<`3F+60;?G24&HLN.@'>7W7R1L".6N#8I@63:V8V/!T6<4>B,NF6D29QRZ,SE:,BBA#/HS`4= M9_>0:V?H!^F1,L09@\[85_#1$EST.+5H=[:[[+RU/#;*'$L7HV,'^\A,CP3&%W224V1\:3I> MVU-]RL^GAV(G?A7MKFPZ[U4JW9G9_FDKI1(Z=_*@5V2O>_+QH1);96X3?=_V M76K_H.3AW'2/G?_\'U!+`P04````"``PC@I'T'D%,5`"``!5!P``&0```'AL M+W=O90.A;ZS"F#L?;=.QM5MQ MWJ\\CY45;A%[)#WNQ):9^3, MF[K#+]1AY[9%].\&-V18NX%[,;S6IXI+@Y=GWL0[U"WN6$TZA^+CVGT.5KM4 M(A3@5XT'-ML[4ON>D#=Y^'%8N[Z4@!M<4=;W'32$6:* MZ[3H0Z]UI]9!?TG]D68G@)$`)L(4QTX(1T)X)42?$J*1$/UO!#@2H!'!T[FK MRA6(HSRC9'"H[G:/Y*4*5E#TII1&U0KU3=2.">M['@91YKU+1R-FHS%@ADG2 M6TBQA`03PA,")A7`IF(#%G1P&V"[1"1/AH8OG>P^=7(C,[06*U3\<)[E$[0[ MB*P.(N4@NJDV--+0F$1A.HT!`0CM8:`U#+2$B8VF0DL8/S&JO@0%<61X*C0( MSD!1Z!O-V2T]@22XDU1L32JV)&7H+>*%E(=XWB*M)5YH>8!^=.?")E8QB46, M^9](%F)`?.>VI-8@J26(4==-NFRC#WWCXA=?H;08;S8T6DQ/:EPSIR3GCLMK M/[-.+\(SD$/'L&^"U3:PV`OQ@NB!?W6?9STZX9^(GNJ..7O"Q:A3`^E(",=" MO/\H2EB)-VXZ-/C(Y381>ZK'OCYPTE\>L>DES?\!4$L#!!0````(`#"."D>C MS!8BF0(``/L(```9````>&PO=V]R:W-H965TVATJJ']NQ-G`0MX!0[F^V_KVT(2^RAEV";>><9 M3^P9RIOHW^29TVJ'$F%B+7S6_R=DX,,&_"O%F)M\/ZS`V,?"& M[Y5QP?3CG6]YTQA/FOQG=/K)-,+Y^.[]J]VN#O^52;X5S>_ZH,XZVC@,#OS( MKHWZ*6[?^+@':ASN12/M;["_2B7:NR0,6O8Q/.O./F_#FSP>9;``CP(\"28. M+""C@'P*DO\*DE&0.()HV(I-Q(XI5I6]N`7]\.]=F#DD:)7H5._-HLVL?:=3 M(?7J>T5P7$;OQM%HLQEL\,P&31:1]CXA,(388$^.'P%;WR(K'DUV@),<#H*` M^R163Q[VN;"+!'206`?)@P-G'YO!)K,VW9"HO,@S&$-!#`4PQ,$,-G2&27*: M$QB3@I@4P"0.)O4P7W(:+R0M`S$9@*$.)O,Q%"4)C,E!3`Y@4@>3>QA*BEDP M#Y@"Q!0`)G,PA8?!E!(,8TQ%@NYD#(!R]U+&_BDHLG@!M'#Y$0`J7!#R0"2F ML7/V=Z/9_/#K&X873B4"2\4SPGY`Q"M'V,]Q3HHE$EP/$`%(R"41_]"D*7$R MM!W-LH<+F9.%LX7@^H*``D/<`H/\"E,D6>K&XUO1C+CE,IJUB);W)]MK9;`7 MUTZ92CM;G?KY,S8MQEG?H-5VZ,J?;JKRPD[\!^M/=2>#5Z%T`[-MYBB$XCK( M^$EG]:R_1*9)PX_*##,][H?>/$R4N-P_-:;OG>H?4$L#!!0````(`#"."D?+ MTGA5^@$``&\%```9````>&PO=V]R:W-H965T6B?/MSSEU\ MN6G/^+NH`*3S04DCMFXE9;M!2.054"P>6`N-NBD8IUBJ(R^1:#G@LR%1@@+/ M>T04UXV;I<;VRK.4=9+4#;QR1W248OYW!X3U6]=WKX:WNJRD-J`L12/O7%-H M1,T:AT.Q=5_\S3'2"`/X54,O)GM'QWYB[%T??IRWKJ=#``*YU`I8+1?8`R%: M2#G^,VC>7&KB=']5_V:R5=&?L(`]([_KLZQ4L)[KG*'`'9%OK/\.0PJQ%LP9 M$>;KY)V0C%XIKD/QAUWKQJR]O4F2@;9."`9",!)&/^N$<""$-T+T*2$:"-'_ M>H@'0CSS@&SNIG('+'&68IS)VJG5#62Q:&88HN M6FC`["PFF&"2IWO(80GQ1P12`8Q1!&M1[((%/;AWL%\BDN=9#%^*'#\5N0LS M7"U6:/CA-,OG>%T@6A6(C$!T5^UH5FV+20RFL4XBSYN58PD*@CGHL`2%3W/0 M<0F*'B<@FQ2:M!,%7IH?63@YZQJI"S*QCK/B)=#M.+/O_,W>7[$?U&RQH^`F MGZ4M+N$GYF7=".?$I/H)3*L6C$E0L7L/JODK-?W&`X%"ZFVB]MP.!'N0K+V. MMW'&9O\`4$L#!!0````(`#"."D<2#ZB*C`(```,*```9````>&PO=V]R:W-H M965T]RN;GDG:]$%/=^OPL]XN2968A4_ M:WZ5HW%@BM\(\6XFWW>K$)D:>,.WRJ1@^G+A+[QI3"9-_NV2_F.:P/'XEOVK M?5Q=_H9)_B*:7_5.'76U*`QV?,_.C7H3UV_0>0*@M?`#9,K\PQ:JR%]>@'_;VQ,Q?B)=$;\36 M+-KGMO=TH5*O7JHX3LKH8A(YS7K0D)$&D^RNB73^.X2`$&(3Q`^0%$X0@PEB MFX`^),@F50Z:Q&HZJR&H(`DJ8!`%010`Y1,0G8$0C$A`1`(@B@DBF2$^%7&6 M(`\H!4'I'$31!)3.07K+?)P,Y&0`!T\XV8R#<:PYGC\G!T$Y`"(34#X'H3Q- M,T^[%2"HF/$$QO*0K=`3'>M$^:C8>)'D'I#'O_B_'?N8`G8G)D]TI!.- M:R6+U+.K&'8Q!FP\ZT@G*AY`A'A`L(LQ8.-92SK1&$07OM<2AKV,`3//6M*) M\@<0]8%@+^,4:$GJ20';%#_C4U"4>#BP2_$S-@5%OBV!38HAE_H^2[!+">!2 M.GW=.U$V=BG!J==E!#8J`8Q*IRYSH@<6PC2?L:+1]_W$#OP'ZP]U)X.-4/JH M8#_H>R$4UTG10O??49_([I.&[Y499GK<#V>48:+$Z7;DNI_[JK]02P,$%``` M``@`,(X*1W7>!GP)`@``-08``!D```!X;"]W;W)K&UL=95-CYLP$(;_"N)>,,9\101ILU75'BJM]M">G<0):`UF;2=L_WUMD[`L M3"ZQ/7[G?<8F#.4@Y)NJ&=/>1\L[M?5KK?M-&*I#S5JJ`M&SSNRBUBA-4AE=K=-/L M1@V>:2*<39K0^$\0#$*P,R!?(-$",FH2I^F+Z`$!"4`B"Q`R0J4DR@J$IB3@IP4X"0+#J1) M84@&0C+`(%M`1DT^.TP4%`\H.4C)`4J^H(R:8GYE0?J`4H"4`J`4"TJQHI"` M/'@LMG-`;R=:<]+5ZXE6EY8$.%^`PEE'Z.F9_:;RW'3*VPMMFHMK`2&UL?57;;J,P M$/T5Q`<4S#6)"%*35=5]6*GJP^ZS0YR`:F/6=D+W[]<70BA,FH=@C^==`=H+@HP4Q&D1A MF`4,-ZU?%C;V)LJ"7Q1M6O(F/'EA#(M_.T)YO_61?PN\-^=:F4!0%L&(.S:, MM++AK2?(:>L_H\T>V12;\;LAO9R,/6/^P/F'F?P\;OW0>""45,I08/VXDCVA MU#!IY;\#Z5W3`*?C&_N++5?;/V!)]IS^:8ZJUFY#WSN2$[Y0]<[[5S+4D!K" MBE-I_[WJ(A5G-XCO,?SIGDUKG[U;R>,!!@.B`1"-@"CY%A`/@'@$(`L(G#-; MUP^L<%D(WGO"?8P.FV^.-K%^O99RA(K@:HB%GYW*B2RB!3SZ*K!?9N1K6"$&BX@M/OE2Q$QCYW)2F].ZG!3%>?*@E`04 M2@"A&"9(08(4($AF3M.%4Z1/G?G!2AFHE`%*Z4S)Y>03I329J+B/`R2M'UG) M02LY8"6;6SL]; MN-RK2:(WP0.SZ,'11H#6XFRCA5:4Z:V&YMLZF'041L39=EKI5?S2*G-V)]&Q MFS]'IB/-XCO3Y6VGNM.418?/Y!<6YZ:5WH$KW>]L5SIQKHCV&3YIA[6^A\8) M)2=EAKD>"]>9W43Q[G;1C+==^1]02P,$%`````@`,(X*1XV&ULE9C;;IM`$(9?!?$`@3W` M0F1;:EQ5[46E*!?M-;'7-@JP+JSC].W+R:[-_DO`%S&'?WYFAGR>A<59E6_5 M04KM?.1942W=@];'1\^K-@>9)]6#.LJB/K-399[H>K?<>]6QE,FV#)>#KRD^X-N#GBKA7>- MVZ:Y+*I4%4XI=TOW"WE<\["1M(I?J3Q7-]M.D_RK4F_-SH_MTO6;'&0F-[JQ M2.JO=[F66=8XU5?^TYO^OV83>+M]?+1?:=%^WWNSH2T#\,!M`^@UP#" M1P-8'\`&`5Z765O7UT0GJT6ISD[9W8QCTMQS\LCJSFV:@VVCVG-U955]]'W% M!%UX[XU1KWGJ-/1&,U"L@2*Z2KPZ@6L6%&9!VWA^&Q]P;,"@`6L-V*V!;S'@ MT("##()!'SJ-:#5%UZLH9J$8-`/(XE@$/DXG@.D$(!U+1T-H$$YOB(`&8D)# M.DUP4ZG@/F'X,A&\3`0N$V.#&!K$TPMM>$8(^!-*[46WM9+(KS]#$C[5W:=D MH9(8*3%AZ2O!2!$ZHS$8*L)`%GS8&&84;/1D3'*?"(:3F'0R$5@L,%`DF-$. MC!0)I[0CG%PKYHZ8X#$16BPP4R2:42NFBL13:HT_O_5CDOO!@.&D)IQ,"(L% MAHF2Z>V@EOED#BBS';THN)L/]6?8$Z2+N0@L?%,,)T5PVH8NQHKR&8W!6%%S M4('&!.:<8#&U_2-@^BBBSS(I*$:+BAGU8K2H.:]`O9$Y`T3(C5D!=1&US0J* M4:4`U&(8A8VAB#1O3B\9^,$8E]XE@5!E`-2(6"\MBK$7B<]F!=2!6>'=//@?D[W\F93[ MM*B<5Z6URMLG_9U26M:>_D-=XT$FV^M.)G>ZV13U=MF][>AVM#I>7MY&UL?5/;;N,@$/T5Q`<4;)JDBAQ+FZRJW8=*51^VS\0>QZA< M7"!Q^_<+V''=K+4O9F8XYW!F,$5O[)MK`3SZ4%*['6Z][[:$N*H%Q=V=Z4"' MG<98Q7U([8FXS@*O$TE)DE.Z)HH+C,1A::'?Z1;0\L(A+@CX#>S6(4O1^->8O)[WJ' M:;0`$BH?%7A8+G``*:-0./A]U/PZ,A+G\57],74;W!^Y@X.1KZ+V;3!+,:JA MX6?I7TS_"\865E&P,M*E+ZK.SAMUI6"D^,>P"IW6?MC9Y"-MF9"/A'PB9/?_ M);"1P&X(9'"6^OK)/2\+:WIDA[OH>+SR;,O"Y*I83(-*>Z$S%ZJ7DCVL"W*) M0B-F/V#R&2;_CC@L(!XF"`D&)A?YHHL\\=F<3]FR`%L48$G@?B:PNNUB@&P2 M1"<(O>GB7T2V8I3>^""ST7;\!$__CM!E``#F7P$` M%````'AL+W-H87)E9%-T&UL[;UI;R/7M2CZ^>Y?40CD9PDHT1Q% MTCDG`%M2VW344D=4MQ-ZJ!HMH) M[GMX!W!;$EFUA[777O/P'T6Q";9I\M=M?)YMT\U__JXW&OXN^+)>I<5__NYQ MLWGZ_KOOBL5CO(Z*5O84I_#-?9:OHPW\F3]\5SSE<;0L'N-XLUY]UVVWS[Y; M1TGZNS_\1Y'\X3\V?[C(%MMUG&Z"*%T&E^DFV>R":P7O7T3HN/W4;+:_C30@#+5H-(YS#G'FT@D>6\9?@C_&N M<6%WNZ?*!)WVZ9\:7W@?YTF&FUD&%]&F\JZ&E?H?_Z,66C#&DL9YNXH>RM_> M1ZNB,N+Y-L_IA:18P);^$D=YX^RGIYWN::]3_GA::.!'P<_Q:G7Z*TV`6 M1T66QLM@6A3;."^_=9WM&^=CM@($CO(=+&Q5?=D\^FT!Y_F4Y9LD?0AFFVBS M+0+94OF=OU014Z:C*8)SV/%#EE<.<[)8Q/`]?+NL7XS&BFR]ADLPVV2+3V$P MHYL0W&PWQ0;0$Y;7>.8">CGZM_!Q9:%_ZK[T-AU<[;OG-]<7E]>SRXL`?IO= M7$TO)G?PQYO)U>3Z_#*8_7AY>3>#N_MA=A$<'YT$1T&2!G>/V;:`=5=&NX@7 M@($=NI#]RE0?;F\OK^^"R6P&8U:^C8I'NJH+_"7^ZS;Y'*U@"Y4Y`.)(OHH@ MCQW/UX>=L` M\1^R;/F5L!H\/$IVC$R1HM%OHWK$*0.VS;9'EPS&\]C@,VVD4`[2)YF,(Y>S&LN M11U9K'D^FZ^2!V*A!8@32\3ZZ"E!$*Z`IE>WX&,T;',.>]TDU0>O;JY_.+V[ MO'VW#]H7[FH/Q8&K)(WI,7@QJ>SQV@78H4/>[(?"PS;X/CB\NWT_/IW0G1B+N_5,Z665*!+`DH_%&KW6YW``YY M`)1W&R,1;X=M_B>R6Q!M-X]9GOPM7OX^Z/?#?GL<]OOCD#"\WPU'W4%X-CS3 M3R?(VY>,_I;5!=$F`%$E-F(=/0"L(U[/`1B:?81PQ,53O-@DG^-5A>^^!PI\ MF@#8&.HUEW*[WJZ(+0MISM8@P#["A83Q@E56U#$6\PY$9D/UM*GNNG#\!KO[9P_CZ M\?L(D>XQWB0@)IP@%@3?-7'R^L/EY6CC///R0($G3C6 MC,42+,12.,4M\L35*GN&?0PN35!4 MIZ[H6/RQ1U8)PZ(<]+('PL&&>X-[:!A5@'_]0W#YY_=X5%4)%*078G!/*,\C M90^!A2]66R):RQC(!V`\KP2@$:V1I/^M5IF\>,W#5T"+`L2V"&4MAC/(++`= M6`S>[J=U#6>>P39S/!N6NNKA(5N!Y6M9I"*%79_?O+L,WM[>O'/PLUZ,E&=) MZFR`X53HFIZO_/V[.$IA.??;5;`M8D#]!6P-"')%:R*BAE<#-!=\HT!@[!<2 M-1SAC=4.%H#[WB;%HZ99LSA-`#V)W=?S82.P`6$"?E$E10)5[^$&B!Y?WXH3]<\ES`4S[<`8>YO@"J]GWP)BJ2Q5>] M>9&LMIL:)G@(3X,MO;^]_!&>FWXT:'XH=_-$BG-/0)LRVC8+%6^S/$X>4A&P M%[L`C7;%2DCN\IV7\SZKQT7GA< MOH;`>@$+>EG: M?80)=RWN?!=#"YKY>>2O*[Y6NUH%0H7/R0I,BT0A5;(HD,C MG6Z"O2:RFC=94G[I1;2BDC!`$IPCO&Z?D"-^B?-%4L0LW8AHLU<`_HKQ:*'5 M&PXOGX4^H^4>KR5IY62C M:^9T%>Q]1-D2$5R0"S'I_C`B4\=WCU'%/!&"434*+QO08Z^_H_R:P8V];QU& MQR>S'X.W5S<_'ZZ;.*^XXB-(V)/SN^G'6O,-0J96][8$&\\,A&WGO&LY(1E)Y<95%JE*9Z?"L0PL["V4),+ULUW^AF^NL%D*Q<#"N>.0!N MT9J@$3QM\\4C7#O&6`0([+<"C1I;>KUDO-\@S<^\8":N%6$O]AD?K^O.N^Z4 M7\+,Z?7'R]D+F/E>`PS@G*RC!YSA/EHT6-K4RZ(KJT!=`8-H]3/;DKEEK7B\:TPU8Y>;`?VB)?QU(WTZO M)]?G+X`T!^J7/`&[?8IV?+?A#K%]FE"7[,5-IFH?8/,LS[-G5`2KED`[]EV< MKX'KP[6[B.>;[_9I?$WNBSIH/>FEP!1Y_#E;?:;'R9JLD:3JYGT--ZHSJ3B[ M3U[+CK][)F-)_78J=\J"H!D!+M^^O3PG&?+RS^<_3JY!EP!J?QGP[\!#KHF' M-.B/MY>3V25:I/FW$_B,60X:$^@7E$4_3JZ0']7B7MV#83`W`A->1/*1ON+M M&`6+IO=F']Z_OR(&.;D*+J:S4!.ZW@>G(GX'CS83:]OIS-:#FHWI-$`7K.##=1!YN; M_"%*A:F&(+VG1;9*EI;'O@?`P#HB[7.RYF:C,A9[=,/?L#2,A_F^>(H6\7_^ M[@E7D7^.?_>'GV-]7X"?1P\I$(IDH32;$)LFTF=M+81O4C2JHS";I71U]=/' M[VZG)R%)PZAU`U%89P]Y]/0(LLSY'7Q#_LH<[_4:[CU"P'WD_24^DVX7<'*Y M`FX/&E(*LN`Z6NN'PF"[`L`4P-J7H;/@((^62;;*'F"8/Y_FT0X&NE]MLSP# M$>5IY\C9>VV>8\7,&/TE((\L-BM@SXC8YJ_-8YYM'QY+ M#`G>'YX9>*`%,,X+D)86-%2"JN$J`:1+DR@,WD7Y#L1=V,C;598#DH1`VU>H M",2ANHZ?@Y_@Y1CV?/N8P?%,BQ796^$??OF7+/_4"FZVN6/5994>Z644%+`" MX,1%_$`W`N_EO<&UW,2.`*.%4T$HW#VBP16TY!28IUH8S+6,!%XL+)(R2L1T M^2,M;0%&BP+Z+DHCMFBS.RDXAA7\^H_*M[_^\X3V]`:MOJN=NC4G^0XQ`.;\ M`2#]%$RGTQ"V!>=V'Q/N$//--RD`Z3%Y"HY__<>;VW<_P'"EK00O;D5%JR(S M^ZFL,)CR#L*ZK]SO:-W)E]JGE\%4L$)<%(5^3)^YT@^\EUWI!RPJ!/6/L)?1 M7H;ZF1!"0.P!0"&Z/X)GH(T`[^P98Y6*[;Q(X#[E*&S7'2+&X$;^T M7Q_D0@P#(AD]1\>'EHDS@/MJI9V<($+SX0.7_O6?H?KU'\\Q_(3/M@7_S+;Y MK__$2X;X].L_T.X1I3OX"&[-YC$I!&=A'8QK$OB4+E%O5N?9,KD';"&R"AN= MS,X1L68QJ0?!J-,^Q?\&IYT^''SR1#864+T>0<5\B`&4`!$D$SO>SBYX3C:/ M081:;K&]1UL-GC8[)'%OC$:QHO`+(UG06]D6^(\U"@%DLQPH9QG[MD^X'4]8 MP>D1I4DQ0G?3B9Y1?+"TWA!A&04/>"M"M8I`5D*0`1=$C@%<&'&@"-#!#"!A MLH,/`$C@S)/%8Q#CC$BXH\"5V.SB-`,/03RCZP//DU86?`0,(=.@-ALIB0(# MF'^<7M+M^SEVKQSA&GQ%,C[/_PS<^AG8(5#V7X#PP=N?LXTK,[)C2;^'I,N\ MB$@&NU%`YM88)CU$;? M4.#0O,CR.1E(:,902(/*DX?'C5A28CPAWL&&]8DP\%8&E`+DOR?0DN#8Z(K/ M8W>E.(Z!_S35:R.I&SBK/OP0D4C?`X6("6)$_!D'`!U)S!J+)%]LU^A&)Y)K M)*;O:89EC-,R8KN0U-/SPA%WS:?:7UV8/<$Q*Y(IZ%9O,GX)2`O('LY8".X* M(GDQ*X_9,SX,9`Z^"]+X`>X?$2@B>P!IP(U/,D,^0[9B^@*",7B MGZ@4DWG3QX;4A4&&4IC^G1?-1+<5_)BA&33XH07B0/X0YZ%ZU[IH(<[B<:#L M3#>09C]_3.+[X/)+O-C23;U!,@VOR)=1@CA&BB.\^B;#<>&/"\)HV$(KN,CU M-$B.Z,BT>!<&X_$W&L]C[;$U@$P#%#5:]']-P0LB6+(?3TI9BQQCA.F(+X:A M?K)&:Y/1$J/R)$8)&T"R:>2/Z"&/^3#>30A2M5R(7V'GPJL'HC\F<0X6B!UARL9'["Z(U*A'P!-YY-G)HO8:0'65> MX>>`6J#;:"@M@/`!K8O9($\"+LWLX"P)S;!Q(D[S>)7`8$SUA.-I%]X\WFS0 MJP^23"Y/E,"(%\P((O`UKL#N43F(F3#;3E.*.P."6&P,\N%;*5EV"`6_8(2; MZ"7X`4A&8LC9YB(GD@)B<`WT0WB<=`O"NFB7LA`9"""1*)(/Z.+!- M'9FTC+%R51,$M*LTP&K>YQE:CK3,["D=(H&K-WD<%1O@JI_JOG?5EZ!!?=&R M?!PMD'T+Z83U$)W)@TZ[_4W`HC@(@O:4M31%]Y;`K`J,`C(G*#=22+'@^8L7 M4DA5B>K`X8+`#_@!/(PWE6?9I]4N#:W&J>X(]I:4(*85R3I9171-"'G=]0JI M?$MW7ZL/LFI\UVSZI^PQ#3X&Y_F6-!;4K)#XAQ*4"#=-:9!J(HX*X9IC*QOI M/+/;.&J2CTO\M`P.WC MQ6-*8]*FEB"H4$H/\3\S#9P"83M?.ORB!F&09R24IA+-,W@;Y/?KOS"N@D)V MHJS0G6RTJ%7XO.<^CD.T'Z`!UTA2VKY2QZ/(R,!T5F!9]Q!:7QXC6!)%J)'; M6T(?D55^1LH'V.O`!>2*!049G:ZC3WAV>@VRI"Q]R,BY"(.E&/C@&$P$&PRL M#`R(\3V[^@0)P6F*T8/S[?*!_5;U+[<:/F?IG38'7,(10\M^,E7QDU'T'$`, M3GP-9(-E$M(9&N&(MXO%+%+P%X],^PEZVE9^#PH$08%6IE>M_%63^H3.-JO; M;YE9TU8,B/`]F*!A[S@*ZG.A?&<958,^P@\BEX'=QBF)9<^^;LD8)V&>.FPM M5/7.1C(1(_TE6&B1DR$H4C-R<.3TTT#;.4W\E7(5BH*BS<$.3??L;N!5$O79!!ST*%#[#?;;7= M`_SZ"U(D7]377H^7U[7G>L#$`CCU^LL1_/9KT>WT[+5@7.N,.H?=B^!5]\+N MM`[$ZN5;T3EKEREDIS=VEOJ;[H5ZQ;UX"1:';7G?K7`XJ!4/9<7(UL2A8`RP MZ"0AHS9[Y.M.GGB4'9:-[B2*RJLZ0JI@-NU$P#`OGL<@ZH$NN!:#,P9]N3Y( MLG*)C&[GET$#2H$O7LYB4@R1YUC+,K+1Z`F.\`LC=^H$HXA1CC.9/2$+%]PM*>I"9X<.T5'@&JAM$!1 M/OUE1FYF`@Y>?Y"18ZT6#-]\B+845V]D+KUY3/(E63AVS@S:_%34ZZEF.\IZ M^>&`\=-"7S&B04]Y;`,7'.>[]G=;GWI(P7^`[35/R7'Q7:I9I,+:&W3D]UM` M#5'*6?/;?SYZ(T3D^`8XUHUG.:;R(;F:)]I7JDO21W2\V3TA`@`-ZK>#71SE MQ4DK^$!667&+.M>68*`=@73[R7Q%[-=P+1)U-"N"FZG$.%`#-S^ZI0().Z:' MGOK$Z_@MCJ.]*!$N1>$QITOMOI6@9ER86>-]E&CO@`3IRHK-J&(U`(3%4'6T MAC+#$L+"$=-9*CMP(8P"IG>@1E:TB*G9-\`[(XV0]1P(O2G=19`O'EU*]&TV(+UBF\)(E&CP> M,%XY41#=([K#<6X7&P[=J1>U=00?*_5L?$DSQX'8:!A[C#VB=HQ6&2*O&:=^ M&^IZ4G?3?T^L&9WC#Z+;+S.%C+.LXM?&G]!)(!FTY"VID6WJWN4C<.4QM4TC M0+`-R^2'!HXX,M<3ELY@%B"[(HF*CH;!5&SRK8AJ`.NW&9`>+(E#@MSM=H7X M==KN4/!%_+"52/S9Z9^#,CZ*=*'C52(2$6TU(KS5]UFVX6C4-$;VBY:5>_8` MD7]3!SA\:,U:UN.B8.'Q$VXVLC$63QSJNA(Z16Z0>%-_)K]'QR)+&H(=V1-0 MO,RXX=9.4!"NV\EFTNX$/`RJ]0#[0:3'^&PRC#F/^IN*F"@]E2+K?,1YDF3N M4!PM14G),O596)[7Y(ZP/5E+=.-^%<'!AG6TC.6>U\Y&RTYWI>%%!-PHO;^$ M?*=+BFOY[$AM/*3L'9DD\B(M`^@Q7X/'Q2-)ER3W1>1VA'=^V:8C9-B*G[:47`01GL!>A85LP5D/8#R87%'2&TI13S M&'`=G5"&[6F]XT.G35B2!)I,P9X2"2S+M-RA'+HHOM"MK!3(&J?FN826(-\\Q4F@) M%^)9F>:L=*)X1)IVX>K-B!PL<^IK)8*)LF*I%]"%6?`EKY+KU:^LK`;21NJ@ MV%BS!:--(E!5+5`+FIX\RNR7\I?N>M@L4W%=3_="(QW;K="`NA-11M83)_M+ M*[=R;[3.,"B)P&XF#7T58+$":M3@'03B5F1I&J]"-<^R3Y_B^$GGVC@4RIZ1 MO@KL@N%`3N2>WH0:"A1>3>$W3#G(F%+$"T0]I(\L0U/^!MD0R6ZUR!/ZQ)F4 M-+\XU?D@>GA$6$J.Y'T!>=XD&-X M2)S-9YJ@:0GO/EZ2R0A?)5X+.FN<$B0AC];%22B7 M#,4E^@9*QZ88#X44D2)U*5LM]E!U7E?- ME`%-2:`D""H#04UC.`BN$K^JB8PWH>-:/G<^]X=*4G\AOH]4V8@CYTB?,$1- M^S69(5`A'\VID`?%\2F0LE--6>@A4C,IGIR1BT/6G1HRRVP[WV"5$&V65,<\ MK;5MPY-`L3897V9[^\BNEB<8NGOBTEP/MQ:9WCR[C$GY(ZNGH"4NPKSQ_)BQ MOB>'0_`A"0C`)8?HQ"QL*DBJ[1^VF(WR;)=>I)F+`:$A_A$"]C1.4<.,]3K9 ML$J&>?$7D&L_^APE*S+BUJCP^IZB!(-,"N<)]+@:)4F.K:V\8\28_?5Y`M_E MI55U)ALZQEF):UN"6GT[JANI4;O&AD`]%WR<^N$ZTU3C90RM?*7I9%U1HY*K MD*C-8Z0=G8;?7AO'#_MDXZ,![_;'Z.0-> MA'72W&H`WS'?I=C97[:@L(["#KPY#$>#7@"ZRF`PQA_M7E]QJC'\`8N%!8?= MX1@AW3OK!)U1V#[KJ*;B5LTG[PO7,,XH[+=AXK-1>#8D&O.X2? M(V7*]2@?,8Y'86\T#$Z"XV$XZ+;Q%UCGZ*Q+O_4!7KW@1#44P8)9VV&[OV`2*P]&$X[@Z#/OP8P5!PA+V>HEH5 MRBF1)4RU.D!6$P(NX9@YDN18Z%">DS?06%(I-,6.IS7*)%=6ON!] M1JOD;S0EO4ML1S_"6H1=L&=R95(I]+QN"Z`3$.W=[)XX"3P"KJ_$RP.'>052Y.DH_/UD`&>=8A M22QM6=[&/A>A!^A+1>KSP&DDFPT(-!LG3HANZ]@J)!E".!$G>97)9[ICW[]!6)LE7HH6[&IX^^_*8 MP=XQR5@`LA$.J]F/'*;@.(PG21Z.@++)@4V@[(]H#*KCPI:"(!F9_OV?%-XXLXJMU322$# MA+:T!Y=P4;;T<"5D3J+268T!),YRM+HN$Y@)R\;8HZW++9U'ND2PG*?>>ND1 MY10`\>=GF]4:T&";F]"8FEK7+),A787M)??60!PB+A#98ZE2/.3XIN0-$3J' MRMX3(V'J-+E07TL#;T8UIL%H6/OY,<;('HQ30*<@B$QP;5;)IY@2A2.J#,'7 M9NG5#`FP2#59?)WA,*@9:;KP0$/%1>S,Q3WGL)$J0/`!C#2R3*/*,-ZBCR:V M2W+1P$EW,F.0MG>_I5PC>%22B_!,73L%#H("*ODYR?H0/T@NA0D4Q:]T=AXG M#=2O`HE//2A+\#V.&=QQP6`Y'$S4G5H5-9_96:M>9HJ00OHVMP"D<^:&@$E]<.-(Z MEH/)F@P[*8A*I)MQ0OMMG-A"XY,%(7>WW1Y+FC2J_11N%:<18RTBH,E6B!E.-=0C?##DFAF(6)"FT2/(`@1J*89RFH8J*BB.Y+7E)V^B%" MR^2^:U@$R;),5 M:MHV^<)MSS';%4"Z@N/;Z>S$3@5(NL%G>)>46HE6?:K#%2_+IX)1*";!N*4F M!5-4^1B>A\&#@B="@[J&DS4M8EHP(GO)+(H%V:Y_J_$4/.%3P%(.O-VA9L'ERB*:`!9P-*I/QN:'DI!V2\YVQ M;X5FI4K`P4P?`T;(1I$%,>6(/L?Q)^N2B9CWD#1K\G@E83S=DM>$.95)4.!W M4"A(XU4AEO`$<[.B9&T-\411V.'WLZF$(`=#3+>^+JQCCO@!_?WG)(D\4"VV M=]DR7F%HPTH[S#!YNS]HG_;:/D?'!T,T-LB-0VDG2`;@*OF.&8J$F1:^RWQMBLGH`;'DQA9U+1-#03S-":]3;G'S9Q/`2I5PRD.[ M(]M(CV0CP0SYYG3[)/JEE4?('_U<9W>V088AQW!B%4/I'8`*ART&XH0C,C+5 MCF="T3!!40)V,:S))FP1%;8;5C8JP:M7HJ$6N:5;],8%0!*K^&R2N9YT*(`K M6+`&Z@K2VE1-8Y4!:,H5I^Q#NV`20V_1R M4\,)5^`89;T96H.X'6N`&,2[4U+"'AMR.G(\I-^ M%0LS)/>2>HWBKJ0;)^D6E5)2,VD/Y#HTNKBK M31^970,XS3E(V)@75&`)%9"N94+%,C<<.PK#^+7-3(SY[DDJE[B+0MB+L8@B MMPE3=#E&*3&96QT#&">1%XW,&\Q8>0A5@3H/WDG6.K6]QEDH.K/,.O%1;Y6H M;6/`E#8ZF7)ONH:)N0+(HQ,=>@@B/J#8',L*H?R[(:-.+`8?2T9A);(S%W*. MYY:(SGZ"90F1>Q+F4\4MVH0#6OHEKE@*M-Y/M=QR%LA@M`B0,RG1!3?%4RV7 MSJU[H="<;/IVT2Z2(5&9$F0'./:2B M+Z`>4_F7#;'FU-0^<1K0,&&"IV3AM%%3H`!@_9D5!:=J349%\%(=E^XB)AL` M8X8>6BWI8;RRSPDJ(E,G28M24.JC)KT,J:JP!'3RZ*S7=01_,NI[!T7)!EPX M&3=X+%%QV]0:H(RG3K&@;271$]A'GGV"/2XQAAWV1"/9\B^45K]L-_OJ1FRDV5E!G(: M@DISW`W[`QR],QR&@_Z8?7TPUUF_%_9&;5Q`IT/^/5P!'$+8'8^T+B&Y;+R)$'@0I#,WY4+'.AEPCYC!)BI1.;!0X M"F%N2/UG#'3:%,[-/N=E3O2A4O3FFBK;L0D$*5H];)4/O]`00!>\U?')(@.3 M8&LO2NC%B-!6PQPTB+*%B(&)30!L*V55UN=2*E1$U)FJ%AE,E2!!4^ZYO*K@ M&-?]NSUKL/M4/_'POSOQ\M1$I#=$E?2?X]I[!6.;:YI@34Q#H)V M88I.'K1H75`AYF@QKIRE+6)LH/I7'%ON;4XNY&;WL#A3O@,R(Z'MTBEXY(G;]6APHVUK31,?,S10YDD;V MS4(.,41R1F&B4>JVHBPEQ)`IP'*"EBE9V%*ZL'9+O8AH)RBQ? MV0`;E`&-DJEK]5D28POJ*(&;M'.;PJG@@^N\]:YX$.0=60[8?J\K.VK5W$]Q&` MH.5R#75N,VEEPEUY'S6/V\-Z[:[NR(DEGH"&?=0L^=:P(UG!6T%Z7N)1I]UI M=0<&QRO5V,D?Y4:N"Q94]H,^'Y`J5HQ.VO_IQ#Q2P1_.U,"(6Y:K5I%XQX.- MW9^B%"P-E](2@\:"\;K()/8K2\AY`#1_L>`*4,?)27`#BB#:E3K,.88A?)IP M&4BWKDL#^TXH%!.42"9\XOC%2?X6YYE7DJ@0=WVWU>D=ST^:L-TX[Y9+.&VD M)I]U(VYE%06>R8KRL&9WT28UT(#/9NPT`6K);7(EV'41Q`9OEHPWJFXWHQ8G MBC5?W'KLF9-WVF3PV;@@K=(Y)-PA&0J/;)L^<3RQD9-8@^/^)C#.Y3;/EM3R M$F@=@./8D2L:4/4$T`ZTVSX@U3<478N!#&M=!!A-1C24.GRHGC^4X-6**^!E M]V[6/;`\#GIG5K*!9?BOFB-V40`#VV"<=LM?,2]JFQ)G9>#'N=8:^$@0VA24 M$;R\&U?#8&D:+S5MC@L@VZ1)TCBEAXF=@H!!]Q[#\1>D0H)V])`03M)`H=3) MH.=A`Y4#%B623)J&>`4EXD4+.T-HE)6BEM>6$%BB(FDQX#2M-@F+3DG2`BOU M'W7;GHS6:0>][T;?:%5JFVIEBG/+\/;`6".RJ^#*V44Q'K7.1NUO6)#\]1_\ MLJ)72%+#HAJV;X?(73P#/>0JY@Z^ZS1X*HQ,4OZ#YF]B*UFQ`%-0`\L51W)' MJK)X#BJ8[SR7AF0WL#A5K9+^]\)VJD'D93/$,EO'9#KF8MY23,^VF5*N7L]H MZ&Y4=!4^!*DNFE)&+QM36/?UCDT#=:H?HGKB\YT.I0!RW5``GK09FBL/RSLG M&1CW)A#%TGYT*GKY._N-I!2296C)&:QOHO131[C&AMF88Q#6[9KD5G&T=!*2_,57]BW5XA9Y M,M>*X/<@ZB!2J!LTG+2PUBYU8T'Y^^9)+*JW\1*#&^G"ZE1,+?6V@G+_BB[< MOMD,&S3_>'EU$;R]N0UFDZM*&]\WVFAY3I57Q'S6W!;C@#'KVU\@5=H^8)C# MT/1^0)J>;5,4*2B0!FWKI&<`;)VH5:.7U=3G!]Q&DSNID-<_3:^Q%KUGIPR5 M#H&4M#YZZN]%Q7=DZ`&7P$2*Z-UU9_)RVPFR[:6Q_,W/*\SXB_(T`AH4_$C! M.A)0H+3L8DBBZ<$4E<4DWRVP`/!E5+S/<0C@YZN,L[2]L4)#/'^,5M;A1W'^Y M:L2JF`K?US;\XEIM1Y3OT!VI'[)L2:#IC,)1KZ=`1XI2C@"1B8>#@7([IP6= M,PG2U_4M]=)XVT?H8.X,QQ5RT0.-<'(^O<)>GI/S/WV8SJ:U79P/>LA(()V! MO>N6X'(\O'?[3#DA&UBF.V]PP=3;]\3^;.D"JC&YXH*K(+TGI^MLB0ZY9J\YEMUC3^>7<[#8/WEW??G=]A[QJG)\\'IR&U1RPC@.[L72LJ*='V?:`-EI8=P;THH:Q_D]&3E6^NJK\)MW< MO@51:,:Q97;8#X$`=Z,NW#FU1%8J,GHT&G?0>-WBJ&_MS;&+(+'KJ.^4Q6""R M@)6Q""+A>6*OHBD=9(.M*;]RX^2F&_\?8:RE%6)4D2YK)C-2\P^.Q$7"#33G M'=R'SH$$QZEL9DF.3UTH?L@C+?OZ35UEA9K`[5XA"W6+[C>3E[X-$V)^5D,X M/%I@KS\=)E,`<]]5Z;Y_U1WW3<'=SE!CMG=IG"`T^,K<&56Z,[T^O8VJL,.C M<(#2C0DJ-\8+'HR,$T<'I5/FW\:I-X=Q%D`^.NZZ]!5E*F"B(`E#);K*A"9Z M]FO`)>+>AR(3BW<4S&F1B<*Z;,@1ARS#YM]?79V7&9EI(K:7E;GH1F:;/$N_ MA%C-@&K9[<,TT!.(3#I8MK/F6$*R*H*I$H*5&D#E*'KRY]!0#F_^7!-+0ZI3?WD]J*FE?"S5ZL& M`$KZB,U[@^:4DU[.@@>N(BIEI;8LX3F9O4.L1 MX\)D]B&XSMBS>-KN<8NN#_I/%**4-K4'O_X7Z%%/6UO)R7P#:WH;S_,M4G]G M63!5_3Q=?YXN"6M^3T:8S/@W3+"X]PC03]T%:,K4G!TZ>Z;NG[;'SM3X)TVM M\\O)VW;N)WF?DQ8%Y+M\$,!%+B>WUW!8,R"YH-O^.+FM*,R7H-.1V?8]7,@9 M!@7M08%7#(M MS]`4AW8?9ITAH=0[S`?;A8U!#U1T]&G#R^"4=[T/M&E%_]+D\VL;LLR=T=6^ MR.5OB]KH8-"`PMYX`#\'8:??IZB&L#,84U##\3#LCMK!B<(VG^>!-)Z]>7<9 M'%_=S&8GRIQC,+F[NYV^^7`W>7-U&=S=!+>3"W@\Q.=;W\X">.G=S35<^IOS M/_YX3L#_LS'J*K'J%&G_4XO'($J^"8JDH5*RX!S3NFK0-ANM4?TH]-#J,&?/88??#("\%U, MKSY@?_A_$P!+]T#]&P$X6:()G+*_2O9>NE;:.$-Y':06H^A>9>JR8(],->>PQ4L&`2)W*V(0?'9V$' M:.>)'I*.31ZD08WOHS1N]VQ06J^1H6AO1[C-`Z\IXM_:>\HL0F(DTC M$QW2:B=0K.X)%=9RR%@IM:OK9$#598N]HKV'V,YZ)5.L9]1[;8L)Y2=733:N MDRK>L2F5(CX-$I/D,A\+EC9RETFQ5J"96[Z>S*=/.K(W-2 MZX^*#*")@F-;4YN2H.,[&74T3NVY2UPYBD+!/\4[)X`-174-Q.IYO^S/$'=K M_2&H!H[;=/UF%/E]`4OZWD=J=>Z91-%/,@K'HZ&ZSE+?6AKT1^%@U%-U-M-C M^*K=P2I*]BWO>]8+3IQ:1V:^02\<=^'B9=DG6TE(?%8$-*5IM3W&(W32#GI= M=4Z?AKD91VEW6AZ7LD&ZMEKWM%T0%Z;>RMGVYO_JK!) M?P,C4)G0_43RF^V>XZ)-_=VS!$EK<,H6CAJJ.*N&K98,S@%10WT#%`6WE]>SR;HC2H_>F%+ZJ+=URD9%MR*'9R* M5X2LS9^R[JV#$/?(0X,+)U.?TL!]ZXKWY"W8:2\A+0`VRG8+FH@DT+*05G(L/ M7JL3#Q32)/%`JKIRK*_`M4!CW>?(-HW@J@!4/M@BB:\F\D)L5#O5`](%[[%: MJ_NT4YSS,T7L4"66YXR3#3]SB7`3"(Y)1?=2$P3%>?[22!(Z2I-VV)S`@=DA M=7H6N;$XJ;B#5?S@\,;.X5$&!Q\@;<%IBU4[0GL$A`:("8^@2((7Y1IY8\LM M3;Y?@N#6"0E%Q?'F*+6J#NRXR-+Y^WS9E'$LW":Q[E!^D-'!<8G MR$93X/Z*&[M(_I.P_[":"Q_`#1YW@8LAK^BU!B/U@]P2PL8(#(^S6X2>[G;M"GR!Q:)@O]4["SJM;INL MB%C@LM<;Z>G9?5O.5[/8UV_U\>5.!UY%&70$;,U`&*^V0(^YLZA=++QQ'+E1 M99GDLR1*1<>_V->%N1,!M\7#L#/U,R:MZX[77#,*44WB:])2%*S.:HH]]`C9 M085UIXUKUIJ5DO04/L"JA?'.W(832?(EPX;-GC?UY644R:P%BJ#P-F@.$9NC M93.)'M59KW`,#GHIPX$RWOD5.]1+-TG56($;.DWB*N\HAQV@D@JQ13,]-QJT'Z,U3T M/%3SZ,[:K!*TYA,>39CY500$A0D$B>"L8=88`M-@2#L&N6,V^?7O$D&\3Q#0 M0P%_Q$'!_/B><%B3`Q+,3Y5'ON4Y(;N4%7?\%R:Y M;]%URW07EO2M;S&O*UD3C+%H;Q?-_9W6&"BK^$4KUG5#FX?=?MBG%T9(BC\R M`(Y'@)_=`>>0`DD>4T_.*LFKB M9\(*N1""XRF3![4(0UA)<4X%IBJP3J]>%"I?)Z2&-46)1#XR&"W;4<<&HS58 M9`4DUWA%)'+2[\07<1*^5M9BRPNHO%@WN=_5\E/%UV@KHF6F+`=?9E-MR+EF M6NIUC>H2'L($P%E1+QQT>N&PWS%[I)+?3A$6H@`5`_D(HQFGM\''R=6'R^#= MY63VX?82+=?5>$9S$0*K*.[3^@X=M_XQA5[P^@*@[LE95'8JM;6W)B; MAC&Q*4CFA64\)D`"\L7CCHIPU'Z#UO1/3)U)I9"05(S^<$C"O`UJCQ<)(>VRD)+XE=+HDBD^K/Y/KBBESN__C^(45J( M*YR6[2CI<#79;1KI5*Z_;C.R&.92J>@L3Y5NM MYLK+Z1ZR'#E;OH-4^5/VTK0ZSG]=4:4+;)JE_YHCQ6.-:LICDE8MO37\P2@B M.0%Q*I+Z([6,Z2<9"LQ"ROVR7 M#S8KDO46RFUQ92'2*$RE7)]C4Z$GTRN40H)?66J#X*0Z#"_5E9\]*;?A4'K] M`3#D_;4W@%ICK8U1.*+Z%Z4_I3)'4Q$.>'J(]N*V\QL7YF@JQ0'/=89G8;\M MD^D_I$2';+HBF^W?^&MW.^Z'PT&O^F=O/(;?VGO7/@HQ2\OY51<7H6P-KP:_ M[K_:G+%;*X92P/V@J3A?Z"HL2RK,[#*H.VY3'&&1Z6K:MYE8EZ"I"OD_VVK- M:N-NR2NDUU!`,G3BO%$QJ8GRYO=JG!+(>NS.6!EV)=[:=M,($8GQ%G\6?HVU MA;0Y`)\%?OC@1P87NHFF#1*0(`6M24J-:PK:L\6F0`(P(2W29M34UZJ!EI&^ MI4X4!7NZ@>BUNPZJNU:U,7(>)3:2"WK(T0(:UZVH\&M*ZX,0^LAEWLN"WK@5 MS#Z\F5W^Z0,&1EQ^K!,&9UL@PG_=XEA2KF"/5^&EP;`8#"72J9X-3Z:QSIJ'LY;(='M9^PSGJ[^"V,2:\B>!5K!4>JG=1OEMISU_%.F+3*@#L M:"&L@SVDSE16VTHC;O]@ M5A]05,+.QFN'P=75>>5T.ZW@>H(1+L'-V^#-A]GT^G(V"R;7%P%&",[PT_>W MES,X)W+]!,>ZW>5))1HXVH@+ZHU;K^\-ESV_#]X[357+[SH]4FP,B"HW8W(R MB.";-,8X$1@TXRYO^NGC=[?3D]`V0MAD.KTH.#Z_@V^H?VN.-J=U0G$IWB/O M+_&9=+N`VYHKZAL'F\%"@TZ:TM9)4W*"5FR\R3%%EL-`]ZMMEF?%(GNJ267R M6CE/RD:!YU@*D:)%KUXBU<79?'\VO#\\VX?S-GL#TZ\8Q\/@[0HHY3)"^_0* M-56X`#8E-`QN'T$0#*8%70C\IQ/,.%C&J4V'H,_1I&JB_HOXP?1\K&OO8,M. M)M>)L;-.-ZM+>]7V$%?SZCVI2_#_9Q?\&\^U7.V6S'-Y)YT!J M/AU,IU.IB6_+4[L7%*X[-F$TKL17=,Y5GGA>K?$SU2GN-5^YWW'U]R^U3R]- M6O',=$KDQ_29*_V`SD[4#]2D)ON/E/-!ZF=""%U,9Q3#CB8LIMJ*J;9;8J#V M$+G@@F'B3C]45)$X8RP7Y[$N=RV-5DA6`,&(#A\SH/\9JE__\0PT.83/M@7_ M!$;RZS]UU9!?_W'.^;?PD=_"MU6;MJ#.J<":5(*GH/US1*R9KK72:9_B?X-3 MD/,`1D];Z4J$RHSU3J+#+>;NG1P1<^*7XA7/N:F1&BL4`QVC*[Z%/0+<^-OM MG"P79>S;/E%38-N)DJ>76KMDP9B?Z!FUSX+:G%!R,#>:#]4*FS>1O/$845!> MCB[914WK1:P^S\8]W1-%RI?JIO!NTP%=(2,IC)Q%UO"/V`H4]2^=SJ$N&5X` M\X_32[I]/WL]I@G7X*O"M-5#H0+K'T9`V7_)L'!7\#F3&OUVF6 MJJX]8HW/A.*-N`',`JM+M'S#K6Y.8E\*:EYB3@_S&(H>B;&*6ZY&DC#V\K]+;!9L#23LM:G`V>3_/D& M4'P?''>X$M)3]LPA(%*.C$F\P7*9GH$&4%EC])&COV/#UTCD)Y_,BR^=4I9UF#(4T*(J,<#M@2`L@#A$(`V]EW,3-U(U= M46GADMW-P'^:ZK61$9L"2W32D*-OD!/1:XXFNE62+[9K-((OO.HSW[/-/\9I MI;B_`TD]/2_<*]U@&TCJ/<$Q*[?"7"@"J!;_''!7$*EPZ_0\9L_X\(X-^TX1 M5HX:S$4O83INP**8 M5E$XK0TM'(31U,[N(M?3(#FB(]/B71B,Q]]H/#?Q4@:0*;6U;G%S:Y/JZ%11 MK.WD78[`-M1/UNBDZ(K$J#R)41?W<1MMVXJ<=');.1F.[8$S>03TA(U.<^9.93N&6Z3QHMT0@9)<\FYO%;+9-!-QR8Z[4K?:/ M;IN,EZ1K$(F-T=GT;*4:'?I55[+7Q-^5@Q`AE&FX0UFZ(A?8>?"JP>B/R9PS M=G5;2;Z_IK:[[AB>23]LX$^$[%R@G?BYU-W6A@MTO"BVM0#=,1JH@[,D-,/& MJ\7VA>/IG)P M>&E+>BXV3LUL-GL;TQS*B:2`&%P+_1[(TC\;#U`E5$6>$8(#-HJXA`/;U)%) MRQ@K5Y4BE5VE@93C#$-LMHC-80[']C1A00!"TIZRE*"&=J##_<$T5 M$]Y4GF6?5CNGI`DY^PJ7-R&F:6^+1(U[ZQ52^3;CPI%\=+)J:JZL-_U3]I@& M'X/S?$L:"VI62/Q#6S=):9!J(HX*X3K6,4+U=%Z*JW08O/0@KZA$_DO"<,G4 MI_(35ANXZS MJD48Y!FP3+SO%`%&E7`85S$Z1EFA.]EH4:OP><]]'(=>G4YC'O8R0KS^[G>V M,Q?"LNXAM+Z0%YYRY@H2PK=`/)A54E@1]5LT<`&Y8D&=9T^EO[@3R42"9?J0 M47E^;1QS#":"#096!@:*$[+\0!`=:3S?+A\XM[G^Y5;#YRR]#7L'4=!?4Z7-;>,JD$?"4UE,#9P.W9_K5LR MQDD3;5U$.E0-7E_*CD()`&&A14Z&H$C-&;?TP')UL2[QZ`2U'75'Y?9+72<_ M25'HF6WI3>S>*17M9D:97-37=[RJS6'"E:G&E7&PHL8Q4VW[-T[=\M)IE0,H M](MOBB8;G,WRR-RN0=@LH>]40J)=C+M.+A828?([PI&N8DXA%J@JMUFYWQW. M.=_?#&O#NH]&9[92#3=0&[J=OIXCGJUZ_HZH55Z>6;=M1B(TS%)^-P.,\VXJ ML/`:M__F,W8OB'KI@@QZ;A,YRJ7K^A7[O_Z"%,D7];77X^5U[;D>^YL4OG`Y M@M]^+;J=GKT6C&N=4>>P>Q&\ZE[LCQ15+]^*SEFE05VG-W:6^IONA7K%O7@) M%J_-ZZS>"H>#6O%05LPI-;8KC7:2D%&;?$.U)V^]_#0L&]U)%-7U*"6`@,-_ MO"0.&[EH\DJY]H);!X>;R+*,WM`8IWBYC:!BB)A8:;W1DJ-V-"Y?NJ'S20T2 M-56M*XT[;G5\5C>V5WG?J%*V3HQPBQRM89Z0Y0N.]C0UP9-CIY@.4"V4%BC* MI[_,*!A*,LI@]MRFU)K.;[:(^89B1[A'FHY7=5OQ.:9,H$UH&-@2?=3&48SX M>HQ6]UP2;U=>CF-IJ(WE$/N"D*N:_FNF)8NV*"OMO2"["(GD.&V5@GHIJ?9[ MN8/L>K6ZJ#+ME".JZ4=ZO:XNJYVIODF,)$3[C:F\>4X^'([)B6L4TAKY%&NL MBC7K#FFMBLPUH4LB3EMI-8;LV!N;5D^.9#M*6X M>B-S:;>^;EUMAEH]U6Q'62\_'#!^6N@K1C2($H(TD:VI&&%]ZJ:SV+[R%'B7 M:A:I,/6`>_1A75-1RFW[]N;SL=7DIKID@F/=T&V-RH?D:IYH7ZDN21_1\6;W MA`@`-*C?YFR5$]O)F=RBSK4E&#B]3<5\1>S7<"VNDB"L:%N8T+5]#44-[GJ0 ML&-ZZ*E/O([?U$B7(IRLT!-DA`NS+95P1`IB5KRXBO-J+HF=E!@MC5: M0YEA"6'QHJ-]"*.`Z1VHD14M8FKV#3"G'"]=_[,9;@;??F:W(WDB]H!744@& MT>1[C$4R(&(;W7U)[LCC9#U'`B]*=ZF!4?5N-"&^8)G"2Y9H\'C`>.5$T@Q\ MR?U.*'2G7M2F>OI&J6?C2YIY?GIM$__1(+<[7:%^'7*'6%N329U,#O] M%\7M3F/3 M?]SIG;$2.J6+E=;"X_=.TUF)`'T"BF?+[:^=H"!<-R1GF$52Z)F6#[&%:DG),E&U+,_;AM(84;&6(-<7 MZGQ9;,`JIKJ'3]ULM.QT5QI>M\E5>G\)^4Z7%-?RV9':>$C9.S))Y$5:!M!C MO@:/BT=='`S$#W([PCN_;-.%E&(6)'YY(,GOH0<8`0EQB9VDXKV16RJV5`[K M08:@K\0?#?1Q6P+RFB[F]\F*.0GWJ^B(LG(6A$TH4QRJ1VT`:*+.DY.-%>R($71]?J?.[=33_I,X@-; M.\1Z_K0B>*-8]P+`+7=/"N1I^^'N@)=0W"4^E):!?BTC26#Y0NR=@"K#2II' M/IKD,JXH4UU>M>F(E%T][(CTPSH$SM7\0V7JDMJ$U@@C:8QB;7NXFFK*=(/Q M1?%1FCI-G&I.JHIVJ(OGDIV8XM&$/:^+&#-=)#\,I5RXWER.T6D(YZX*31@D M]$34T&A%D;UVI?>.3Y\V84DD93>3YT8"W3(M!RG'34H7V[/\:YV(H[I"1M6)Z,.%J:*S&D`!?B5#6*F4,9-C8I'8EB'3/,7(,"5_B69D&H@+)6C-I M_H6KQV=4;QYE8'TG15!25DSV`LRPUE7)R^5&&5165@-I(P51K*[9@M%N$:BJ M%JB%+JBFXQ'\I;L>/\OD7%?8O=!LO\AYTXDH(WN*T_^EE3M=Q[%+E&X)KR<- M?95DL0)2UN"M!,I89&D:KT(J'/4ICI]T<4.'O-DSTE>!74(<6$H-JMT)-12D MO!ENC,@.&7>*&+M:8UC4BF7ZIXTVIY(=;9$G7!K%3DJ::)SJL@)Z>*[.)HZL M:`FT?9-PDQQ6C/0Z86WK3,)`;=!7JXXHP;5TZ\A7"\LRTC/IL0I<'ENC::FP ML\V%TPDH2UVTVAE+AV8D^?*4S`:*B1A7#(4NY`)4NJ&PE)41'37:RRI040#F`2= M`$OKB9!H*5^$2[V4K19[J#JOJV9*JG[%H.3B&`:"FL9P4%XEGE83&6]"Q]7M MUDOPATI2?R&^S]:IEN0<*?:TMTF9G`&*!5\UIT(>%,>G0,I.-67AI")J$(_Q M[8Q<'$(O5P8)WS+;SC<@1-KN'L<\K;6UPY-`L3897V9[^[C51H*AQ"\\?R8L?XIAT/P(?$I,DDW3@S%IH*DVA[#F5]\ MPUU;JA?YYF)`:(A_A(`]C5/4>&.]3C;TDJ-`_!<4:F"SJ6M,"OJ>HOB#3(KJ MK.EQW6)>=K&N!:EE2LUO2UORS<.^"TZ;#IALZ)AK):YV";+U[;INY$CM&AL" M!UWPM72W=N/<4XV7,;3RE::3#D+.HR6EZ):]M41M#JRXC/Q5IP8;D-AP:4XA M+N?]_NNJR9_7D2]LO34,.^TA_M;NAV-0]H\"K/0T&F+ID2Y^-APJ0S>Q*LIH M%/3&8;_3#8;CL`//#8=AKZ,?`GHZ@'?ZP5G8[;6IM=?9F*K2]86&.8!B.!CULJ348C/%'N]>7WE_P!RP6>_QVAV.$ M=.^L@[4QVV<=52=<[S]Y7[B&<49AOPT3GXW"L^$@Z`UZ8;_7"WK=(?P<82/XH<;AS!K-B=7Z8 M%0M[#3N@X?3"=G>@Y-:I_;>NVP>(P-*'X;@[#/KP8P1#P1'V>DYY3UN1$H^W M.\(R8QTXRO:H2UG>"'$L1=G#`0;58I3OO:OQ)D*%#"!PX&.!D]V'[@VJ1"!G M84)5ZYQNCL=I'E/53%.$-I&H4F[8+.3+S;Y&VBQ-,4U*L@BA2:ZL6,+@H61? M'%+RJ'^VD@LK'W;!GN68*:RP@;HMS'=,LK$M,GD*HAV6\V=G%>#`*=/R%0B? MIW-,HF&*&?JY@C;(GWC+Q-/#'9>S43,J9,Q1#-0B.S7JDL\-071YUI%5+*19 MELBN(R$CZ!)&HO7`V3";#?;M=+*MO#&9_YHYE9$`&P;7D>F4R(W'R+='U,": MR>J?1XZ$%DI$-_10%A+4H!S!DYSD4@2&1(8=FOPDATR4=U[9=+"AD@Q(;=O#`N!:SP MZ89800G'9WT)T#[+T=QLRQX:9*A+JD5L-<4-9#*ID>H]0F7P&JKLH&7-J0)$ M+E>37&G73<(?4F+87G)O+>.AKGYH"R*@P1G?E(0IN@"AK59D15F='QCJBUPI M\X=4&\U_/S]BH:P-!FA0E59*?U\EGV+*D(Y2[JF&%\U=.R5*4@SO1CG#832W MK89CZ7[BUD/W&$\5(/@`AEA9-E-E,=B^`YF/?MM%`[>N1.RJE5)[#!Z5K"H\ M4Z\K+@R"DG#*]2\1"1\DB<1$R.)7.BV1LR7J5X'DJAZ4/OP;+]Y;TS*7ZD\? M^IS\'[>KOU`<12S/D\%CC2C\-T$:VBJFY)VN,$B:(P*-KWZ%U5N%2#L.RU5F MBT=[93&(NIK+K%V-BI)HI)U#>2_OX@CABAHLUAJVVV/)1D=K!D6UQ2GWQ.`^%SHIS,W"E!E%Y>4G-"," M5H,W%[TYV)M/F\J)YFT2/&YL2;O`Z@F@88KF)2H].:/9MXKHS^WLC+4(=0G6 MSHKL?O/,Y_DY7F5/8I*`]5-031HM(]<4C>)B9HHP(>IM$RH%8G-/C>?\Z4U#YHLN?3@C1LV,WR+`&EN7HW15"+'<8&HF\FVUC$%,96JR1':@ M@>4$4%3[#Y)2;?E2SI?YHLD#X7=0:$FQVAD;^!-,@8N2 MM?4O$"%BO^K/IN"$'`RQ>`\V%M[6RO(#AE6P,>S:]S\D3BGY M"@F_2OZZ39:Z/.2YU&RZC0O`L\6!'K\7QM#%0G4%+56NH$75OP8EF-3IE5PE M[,P)'J_65R5+M:Z"T52S"X6_HUZ;N^#NG:WO99W4E"XSM5"CX#G+/W$]2H:` M#NVE@3H#V\66X\@'(S=$]Z6XW]I(:)G:Z<*VK^F:U'=57K.&5^90$"/ME3+U: M=3P@50M.ET[T"[%))S!2V:]";D#"%7JCFJ'=D6V,3K*1,)1\<[I]$I7:BCCD MN7^NL]#;\-"0HV_]YLM.&1NK&+J[!J17AOU*0"]QCMB@XA)$7VC%43: M"=>M4US/U@MJJN:AFVV7=\WDSLA2^!S6K'^0@BU4>L=\.\>2HEPJCH?9YJJ( MTP2KO&)T&'K1O"J+I'5IF04$!F"A&Z)#V!.&:X$:9D'YZBP=BX9GOW/!;,9# M,VJ)QH;F8,BR`>]R"#19_[1)#'=L0O]M80!3?0M7X-BNS%++]!QYES>PCPPV M_LZO^LQ[,S58,#8L<5+SG6#/T.;)6DNHV)G(9[M3)MV'>TWN,K$>29@HW.][ MG=I)9D!A`[0GL0R7$+@FZ:``L=*[@!I]*04]CW6EVQ0;%6G[ID>92@)5$\2;>H'I/"2WL@)ZLQ'FAK MHY>BL\F,.9"KCDMQ'ZE$C5[M])'9-8#3G(,$_'GA%Y90`>E:)E2(75JJI:4V M7S8[8/$*71UR02(]1QL'4Y0W[9L\]7(O,%GJ,^8*((].=-`H:`V`8G,L M"(4B]8:L4K%8K"P9A97HZO$.Y!P?-Q&=_03+$B+W),RGBMXQU3X-_;(]>UZB M6FXA$F0P6@3(F93H2O_BTY=+YU8LP8*I)KR+3Y85";3/HQR>L,V*"['DHF@5 MV8KC\?)88FK@0H"F3J'O<.XAE>L!C9L*]VR(-:>F:HU3^)\)4V;:!M)&36D) M@/5GUCV<>D,9E2],=4:!BYALP8P9>FAV-06RGY."ZH#;]#I*'JJ/=_5RVZK" M$M#)H[->UQ'\R8_A'12EB:#-BL_A6.('MZDUA1F?IF)!VTJB)["///L$>UQB M]@'LB4:RA7M>68D:BRTKVU6`A"+V-YYK-]S^4LQ26AK[&9,;E]IE]$:=L-<^ M:ZHWS;6E@^/!$)VM0VPOC M3H<\H;@".(2P.Q[I,`*NGZS*]9-9R3D"A2-(B*Z_3ZJ/5Z:>X91 M,2R*?5X_P14R\?LHA+G)$)\Q)&SC=N,ZYV5.]*%2D.R::A+&I@]1/6R5#[_0 M$$`7O-7QR<@38:7V>T[%QL#;5L,<-(@RD-427]9SCP4[439^Q[&GN%8YMK M2HU^#H)V8$NL(/ITE6DYE(E.`Y00M4VRRI73OS)9ZAU7O8&)U`2^V M6/.>8%BZ1E4+0V4Q%.?==['P:E`Z@>H.M.)UBOW=4=>>'$N="PCYHEWQIV)"MX*TC/2SSJ MM#NM[L#@>*7Z/WG&W!A_P8+*?M"-!%+%BM%).W"=Z%`JU<0Y-AB;S'+5*I*` M@&!C]Z4[#I;3$H+E!@90'C:,L?SDR9L-V[$Y1). M&ZD)S`U20)3OE%44>"8KRL.:W46;I$X#/IMKU00HC*7!97)8\"*(#=XL&6]4 MW6Y&+4[Q:[ZX]=@S)_>ZR;VTH5!:I7-(N$,R%![9-GWBR&LC)[$&-]&=@BZW M>;;$&YX#K0-P'#MR10.JG@#:@7;;;V%;@*>8LW?6NGPSFHQH*'7X4+W24()8 M*RY>B&8_2RR`YW%^`/.2#:S#?3>T9^SB`,8`PCCMEK]D7M4V)=;*T(]SK3;P MF2"XN=?#R]MQ50P6I_%6T^Y*;:Q8Y91&$'8*@@9=?,Q<6.B>/0\)(24-I!L\ MTO.P@_L-Y(-2J:A)2__^V\'Q2J0_"WO\_FO+*T.H"_Y[-+N]FP8^75Q?!VYO; M8#:YNFRB%/6`!*2#2R(&!^-OY7*"1W3'NB/U0Y8MR0<$5V$$)P[*(*`&IYUQ MB.5P,)`K)!]TS@0Q=`G61VRM2+TDHQ5B2`_0$>Y8>5,@+%U.;J^GUS_,@O>7 ML*,?)[>-6_H7$K%K&V]QC&$-)VI?V,6W16UH`_::[XT'V/@X[/3[=(YPZ<9T MC'![NW"V)PKI^WEP?7D73*_/;][![JYN9K,39;<[N;N[G;[Y<#=Y`\=Y=Q/< M3B[@\1"?;WT["^"E=\`19G;JXO)V9II.*]U4S39[URN5[L>.1:J: M%XL(.`0L[?:#?CLDI;(BU4&D9<*0,T&1[ M(U<:0=ANM4?THX.]#(_ASQ[##SX9`?@NIE.O_X7#*K=C#B^; MW%WD0*,2"2+`D'N&FVD[39Z?B?;#+>[#^L]&0/>!#`S"8:\K4QR,;;HMZR): M+;82P;9,5EN=L2288U&FWX<)@4^,QPBT[EDW',.%JH??!0_T[T3!;AT*EJG0 M60L0Z^/E[`X;1\.OP4\W4_@%>P*"?#=['4%^HUM:BM&L5"82:4PW['1[ZE+W MT:`T6S15J$37:?,=UD$?.-@8P%4P+$2EU*\%QV?4G/Q$#TG2C#Q(@QK+>VG< M[ME`^>LUQ)8HZQ$RYT&[6Z'R?XQWCGT6V]GB/OS17P6M&;DC+V"@[_TUJ'._ M;><1\K#Q:*BNL[34T;,_"@>CGGG!35\!>6```NR)^Y;W/=/[$T<6,O,-L)\L MP"G+/MF,/JD.23M6VF5O6Z((PZ'75.4>*.64?YV8<2G=92(B'[_RW(Z&4 MW99EN;.G>O::=_2QR6MS;^4&_*CT@_`V`U#KN54Y^V&*R>PI<$(@X4.+W ME]>S%U0FP MIJ$,).VQ M(C284QR"FM6G%T9X:!]9,#@>P>ET!ZP,`/`&]?/[X![U.T34VZTQ\K!!JUL% M\J@5O)U,;X./DZL/E\&[R\D,V!7RL%>RK/_N(_[??<0K?<1_L[WK`@MWKHK@ M5-?M.(%?/\PN@N,CO`B`'7<:.\IS.1:IJ;9(51/8V/!4_WFRK'3V90,34GIK M7WHO]B68!NU+E0;0R"L/`X2S7?822'7MPS===\85?=G&2]PC=M!5W/.0-EXU M/E(J5E`Q4=3>DZH)LPZ_*D]A>W0F%5B-(?B?[^A.5-IR?S6B7:/6@_[KPV%N MBGN]^;^B]=/OS[G"%R<\U];7V_-&M=YW!>H'%.*OH/,+C0$:UW/XPFL2;;[B M9<'WNFOG!&Q74<<:[JMY4%S92#R=)G7'LLV:HHCUOKT7AEY'7Y+U=NW$67'L M7#51&.-.W6[W58/6U[M'@__#[M'@:]VCE?(KCD>2HZ+BFLOP&/N@M`T)Q)GU MFA@T'7#&`]E8LM*0Y1"TP`M!LP%>4M"S,;PB`?$F.OE7A0V4??UP(3#$PPL= M>,5P77\X"O`D[(A-#S`W3+`&$N'^G3U2AT;JO06KO5]E&5F..JWV-^R\:WRS M%MO;K7[_FR8D"NYS:G>UJ-QA<@'#RI=;)*=_W8(.2RT')0K9BULY$)4P^GD\ MHA1$;`X!ERCE3%9>=2VR$TU82_0=^9GK%NH]8.*0#EQ6\1AQ_H;&8HI&RE\* M1AJ9P`\WMD=WG7[U_";67-=`6DJ2AKYCND5!<\QF:,H]H)M]@1JMKMWIQK)_ M%:GH'T(>)!+5'V/_>G5BS_^'[OO/"15#*'3.AQ/:6DOMJMO^/W_]_=M==Z:YF@\9+,*P+#^B5)H[\`FIH8V=CK6!6OV$SH]D,WI^CSIF3HLYUK/+XM!SYBSE!)N`ERO,;T M2L=%1%B7CYCW7D:I)!2PE(2915,JC)[&I;KHAY$5B8MYB8*;9.C#,->I0/.* ME2`>^L`5-D#7QS_D,_>0#V02+U.P!AW]:RG/OJ!N(1M#N*]?080.&/G,&_D% MFK"'FNR'#8_["A(CC48VH&VXY6O3+<=/>@Q0O37=R/Z0;0TO$5G*XA61/?$GYT4I42;W]0QQK M7CQ)^[5L%GVM&9RECE9WZD@ET4-]CXS%LLM=$P1T.4 M42UV?V!?&Z)1T:&;0H+^I?!I"M<)#@K7J1OM7Q.E\]7G^-K@G`K8J\_^&P[WQ>@: MN;6G/WGA(Z\PXAL97/2K.O*XV=EXF88PFRIXZN-M&H;WHFZ"YJB;RNM\$1O6 M?C#TJB$YAT.P)ISGOER0HDKG_>B;TQ<>K\;KO/1&72#/*V9YS6LLF3AA/Z?[ MGZ\$`^T)QZDZ-YM#@H(#0H+JU_Z5BQ&7U.LCA.J89H,+R_+3KT7NKY'LJHXS MIW>1[I%+POQJ]_(EW1OVI*^@&UQ41^AQ\6>5FFDMJUV>2K",CDPR>ZVXS7`M M074MM:01E_.FGKI(X$J%).DXI*ILQV%(3NQ1`SEKF+`48D3:75KUU9>CO$JQ M74[$UJR.L35'B7EA81CM5?$^<[>WKCZF3A?HX:Z"#_)81UJ@=-JU3YFX,QM3 MQ@$=S0_*+6SV<98?C2U$OP9I,3QC]N';0W#3QG01EK+['CZW(G;%'UN.R5A-"MA]+T%10.?Z.P0\\^,:1M01GXZ8.@,#> MMQL`L_>=>GCM?64_Y`Y"K*^@V>>.-&F2.29X+JL" M]3J:4*.^1LINOY8HG`46>:;MH3L/N$*W[4(]B^\,17VZ$H0`YNV_]= M;\*O/(YAB7&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"%`,4````"``PC@I'\C..^\4"``"P"@``$```````````````@`&G M!```9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(`#"."D<2H'&W/P$``&D# M```1``````````````"``9H'``!D;V-097)PC$`8``)PG```3``````````````"``0@)``!X;"]T:&5M M92]T:&5M93$N>&UL4$L!`A0#%`````@`,(X*1Z'-[4X]`@``@@D```T````` M`````````(`!20\``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M`A0#%`````@`,(X*1TB1U^ME`@``OP@``!@``````````````(`!F14``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(X*1^/J M+Z1G!0``;1L``!@``````````````(`!/A\``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0#%`````@`,(X*1TEGP!P+!0``:AD``!@````` M`````````(`!T2H``'AL+W=O&PO=V]R:W-H965T&UL4$L! M`A0#%`````@`,(X*1\3T"C^A`0``L0,``!D``````````````(`!OS,``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(X* M1[Y/&0:B`0``L0,``!D``````````````(`!2#D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(X*1T(F)."B`0``L0,` M`!D``````````````(`!TCX``'AL+W=OTJ_P!``![!@``&0``````````````@`&K0``` M>&PO=V]R:W-H965T_$M/Y MK0$``!8$```9``````````````"``=Y"``!X;"]W;W)K&UL4$L!`A0#%`````@`,(X*1_#HTK&D`0``L`,``!D````````````` M`(`!PD0``'AL+W=O&PO=V]R:W-H965T M5#701KP$``!4$```9```` M``````````"``7A(``!X;"]W;W)K&UL4$L!`A0# M%`````@`,(X*1^8/$7"O`0``%@0``!D``````````````(`!7DH``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(X*1[#> M@1)W`@``*0D``!D``````````````(`!J%$``'AL+W=O&PO=V]R:W-H965T5!Y(L,P(``%X'```9``````````````"``8%8``!X;"]W;W)K&UL4$L!`A0#%`````@`,(X*1U8&Q@GM`@``:`P``!D` M`````````````(`!ZUH``'AL+W=O&PO M=V]R:W-H965T04Q4`(` M`%4'```9``````````````"``4)A``!X;"]W;W)K&UL4$L!`A0#%`````@`,(X*1Z/,%B*9`@``^P@``!D``````````````(`! MR6,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`,(X*1W7>!GP)`@``-08``!D``````````````(`!C6L``'AL+W=O&PO=V]R:W-H965T-G+V8:`,``$T2```9``````````````"``3IP``!X M;"]W;W)K&UL4$L!`A0#%`````@`,(X*1PYTLBJ< M`0``K@,``!D``````````````(`!V7,``'AL+W=O_CM!E``#F7P$`%``````````````` M@`&L=0``>&PO XML 14 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727
7. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) - 6 months ended Jun. 30, 2015 - Stock Options - USD ($)
Total
STOCK BASED COMPENSATION  
Begining Balance 2,092,509
Granted 0
Exercised (937,500)
Canceled or expired (25,000)
Ending Balance 1,130,009
Exercisable at the end 1,086,676
Weighted Average Exercise price Per Common Share  
Begining Balance $ 3.58
Granted  
Exercised $ 2.66
Canceled or expired 2.22
Ending Balance 4.36
Exercisable at the end $ 4.46
Weighted Average Remaining Contractual Life  
Ending Balance 1 year 2 months 12 days
Exercisable at the end 1 year 1 month 10 days
Aggregate Intrinsic Value  
Aggregate value outstanding $ 3,216,338
Aggregate value exercisable $ 3,014,838

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727
1. NATURE OF BUSINESS (Details - Notes payable) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
First Lien Term Loan    
Term loans face value $ 389,367 $ 399,750
Term loans discount (8,061)  
Term loan carrying value 381,306  
2015 Incremental First    
Term loans face value 74,013  
Term loans discount (570)  
Term loan carrying value 73,443  
Second Lien Term Loans    
Term loans face value 180,000 $ 180,000
Term loans discount (2,451)  
Term loan carrying value 177,549  
Short-term Debt [Member]    
Term loans face value 643,380  
Term loans discount (11,082)  
Term loan carrying value $ 632,298  
XML 17 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727
8. FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Fair Value Disclosures [Abstract]    
Line of credit $ 0 $ 15,300
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727
2. ASSETS HELD FOR SALE
6 Months Ended
Jun. 30, 2015
Business Combinations [Abstract]  
ASSETS HELD FOR SALE

On August 7, 2015 we announced a proposed expansion of our existing New Jersey Imaging Networks (“NJIN”) joint venture, which includes NJIN’s acquisition of all of RadNet’s 10 wholly owned New Jersey imaging centers and one center owned by Barnabas Health.

Under the terms of the purchase agreement, which is subject to customary conditions to closing, including the approval of certain New Jersey state licensure bodies, third party consents and consummation of acquisition financing and is expected to close in the third quarter, NJIN will pay RadNet a purchase price of $35.5 million.

The company committed to the board approved plan for such sale prior to June 30, 2015. As such, the following assets are presented as assets held for sale as of June 30, 2015 (in thousands):

 

Property and equipment, net  $11,428 
Goodwill   18,833 
Intangible assets   755 
Other assets   163 
Total assets held for sale  $31,179 

 

XML 19 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727
5. EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Earnings Per Share [Abstract]        
Net income (loss) attributable to RadNet, Inc.'s common stockholders $ 3,395 $ 5,144 $ (1,159) $ (7,280)
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS        
Weighted average number of common shares outstanding during the period 43,370,024 40,817,333 43,059,686 40,413,863
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders $ .08 $ .13 $ (.03) $ (.18)
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS        
Weighted average number of common shares outstanding during the period 44,685,599 43,262,995 43,059,686 40,413,863
Add nonvested restricted stock subject only to service vesting 897,892 1,019,930 0 0
Add additional shares issuable upon exercise of stock options and warrants 417,683 1,425,732 0 0
Weighted average number of common shares used in calculating diluted net income per share 44,685,599 43,262,995 43,059,686 40,413,863
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders $ .08 $ .12 $ (.03) $ (.18)
XML 20 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727
3. FACILITY ACQUISITIONS (Details Narrative) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Dec. 31, 2014
Goodwill $ 196,672 $ 200,304
NYRP    
Cash consideration paid 29,800  
Note issued 1,500  
Assets acquired 34,500  
Assumed equipment debt 2,300  
Assumed current liabilities 891  
Equipment acquired 4,600  
Leasehold improvements acquired 12,000  
Goodwill 12,900  
Other intangible assets 600  
Accounts receivable and other current assets 4,400  
California Radiology    
Cash consideration paid 4,200  
Equipment acquired 217  
Leasehold improvements acquired 1,700  
Goodwill 2,100  
Other intangible assets 100  
Other assets 34  
Healthcare Radiology    
Cash consideration paid 425  
Leasehold improvements acquired 290  
Fixed assets $ 134  
XML 21 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727
6. INVESTMENT IN JOINT VENTURES (Details-Joint ventures) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]        
Beginning balance     $ 32,123  
Equity earnings in these joint ventures $ 3,207 $ 1,646 4,309 $ 2,713
Distribution of earnings     (6,195) $ (5,041)
Equity contributions in existing joint ventures     265  
Ending balance $ 30,502   $ 30,502  
XML 22 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727
6. INVESTMENT IN JOINT VENTURES (Details-Key financial data) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Key financial data for joint ventures      
Current assets - joint ventures $ 18,987    
Noncurrent assets - joint ventures 48,583    
Current liabilities - joint ventures (8,501)    
Noncurrent liabilities - joint ventures (5,144)    
Total net assets -joint ventures 53,925    
Book value of Radnet joint venture interests 25,532    
Cost in excess of book value of acquired joint venture interests 4,970    
Total value of Radnet joint venture interests 30,502   $ 32,123
Total book value of other joint venture partner interests 28,393    
Net revenue 56,639 $ 48,835  
Net income $ 9,476 $ 5,738  
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
6 Months Ended
Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION

We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. At June 30, 2015 we operated directly or indirectly through joint ventures, 276 imaging centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York.  Our operations comprise a single segment for financial reporting purposes.

 

The condensed consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). The condensed consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

 

Accounting Standards Codification (“ASC”) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

 

Howard G. Berger, M.D. is our President and Chief Executive Officer, and Chairman of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which is 99% or 100% owned by Dr. Berger.

 

We contract with seven medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Four of these groups are owned by John V Crues, III, M.D., RadNet’s Medical Director, a member of our Board of Directors and a 1% owner of BRMG.  Dr. Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities. 

 

RadNet provides non-medical, technical and administrative services to BRMG and the seven medical groups mentioned above (“NY Groups”) for which it receives a management fee, pursuant to the related management agreements. Through these management agreements we have exclusive authority over all non-medical decision-making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. These management agreements are designed such that all net cash flows of both BRMG and the NY Groups are transferred to us.

 

We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue, expenses, assets and liabilities of each such entity.  These VIE’s on a combined basis recognized $28.2 million and $21.4 million of revenue, net of management service fees to RadNet for the three months ended June 30, 2015 and 2014, respectively, and $28.2 million and $21.4 million of operating expenses for the three months ended June 30, 2015 and 2014, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations $114.9 million and $92.6 million of total billed net service fee revenue relating to these VIE’s for the three months ended June 30, 2015 and 2014, respectively, of which $86.7 million and $71.2 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the three months ended June 30, 2015 and 2014, respectively.

  

These VIE’s on a combined basis recognized $53.7 million and $42.0 million of revenue, net of management service fees to RadNet for the six months ended June 30, 2015 and 2014, respectively, and $53.7 million and $42.0 million of operating expenses for the six months ended June 30, 2015 and 2014, respectively. RadNet recognized in its condensed consolidated statement of operations $213.9 million and $181.6 million of total billed net service fee revenue relating to these VIE’s for the six months ended June 30, 2015 and 2014, respectively, of which $160.2 million and $139.6 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the six months ended June 30, 2015 and 2014, respectively.

 

The cash flows of these VIE’s are included in the accompanying consolidated statements of cash flows.  All intercompany balances and transactions have been eliminated in consolidation.  In our consolidated balance sheets at June 30, 2015 and December 31, 2014, we have included approximately $89.7 million and $79.7 million, respectively, of accounts receivable and approximately $9.1 million and $9.0 million, respectively, of accounts payable and accrued liabilities, related to these VIE’s combined.

 

The creditors of each of these VIE’s do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of any of these VIE’s. However, because of the relationship RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

 

At all of our centers, aside from certain centers in California and centers in New York City where we contract with BRMG and the NY Groups for the provision of professional medical services, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee intended to compensate us for the fair market value of our services which in some instances may be based on the practice group’s professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.  We have no financial controlling interest in the independent (non-BRMG or non-NY Groups) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2014, filed on March 16, 2015, as amended.

 

Significant Accounting Policies

 

During the period covered in this report, there have been no material changes to the significant accounting policies we use, and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended. The information below is intended only to supplement the disclosure in our annual report.

 

Revenues

 

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to centers affiliated with both BRMG and the NY Entity, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Entity as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Entity. As it relates to non-BRMG and NY Entity centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG and NY Entity centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

  

Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payors.

 

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

 

Our revenue, net of contractual allowances, discounts and provision for bad debts for the three and six months ended June 30, 2015 and 2014 is summarized in the following table (in thousands):

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
Commercial insurance  $117,107   $104,901   $216,872   $204,977 
Medicare   42,088    39,412    79,172    77,317 
Medicaid   5,974    6,230    11,469    12,049 
Workers' compensation/personal injury   8,130    7,853    15,559    15,034 
Other   15,104    10,279    30,361    18,061 
Service fee revenue, net of contractual allowances and discounts   188,403    168,675    353,433    327,438 
Provision for bad debts   (8,387)   (7,520)   (15,862)   (14,413)
Net service fee revenue   180,016    161,155    337,571    313,025 
Revenue under capitation arrangements   24,273    17,927    47,985    34,933 
Total net revenue  $204,289   $179,082   $385,556   $347,958 

 

Provision for Bad Debts

 

We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

 

Deferred Tax Assets

 

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.

 

Deferred Financing Costs

 

Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method.

  

Meaningful Use Incentive

 

Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software will be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. Once an attestation is accepted by Medicare, payments will be made in four to eight weeks to the same taxpayer identification number and through the same channels as their claims payments are made. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $3.3 million and $1.8 million during the six months ended June 30, 2015, and 2014, respectively, relating to this incentive.

 

Liquidity and Capital Resources

 

We had cash and cash equivalents of $5.3 million and accounts receivable of $156.0 million at June 30, 2015, compared to cash and cash equivalents of $307,000 and accounts receivable of $148.2 million at December 31, 2014. We had a working capital balance of $115.1 million and $58.7 million at June 30, 2015 and December 31, 2014, respectively. We had net income attributable to RadNet, Inc. common stockholders for the three months ended June 30, 2015 and 2014 of $3.4 million and $5.1 million respectively, and net loss attributable to RadNet, Inc common stockholders for the six months ended June 30, 2015 and 2014 of $1.2 million and $7.3 million, respectively. We had stockholders’ equity of $10.2 million and $5.4 million at June 30, 2015 and December 31, 2014, respectively.

 

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment.  Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

 

Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

 

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

 

We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.

 

Included in our condensed consolidated balance sheet at June 30, 2015 is $632.3 million of senior secured term loan debt (net of unamortized discounts of $11.1 million), broken down by loan agreement as follows (in thousands):

 

   As of June 30, 2015 
   Face Value   Discount   Total Carrying Value 
First Lien Term Loans  $389,367   $(8,061)  $381,306 
2015 Incremental First   74,013    (570)   73,443 
Second Lien Term Loans   180,000    (2,451)   177,549 
Total  $643,380   $(11,082)  $632,298 

 

Our revolving credit facility had a $0 aggregate principal amount outstanding as of June 30, 2015.

 

As of June 30, 2015, we were in compliance with all financial covenants under our Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan, and the Second Lien Credit Agreement, each as defined below.

  

2015 Incremental First Lien Term Loan:

 

On April 30, 2015, we entered into a joinder agreement to our existing Credit Agreement (the "2015 Incremental First Lien Term Loan Joinder") to provide for the borrowing of $75.0 million of incremental first lien term loans (“2015 Incremental First Lien Term Loans”). The 2015 Incremental First Lien Term Loans are treated as part of the same class as the existing tranche B term loans currently outstanding under the Credit Agreement. We used the proceeds from the 2015 Incremental First Lien Term Loans to repay all of the borrowings outstanding under the first lien revolving loan facility and to pay approximately $1.1 million of fees and expenses associated with the transaction.

 

Interest. The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.

 

Maturity Date. The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.

 

2014 Amendment to the Credit Agreement and Second Lien Credit Agreement:

 

On March 25, 2014, Radnet Management simultaneously entered into two agreements which resulted in the creation of a direct financial obligation as follows:

 

2014 Amendment of the Credit Agreement. Radnet Management amended that certain Credit and Guaranty Agreement dated October 10, 2012 (the “Original Credit Agreement”), by that certain first amendment dated April 3, 2013 (the “2013 Amendment”), and subsequently by entering into a second amendment dated on March 25, 2014 (the “2014 Amendment”) ( the Original Credit Agreement, as amended by the 2013 Amendment and the 2014 Amendment is collectively referred to herein as the "Credit Agreement") to provide for, among other things, the borrowing by Radnet Management of $30.0 million of additional first lien term loans (the “2014 First Lien Term Loans”).

 

The 2014 Amendment provides for the following:

 

Interest. The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015.

 

Guarantees and Collateral. The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, are guaranteed by RadNet, Inc., all of our current and future domestic subsidiaries and certain of our affiliates (other than certain excluded foreign subsidiaries). The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, and the guarantees are secured by a perfected first priority security interest (subject to certain permitted exceptions) in substantially all of our tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

 

Restrictive Covenants. In addition to certain covenants, the Credit Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

  

Financial Covenants. The Credit Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.

 

Events of Default. In addition to certain customary events of default, events of default under the Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, within five days after the due date, failure of any loan party to comply with any covenant or agreement in the loan documents (subject to applicable grace periods and/or notice requirement), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Second Lien Credit and Guaranty Agreement. Radnet Management entered into a Second Lien Credit and Guaranty Agreement dated March 25, 2014 (the “Second Lien Credit Agreement”) to provide for, among other things, the borrowing by Radnet Management of $180.0 million of second lien term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans and the 2014 First Lien Term Loans were used to redeem the outstanding senior notes, as more fully described below under the heading “Senior Notes”, to pay the expenses related to the transaction and for general corporate purposes.

  

The Second Lien Credit Agreement provides for the following:

 

Interest. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.

 

Payments. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.

 

Termination. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.

 

Restrictive Covenants. In addition to certain covenants, the Second Lien Credit Agreement places limits on our ability declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transaction, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

 

Events of Default. In addition to certain events of default, events of default under the Second Lien Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Second Lien Term Loans within five days after the due date, failure of any loan party to comply with any covenant or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Second Lien Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Revolving Credit Facility.

 

The $101.25 million revolving credit line established in the Credit Agreement was unaltered by the agreements above and remains in place. The termination date for the $101.25 million revolving credit facility is the earliest to occur of (i) October 10, 2017, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Credit Agreement, which addresses voluntary commitment reductions and (iii) the date of the termination of the revolving credit facility due to specific events of default pursuant to section 8.01 of the Credit Agreement. The revolving credit line bears interest based on types of borrowings as follows: (i) unpaid principal at the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 4.25% per annum or the Base Rate (as defined in the Credit Agreement) plus 3.25% per annum, (ii) letter of credit and fronting fees at 4.5% per annum, and (iii) commitment fee of 0.5% per annum on the unused revolver balance. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.

  

Senior Notes

 

On April 6, 2010, we issued and sold $200 million of 10 3/8% senior unsecured notes due 2018 at a price of 98.680% (the “senior notes”). All payments of the senior notes, including principal and interest, were guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc., and all of Radnet Management’s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture dated April 6, 2010 (the “Indenture”), by and among Radnet Management, Inc., as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee. We paid interest on the senior notes on April 1 and October 1 of each year, commencing October 1, 2010, and they were scheduled to expire on April 1, 2018.

 

We completed the retirement of our $200 million in senior notes on April 24, 2014 and following such retirement we completed the satisfaction and discharge of the Indenture. The transactions leading to the retirement of the senior notes are described below:

 

Tender Offer. On March 7, 2014, we commenced a tender offer to purchase for cash any and all outstanding senior notes. In connection with the tender offer, we also commenced a consent solicitation to amend the Indenture to eliminate or modify certain restrictive covenants. On March 25, 2014, we made a payment in cash for all senior notes tendered prior to 5:00 P.M., New York City time, on March 20, 2014 (the “Consent Payment Deadline”). As of the Consent Payment Deadline, we received tenders and consents in respect of $193,464,000 aggregate principal amount of the senior notes, representing 96.73% of the outstanding senior notes, all of which were accepted for purchase. The total consideration for each $1,000 principal amount of senior notes validly tendered and not withdrawn at or prior to the Consent Payment Deadline and accepted for purchase was $1,056.88, which amount included a consent payment (the “Consent Payment”) of $30.00 per $1,000 principal amount of senior notes. In addition, all senior notes accepted for payment received accrued and unpaid interest in respect of such notes from the last interest payment date prior to the applicable settlement date to, but not including, the applicable settlement date. The tender offer expired on April 3, 2014 and between the Consent Payment Deadline and the expiration of the tender offer, no additional senior notes were tendered. With a net carrying amount including discount and unamortized issue costs of $189.2 million, a loss on early extinguishment of debt of $15.5 million was recorded in the first quarter of 2014.

 

Exercise of Optional Redemption on March 25, 2014. On March 25, 2014, we called for redemption of all of our remaining outstanding senior notes not purchased prior to the expiration of the tender offer described above, with a redemption date of April 24, 2014 (the “Redemption Date”). Upon redemption on April 24, 2014, the holders of the senior notes being redeemed received a redemption price equal to 105.188% of the outstanding principal amount of the senior notes being redeemed (or $1,051.88 per $1,000 in principal amount of the senior notes) in accordance with the terms of the Indenture, or approximately $6.9 million in total, including approximately $43,000 of accrued and unpaid interest up to, but excluding the Redemption Date.  As of that date, we completed the satisfaction and discharge of the Indenture in accordance with its terms and no senior notes remained outstanding.  With a net carrying amount including discount and unamortized issue costs of $6.4 million, a loss on early extinguishment of debt of $471,000 was recorded in the second quarter of 2014.

XML 24 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727
6. INVESTMENT IN JOINT VENTURES (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]        
Management service fees from centers underlying joint ventures $ 1,400 $ 2,200 $ 3,800 $ 4,600
XML 25 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
CURRENT ASSETS    
Cash and cash equivalents $ 5,319 $ 307
Accounts receivable, net 155,964 148,235
Current portion of deferred tax assets 17,246 17,246
Due from affiliates 5,153 1,561
Prepaid expenses and other current assets 28,528 24,671
Assets held for sale 31,179 0
Total current assets 243,389 192,020
PROPERTY AND EQUIPMENT, NET 225,867 223,127
OTHER ASSETS    
Goodwill 196,672 200,304
Other intangible assets 46,000 47,624
Deferred financing costs, net of current portion 4,893 6,122
Investment in joint ventures 30,502 32,123
Deferred tax assets, net of current portion 37,188 35,334
Deposits and other 3,992 4,026
Total assets 788,503 740,680
CURRENT LIABILITIES    
Accounts payable, accrued expenses and other 94,078 97,816
Due to affiliates 729 6,289
Deferred revenue 1,400 1,964
Current portion of notes payable 23,666 19,468
Current portion of deferred rent 2,206 2,100
Current portion of obligations under capital leases 6,256 5,637
Total current liabilities 128,335 133,274
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 25,461 20,965
Line of credit 0 15,300
Notes payable, net of current portion 612,399 551,059
Obligations under capital lease, net of current portion 4,329 6,143
Other non-current liabilities 5,795 6,241
Total liabilities 776,319 732,982
STOCKHOLDERS' (DEFICIT) EQUITY    
Common stock - $.0001 par value, 200,000,000 shares authorized; 44,409,449, and 42,825,676 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively 4 4
Paid-in-capital 183,803 177,750
Accumulated other comprehensive loss (153) (112)
Accumulated deficit (173,439) (172,280)
Total RadNet, Inc.'s stockholders' deficit 10,215 5,362
Noncontrolling interests 1,969 2,336
Total equity 12,184 7,698
Total liabilities and equity $ 788,503 $ 740,680
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2015 - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income / Loss
Total Radnet Inc Equity
Noncontrolling Interest
Total
Beginning balance, shares at Dec. 31, 2014 42,825,676            
Beginning balance, value at Dec. 31, 2014 $ 4 $ 177,750 $ (172,280) $ (112) $ 5,362 $ 2,336 $ 7,698
Issuance of common stock upon exercise of options, shares issued 719,350            
Issuance of common stock upon exercise of options, value   594     594   594
Stock-based compensation   5,459     5,459   5,459
Issuance of restricted stock and other awards, shares 864,423            
Distributions paid to noncontrolling interest           (613) (613)
Change in cumulative foreign currency translation adjustment       (41) (41)   (41)
Net (loss) income     (1,159)   (1,159) 246 (913)
Ending balance, shares at Jun. 30, 2015 44,409,449            
Ending balance, value at Jun. 30, 2015 $ 4 $ 183,803 $ (173,439) $ (153) $ 10,215 $ 1,969 $ 12,184
XML 27 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727
7. STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Common stock issued upon exercise of options and other awards 3,513,741  
Stock Options    
Shares authorized under plan 12,000,000  
Aggregate intrinsic value $ 5,400 $ 5,900
Unrecognized stock-based compensation expense $ 25  
Unrecognized expense weighted average period 1 year 4 months 24 days  
RestrictedStockMember    
Total shares issued 3,441,208  
RSA's previously vested 2,600,013  
XML 28 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727
7. STOCK-BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock option activity
       Weighted Average   Weighted Average Remaining     
       Exercise price   Contractual   Aggregate 
Outstanding Options      Per Common   Life   Intrinsic  
Under the Restated Plan  Shares   Share   (in years)   Value 
                 
Balance, December 31, 2014   2,092,509   $3.58           
Granted                  
Exercised   (937,500)   2.66           
Canceled, forfeited or expired   (25,000)   2.22           
Balance, June 30, 2015   1,130,009    4.36    1.20   $3,216,338 
Exercisable at June 30, 2015   1,086,676    4.46    1.11    3,014,838 
Restricted Stock Awards activity
      

Weighted-

Average

     
       Remaining   Weighted- 
       Contractual   Average 
   Shares   Term (Years)   Fair Value 
RSA's outstanding at December 31, 2014   942,023        $     1.96 
Changes during the period               
Granted   724,423        $8.66 
Vested   (825,252)       $4.45 
RSA's outstanding at June 30, 2015   841,195    0.92   $5.28 
XML 29 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727
8. FAIR VALUE MEASUREMENTS (Details) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
First Lien Term Loan    
FAIR VALUE MEASUREMENTS    
Term loans face value $ 389,367 $ 399,750
2015 Incremental First    
FAIR VALUE MEASUREMENTS    
Term loans face value 74,013  
Second Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Term loans face value 180,000 180,000
Level 1 | First Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 0 0
Level 1 | 2015 Incremental First    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 0  
Level 1 | Second Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 0 0
Level 2 | First Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 388,880 394,753
Level 2 | 2015 Incremental First    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 73,920  
Level 2 | Second Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 176,400 178,200
Level 3 | First Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 0 0
Level 3 | 2015 Incremental First    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 0  
Level 3 | Second Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 0 0
Total Fair Value | First Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 388,880 394,753
Total Fair Value | 2015 Incremental First    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value 73,920  
Total Fair Value | Second Lien Term Loans    
FAIR VALUE MEASUREMENTS    
Long-Term Debt fair value $ 176,400 $ 178,200
XML 30 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details - Revenue) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Commercial Insurance $ 117,107 $ 104,901 $ 216,872 $ 204,977
Medicare 42,088 39,412 79,172 77,317
Medicaid 5,974 6,230 11,469 12,049
Workers Compensation/Personal Injury 8,130 7,853 15,559 15,034
Other 15,104 10,279 30,361 18,061
Service fee revenue, net of contractual allowances and discounts 188,403 168,675 353,433 327,438
Provision for bad debts (8,387) (7,520) (15,862) (14,413)
Net service fee revenue 180,016 161,155 337,571 313,025
Revenue under capitation arrangements 24,273 17,927 47,985 34,933
Total net revenue $ 204,289 $ 179,082 $ 385,556 $ 347,958
XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 32 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (913) $ (7,119)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 29,235 30,770
Provision for bad debts 15,862 14,413
Equity in earnings of joint ventures (4,309) (2,713)
Distributions from joint ventures 6,195 5,041
Amortization and write off of deferred financing costs and loan discount 2,631 3,156
Loss on sale and disposal of equipment 36 292
Loss on early extinguishment of Senior Notes 0 15,927
Stock-based compensation 5,571 1,636
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:    
Accounts receivable (19,368) (27,361)
Other current assets (3,058) (2,877)
Other assets (3,687) 55
Deferred taxes (1,854) (4,117)
Deferred rent 4,602 420
Deferred revenue (564) 132
Accounts payable, accrued expenses and other (2,423) (7,977)
Net cash provided by operating activities 27,956 19,678
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of imaging facilities (34,407) (1,811)
Purchase of property and equipment (31,649) (26,798)
Proceeds from sale of equipment 205 4
Equity contributions in existing and purchase of interest in joint ventures (265) (900)
Net cash used in investing activities (66,116) (29,505)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on notes and leases payable (3,969) (9,368)
Proceeds from borrowings 74,401 205,737
Payments on Term Loan Debt/Senior Notes (11,369) (211,344)
Deferred financing costs (531) (2,387)
Net proceeds on revolving credit facility (15,300) 18,980
Distributions paid to noncontrolling interests (613) (139)
Proceeds from issuance of common stock upon exercise of options/warrants 594 786
Net cash provided by financing activities 43,213 2,265
EFFECT OF EXCHANGE RATE CHANGES ON CASH (41) (19)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 5,012 (7,581)
CASH AND CASH EQUIVALENTS, beginning of period 307 8,412
CASH AND CASH EQUIVALENTS, end of period 5,319 831
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid during the period for interest 18,283 23,464
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Purchase of equipment and leasehold improvements not yet paid for $ 10,800 $ 13,800
XML 33 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Common stock - par value (in Dollars per share) $ .0001 $ .0001
Common stock - shares authorized 200,000,000 200,000,000
Common stock - shares issued 44,409,449 42,825,676
Common stock - shares outstanding 44,409,449 42,825,676
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)
6 Months Ended
Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Basis of Presentation

We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. At June 30, 2015 we operated directly or indirectly through joint ventures, 276 imaging centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York.  Our operations comprise a single segment for financial reporting purposes.

 

The condensed consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). The condensed consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

 

Accounting Standards Codification (“ASC”) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

 

Howard G. Berger, M.D. is our President and Chief Executive Officer, and Chairman of our Board of Directors. Dr. Berger owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which is 99% or 100% owned by Dr. Berger.

 

We contract with seven medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Four of these groups are owned by John V Crues, III, M.D., RadNet’s Medical Director, a member of our Board of Directors and a 1% owner of BRMG.  Dr. Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities. 

 

RadNet provides non-medical, technical and administrative services to BRMG and the seven medical groups mentioned above (“NY Groups”) for which it receives a management fee, pursuant to the related management agreements. Through these management agreements we have exclusive authority over all non-medical decision-making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. These management agreements are designed such that all net cash flows of both BRMG and the NY Groups are transferred to us.

 

We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue, expenses, assets and liabilities of each such entity.  These VIE’s on a combined basis recognized $28.2 million and $21.4 million of revenue, net of management service fees to RadNet for the three months ended June 30, 2015 and 2014, respectively, and $28.2 million and $21.4 million of operating expenses for the three months ended June 30, 2015 and 2014, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations $114.9 million and $92.6 million of total billed net service fee revenue relating to these VIE’s for the three months ended June 30, 2015 and 2014, respectively, of which $86.7 million and $71.2 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the three months ended June 30, 2015 and 2014, respectively.

  

These VIE’s on a combined basis recognized $53.7 million and $42.0 million of revenue, net of management service fees to RadNet for the six months ended June 30, 2015 and 2014, respectively, and $53.7 million and $42.0 million of operating expenses for the six months ended June 30, 2015 and 2014, respectively. RadNet recognized in its condensed consolidated statement of operations $213.9 million and $181.6 million of total billed net service fee revenue relating to these VIE’s for the six months ended June 30, 2015 and 2014, respectively, of which $160.2 million and $139.6 million was for management services provided to these VIE’s relating primarily to the technical portion of total billed net service fee revenue for the six months ended June 30, 2015 and 2014, respectively.

 

The cash flows of these VIE’s are included in the accompanying consolidated statements of cash flows.  All intercompany balances and transactions have been eliminated in consolidation.  In our consolidated balance sheets at June 30, 2015 and December 31, 2014, we have included approximately $89.7 million and $79.7 million, respectively, of accounts receivable and approximately $9.1 million and $9.0 million, respectively, of accounts payable and accrued liabilities, related to these VIE’s combined.

 

The creditors of each of these VIE’s do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of any of these VIE’s. However, because of the relationship RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

 

At all of our centers, aside from certain centers in California and centers in New York City where we contract with BRMG and the NY Groups for the provision of professional medical services, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee intended to compensate us for the fair market value of our services which in some instances may be based on the practice group’s professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us.  We have no financial controlling interest in the independent (non-BRMG or non-NY Groups) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2015 and 2014 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2014, filed on March 16, 2015, as amended.

Significant Accounting Policies

Significant Accounting Policies

 

During the period covered in this report, there have been no material changes to the significant accounting policies we use, and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended. The information below is intended only to supplement the disclosure in our annual report.

 

Revenues

Revenues

 

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to centers affiliated with both BRMG and the NY Entity, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Entity as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Entity. As it relates to non-BRMG and NY Entity centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG and NY Entity centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

  

Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payors.

 

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

 

Our revenue, net of contractual allowances, discounts and provision for bad debts for the three and six months ended June 30, 2015 and 2014 is summarized in the following table (in thousands):

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
Commercial insurance  $117,107   $104,901   $216,872   $204,977 
Medicare   42,088    39,412    79,172    77,317 
Medicaid   5,974    6,230    11,469    12,049 
Workers' compensation/personal injury   8,130    7,853    15,559    15,034 
Other   15,104    10,279    30,361    18,061 
Service fee revenue, net of contractual allowances and discounts   188,403    168,675    353,433    327,438 
Provision for bad debts   (8,387)   (7,520)   (15,862)   (14,413)
Net service fee revenue   180,016    161,155    337,571    313,025 
Revenue under capitation arrangements   24,273    17,927    47,985    34,933 
Total net revenue  $204,289   $179,082   $385,556   $347,958 

 

Provision for Bad Debts

Provision for Bad Debts

 

We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

Deferred Tax Assets

Deferred Tax Assets

 

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.

Deferred Financing Costs

Deferred Financing Costs

 

Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method.

Meaningful Use Incentive

Meaningful Use Incentive

 

Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software will be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. Once an attestation is accepted by Medicare, payments will be made in four to eight weeks to the same taxpayer identification number and through the same channels as their claims payments are made. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $3.3 million and $1.8 million during the six months ended June 30, 2015, and 2014, respectively, relating to this incentive.

Liquidity and Capital Resources

Liquidity and Capital Resources

 

We had cash and cash equivalents of $5.3 million and accounts receivable of $156.0 million at June 30, 2015, compared to cash and cash equivalents of $307,000 and accounts receivable of $148.2 million at December 31, 2014. We had a working capital balance of $115.1 million and $58.7 million at June 30, 2015 and December 31, 2014, respectively. We had net income attributable to RadNet, Inc. common stockholders for the three months ended June 30, 2015 and 2014 of $3.4 million and $5.1 million respectively, and net loss attributable to RadNet, Inc common stockholders for the six months ended June 30, 2015 and 2014 of $1.2 million and $7.3 million, respectively. We had stockholders’ equity of $10.2 million and $5.4 million at June 30, 2015 and December 31, 2014, respectively.

 

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment.  Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

 

Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

 

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

 

We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.

 

Included in our condensed consolidated balance sheet at June 30, 2015 is $632.3 million of senior secured term loan debt (net of unamortized discounts of $11.1 million), broken down by loan agreement as follows (in thousands):

 

   As of June 30, 2015 
   Face Value   Discount   Total Carrying Value 
First Lien Term Loans  $389,367   $(8,061)  $381,306 
2015 Incremental First   74,013    (570)   73,443 
Second Lien Term Loans   180,000    (2,451)   177,549 
Total  $643,380   $(11,082)  $632,298 

 

Our revolving credit facility had a $0 aggregate principal amount outstanding as of June 30, 2015.

 

As of June 30, 2015, we were in compliance with all financial covenants under our Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan, and the Second Lien Credit Agreement, each as defined below.

  

2015 Incremental First Lien Term Loan:

 

On April 30, 2015, we entered into a joinder agreement to our existing Credit Agreement (the "2015 Incremental First Lien Term Loan Joinder") to provide for the borrowing of $75.0 million of incremental first lien term loans (“2015 Incremental First Lien Term Loans”). The 2015 Incremental First Lien Term Loans are treated as part of the same class as the existing tranche B term loans currently outstanding under the Credit Agreement. We used the proceeds from the 2015 Incremental First Lien Term Loans to repay all of the borrowings outstanding under the first lien revolving loan facility and to pay approximately $1.1 million of fees and expenses associated with the transaction.

 

Interest. The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.

 

Maturity Date. The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.

 

2014 Amendment to the Credit Agreement and Second Lien Credit Agreement:

 

On March 25, 2014, Radnet Management simultaneously entered into two agreements which resulted in the creation of a direct financial obligation as follows:

 

2014 Amendment of the Credit Agreement. Radnet Management amended that certain Credit and Guaranty Agreement dated October 10, 2012 (the “Original Credit Agreement”), by that certain first amendment dated April 3, 2013 (the “2013 Amendment”), and subsequently by entering into a second amendment dated on March 25, 2014 (the “2014 Amendment”) ( the Original Credit Agreement, as amended by the 2013 Amendment and the 2014 Amendment is collectively referred to herein as the "Credit Agreement") to provide for, among other things, the borrowing by Radnet Management of $30.0 million of additional first lien term loans (the “2014 First Lien Term Loans”).

 

The 2014 Amendment provides for the following:

 

Interest. The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.

 

Payments. The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015.

 

Guarantees and Collateral. The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, are guaranteed by RadNet, Inc., all of our current and future domestic subsidiaries and certain of our affiliates (other than certain excluded foreign subsidiaries). The obligations under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, and the guarantees are secured by a perfected first priority security interest (subject to certain permitted exceptions) in substantially all of our tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

 

Restrictive Covenants. In addition to certain covenants, the Credit Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

  

Financial Covenants. The Credit Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.

 

Events of Default. In addition to certain customary events of default, events of default under the Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Credit Agreement, as modified by the 2015 Incremental First Lien Term Loan Joinder, within five days after the due date, failure of any loan party to comply with any covenant or agreement in the loan documents (subject to applicable grace periods and/or notice requirement), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Second Lien Credit and Guaranty Agreement. Radnet Management entered into a Second Lien Credit and Guaranty Agreement dated March 25, 2014 (the “Second Lien Credit Agreement”) to provide for, among other things, the borrowing by Radnet Management of $180.0 million of second lien term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans and the 2014 First Lien Term Loans were used to redeem the outstanding senior notes, as more fully described below under the heading “Senior Notes”, to pay the expenses related to the transaction and for general corporate purposes.

  

The Second Lien Credit Agreement provides for the following:

 

Interest. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.

 

Payments. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.

 

Termination. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.

 

Restrictive Covenants. In addition to certain covenants, the Second Lien Credit Agreement places limits on our ability declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transaction, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

 

Events of Default. In addition to certain events of default, events of default under the Second Lien Credit Agreement include failure to pay the outstanding principal of any loans as and on the date when due, failure to pay any interest on any loan or any fee or other amount payable under the Second Lien Term Loans within five days after the due date, failure of any loan party to comply with any covenant or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is false in a material respect, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Second Lien Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

 

Revolving Credit Facility.

 

The $101.25 million revolving credit line established in the Credit Agreement was unaltered by the agreements above and remains in place. The termination date for the $101.25 million revolving credit facility is the earliest to occur of (i) October 10, 2017, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Credit Agreement, which addresses voluntary commitment reductions and (iii) the date of the termination of the revolving credit facility due to specific events of default pursuant to section 8.01 of the Credit Agreement. The revolving credit line bears interest based on types of borrowings as follows: (i) unpaid principal at the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 4.25% per annum or the Base Rate (as defined in the Credit Agreement) plus 3.25% per annum , (ii) letter of credit and fronting fees at 4.5% per annum, and (iii) commitment fee of 0.5% per annum on the unused revolver balance. The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.

  

Senior Notes

 

On April 6, 2010, we issued and sold $200 million of 10 3/8% senior unsecured notes due 2018 at a price of 98.680% (the “senior notes”). All payments of the senior notes, including principal and interest, were guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc., and all of Radnet Management’s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture dated April 6, 2010 (the “Indenture”), by and among Radnet Management, Inc., as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee. We paid interest on the senior notes on April 1 and October 1 of each year, commencing October 1, 2010, and they were scheduled to expire on April 1, 2018.

 

We completed the retirement of our $200 million in senior notes on April 24, 2014 and following such retirement we completed the satisfaction and discharge of the Indenture. The transactions leading to the retirement of the senior notes are described below:

 

Tender Offer. On March 7, 2014, we commenced a tender offer to purchase for cash any and all outstanding senior notes. In connection with the tender offer, we also commenced a consent solicitation to amend the Indenture to eliminate or modify certain restrictive covenants. On March 25, 2014, we made a payment in cash for all senior notes tendered prior to 5:00 P.M., New York City time, on March 20, 2014 (the “Consent Payment Deadline”). As of the Consent Payment Deadline, we received tenders and consents in respect of $193,464,000 aggregate principal amount of the senior notes, representing 96.73% of the outstanding senior notes, all of which were accepted for purchase. The total consideration for each $1,000 principal amount of senior notes validly tendered and not withdrawn at or prior to the Consent Payment Deadline and accepted for purchase was $1,056.88, which amount included a consent payment (the “Consent Payment”) of $30.00 per $1,000 principal amount of senior notes. In addition, all senior notes accepted for payment received accrued and unpaid interest in respect of such notes from the last interest payment date prior to the applicable settlement date to, but not including, the applicable settlement date. The tender offer expired on April 3, 2014 and between the Consent Payment Deadline and the expiration of the tender offer, no additional senior notes were tendered. With a net carrying amount including discount and unamortized issue costs of $189.2 million, a loss on early extinguishment of debt of $15.5 million was recorded in the first quarter of 2014.

 

Exercise of Optional Redemption on March 25, 2014. On March 25, 2014, we called for redemption of all of our remaining outstanding senior notes not purchased prior to the expiration of the tender offer described above, with a redemption date of April 24, 2014 (the “Redemption Date”). Upon redemption on April 24, 2014, the holders of the senior notes being redeemed received a redemption price equal to 105.188% of the outstanding principal amount of the senior notes being redeemed (or $1,051.88 per $1,000 in principal amount of the senior notes) in accordance with the terms of the Indenture, or approximately $6.9 million in total, including approximately $43,000 of accrued and unpaid interest up to, but excluding the Redemption Date.  As of that date, we completed the satisfaction and discharge of the Indenture in accordance with its terms and no senior notes remained outstanding.  With a net carrying amount including discount and unamortized issue costs of $6.4 million, a loss on early extinguishment of debt of $471,000 was recorded in the second quarter of 2014.

XML 35 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2015
Aug. 07, 2015
Document and Entity Information    
Entity Registrant Name RadNet, Inc.  
Entity Central Index Key 0000790526  
Document Type 10-Q  
Document Period End Date Jun. 30, 2015  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer No  
Is Entity a Voluntary Filer No  
Is Entity's Reporting Status Current Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   44,466,338
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2015  
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Tables)
6 Months Ended
Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Service fee revenue
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
Commercial insurance  $117,107   $104,901   $216,872   $204,977 
Medicare   42,088    39,412    79,172    77,317 
Medicaid   5,974    6,230    11,469    12,049 
Workers' compensation/personal injury   8,130    7,853    15,559    15,034 
Other   15,104    10,279    30,361    18,061 
Service fee revenue, net of contractual allowances and discounts   188,403    168,675    353,433    327,438 
Provision for bad debts   (8,387)   (7,520)   (15,862)   (14,413)
Net service fee revenue   180,016    161,155    337,571    313,025 
Revenue under capitation arrangements   24,273    17,927    47,985    34,933 
Total net revenue  $204,289   $179,082   $385,556   $347,958 
Loans
   As of June 30, 2015 
   Face Value   Discount   Total Carrying Value 
First Lien Term Loans  $389,367   $(8,061)  $381,306 
2015 Incremental First   74,013    (570)   73,443 
Second Lien Term Loans   180,000    (2,451)   177,549 
Total  $643,380   $(11,082)  $632,298 
XML 37 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
NET REVENUE        
Service fee revenue, net of contractual allowances and discounts $ 188,403 $ 168,675 $ 353,433 $ 327,438
Provision for bad debts (8,387) (7,520) (15,862) (14,413)
Net service fee revenue 180,016 161,155 337,571 313,025
Revenue under capitation arrangements 24,273 17,927 47,985 34,933
Total net revenue 204,289 179,082 385,556 347,958
OPERATING EXPENSES        
Cost of operations, excluding depreciation and amortization 175,796 147,808 344,717 292,838
Depreciation and amortization 14,941 15,199 29,235 30,770
Loss on sale and disposal of equipment 74 46 36 292
Severance costs 94 383 130 864
Total operating expenses 190,905 163,436 374,118 324,764
INCOME FROM OPERATIONS 13,384 15,646 11,438 23,194
OTHER INCOME AND EXPENSES        
Interest expense 10,423 10,336 20,419 22,108
Meaningful use incentive 0 0 (3,270) (1,762)
Equity in earnings of joint ventures (3,207) (1,646) (4,309) (2,713)
Loss on early extinguishment of Senior Notes 0 471 0 15,927
Other expenses (income) 413 (4) 410 (2)
Total other expenses 7,629 9,157 13,250 33,558
INCOME (LOSS) BEFORE INCOME TAXES 5,755 6,489 (1,812) (10,364)
(Provision for) Benefit from income taxes (2,192) (1,233) 899 3,245
NET INCOME (LOSS) 3,563 5,256 (913) (7,119)
Net income attributable to noncontrolling interests 168 112 246 161
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 3,395 $ 5,144 $ (1,159) $ (7,280)
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ .08 $ .13 $ (.03) $ (.18)
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ .08 $ .12 $ (.03) $ (.18)
WEIGHTED AVERAGE SHARES OUTSTANDING: Basic 43,370,024 40,817,333 43,059,686 40,413,863
WEIGHTED AVERAGE SHARES OUTSTANDING: Diluted 44,685,599 43,262,995 43,059,686 40,413,863
XML 38 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727
5. EARNINGS PER SHARE
6 Months Ended
Jun. 30, 2015
Earnings Per Share [Abstract]  
EARNINGS PER SHARE

Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
Net income (loss) attributable to RadNet, Inc.'s common stockholders  $3,395   $5,144   $(1,159)  $(7,280)
                     
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS                    
Weighted average number of common shares outstanding during the period   43,370,024    40,817,333    43,059,686    40,413,863 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders  $0.08   $0.13   $(0.03)  $(0.18)
                     
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS                    
Weighted average number of common shares outstanding during the period   43,370,024    40,817,333    43,059,686    40,413,863 
Add nonvested restricted stock subject only to service vesting   897,892    1,019,930         
Add additional shares issuable upon exercise of stock options and warrants   417,683    1,425,732         
Weighted average number of common shares used in calculating diluted net income per share   44,685,599    43,262,995    43,059,686    40,413,863 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders  $0.08   $0.12   $(0.03)  $(0.18)

 

For the six months ended June 30, 2015 and 2014 we excluded all outstanding options and restricted stock awards in the calculation of diluted earnings per share because their effect would be antidilutive.

XML 39 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727
4. NEW ACCOUNTING STANDARDS
6 Months Ended
Jun. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
NEW ACCOUNTING STANDARDS

In April 2015, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2015-03 (“ASU 2015-03”), Interest – Imputation of Interest, (Subtopic 835-30). ASU 2015-03 changes the accounting method for debt issuance costs from a deferred charge (i.e. an asset) to a contra liability in part because such costs provide no future economic benefit. Debt issue costs related to a recognized debt liability are to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with the presentation of debt discounts. The update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

In February 2015, the FASB issued ASU No. 2015-02 (“ASU 2015-02”), Consolidation – Amendments to the Consolidation Analysis, (Topic 810). ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

 

In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The update was effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which has recently been extended to December 31, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

XML 40 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727
8. FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2015
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

 

The table below summarizes the estimated fair value of our long-term debt as follows (in thousands):

 

   As of June 30, 2015 
   Level 1   Level 2   Level 3   Total Fair Value   Total Face Value 
First Lien Term Loans  $    –   $388,880   $    –   $388,880   $389,367 
2015 Incremental First       73,920        73,920    74,013 
Second Lien Term Loans       176,400   $    176,400    180,000 

 

   As of December 31, 2014 
   Level 1   Level 2   Level 3   Total   Total Face Value 
First Lien Term Loans  $    –   $394,753   $    –   $394,753   $399,750 
Second Lien Term Loans       178,200        178,200    180,000 

 

XML 41 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727
2. ASSETS HELD FOR SALE (Tables)
6 Months Ended
Jun. 30, 2015
Business Combinations [Abstract]  
Assets held for sale
Property and equipment, net  $11,428 
Goodwill   18,833 
Intangible assets   755 
Other assets   163 
Total assets held for sale  $31,179 
XML 42 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727
8. FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2015
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

 

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

 

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

 

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

  

The table below summarizes the estimated fair value of our long-term debt as follows (in thousands):

 

   As of June 30, 2015 
   Level 1   Level 2   Level 3   Total Fair Value   Total Face Value 
First Lien Term Loans  $    –   $388,880   $    –   $388,880   $389,367 
2015 Incremental First       73,920        73,920    74,013 
Second Lien Term Loans       176,400   $    176,400    180,000 

 

   As of December 31, 2014 
   Level 1   Level 2   Level 3   Total   Total Face Value 
First Lien Term Loans  $    –   $394,753   $    –   $394,753   $399,750 
Second Lien Term Loans       178,200        178,200    180,000 

 

The carrying value of our revolving credit facility at December 31, 2014 of $15.3 million, respectively, approximated its fair value. There was no revolving credit facility balance at June 30, 2015.

 

We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.

XML 43 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727
6. INVESTMENT IN JOINT VENTURES
6 Months Ended
Jun. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]  
INVESTMENT IN JOINT VENTURES

We have ten unconsolidated joint ventures where our ownership interests range from 35% to 50%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method.

 

The following table is a roll forward of our investment in joint ventures during the six months ended June 30, 2015 (in thousands):

 

Balance as of December 31, 2014  $32,123 
Equity in earnings in these joint ventures   4,309 
Distribution of earnings   (6,195)
Equity contributions in existing joint ventures   265 
Balance as of June 30, 2015  $30,502 

 

We earned management service fees from the centers underlying these joint ventures of approximately $1.4 million and $2.2 million for the three months ended June 30, 2015 and 2014, respectively, and $3.8 million and $4.6 million for the six months ended June 30, 2015 and 2014, respectively. At the end of the period we eliminate from total fees recorded the uncollected portion of these fees that are associated with our ownership interests and offset this with an increase to our equity earnings.

  

The following table is a summary of key financial data for these joint ventures as of June 30, 2015 (in thousands) and for the six months ended June 30, 2015 and 2014 (in thousands):

 

Balance Sheet Data:  June 30, 2015 
Current assets  $18,987 
Noncurrent assets   48,583 
Current liabilities   (8,501)
Noncurrent liabilities   (5,144)
Total net assets  $53,925 
      
Book value of RadNet joint venture interests  $25,532 
Cost in excess of book value of acquired joint venture interests   4,970 
Total value of Radnet joint venture interests  $30,502 
      
Total book value of other joint venture partner interests  $28,393 

 

Income statement data for the six months ended June 30,  2015   2014 
Net revenue  $56,639   $48,835 
Net income  $9,476   $5,738 

 

XML 44 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727
7. STOCK-BASED COMPENSATION
6 Months Ended
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION

Equity Incentive Plans

 

Options

 

We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we amended and restated as of April 20, 2015 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 11, 2015. As of June 30, 2015, we have reserved for issuance under the Restated Plan 12,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over two to five years and expire five to ten years from the date of grant.

 

As of June 30, 2015, we had outstanding options to acquire 1,130,009 shares of our Common Stock, of which options to acquire 1,086,676 shares were exercisable. During the six months ended June 30, 2015, we did not grant any stock options under our Restated Plan.

 

The following summarizes all of our stock option transactions during the six months ended June 30, 2015:

 

       Weighted Average   Weighted Average Remaining     
       Exercise price   Contractual   Aggregate 
Outstanding Options      Per Common   Life   Intrinsic  
Under the Restated Plan  Shares   Share   (in years)   Value 
                 
Balance, December 31, 2014   2,092,509   $3.58           
Granted                  
Exercised   (937,500)   2.66           
Canceled, forfeited or expired   (25,000)   2.22           
Balance, June 30, 2015   1,130,009    4.36    1.20   $3,216,338 
Exercisable at June 30, 2015   1,086,676    4.46    1.11    3,014,838 

 

Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on June 30, 2015 and the exercise price, multiplied by the number of in-the-money options ) that would have been received by the holder had all holders exercised their options on June 30, 2015. Total intrinsic value of options exercised during the six months ended June 30, 2015 and 2014 was approximately $5.4 million and $5.9 million, respectively. As of June 30, 2015, total unrecognized stock-based compensation expense related to non-vested options was $25,000, which is expected to be recognized over a weighted average period of approximately 1.4 years.

  

Restricted Stock Awards

 

The Restated Plan permits the issuance of restricted stock awards (“RSA’s”). As of June 30, 2015, we have issued a total of 3,441,208 RSA’s, of which 2,600,013 RSA’s have previously vested and 841,195 RSA’s remained unvested at June 30, 2015.

 

The following summarizes all unvested RSA activities during the six months ended June 30, 2015:

 

      

Weighted-

Average

     
       Remaining   Weighted- 
       Contractual   Average 
   Shares   Term (Years)   Fair Value 
RSA's outstanding at December 31, 2014   942,023        $     1.96 
Changes during the period               
Granted   724,423        $8.66 
Vested   (825,252)       $4.45 
RSA's outstanding at June 30, 2015   841,195    0.92   $5.28 

 

We determine the fair value of all RSA’s based on the closing price of our common stock on the date of award.

 

In sum, of the 12,000,000 shares of common stock reserved for issuance under the Restated Plan, at June 30, 2015, we had 3,441,208 RSA’s (of which 841,195 shares were subject to further vesting), outstanding options to acquire 1,130,009 shares, and 3,915,042 shares of common stock available for future awards. We had previously granted options and other awards to acquire 3,513,741 shares which have been issued.

XML 45 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727
9. SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2015
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

On August 3, 2015 we sold a 25% interest in two of our wholly owned multi-modality imaging centers located in Owings Mills and Baltimore, Maryland for approximately $5.0 million to Lifebridge Health, Inc. (“Lifebridge”). This transaction resulted in the formation of a partnership with Lifebridge under the name of Baltimore county Radiology, LLC.

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727
7. STOCK-BASED COMPENSATION (Details - RSU's) - 6 months ended Jun. 30, 2015 - RestrictedStockMember - $ / shares
Total
RSA's outstanding, beginning balance 942,023
RSA's granted 724,423
RSA's vested (825,252)
RSA's outstanding, ending balance 841,195
Weighted-Average Remaining Contractual Term 11 months 1 day
Weighted-average fair value, beginning balance $ 1.96
Weighted-average fair value, granted 8.66
Weighted-average fair value, vested 4.45
Weighted-average fair value, ending balance $ 5.28
XML 47 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727
6. INVESTMENT IN JOINT VENTURES (Tables)
6 Months Ended
Jun. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]  
Investment in joint ventures
Balance as of December 31, 2014  $32,123 
Equity in earnings in these joint ventures   4,309 
Distribution of earnings   (6,195)
Equity contributions in existing joint ventures   265 
Balance as of June 30, 2015  $30,502 
Key financial data in joint ventures
Balance Sheet Data:  June 30, 2015 
Current assets  $18,987 
Noncurrent assets   48,583 
Current liabilities   (8,501)
Noncurrent liabilities   (5,144)
Total net assets  $53,925 
      
Book value of RadNet joint venture interests  $25,532 
Cost in excess of book value of acquired joint venture interests   4,970 
Total value of Radnet joint venture interests  $30,502 
      
Total book value of other joint venture partner interests  $28,393 
XML 48 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
BRMG and B&C Entities revenues $ 28,200 $ 21,400 $ 53,700 $ 42,000  
BRMG and B&C Entities operating expenses 28,200 21,400 53,700 42,000  
Total billed net service fee revenue 114,900 92,600 213,900 181,600  
Management services provided to BRMG and B&C Entities 86,700 71,200 160,200 139,600  
BRMG and B&C Entities accounts receivable 89,700   89,700   $ 79,700
BRMG and B&C Entities accounts payable 9,100   9,100   9,000
Meaningful use incentive 0 $ 0 (3,270) $ (1,762)  
Working capital 115,100   115,100   58,700
Senior notes 623,300   623,300    
Line of credit balance outstanding 0   0   $ 15,300
Revolving Credit Facility          
Line of credit maximum borrowing amount 101,250   $ 101,250    
Debt interest rate     The base rate as defined in the Credit Agreement at June 30, 2015 was 3.25%. Accordingly, with current base rate plus the applicable margin of 3.25%, total rate on unpaid principal through the Revolving Credit Facility was 6.5% at June 30, 2015.    
2015 Incremental First          
Line of credit maximum borrowing amount 75,000   $ 75,000    
Payments of loan fees     $ 1,100    
Debt interest rate     The interest rates payable on the 2015 Incremental First Lien Term Loans are the same rates currently payable on the existing tranche B term loans under the amended Credit Agreement, which is (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. As applied to the first lien tranche B term loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.    
Payment frequency     The scheduled quarterly amortization of the 2015 Incremental First Lien Term Loans is $987,000, beginning in June 2015.    
Debt maturity date     The maturity date for the 2015 Incremental First Lien Term Loans shall be on the earlier to occur of (i) October 10, 2018, and (ii) the date on which the 2015 Incremental First Lien Term Loans shall otherwise become due and payable in full under the Credit Agreement, whether by acceleration or otherwise.    
First Lien Term Loan          
Line of credit maximum borrowing amount 30,000   $ 30,000    
Debt interest rate     The interest rates payable on the 2014 First Lien Term Loans are the same as the rates payable under the Credit Agreement, which are (a) the Adjusted Eurodollar Rate (as defined in the Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the Credit Agreement) plus 2.25% per annum. With respect to all of the term loans under the Credit Agreement, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The Adjusted Eurodollar Rate at June 30, 2015 was 0.44%.    
Payment frequency     The scheduled amortization of the term loans under the Credit Agreement increased, starting in June 2014 from quarterly payments of $975,000 to quarterly payments of approximately $5.2 million, with the remaining balance to be paid at maturity. Scheduled amortization payments increased by $16.8 million from pre-2014 Amendment terms, representing a rise from 1% per annum to 5% per annum of the initial amount borrowed. In connection with the 2015 Incremental First Lien Term Loans, the scheduled quarterly amortization for the term loans under the Credit Agreement, including the 2015 Incremental First Lien Term Loans, was increased by $987,000 to approximately $6.2 million, beginning in June 2015.    
Second Lien Term Loans          
Line of credit maximum borrowing amount $ 180,000   $ 180,000    
Debt interest rate     The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% per annum or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0% per annum. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The Eurodollar Rate at June 30, 2015 was 0.44%. The rate paid on the Second Lien Credit Agreement at June 30, 2015 was 8%.    
Payment frequency     There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.    
Debt maturity date     The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) or events of default per section 8.01 as described below.    
XML 49 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Statement of Comprehensive Income [Abstract]        
NET INCOME (LOSS) $ 3,563 $ 5,256 $ (913) $ (7,119)
Foreign currency translation adjustments (4) (1) (41) (19)
COMPREHENSIVE INCOME (LOSS) 3,559 5,255 (954) (7,138)
Less comprehensive income attributable to non-controlling interests 168 112 246 161
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 3,391 $ 5,143 $ (1,200) $ (7,299)
XML 50 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727
3. FACILITY ACQUISITIONS
6 Months Ended
Jun. 30, 2015
Business Combinations [Abstract]  
FACILITY ACQUISITIONS

On April 15, 2015 we completed our acquisition of New York Radiology Partners (“NYRP”), consisting of eleven multi-modality imaging centers located in Manhattan, New York for cash consideration of $29.8 million and a note to seller of $1.5 million. The facilities provide a full range of radiology services including MRI, PET/CT, Mammography, Ultrasound, X-ray and other related services. We have made a preliminary fair value determination of the acquired assets and assumed liabilities. In total, RadNet acquired assets of $34.5 million, assumed equipment debt of $2.3 million, and assumed current liabilities of $891,000. Asset amounts acquired were $4.6 million in equipment, $12.0 million in leasehold improvements, $12.9 million in goodwill, $600,000 of other intangible assets, and $4.4 million of accounts receivable and other current assets. Current liabilities assumed related to accounts payable, payroll and other related short term obligations. Our preliminary fair value determination will be made final with the help of an outside valuation expert which we expect to have completed by the end of our third quarter of 2015.

 

On May 1, 2015 we completed our acquisition of California Radiology consisting of six multi-modality imaging centers located in Los Angeles, California for cash consideration of $4.2 million. The facilities provide MRI, PET/CT, Ultrasound and X-ray services. We have made a fair value determination of the acquired assets and approximately $217,000 of equipment, $1.7 million of leasehold improvements, $34,000 in other assets, $100,000 of other intangible assets relating to a covenant not to compete contract and $2.1 million of goodwill were recorded with respect to this transaction.

 

On June 1, 2015 we completed our acquisition of Healthcare Radiology and Diagnostic systems, PLLC, consisting of a single multi-modality imaging center located in the Bronx, NY area for cash consideration of $425,000. The facility provides MRI, CT, Ultrasound and X-ray services. We have made a fair value determination of net assets and approximately $134,500 of fixed assets and $290,500 of leasehold improvements were recorded.

XML 51 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727
2. ASSETS HELD FOR SALE (Details) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Property and equipment, net $ 225,867 $ 223,127
Goodwill 196,672 200,304
Intangible assets 46,000 47,624
Total assets held for sale 31,179 $ 0
NJIN    
Property and equipment, net 11,428  
Goodwill 18,833  
Intangible assets 755  
Other assets 163  
Total assets held for sale $ 31,179  
XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 72 221 1 false 24 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://radnet.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://radnet.com/role/ConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://radnet.com/role/ConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://radnet.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://radnet.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://radnet.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://radnet.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentation 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 00000009 - Disclosure - 2. ASSETS HELD FOR SALE Sheet http://radnet.com/role/AssetsHeldForSale 2. ASSETS HELD FOR SALE Notes 9 false false R10.htm 00000010 - Disclosure - 3. FACILITY ACQUISITIONS Sheet http://radnet.com/role/FacilityAcquisitions 3. FACILITY ACQUISITIONS Notes 10 false false R11.htm 00000011 - Disclosure - 4. NEW ACCOUNTING STANDARDS Sheet http://radnet.com/role/NewAccountingStandards 4. NEW ACCOUNTING STANDARDS Notes 11 false false R12.htm 00000012 - Disclosure - 5. EARNINGS PER SHARE Sheet http://radnet.com/role/EarningsPerShare 5. EARNINGS PER SHARE Notes 12 false false R13.htm 00000013 - Disclosure - 6. INVESTMENT IN JOINT VENTURES Sheet http://radnet.com/role/InvestmentInJointVentures 6. INVESTMENT IN JOINT VENTURES Notes 13 false false R14.htm 00000014 - Disclosure - 7. STOCK-BASED COMPENSATION Sheet http://radnet.com/role/Stock-basedCompensation 7. STOCK-BASED COMPENSATION Notes 14 false false R15.htm 00000015 - Disclosure - 8. FAIR VALUE MEASUREMENTS Sheet http://radnet.com/role/FairValueMeasurements 8. FAIR VALUE MEASUREMENTS Notes 15 false false R16.htm 00000016 - Disclosure - 9. SUBSEQUENT EVENTS Sheet http://radnet.com/role/SubsequentEvents 9. SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies) Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationPolicies 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Tables) Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationTables 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Tables) Tables http://radnet.com/role/NatureOfBusinessAndBasisOfPresentation 18 false false R19.htm 00000019 - Disclosure - 2. ASSETS HELD FOR SALE (Tables) Sheet http://radnet.com/role/AssetsHeldForSaleTables 2. ASSETS HELD FOR SALE (Tables) Tables http://radnet.com/role/AssetsHeldForSale 19 false false R20.htm 00000020 - Disclosure - 5. EARNINGS PER SHARE (Tables) Sheet http://radnet.com/role/EarningsPerShareTables 5. EARNINGS PER SHARE (Tables) Tables http://radnet.com/role/EarningsPerShare 20 false false R21.htm 00000021 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Tables) Sheet http://radnet.com/role/InvestmentInJointVenturesTables 6. INVESTMENT IN JOINT VENTURES (Tables) Tables http://radnet.com/role/InvestmentInJointVentures 21 false false R22.htm 00000022 - Disclosure - 7. STOCK-BASED COMPENSATION (Tables) Sheet http://radnet.com/role/Stock-basedCompensationTables 7. STOCK-BASED COMPENSATION (Tables) Tables http://radnet.com/role/Stock-basedCompensation 22 false false R23.htm 00000023 - Disclosure - 8. FAIR VALUE MEASUREMENTS (Tables) Sheet http://radnet.com/role/FairValueMeasurementsTables 8. FAIR VALUE MEASUREMENTS (Tables) Tables http://radnet.com/role/FairValueMeasurements 23 false false R24.htm 00000024 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details - Revenue) Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationDetails-Revenue 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details - Revenue) Details http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationTables 24 false false R25.htm 00000025 - Disclosure - 1. NATURE OF BUSINESS (Details - Notes payable) Notes http://radnet.com/role/NatureOfBusinessDetails-NotesPayable 1. NATURE OF BUSINESS (Details - Notes payable) Details http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationTables 25 false false R26.htm 00000026 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Details http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationTables 26 false false R27.htm 00000027 - Disclosure - 2. ASSETS HELD FOR SALE (Details) Sheet http://radnet.com/role/AssetsHeldForSaleDetails 2. ASSETS HELD FOR SALE (Details) Details http://radnet.com/role/AssetsHeldForSaleTables 27 false false R28.htm 00000028 - Disclosure - 3. FACILITY ACQUISITIONS (Details Narrative) Sheet http://radnet.com/role/FacilityAcquisitionsDetailsNarrative 3. FACILITY ACQUISITIONS (Details Narrative) Details http://radnet.com/role/FacilityAcquisitions 28 false false R29.htm 00000029 - Disclosure - 5. EARNINGS PER SHARE (Details) Sheet http://radnet.com/role/EarningsPerShareDetails 5. EARNINGS PER SHARE (Details) Details http://radnet.com/role/EarningsPerShareTables 29 false false R30.htm 00000030 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Details-Joint ventures) Sheet http://radnet.com/role/InvestmentInJointVenturesDetails-jointVentures 6. INVESTMENT IN JOINT VENTURES (Details-Joint ventures) Details http://radnet.com/role/InvestmentInJointVenturesTables 30 false false R31.htm 00000031 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Details-Key financial data) Sheet http://radnet.com/role/InvestmentInJointVenturesDetails-keyFinancialData 6. INVESTMENT IN JOINT VENTURES (Details-Key financial data) Details http://radnet.com/role/InvestmentInJointVenturesTables 31 false false R32.htm 00000032 - Disclosure - 6. INVESTMENT IN JOINT VENTURES (Details Narrative) Sheet http://radnet.com/role/InvestmentInJointVenturesDetailsNarrative 6. INVESTMENT IN JOINT VENTURES (Details Narrative) Details http://radnet.com/role/InvestmentInJointVenturesTables 32 false false R33.htm 00000033 - Disclosure - 7. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Sheet http://radnet.com/role/Stock-basedCompensationDetails-outstandingOptionsAndWarrants 7. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Details http://radnet.com/role/Stock-basedCompensationTables 33 false false R34.htm 00000034 - Disclosure - 7. STOCK-BASED COMPENSATION (Details - RSU's) Sheet http://radnet.com/role/Stock-basedCompensationDetails-Rsus 7. STOCK-BASED COMPENSATION (Details - RSU's) Details http://radnet.com/role/Stock-basedCompensationTables 34 false false R35.htm 00000035 - Disclosure - 7. STOCK-BASED COMPENSATION (Details Narrative) Sheet http://radnet.com/role/Stock-basedCompensationDetailsNarrative 7. STOCK-BASED COMPENSATION (Details Narrative) Details http://radnet.com/role/Stock-basedCompensationTables 35 false false R36.htm 00000036 - Disclosure - 8. FAIR VALUE MEASUREMENTS (Details) Sheet http://radnet.com/role/FairValueMeasurementsDetails 8. FAIR VALUE MEASUREMENTS (Details) Details http://radnet.com/role/FairValueMeasurementsTables 36 false false R37.htm 00000037 - Disclosure - 8. FAIR VALUE MEASUREMENTS (Details Narrative) Sheet http://radnet.com/role/FairValueMeasurementsDetailsNarrative 8. FAIR VALUE MEASUREMENTS (Details Narrative) Details http://radnet.com/role/FairValueMeasurementsTables 37 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. rdnt-20150630.xml rdnt-20150630_cal.xml rdnt-20150630_def.xml rdnt-20150630_lab.xml rdnt-20150630_pre.xml rdnt-20150630.xsd true true XML 53 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727
5. EARNINGS PER SHARE (Tables)
6 Months Ended
Jun. 30, 2015
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2015   2014   2015   2014 
Net income (loss) attributable to RadNet, Inc.'s common stockholders  $3,395   $5,144   $(1,159)  $(7,280)
                     
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS                    
Weighted average number of common shares outstanding during the period   43,370,024    40,817,333    43,059,686    40,413,863 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders  $0.08   $0.13   $(0.03)  $(0.18)
                     
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS                    
Weighted average number of common shares outstanding during the period   43,370,024    40,817,333    43,059,686    40,413,863 
Add nonvested restricted stock subject only to service vesting   897,892    1,019,930         
Add additional shares issuable upon exercise of stock options and warrants   417,683    1,425,732         
Weighted average number of common shares used in calculating diluted net income per share   44,685,599    43,262,995    43,059,686    40,413,863 
Diluted net income (loss) per share attributable to RadNet, Inc.'s common stockholders  $0.08   $0.12   $(0.03)  $(0.18)